
<html lang="en"     class="pb-page"  data-request-id="fc1520c8-dbdf-4dba-9d6f-86bd847313fb"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;article:article:10.1021/acs.jmedchem.0c02085;issue:issue:10.1021/jmcmar.2021.64.issue-7;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Targeting KRAS Mutant Cancers via Combination Treatment: Discovery of a 5-Fluoro-4-(3H)-quinazolinone Aryl Urea pan-RAF Kinase Inhibitor" /></meta><meta name="dc.Creator" content="Malcolm P.  Huestis" /></meta><meta name="dc.Creator" content="Darlene  Dela Cruz" /></meta><meta name="dc.Creator" content="Antonio G.  DiPasquale" /></meta><meta name="dc.Creator" content="Matthew R.  Durk" /></meta><meta name="dc.Creator" content="Charles  Eigenbrot" /></meta><meta name="dc.Creator" content="Paul  Gibbons" /></meta><meta name="dc.Creator" content="Alberto  Gobbi" /></meta><meta name="dc.Creator" content="Thomas L.  Hunsaker" /></meta><meta name="dc.Creator" content="Hank  La" /></meta><meta name="dc.Creator" content="Dennis H.  Leung" /></meta><meta name="dc.Creator" content="Wendy  Liu" /></meta><meta name="dc.Creator" content="Shiva  Malek" /></meta><meta name="dc.Creator" content="Mark  Merchant" /></meta><meta name="dc.Creator" content="John G.  Moffat" /></meta><meta name="dc.Creator" content="Christine S.  Muli" /></meta><meta name="dc.Creator" content="Christine J.  Orr" /></meta><meta name="dc.Creator" content="Brendan T.  Parr" /></meta><meta name="dc.Creator" content="Frances  Shanahan" /></meta><meta name="dc.Creator" content="Christopher J.  Sneeringer" /></meta><meta name="dc.Creator" content="Weiru  Wang" /></meta><meta name="dc.Creator" content="Ivana  Yen" /></meta><meta name="dc.Creator" content="Jianping  Yin" /></meta><meta name="dc.Creator" content="Michael  Siu" /></meta><meta name="dc.Creator" content="Joachim  Rudolph" /></meta><meta name="dc.Description" content="Optimization of a series of aryl urea RAF inhibitors led to the identification of type II pan-RAF inhibitor GNE-0749 (7), which features a fluoroquinazolinone hinge-binding motif. By minimizing rel..." /></meta><meta name="Description" content="Optimization of a series of aryl urea RAF inhibitors led to the identification of type II pan-RAF inhibitor GNE-0749 (7), which features a fluoroquinazolinone hinge-binding motif. By minimizing rel..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="March 29, 2021" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.0c02085" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2021 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c02085" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.0c02085" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c02085" /></link>
        
    
    

<title>Targeting KRAS Mutant Cancers via Combination Treatment: Discovery of a 5-Fluoro-4-(3H)-quinazolinone Aryl Urea pan-RAF Kinase Inhibitor | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.0c02085" /></meta><meta property="og:title" content="Targeting KRAS Mutant Cancers via Combination Treatment: Discovery of a 5-Fluoro-4-(3H)-quinazolinone Aryl Urea pan-RAF Kinase Inhibitor" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02085/20210331/images/large/jm0c02085_0013.jpeg" /></meta><meta property="og:description" content="Optimization of a series of aryl urea RAF inhibitors led to the identification of type II pan-RAF inhibitor GNE-0749 (7), which features a fluoroquinazolinone hinge-binding motif. By minimizing reliance on common polar hinge contacts, this hinge binder allows for a greater contribution of RAF-specific residue interactions, resulting in exquisite kinase selectivity. Strategic substitution of fluorine at the C5 position efficiently masked the adjacent polar NH functionality and increased solubility by impeding a solid-state conformation associated with stronger crystal packing of the molecule. The resulting improvements in permeability and solubility enabled oral dosing of 7. In vivo evaluation of 7 in combination with the MEK inhibitor cobimetinib demonstrated synergistic pathway inhibition and significant tumor growth inhibition in a KRAS mutant xenograft mouse model." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.0c02085"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c02085">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-14/achre4.2021.54.issue-14/20210720/achre4.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-29/aamick.2021.13.issue-29/20210728/aamick.2021.13.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-14/acncdm.2021.12.issue-14/20210721/acncdm.2021.12.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-7/amlcef.2021.3.issue-7/20210705/amlcef.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-29/acsodf.2021.6.issue-29/20210727/acsodf.2021.6.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-29/ascecg.2021.9.issue-29/20210726/ascecg.2021.9.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-29/ancham.2021.93.issue-29/20210727/ancham.2021.93.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-29/bichaw.2021.60.issue-29/20210727/bichaw.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-27/cgeabj.2021.99.issue-27/20210726-01/cgeabj.2021.99.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-7/cgdefu.2021.21.issue-7/20210707/cgdefu.2021.21.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-14/esthag.2021.55.issue-14/20210720/esthag.2021.55.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-29/iecred.2021.60.issue-29/20210728/iecred.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-14/inocaj.2021.60.issue-14/20210719/inocaj.2021.60.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-29/jafcau.2021.69.issue-29/20210728/jafcau.2021.69.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-29/jacsat.2021.143.issue-29/20210728/jacsat.2021.143.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-7/jamsef.2021.32.issue-7/20210707/jamsef.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-29/langd5.2021.37.issue-29/20210727/langd5.2021.37.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-7/mpohbp.2021.18.issue-7/20210705/mpohbp.2021.18.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.0c02085&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.0c02085&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.0c02085&amp;href=/doi/10.1021/acs.jmedchem.0c02085" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2021</span><span class="cit-fg-volume">, 64</span><span class="cit-fg-issue">, 7</span><span class="cit-fg-pageRange">, 3940-3955</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/64/7" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.0c02083" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.0c02093" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Targeting KRAS Mutant Cancers via Combination Treatment: Discovery of a 5-Fluoro-4-(3<i>H</i>)-quinazolinone Aryl Urea pan-RAF Kinase Inhibitor</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Malcolm P. Huestis</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Malcolm P. Huestis</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Discovery Chemistry, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Malcolm+P.++Huestis">Malcolm P. Huestis</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-6038-3838" title="Orcid link">http://orcid.org/0000-0002-6038-3838</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Darlene Dela Cruz</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Darlene Dela Cruz</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Translational Oncology, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Darlene++Dela+Cruz">Darlene Dela Cruz</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Antonio G. DiPasquale</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Antonio G. DiPasquale</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Small Molecule Pharmaceutical Sciences, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Antonio+G.++DiPasquale">Antonio G. DiPasquale</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Matthew R. Durk</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Matthew R. Durk</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Drug Metabolism and Pharmacokinetics, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Matthew+R.++Durk">Matthew R. Durk</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Charles Eigenbrot</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Charles Eigenbrot</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Structural Biology, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Charles++Eigenbrot">Charles Eigenbrot</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Paul Gibbons</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Paul Gibbons</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Discovery Chemistry, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Paul++Gibbons">Paul Gibbons</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Alberto Gobbi</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Alberto Gobbi</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Discovery Chemistry, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Alberto++Gobbi">Alberto Gobbi</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Thomas L. Hunsaker</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Thomas L. Hunsaker</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Translational Oncology, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Thomas+L.++Hunsaker">Thomas L. Hunsaker</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Hank La</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Hank La</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Drug Metabolism and Pharmacokinetics, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Hank++La">Hank La</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Dennis H. Leung</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Dennis H. Leung</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Small Molecule Pharmaceutical Sciences, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Dennis+H.++Leung">Dennis H. Leung</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Wendy Liu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Wendy Liu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Discovery Chemistry, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Wendy++Liu">Wendy Liu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Shiva Malek</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Shiva Malek</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Molecular Oncology, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Shiva++Malek">Shiva Malek</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Mark Merchant</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Mark Merchant</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Translational Oncology, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Mark++Merchant">Mark Merchant</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">John G. Moffat</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">John G. Moffat</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Biochemical and Cellular Pharmacology, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=John+G.++Moffat">John G. Moffat</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Christine S. Muli</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Christine S. Muli</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Small Molecule Pharmaceutical Sciences, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Christine+S.++Muli">Christine S. Muli</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Christine J. Orr</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Christine J. Orr</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Translational Oncology, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Christine+J.++Orr">Christine J. Orr</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Brendan T. Parr</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Brendan T. Parr</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Discovery Chemistry, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Brendan+T.++Parr">Brendan T. Parr</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Frances Shanahan</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Frances Shanahan</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Molecular Oncology, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Frances++Shanahan">Frances Shanahan</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Christopher J. Sneeringer</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Christopher J. Sneeringer</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Biochemical and Cellular Pharmacology, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Christopher+J.++Sneeringer">Christopher J. Sneeringer</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Weiru Wang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Weiru Wang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Structural Biology, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Weiru++Wang">Weiru Wang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Ivana Yen</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ivana Yen</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Molecular Oncology, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ivana++Yen">Ivana Yen</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jianping Yin</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jianping Yin</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Structural Biology, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jianping++Yin">Jianping Yin</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Michael Siu</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Michael Siu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Discovery Chemistry, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#681b011d4605010b00090d04280f0d060d460b0705"><span class="__cf_email__" data-cfemail="6c1f05194201050f040d09002c0b090209420f0301">[email protected]</span></a>. Phone: +1-650-467-7764.</span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Michael++Siu">Michael Siu</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-2822-6584" title="Orcid link">http://orcid.org/0000-0002-2822-6584</a></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Joachim Rudolph</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Joachim Rudolph</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Discovery Chemistry, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#77050213181b071f591d1816141f1e1a37101219125914181a"><span class="__cf_email__" data-cfemail="bac8cfded5d6cad294d0d5dbd9d2d3d7fadddfd4df94d9d5d7">[email protected]</span></a>. Phone: +1-650-467-8867.</span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Joachim++Rudolph">Joachim Rudolph</a></span></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c02085&amp;href=/doi/10.1021%2Facs.jmedchem.0c02085" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2021</span></span><span class="cit-volume">, 64</span><span class="cit-issue">, 7</span><span class="cit-pageRange">, 3940–3955</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">March 29, 2021</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>1 December 2020</li><li><span class="item_label"><b>Published</b> online</span>29 March 2021</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 8 April 2021</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.0c02085" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c02085</a></div><div class="article_header-article-copyright"><strong>Copyright © 2021 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D3940%26pageCount%3D16%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DMalcolm%2BP.%2BHuestis%252C%2BDarlene%2BDela%2BCruz%252C%2BAntonio%2BG.%2BDiPasquale%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D64%26issueNum%3D7%26contentID%3Dacs.jmedchem.0c02085%26title%3DTargeting%2BKRAS%2BMutant%2BCancers%2Bvia%2BCombination%2BTreatment%253A%2BDiscovery%2Bof%2Ba%2B5-Fluoro-4-%25283H%2529-quinazolinone%2BAryl%2BUrea%2Bpan-RAF%2BKinase%2BInhibitor%26numPages%3D16%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D3955%26publicationDate%3DApril%2B2021">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.0c02085"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1542</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">1</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.0c02085" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Targeting KRAS Mutant Cancers via Combination Treatment: Discovery of a 5-Fluoro-4-(3H)-quinazolinone Aryl Urea pan-RAF Kinase Inhibitor&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Malcolm&quot;,&quot;last_name&quot;:&quot;P. Huestis&quot;},{&quot;first_name&quot;:&quot;Darlene&quot;,&quot;last_name&quot;:&quot;Dela Cruz&quot;},{&quot;first_name&quot;:&quot;Antonio&quot;,&quot;last_name&quot;:&quot;G. DiPasquale&quot;},{&quot;first_name&quot;:&quot;Matthew&quot;,&quot;last_name&quot;:&quot;R. Durk&quot;},{&quot;first_name&quot;:&quot;Charles&quot;,&quot;last_name&quot;:&quot;Eigenbrot&quot;},{&quot;first_name&quot;:&quot;Paul&quot;,&quot;last_name&quot;:&quot;Gibbons&quot;},{&quot;first_name&quot;:&quot;Alberto&quot;,&quot;last_name&quot;:&quot;Gobbi&quot;},{&quot;first_name&quot;:&quot;Thomas&quot;,&quot;last_name&quot;:&quot;L. Hunsaker&quot;},{&quot;first_name&quot;:&quot;Hank&quot;,&quot;last_name&quot;:&quot;La&quot;},{&quot;first_name&quot;:&quot;Dennis&quot;,&quot;last_name&quot;:&quot;H. Leung&quot;},{&quot;first_name&quot;:&quot;Wendy&quot;,&quot;last_name&quot;:&quot;Liu&quot;},{&quot;first_name&quot;:&quot;Shiva&quot;,&quot;last_name&quot;:&quot;Malek&quot;},{&quot;first_name&quot;:&quot;Mark&quot;,&quot;last_name&quot;:&quot;Merchant&quot;},{&quot;first_name&quot;:&quot;John&quot;,&quot;last_name&quot;:&quot;G. Moffat&quot;},{&quot;first_name&quot;:&quot;Christine&quot;,&quot;last_name&quot;:&quot;S. Muli&quot;},{&quot;first_name&quot;:&quot;Christine&quot;,&quot;last_name&quot;:&quot;J. Orr&quot;},{&quot;first_name&quot;:&quot;Brendan&quot;,&quot;last_name&quot;:&quot;T. Parr&quot;},{&quot;first_name&quot;:&quot;Frances&quot;,&quot;last_name&quot;:&quot;Shanahan&quot;},{&quot;first_name&quot;:&quot;Christopher&quot;,&quot;last_name&quot;:&quot;J. Sneeringer&quot;},{&quot;first_name&quot;:&quot;Weiru&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Ivana&quot;,&quot;last_name&quot;:&quot;Yen&quot;},{&quot;first_name&quot;:&quot;Jianping&quot;,&quot;last_name&quot;:&quot;Yin&quot;},{&quot;first_name&quot;:&quot;Michael&quot;,&quot;last_name&quot;:&quot;Siu&quot;},{&quot;first_name&quot;:&quot;Joachim&quot;,&quot;last_name&quot;:&quot;Rudolph&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2021&quot;,&quot;month&quot;:&quot;03&quot;,&quot;day&quot;:&quot;29&quot;,&quot;issue&quot;:&quot;7&quot;,&quot;volume&quot;:&quot;64&quot;,&quot;pages&quot;:&quot;3940-3955&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.0c02085&quot;},&quot;abstract&quot;:&quot;Optimization of a series of aryl urea RAF inhibitors led to the identification of type II pan-RAF inhibitor GNE-0749 (7), which features a fluoroquinazolinone hinge-binding motif. By minimizing reliance on common polar hinge contacts, this hinge binder allows for a greater contribution of RAF-specific residue interactions, resulting in exquisite kinase selectivity. Strategic substitution of fluorine at the C5 position efficiently masked the adjacent polar NH functionality and increased solubility by impeding a solid-state conformation associated with stronger crystal packing of the molecule. The resulting improvements in permeability and solubility enabled oral dosing of 7. In vivo evaluation of 7 in combination with the MEK inhibitor cobimetinib demonstrated synergistic pathway inhibition and significant tumor growth inhibition in a KRAS mutant xenograft mouse model.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c02085&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c02085" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c02085&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c02085" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c02085&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c02085" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c02085&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c02085&amp;href=/doi/10.1021/acs.jmedchem.0c02085" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.0c02085" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.0c02085" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (5 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c02085&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.0c02085%26sid%3Dliteratum%253Aachs%26pmid%3D33780623%26genre%3Darticle%26aulast%3DHuestis%26date%3D2021%26atitle%3DTargeting%2BKRAS%2BMutant%2BCancers%2Bvia%2BCombination%2BTreatment%253A%2BDiscovery%2Bof%2Ba%2B5-Fluoro-4-%25283H%2529-quinazolinone%2BAryl%2BUrea%2Bpan-RAF%2BKinase%2BInhibitor%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D64%26issue%3D7%26spage%3D3940%26epage%3D3955%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (4)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=291316" title="Mixtures">Mixtures</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=291026" title="Conformation">Conformation</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/64/7" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/jmcmar.2021.64.issue-7/20210408/jmcmar.2021.64.issue-7.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02085/20210331/images/medium/jm0c02085_0013.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02085/20210331/images/large/jm0c02085_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02085&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Optimization of a series of aryl urea RAF inhibitors led to the identification of type II pan-RAF inhibitor GNE-0749 (<b>7</b>), which features a fluoroquinazolinone hinge-binding motif. By minimizing reliance on common polar hinge contacts, this hinge binder allows for a greater contribution of RAF-specific residue interactions, resulting in exquisite kinase selectivity. Strategic substitution of fluorine at the C5 position efficiently masked the adjacent polar NH functionality and increased solubility by impeding a solid-state conformation associated with stronger crystal packing of the molecule. The resulting improvements in permeability and solubility enabled oral dosing of <b>7</b>. In vivo evaluation of <b>7</b> in combination with the MEK inhibitor cobimetinib demonstrated synergistic pathway inhibition and significant tumor growth inhibition in a KRAS mutant xenograft mouse model.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_37637" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_37637" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The RAS–ERK pathway is a central mitogen-activated protein kinase (MAPK) signal transduction cascade, and hyperactivation frequently promotes cancer. Given its importance, this pathway has been the subject of intense drug discovery efforts, and a number of oral small-molecule drugs that target RAF, MEK, and ERK have been approved over the past 10 years.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> The first launched BRAF inhibitors, vemurafenib<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> and dabrafenib,<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> approved in 2011 and 2013, respectively, were designed to target BRAF<sup>V600E</sup> mutant melanoma as single agents (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>). Despite initial promise, patients were found to rapidly develop resistance, prompting the clinical exploration of combined RAF and MEK inhibitor treatment, with the goal of achieving more sustained inhibition of the MAPK pathway. This led to the approval of the combination treatment regimens of dabrafenib/trametinib in 2014,<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> vemurafenib/cobimetinib in 2015,<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> and encorafenib/binimetinib in 2018.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02085/20210331/images/medium/jm0c02085_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02085/20210331/images/large/jm0c02085_0002.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Marketed BRAF<sup>V600E</sup> inhibitors and MEK inhibitor combination partners.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02085/20210331/images/large/jm0c02085_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02085&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Despite the benefits of type I BRAF inhibitors in targeting BRAF<sup>V600E</sup> mutant melanoma, inhibition of RAF kinases has not been successful in the context of KRAS mutant cancers. RAS mutations are the most frequently observed oncogenic mutations, found in almost 20% of all cancers, and effective treatment of such cancers remains an area of significant medical need. Not only are KRAS mutant tumors refractory to BRAF<sup>V600E</sup> inhibitor treatment, but, even worse, the MAPK pathway was found to be “paradoxically” activated in such contexts.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> It is now understood that the inhibitor binding mode is a crucial factor in determining the occurrence of paradoxical activation. Vemurafenib and dabrafenib are examples of type 1.5 binders, compounds that induce an outward shift of the αC helix within the kinase domain of BRAF.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> These compounds are believed to bind to BRAF monomers and robustly inhibit BRAF<sup>V600E</sup>, which can signal in the monomeric state.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> However, in the context of KRAS mutant tumors, type 1.5 binders promote formation of nonsymmetrical RAF homo- and heterodimers, fueling the pathway in such tumors and thus causing undesirable activation.<a onclick="showRef(event, 'cit1d ref10'); return false;" href="javascript:void(0);" class="ref cit1d ref10">(1d,10)</a></div><div class="NLM_p">Conversely, type II RAF inhibitors, compounds that promote an outward shift of the DFG activation loop but leave the αC helix in the “in position”, were found to have no predisposition for causing paradoxical activation in KRAS mutant/BRAF wild-type cells.<a onclick="showRef(event, 'ref10 ref11 ref12'); return false;" href="javascript:void(0);" class="ref ref10 ref11 ref12">(10−12)</a> Examples of such compounds are AZ628, a tool compound first reported in 2007,<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> and, later, LY3009120 (<b>1</b>).<a onclick="showRef(event, 'ref11 ref14'); return false;" href="javascript:void(0);" class="ref ref11 ref14">(11,14)</a> Although these compounds promote rapid formation of RAF homo- or heterodimers, the induced symmetrical dimer allows for full inhibitor occupancy of both protomers, leading to robust inhibition of signaling. Such compounds have the ability to inhibit not only BRAF<sup>V600E</sup> but also wild-type BRAF and CRAF and hence are collectively referred to as RAF dimer inhibitors or pan-RAF inhibitors. With no predisposition to induce RAF activation and a clear rationale for targeting CRAF as a downstream effector of KRAS emerging at the time,<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> type II pan-RAF inhibitors were uniquely positioned to target KRAS mutant cancers in combination with other MAPK pathway inhibitors.</div><div class="NLM_p">The chemical structures of recently reported pan-RAF inhibitors are shown in <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>. At the time of the study reported here, the structures of naporafenib<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> (LXH254) and belvarafenib<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> (GDC-5573) were not disclosed. Our interest initially began with AZ628 but peaked with the report from Eli Lilly and Deciphera describing LY3009120 (<b>1</b>), a pyrido[2,3-<i>d</i>]pyrimidine aryl alkyl urea with potent in vivo activity in multiple mouse xenograft tumor models. Following a favorable pharmacological assessment of compound <b>1</b>, the investigators developed a formulation strategy to enable advancement into phase 1 clinical trials.<a onclick="showRef(event, 'ref11 ref14 ref18'); return false;" href="javascript:void(0);" class="ref ref11 ref14 ref18">(11,14,18)</a></div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02085/20210331/images/medium/jm0c02085_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02085/20210331/images/large/jm0c02085_0003.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Recently disclosed pan-RAF inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02085/20210331/images/large/jm0c02085_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02085&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_11400" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_11400" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Motivated by the strong biological rationale for the combination of pan-RAF and MEK inhibitors to target KRAS mutant cancers,<a onclick="showRef(event, 'cit7c ref19'); return false;" href="javascript:void(0);" class="ref cit7c ref19">(7c,19)</a> we confirmed in our laboratories that literature pan-RAF inhibitors in combination with the MEK inhibitor cobimetinib provided synergistic antiproliferative effects in KRAS mutant A549 cells.<a onclick="showRef(event, 'cit19b'); return false;" href="javascript:void(0);" class="ref cit19b">(19b)</a> From there, we initiated a medicinal chemistry campaign with the goal of identifying a selective pan-RAF inhibitor with a pharmacokinetic profile suitable for preclinical oral dosing.</div><div class="NLM_p">Armed with the experience gained during our legacy BRAF<sup>V600E</sup> program, we began with a strategy that sought to use the dimethylbutyl phenyl urea of pan-RAF inhibitor LY3009120 (<b>1</b>) in combination with a variety of different hinge binder motifs (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>) that we predicted to be compatible based on docking studies. Investigation of various hinge binders allowed for quick examination of kinase selectivity SAR along this region of the active site. Pharmacological evaluation included BRAF and CRAF biochemical assays. To identify compounds with greater-than-additive effects when combined with a MEK inhibitor, antiproliferative activity was compared in BRAF mutant A375 and KRAS mutant A549 cells along with A549 in the presence of a sub-efficacious concentration (100 nM) of cobimetinib (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>).<a onclick="showRef(event, 'cit19b'); return false;" href="javascript:void(0);" class="ref cit19b">(19b)</a> Compounds with a significant A549 potency shift in the presence versus absence of cobimetinib cotreatment were selected for a quantitative determination of synergistic inhibition of A549 DNA synthesis using a full dose matrix assay format (<i>vide infra</i>). Starting with the 3-methoxy-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridine benzamide hinge binder moiety described in an earlier BRAF series (compound <b>2</b>),<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> we saw similar potency but a loss in selectivity compared to compound <b>1</b>. Inhibitors <b>3</b> and <b>4</b>, which were based on a 4-aminopyrimidine hinge binder,<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> demonstrated biochemical potency improvements. The cellular assays were found to be critical for the triage of compounds since many compounds synthesized at this stage of the program reached the lower limit of detection in the biochemical assay. For reasons that are not immediately apparent, compounds <b>3</b> and <b>4</b> showed greater selectivity in a focused kinase panel<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> (8/26 kinases >70% inhibition for <b>4</b>) in stark contrast to 4-aminoquinazoline <b>5</b>, which was fairly promiscuous (24/26 kinases >70% inhibition at 0.1 μM).</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Hinge Binder Optimization of RAF Inhibitors</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02085/20210331/images/medium/jm0c02085_0012.gif" alt="" id="gr11" /></img><div></div></div><div class="NLM_p">A conceivable strategy to increase kinase inhibitor selectivity is to reduce reliance on common kinase hinge contacts. Previously, it has been noted that compounds with a single hinge H-bond contact tend to have higher selectivity, and those with three hydrogen bonds have some of the lowest Gini coefficients.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> In this vein, we explored hinge binders with lesser donor–acceptor–donor contacts and emphasized RAF-specific residue interactions, particularly Trp424 (unique to ARAF, BRAF, and CRAF) and Phe595 (DFG) interactions. This led us to synthesize 6-amino-4-(3<i>H</i>)-quinazolinone aryl urea <b>6</b>. We were pleased to see synergistic activity with cobimetinib (A549 IC<sub>50</sub> = 253 nM in combination with cobimetinib) and improved kinase selectivity (5/26 kinases >70% inhibition at 0.1 μM).<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a></div><div class="NLM_p">While excellent potency and kinase selectivity were achieved, oral exposure proved to be challenging for this series of urea analogues, presumably due to poor solubility (compounds <b>2</b>–<b>6</b> kinetic solubility <1 μM). A conventional crystalline suspension of <b>6</b> in aqueous MCT (0.5% methylcellulose with 0.2% Tween 80) resulted in no measurable oral absorption in mouse (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). The poor solubility of <b>6</b> likely results from a combination of high lipophilicity (log <i>D</i> = 4.47) and strong crystal lattice energy as evidenced by a high melting point (293 °C). A small-molecule X-ray crystal structure of <b>6</b> did indeed show well-ordered crystal lattice interactions with a robust intermolecular hydrogen-bond network (<a href="/doi/suppl/10.1021/acs.jmedchem.0c02085/suppl_file/jm0c02085_si_004.pdf" class="ext-link">Figure S1</a>). Interestingly, we found the conformation adopted in the small-molecule structure (torsional angle between the two ring systems) to be significantly different from the expected conformation in the kinase-bound state (<i>vide infra</i>). Not even the use of enabling formulations such as PEG 400, nanosuspension, or amorphous spray-dried dispersion (ASD) formulations was able to provide remedy. We reasoned that the high lipophilicity and crystal lattice energy presented a barrier too difficult to overcome and that the relatively low permeability of the compound (<i>P</i><sub>app</sub> = 3.6 × 10<sup>–6</sup> cm s<sup>–1</sup> in MDCK cells) was likely a compounding factor.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Physicochemical Properties and PK Data of Compounds <b>6</b> and <b>7</b></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="char" char="." /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center" char=".">compound</th><th class="colsep0 rowsep0" align="center">mouse IV CL<sub>b</sub><a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">mouse IV <i>V</i><sub>dss</sub><a class="ref internalNav" href="#t2fn1" aria-label="a">a</a>, <i>t</i><sub>1/2</sub></th><th class="colsep0 rowsep0" align="center">mouse <i>F</i> (PO)</th><th class="colsep0 rowsep0" align="center">kinetic sol, mp<a class="ref internalNav" href="#t2fn6" aria-label="f">f</a></th><th class="colsep0 rowsep0" align="center">log <i>D</i><sub>7.4</sub>, TPSA, MDCK <i>P</i><sub>app</sub>(AB)<a class="ref internalNav" href="#t2fn7" aria-label="g">g</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>6</b></td><td class="colsep0 rowsep0" align="left">50 mL min<sup>–1</sup> kg<sup>–1</sup></td><td class="colsep0 rowsep0" align="left">0.94 L kg<sup>–1</sup>, 0.5 h</td><td class="colsep0 rowsep0" align="left">0% (MCT)<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a>, 2% (ASD)<a class="ref internalNav" href="#t2fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left"><1 μM, 293 °C</td><td class="colsep0 rowsep0" align="left">4.47, 88 Å<sup>2</sup>, 3.6 × 10<sup>–6</sup> cm s<sup>–1</sup></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>7</b></td><td class="colsep0 rowsep0" align="left">27 mL min<sup>–1</sup> kg<sup>–1</sup></td><td class="colsep0 rowsep0" align="left">1.4 L kg<sup>–1</sup>, 0.8 h</td><td class="colsep0 rowsep0" align="left">26% (PEG 400)<a class="ref internalNav" href="#t2fn4" aria-label="d">d</a>, 60% (ASD)<a class="ref internalNav" href="#t2fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left">3 μM, 215 °C</td><td class="colsep0 rowsep0" align="left">4.47, 88 Å<sup>2</sup>, 13 × 10<sup>–6</sup> cm s<sup>–1</sup></td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">IV: 1 mg kg<sup>–1</sup> dose.</p></div><div class="footnote" id="t2fn2"><sup><sup>b</sup></sup><p class="last">5 mg kg<sup>–1</sup> dose.</p></div><div class="footnote" id="t2fn3"><sup><sup>c</sup></sup><p class="last">25 mg kg<sup>–1</sup> dose, hydroxypropyl methylcellulose acetate succinate.</p></div><div class="footnote" id="t2fn4"><sup><sup>d</sup></sup><p class="last">5 mg kg<sup>–1</sup> dose.</p></div><div class="footnote" id="t2fn5"><sup><sup>e</sup></sup><p class="last">30 mg kg<sup>–1</sup> dose.</p></div><div class="footnote" id="t2fn6"><sup><sup>f</sup></sup><p class="last">mp = melting point; kinetic solubility in pH 7.4 PBS buffer.</p></div><div class="footnote" id="t2fn7"><sup><sup>g</sup></sup><p class="last">MDCK apical → basolateral <i>P</i><sub>app</sub> (apparent permeability).</p></div></div></div><div class="NLM_p">Fortuitously, we found that the introduction of a fluorine substituent at the C5 position (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>, GNE-0749, <b>7</b>) provided improvements compared to compound <b>6</b> in cellular potency (1.5×) and kinase selectivity (1/222 kinase >70% inhibition at 0.1 μM, <a href="/doi/suppl/10.1021/acs.jmedchem.0c02085/suppl_file/jm0c02085_si_004.pdf" class="ext-link">Table S3</a> and <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>). An X-ray crystal structure of <b>7</b> bound in a mutant BRAF construct (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>) revealed the quinazolinone ring system interacting with Cys532 backbone NH (3.1 Å) at the hinge of the protein in addition to a polarized CH interaction with Cys532 C═O (3.1 Å).<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> With less discrete polarized hinge contacts, the exquisite selectivity for RAF kinases may be due to van der Waals π-stacking interactions of the heteroaryl hinge binder with Trp531 in ARAF, BRAF, and CRAF.</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02085/20210331/images/medium/jm0c02085_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02085/20210331/images/large/jm0c02085_0004.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Kinome tree for <b>7</b>, tested against 222 kinases at a concentration of 0.1 μM. Red circles represent BRAF and CRAF.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02085/20210331/images/large/jm0c02085_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02085&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02085/20210331/images/medium/jm0c02085_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02085/20210331/images/large/jm0c02085_0005.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. X-ray crystal structure of <b>7</b> bound in a mutant BRAF construct (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7K0V">7K0V</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02085/20210331/images/large/jm0c02085_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02085&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The potency and selectivity gain associated with this single fluorine substitution were already desirable traits, but the most impactful benefits imparted by this modification were property improvements. Specifically, compound <b>7</b> demonstrated significantly increased permeability and a substantial decrease in the melting temperature, associated with a gain in solubility (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). We reasoned that the presence of fluorine masks the adjacent polar NH functionality to improve permeability, but the observed melting point decrease could not be easily rationalized. We proceeded with determining the small-molecule X-ray crystal structure of this compound (<a href="/doi/suppl/10.1021/acs.jmedchem.0c02085/suppl_file/jm0c02085_si_004.pdf" class="ext-link">Figure S2</a>) and juxtaposed it with the small-molecule X-ray structure of compound <b>6</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.0c02085/suppl_file/jm0c02085_si_004.pdf" class="ext-link">Figure S1</a>). This comparison revealed important differences. The fluorine analogue <b>7</b> adopts a rotational angle between the two rings that is similar to the angle observed in its ligand protein cocrystal structure (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>). Compound <b>6</b>, on the other hand, adopts a conformation in the small-molecule X-ray structure that does not match the required conformation in the kinase-bound state, namely, the quinazoline ring is rotated by ∼170° (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>).</div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02085/20210331/images/medium/jm0c02085_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02085/20210331/images/large/jm0c02085_0006.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Conformations of <b>6</b> (yellow) and <b>7</b> (orange) determined by small-molecule X-ray crystallography and overlay with protein ligand conformation of <b>7</b> (gray). The largest difference between the conformations of <b>6</b> and <b>7</b> is an ∼170° rotation around <i>T</i><sub>1</sub> (indicated). In the overlay, the urea side chain is hidden for clarity.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02085/20210331/images/large/jm0c02085_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02085&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">To explain these observations, we generated a conformational energy profile for the rotation around the quinazolinone N bond (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>), using simplified analogues of <b>6</b> and <b>7</b>, <b>6′</b> and <b>7′</b>, respectively. Compound <b>6</b> in the small-molecule X-ray structure adopts a <i>T</i><sub>1</sub> of ∼0°, one of the two low energy regions for <b>6′</b>. While both <i>T</i><sub>1</sub> ∼0 and ∼180° are ground-state energy minima, we hypothesize that <i>T</i><sub>1</sub> at ∼0° is associated with crystal packing benefits, as discussed later. For the fluorine counterpart <b>7′</b>, <i>T</i><sub>1</sub> at 0°, despite being located at a local minimum, is 4 kcal mol<sup>–1</sup> above the ground state, sufficient to disfavor this torsion angle. <b>7′</b> only has one ground-state conformation at ∼180°, and adoption of this angle is indeed what is experimentally observed in the small-molecule X-ray structure. A <i>T</i><sub>1</sub> of 180° is also the required conformation in the kinase-bound state, and although other effects might be responsible for the 2-fold higher potency of <b>7</b> compared to <b>6</b>, this reduced conformational flexibility of <b>7</b> and bias toward the conformation required for kinase binding might be a contributing factor to this potency gain.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a></div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02085/20210331/images/medium/jm0c02085_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02085/20210331/images/large/jm0c02085_0007.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Quantum mechanical (B3LYP-D3/6-311+g**) torsion scan for model compounds representing <b>6</b> and <b>7</b>. Torsion <i>T</i><sub>1</sub> was scanned from −180 to 180° in steps of 30°. <i>T</i><sub>2</sub> was kept constant at −120°, the angle found in the protein ligand crystal structure. The gray line indicates the torsion angle of <i>T</i><sub>1</sub> found in the protein ligand crystal structure, and the blue and orange lines denote the torsion angles of <i>T</i><sub>1</sub> in the small-molecule X-ray structures of <b>6</b> and <b>7</b>, respectively. <i>T</i><sub>2</sub> in the small-molecule crystal structures is approximately −60°; however, the change accounts for just 0.3 kcal mol<sup>–1</sup> energy difference.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02085/20210331/images/large/jm0c02085_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02085&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The observation that <i>T</i><sub>1</sub> in compound <b>6</b> adopts a torsion angle of ∼0 instead 180°, despite energetic equivalency, can likely be explained by crystal packing benefits. Indeed, we conclude from a comparison to the small-molecule X-ray structure of compound <b>7</b>, which is confined to a <i>T</i><sub>1</sub> of ∼180°, that the network of molecular interactions in their respective small-molecule X-ray structures is stronger for compound <b>6</b> than for <b>7</b>, consistent with its higher melting point and lower solubility. A detailed qualitative comparison is provided in the <a href="/doi/suppl/10.1021/acs.jmedchem.0c02085/suppl_file/jm0c02085_si_004.pdf" class="ext-link">Supporting Information</a>. Taken together, the absence of a fluorine atom at C5 in compound <b>6</b> offers two conformational energy minima, and the molecule selects in the solid state for the conformation that is associated with a stronger crystal lattice. The fluorine atom in C5 of compound <b>7</b>, on the other hand, does not allow for adopting an equivalent solid-state conformation to compound <b>6</b> and leaves, as the only option, adoption of a conformation that affords a weaker crystal lattice and resembles the conformation required for kinase binding. Gratifyingly, the improvements in permeability and solubility afforded measurable oral exposure of <b>7</b> in mice when using enabling formulations (<i>F</i> = 26% using PEG 400 and <i>F</i> = 60% using ASD), marking a significant improvement over compound <b>6</b>.</div><div class="NLM_p">We have shown in a previous study that the combination of type II RAF inhibitors and MEK inhibitors is efficacious in targeting KRAS mutant tumors.<a onclick="showRef(event, 'cit19b'); return false;" href="javascript:void(0);" class="ref cit19b">(19b)</a> This synergy results from the increased dependence of KRAS mutant tumors on RAF signaling in the presence of a MEK inhibitor. RAF dimer (type II) inhibitors are able to robustly inhibit MAPK signaling,<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> effectively abrogating negative feedback caused by MEK inhibition in KRAS mutant cells. This approach results in a chemical synthetic lethal effect where at drug concentrations in which neither inhibitor has single-agent activity, the combination prevents tumor growth.</div><div class="NLM_p">To confirm that the observed enhancement of the antiproliferative effect of compound <b>7</b> in combination with cobimetinib met quantitative criteria for synergy, A549 (KRAS<sup>G12S</sup> mutant) cells were treated with a combinatorial matrix of doses of the two compounds (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>). A robust leftward shift in dose–response for each compound in the presence of increasing dose of the second compound was observed. When analyzed using the isobologram approach (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>B) and by calculating the excess activity over that predicted using the Loewe additivity model (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>C), a strong and reproducible deviation from the additive model was observed.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> A similar degree of synergy was observed with a second KRAS mutant cell line, HCT116 (<a href="/doi/suppl/10.1021/acs.jmedchem.0c02085/suppl_file/jm0c02085_si_004.pdf" class="ext-link">Figure S3</a>), whereas no greater-than-additive effect was observed for a BRAF mutant cell line (A375). In contrast, the combination of vemurafenib (type 1.5 RAF inhibitor) and cobimetinib did not demonstrate any synergistic effect (<a href="/doi/suppl/10.1021/acs.jmedchem.0c02085/suppl_file/jm0c02085_si_004.pdf" class="ext-link">Figure S4</a>).</div><figure id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02085/20210331/images/medium/jm0c02085_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02085/20210331/images/large/jm0c02085_0008.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Synergistic activity of <b>7</b> combined with cobimetinib. (A) Proliferation of A549 cells, determined by incorporation of 5-ethynyl-2′-deoxyuridine (EdU) into newly synthesized DNA, is inhibited in a dose-dependent manner by each agent separately (green curves), and potency is strongly enhanced by increasing concentrations of the second compound. (B) Isobologram plot of fractional EdU uptake inhibition at different dose combinations shows that the doses required to attain 50% inhibition (blue line) are significantly lower than predicted by a simple additivity model (red line). (C) Difference between the observed percent effect and expected fractional effect according to the Loewe additivity model plotted for each dose combination.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02085/20210331/images/large/jm0c02085_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02085&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">These encouraging cellular data motivated us to investigate the combinatorial effects of both compounds in vivo using the KRAS<sup>G12D</sup> mutant HCT116 xenograft tumor model (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>A). In this study, GNE-0749 (10 mg kg<sup>–1</sup>, PO, BID) or cobimetinib (5 mg kg<sup>–1</sup>, PO, QD) showed, as expected, minimal single-agent activity, whereas the combination resulted in significant antitumor efficacy (111% TGI). While there was apparent tolerated body weight loss with single-agent <b>7</b> (averaging ∼10% body weight loss), combination with cobimetinib did not appear to exacerbate this effect, and all animals tolerated treatment to the end of the study (21 days).</div><figure id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02085/20210331/images/medium/jm0c02085_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02085/20210331/images/large/jm0c02085_0009.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. (A) In vivo tumor growth inhibition study over 21 days using HCT116 tumor-bearing mice treated with cobimetinib (5 mg kg<sup>–1</sup> PO, QD), GNE-0749 (<b>7</b>) (10 mg kg<sup>–1</sup> PO, BID), or a combination. (B) In vivo PK/PD study over 4 days using HCT116 tumor-bearing mice treated with cobimetinib (5 mg kg<sup>–1</sup> PO, QD), GNE-0749 (<b>7</b>) (10 mg kg<sup>–1</sup> PO, BID), or a combination.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02085/20210331/images/large/jm0c02085_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02085&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Dedicated pharmacokinetic/pharmacodynamic (PK/PD) studies also demonstrated improved pathway engagement with the combination of <b>7</b> and cobimetinib at 2 and 8 h following 4 days of treatment. Whereas single-agent cobimetinib showed minimal activity with modest inhibition of pERK at 2 and 8 h, single-agent <b>7</b> resulted in increased stabilization of CRAF phosphorylation with a corresponding transient decrease in downstream signaling at the level of pMEK, pERK, and pRSK (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>B). In contrast, the combination of <b>7</b> and cobimetinib resulted in increased levels of pCRAF, relative to <b>7</b> alone, and improved and sustained reduction of pERK and pRSK through 8 h post-dose (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>B).</div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i6">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_21000" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_21000" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">In summary, we have reported here the discovery of pan-RAF inhibitors that abrogate paradoxical activation based on a type II kinase binding mode. Limiting hinge binder interactions led to improved kinome selectivity (compound <b>6</b>), and the subsequent introduction of a fluorine atom afforded GNE-0749 (<b>7</b>) as a potent and selective pan-RAF inhibitor with properties that allowed for oral dosing. Cellular studies in two KRAS mutant models revealed strong synergistic activity of this compound in combination with the MEK inhibitor cobimetinib. This in vitro synergy was recapitulated in vivo, and oral treatment of a combination of <b>7</b> with cobimetinib in the KRAS mutant HCT116 tumor-bearing mice demonstrated synergistic pharmacodynamic effects and substantial tumor growth inhibition. The data provide preclinical proof-of-concept for the combination of type II RAF inhibitors with MEK inhibitors as an approach for targeting KRAS mutant cancers.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i7">Chemistry<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_10300" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_10300" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The synthesis of LY3009120 (<b>1</b>) was accomplished as previously described.<a onclick="showRef(event, 'cit14a'); return false;" href="javascript:void(0);" class="ref cit14a">(14a)</a> The preparation of common intermediates used in the synthesis of compounds <b>2</b>–<b>7</b> are outlined in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>. Thus, hydrogenative reduction of methyl 4-fluoro-2-methyl-5-nitrobenzoate afforded aniline <b>8a</b> (94% yield), which was elaborated to urea <b>8b</b> by way of a one-pot operation involving formation of phenyl carbamate and displacement with 3,3-dimethylbutylamine (20% over two steps). Saponification of <b>8b</b> produced benzoic acid <b>8c</b> in 97% yield.</div><figure id="sch1" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02085/20210331/images/medium/jm0c02085_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02085/20210331/images/large/jm0c02085_0010.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Common Intermediates for Hinge Binder Analysis<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02085/20210331/images/large/jm0c02085_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02085&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Conditions: (a) 10% Pd/C (50% w/w), H<sub>2</sub> (1 atm), EtOH, 23 °C, 94%; (b) PhOCOCl (1.1 equiv), NaHCO<sub>3</sub> (2 equiv), THF, 23–60 °C; then, NEt<sub>3</sub> (2 equiv), 3,3-dimethylbutylamine (1.1 equiv), toluene, 23–90 °C, 20% (two steps); (c) LiOH·H<sub>2</sub>O (1.1 equiv), THF/H<sub>2</sub>O (5:1), 80 °C, 97%; (d) PhOCOCl (1.1 equiv), NaHCO<sub>3</sub> (2 equiv), THF, 0–23 °C; then, NEt<sub>3</sub> (2 equiv), 3,3-dimethylbutylamine (1.2 equiv), toluene, 23 °C, 95% (two steps); (e) <i>tert</i>-butyl carbamate (2 × 1.2 equiv), Pd<sub>2</sub>(dba)<sub>3</sub> (2 × 0.025 equiv), Xantphos (2 × 0.06 equiv), Cs<sub>2</sub>CO<sub>3</sub> (3 equiv), THF, 90–110 °C, 32%; (f) <i>tert</i>-butyl carbamate (1.2 equiv), X-Phos Pd G2 (0.05 equiv), X-Phos (0.10 equiv), Cs<sub>2</sub>CO<sub>3</sub> (1.4 equiv), 1,4-dioxane, 110 °C; then, HCl in isopropanol, 23 °C, 45% (two steps).</p></p></figure><div class="NLM_p">Similarly, interception of the phenyl carbamate derived from 5-bromo-2-fluoro-4-methylaniline and phenyl chloroformate with 3,3-dimethylbutylamine resulted in <b>9a</b> as a key intermediate (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>). Under standard palladium-catalyzed conditions, the aryl bromide urea <b>9a</b> could then be converted to aniline derivatives <b>9b</b> and <b>9c</b>.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a></div><div class="NLM_p">The syntheses of RAF inhibitors <b>2</b>–<b>7</b> are shown in <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>. Intermediate acid <b>8c</b> was converted to an acid chloride followed by treatment with 3-methoxy-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridin-5-amine to afford trione <b>8d</b> (44% over two steps). The trione motif could then be unwound to compound <b>2</b> using the conditions of Ryabukhin (72% yield).<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> The Suzuki–Miyaura cross-coupling of 3-(Bpin)pyridin-2-amine with 6-chloro-<i>N</i>-methylpyrimidin-4-amine afforded <b>10a</b> (80% yield).<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> Aminopyridine <b>10a</b> could then be fastened to intermediate <b>9a</b> through a Buchwald–Hartwig reaction under the conditions of Yin, affording <b>3</b> in 61% yield.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> For the synthesis of diurea <b>4</b>, <i>tert</i>-butyl <i>N</i>-<i>tert</i>-butoxycarbonyl-<i>N</i>-(6-chloropyrimidin-4-yl)carbamate was subjected to nucleophilic aromatic substitution with methylamine followed by formation of the phenyl carbamate <b>11b</b> (44% over two steps). Addition of aniline <b>9c</b> to <b>11b</b> afforded <b>4</b> in 14% yield. Acidic rupture of the <i>tert</i>-butoxycarbamate in <b>9b</b> afforded the free aryl amine, which was coupled to a protected aminoquinazoline using HATU (<b>12a</b>, 54% over two steps). Deprotection of the dimethoxybenzyl group using trifluoroacetic acid afforded <b>5</b> in 75% yield.</div><figure id="sch2" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02085/20210331/images/medium/jm0c02085_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02085/20210331/images/large/jm0c02085_0011.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Compounds in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02085/20210331/images/large/jm0c02085_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02085&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Conditions: (a) DMF (0.2 equiv), oxalyl chloride (3 equiv), THF, 23 °C; then, 3-methoxy-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridin-5-amine (1.2 equiv), NEt<sub>3</sub> (2 equiv), 55 °C, 48%; (b) Hunig’s base (2 equiv), 10% aq NaOH/DMF (2:1), 23 °C, 72%; (c) 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-amine (1 equiv), X-Phos Pd G2 (0.05 equiv), X-Phos (0.05 equiv), K<sub>3</sub>PO<sub>4</sub>·H<sub>2</sub>O (3 equiv), THF/H<sub>2</sub>O (10:1), 80 °C, 80%; (d) <b>9a</b> (1 equiv), <b>10a</b> (1.4 equiv), Pd<sub>2</sub>(dba)<sub>3</sub> (0.02 equiv), Xantphos (0.06 equiv), Cs<sub>2</sub>CO<sub>3</sub> (1.4 equiv), 1,4-dioxane, 80 °C, 61%; (e) methylamine hydrochloride (3.8 equiv), K<sub>2</sub>CO<sub>3</sub> (2 equiv), DMSO, 90 °C, 92%; (f) diphenyl carbonate (1.15 equiv), DMAP (1.2 equiv), DMF, 100 °C, 48%; (g) <b>9c</b> (1 equiv), DMAP (1.1 equiv), DMF, 90 °C, 14%; (h) TFA/CH<sub>2</sub>Cl<sub>2</sub> (1:1), 23 °C; then, 4-((2,4-dimethoxybenzyl)amino)quinazoline-8-carboxylic acid (1 equiv), HATU (2 equiv), NEt<sub>3</sub> (7 equiv), DMF, 23 °C, 54% (two steps); (i) TFA, 70 °C, 75%; (j) <i>tert</i>-butyl carbamate (1.5 equiv), Pd<sub>2</sub>(dba)<sub>3</sub> (0.025 equiv), Xantphos (0.05 equiv), Cs<sub>2</sub>CO<sub>3</sub> (2 equiv), THF, 80 °C, 95%; (k) TFA 23 °C; then, <b>9a</b> (1 equiv), BrettPhos Pd G1 (0.05 equiv), BrettPhos (0.05 equiv), NaO<i>t</i>Bu (4 equiv), 1,4-dioxane, 100 °C, 80% (two steps); (l) 4.0 M HCl in 1,4-dioxane/(EtO)<sub>3</sub>CH (1:6), 110 °C, 69%; (m) <i>tert</i>-butyl carbamate (1.2 equiv), Pd<sub>2</sub>(dba)<sub>3</sub> (0.02 equiv), Xantphos (0.06 equiv), Cs<sub>2</sub>CO<sub>3</sub> (1.2 equiv), toluene, 90 °C, 86%; (n) 4.0 M HCl in 1,4-dioxane (12 equiv), EtOAc, 23 °C, 88%; (o) <b>9a</b> (1 equiv), Pd(OAc)<sub>2</sub> (0.05 equiv), Xantphos (0.05 equiv), Cs<sub>2</sub>CO<sub>3</sub> (3 equiv), 3 Å molecular sieves, 1,4-dioxane, 100 °C, 34%.</p></p></figure><div class="NLM_p last">The preparation of <b>6</b> began from 6-bromo-3-methylquinazolin-4(3<i>H</i>)-one. Buchwald–Hartwig amination afforded <b>13a</b> (95%), which was deprotected and subjected to amination with aryl bromide <b>9a</b> using BrettPhos (<b>6</b>, 80% over two steps).<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> For the synthesis of GNE-0749 (<b>7</b>), amino benzamide <b>14b</b> (prepared in two steps from 2-amino-6-fluorobenzoic acid) was cyclized to a quinazolinone <b>14c</b> and then elaborated to aminoquinazolinone <b>14e</b> (52% over three steps). Gram-scale amination of <b>9a</b> with <b>14e</b> afforded <b>7</b> in 34% yield.</div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i10">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_26620" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_26620" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> General Methods</h3><div id="sec5_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i12" class="anchor-spacer"></div><h4 class="article-section__title" id="_i12"> Enzymatic Assays Measuring RAF Kinase Activity</h4><div class="NLM_p last">Compounds are evaluated for potency against BRAF (416-766aa, Sigma B4062) and CRAF (Y340D Y341D, Life Technologies PV3805), using a DELFIA assay by PerkinElmer. Phosphorylated MAP2K1 (inactive, Carna 07-141-10-3000) is directly measured by detection of Eu-anti-p-MEK1/2 (Ser 217/221) (PerkinElmer TRF0213). Assay buffer (1×) shared by both enzymes includes the following: 50 mM HEPES (pH 7.5), 10 mM MgCl<sub>2</sub>, 0.01% Brij 35, 2 mM TCEP, and 0.05% bovine gamma-globulins. Inactive MAP2K1 is 50 nM [final] in the assay. The assays are run at 10× ATP <i>K</i><sub>m</sub> for both enzymes, which translates to 500 μM [ATP] for CRAF and 50 μM [ATP] for BRAF. The enzyme concentration for both CRAF and BRAF is 1 nM [final]. Endpoint assays are run for 90 min at room temperature, with 30 min preincubations of the compound and enzyme. Assays are quenched and transferred to glutathione-coated plates for the capture of the GST-MAP2K1, and time-resolved fluorescence of europium-ab is measured following the DELFIA assay protocol. Potency is determined from the IC<sub>50</sub> value and converted to <i>K</i><sub>i</sub> via the Cheng–Prusoff equation.</div></div><div id="sec5_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i13" class="anchor-spacer"></div><h4 class="article-section__title" id="_i13"> Cell Lines</h4><div class="NLM_p last">All cell lines and compounds were obtained from the Genentech in-house repositories. Cell lines were maintained in RPMI-1640 media and supplemented with 10% heat-inactivated FBS (HyClone, SH3007003HI), 1× GlutaMAX (Gibco, 35050-061), and 1× Pen Strep (Gibco, 15140-122). The cells were maintained in a humidity-controlled environment (37 °C, 5% CO<sub>2</sub>; Forma Scientific II). All cell lines were utilized before passage 20 and treated in an exponential growth phase at 50–75% confluence.</div></div><div id="sec5_1_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i14" class="anchor-spacer"></div><h4 class="article-section__title" id="_i14"> Drug Combination Assays: Click-iT EdU Cell Proliferation Imaging Assay of A549 Cell Line, Combination Studies with Cobimetinib</h4><div class="NLM_p">A volume of 50 μL was dispensed in 384-well plates at 2000 cells per well, and compounds were dispensed directly to wells via the Echo acoustic dispenser. Cells were grown in the presence of compound for 24 h.</div><div id="sec5_1_3_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i15" class="anchor-spacer"></div><h5 class="article-section__title" id="_i15"> Pulse Cells</h5><div class="NLM_p last">Plates were dispensed with 20 μM EdU 647, 5 μL of volume dispensed to 50 μL cells in media, and incubated for 30 min in 37 °C and 5% CO<sub>2</sub>. All proceeding steps were performed at room temperature on the bench.</div></div><div id="sec5_1_3_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i16" class="anchor-spacer"></div><h5 class="article-section__title" id="_i16"> Fix Cells</h5><div class="NLM_p last">An equal volume of 4% paraformaldehyde and 2% final was dispensed to each well and incubated for 15 min. Cells were washed for two cycles using PBS, with final aspiration.</div></div><div id="sec5_1_3_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i17" class="anchor-spacer"></div><h5 class="article-section__title" id="_i17"> Permeabilize Cells</h5><div class="NLM_p last">Triton X-100 at 0.5% in PBS was dispensed to each well at 50 μL for 20 min. Cells were washed for two cycles using PBS, with final aspiration. At 25 μL per well, a solution of 1× Alexa Fluor 647, 4 mM CuSO<sub>4</sub>, and 2 mg mL<sup>–1</sup> sodium ascorbate in TBS was dispensed to the cells and incubated for 30 min. Cells were washed for six cycles using PBS, with final aspiration.</div></div><div id="sec5_1_3_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i18" class="anchor-spacer"></div><h5 class="article-section__title" id="_i18"> Stain Cells</h5><div class="NLM_p last">A solution of 3.2 μM Hoechst 33342 in PBS was added to the cells at 25 μL per well and incubated in the dark for 30 min. Cells were washed for two cycles with final aspiration. A PerkinElmer PHENIX was used to image cellular DNA and cytoplasm (Alexa Fluor 647 multiplexed with Hoechst stain) and calculate cell number. Columbus software was used for analysis and visualization. Genedata was used to calculate potencies and visualize the synergies of the double titrations of experimental compounds against cobimetinib.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a></div></div></div><div id="sec5_1_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i19" class="anchor-spacer"></div><h4 class="article-section__title" id="_i19"> Cloning, Expression, Purification, and Crystallization of BRAF Mutant</h4><div class="NLM_p">cDNA-encoding BRAF residue R444-K723 with H539K was generated in the background of 16 mutations to improve expression (I543A, I544S, I551K, Q562R, L588N, K630S, F667E, Y673S, A688R, L706S, Q709R, S713E, L716E, S720E, P722S, and K723G) with an N-terminal histidine tag that was generated by gene synthesis for bacterial expression. Expression was auto-induced at 16 °C. <i>Escherichia coli</i> cells were lysed in 25 mM Tris (pH 8.0), 150 mM NaCl, 1 mM TCEP, 5% glycerol, and 10 μM GNE-0749 with protease inhibitor tablets (Roche). The cell suspension was homogenized and passed through a microfluidizer twice. The lysate was clarified by centrifugation at 8000 rpm for 30 min. The supernatant was loaded onto a 4 mL Ni-NTA column (Qiagen) and then washed with 25 mM Tris (pH 8.0), 150 mM NaCl, 1 mM TCEP, 5% glycerol, and 15 mM imidazole. Protein was eluted with 0.3 M imidazole in the same buffer. After verification by SDS-PAGE, the protein was concentrated to 2 mL and loaded onto a HiLoad 16/60 Superdex 200 column (GE Healthcare) pre-equilibrated with 25 mM HEPES, 150 mM NaCl, 1 mM TCEP, and 5% glycerol. The peak corresponding to monomeric protein was pooled, diluted 3-fold with 25 mM HEPES, 5% glycerol, and 1 mM TCEP, and directly loaded onto a 5 mL HiTrap SP HP column (GE Healthcare). The protein was eluted with a 0–500 mM NaCl gradient in 25 mM HEPES, 1 mM TCEP, and 5% glycerol. The eluted protein was pooled and concentrated to 5 mg mL<sup>–1</sup>.</div><div class="NLM_p last">The BRAF mutant GNE-0749 complex was crystallized by vapor diffusion. Hanging drops were set up by mixing 1 μL of protein and 1 μL of well solution (18% PEG 3350, 0.2 M Na nitrate, and 0.1 M bis-Tris propane (pH 6.5)) and incubated at 19 °C. Crystals grew after 2 days. Crystals were washed and transferred to a cryoprotectant solution of 25% glycerol, 18% PEG 3350, 0.2 M Na nitrate, and 0.1 M bis-Tris propane (pH 6.5) prior to flash cooling in liquid nitrogen.</div></div><div id="sec5_1_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i20" class="anchor-spacer"></div><h4 class="article-section__title" id="_i20"> Data Collection and Structure Determination of BRAF/GNE-0749</h4><div class="NLM_p">The diffraction data of BRAF/GNE-0749 were collected using monochromatic X-rays at the Advanced Light Source (ALS) beamline 5.0.2 using a PILATUS3 6M detector. The rotation method was applied to a single crystal for each of the complete data set. The crystals were kept at cryogenic temperature throughout the data collection process. Data reduction was performed using the program XDS<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> and the CCP4 program suites.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> Data reduction statistics are shown in <a href="/doi/suppl/10.1021/acs.jmedchem.0c02085/suppl_file/jm0c02085_si_004.pdf" class="ext-link">Table S5</a>.</div><div class="NLM_p last">The structures were phased by molecular replacement (MR) using program PHASER.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> A previously published crystal structure of BRAF (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3C4C">3C4C</a>) was used as the MR search models. Manual rebuilding was performed with graphics program Coot.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> The structures were further refined iteratively using program REFMAC5<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> and PHENIX<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> using maximum likelihood target functions, anisotropic individual B-factor refinement and TLS refinement, to achieve final statistics shown in <a href="/doi/suppl/10.1021/acs.jmedchem.0c02085/suppl_file/jm0c02085_si_004.pdf" class="ext-link">Table S5</a>.</div></div><div id="sec5_1_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i21" class="anchor-spacer"></div><h4 class="article-section__title" id="_i21"> Animal Studies</h4><div class="NLM_p last">All individuals participating in animal care and use are required to undergo training by the institution’s veterinary staff. Any procedures, including handling, dosing, and sample collection, mandate training and validation of proficiency under the direction of the veterinary staff prior to performing procedures in experimental in vivo studies. All animals were dosed and monitored according to guidelines from the Institutional Animal Care and Use Committee (IACUC) on study protocols approved by Genentech’s Laboratory Animal Resource Committee at Genentech, Inc.</div></div><div id="sec5_1_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i22" class="anchor-spacer"></div><h4 class="article-section__title" id="_i22"> Xenograft Tumor Studies</h4><div class="NLM_p last">All xenograft studies were done as previously described.<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> Briefly, the HCT116 cells were grown in normal growth media (RPMI 1640 with <span class="smallcaps smallerCapital">l</span>-glutamine and 10% FCS), harvested, and implanted subcutaneously into the right flank of female NCR nude mice (6–8 weeks old) obtained from Taconic (Cambridge City, IN) weighing an average of 24–26 g. The mice were housed at Genentech in standard rodent micro-isolator cages and were acclimated to study conditions at least 3 days before tumor cell implantation. Only animals that appeared to be healthy, free of obvious abnormalities, and harbored tumors without signs of ulceration were used for each study. Tumor volumes were determined using digital calipers (Fred V. Fowler Company, Inc.) using the formula (<i>L</i> × <i>W</i> × <i>W</i>)/2. Tumor growth inhibition (%TGI) was calculated as the percentage of the area under the fitted curve (AUC) for the respective dose group per day in relation to the vehicle such that %TGI = 100 × [1 – (AUC<sub>treatment</sub>/day)/(AUC<sub>vehicle</sub>/day)]. Curve fitting was applied to log<sub>2</sub>-transformed individual tumor volume data using a linear mixed-effect model using the R package nlme, version 3.1–97 in R v2.12.0. Mice were weighed twice a week using a standard scale and checked daily for signs of morbidity as detailed above. Animals were euthanized within 4 h if deemed moribund or if tumor volumes exceeded 1500 mm<sup>3</sup>.</div></div><div id="sec5_1_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i23" class="anchor-spacer"></div><h4 class="article-section__title" id="_i23"> Chemistry</h4><div class="NLM_p">All metal catalysts, ligands, and bases were purchased from MilliporeSigma or Strem Chemicals, Inc. and stored in a desiccator (weighing to air). Anhydrous solvents were purchased from MilliporeSigma. Thin-layer chromatography was performed on EMD TLC silica gel 60 F<sub>254</sub> aluminum-backed plates and visualized with UV light. Flash chromatographic purifications were performed with Teledyne ICSO RediSep Rf Gold silica cartridges on a Teledyne ISCO Combiflash Rf. Preparative HPLC purification was conducted on C18 (Gemini NX-C18 50 × 30 mm, 5 μm packing, 110 Å particle size) with mixtures of acetonitrile and either 0.1% aq NH<sub>4</sub>OH or formic acid. Nuclear magnetic resonance data were acquired on a Bruker Avance III HD 400 Ascend with a Z-GRD Prodigy BBO 5 mm cryoprobe. Chemical shift values are reported relative to internal standards and operating frequencies shown in parentheses: <sup>1</sup>H (400.33 MHz), trimethylsilane = 0.00 ppm; <sup>13</sup>C{<sup>1</sup>H} (100.67 MHz), trimethylsilane = 0.00 ppm; and <sup>19</sup>F (376.52 MHz), trichlorofluoromethane = 0.00 ppm. In cases of uncertain assignments, structural confirmation was secured through 2D NMR experiments. Reactions were monitored by HPLC/MS analysis on a Shimadzu LC-30AD with a Waters 2.1 mm × 30 mm, 1.7 μm BEH C18 column, UV detection at 254 nm, and dual ESI/APCI to a Shimadzu LCMS-2020 single quadrupole mass analyzer. The method was conducted at a flow rate of 0.7 mL min<sup>–1</sup> whereby mobile phase A was 0.1% formic acid in water and mobile phase B was acetonitrile. The method began at 2% B, ramping linearly to 98% B over 2 min. The gradient was held at 98% B for 0.2 min, then ramped down to 2% B over 0.1 min, and held at 2% B for 0.1 min. The purity of final compounds was verified by LCMS to be >95% in all cases using either of the following methods: (1) 10 min LCMS method: experiments were performed on an Agilent 1290 UHPLC coupled with an Agilent MSD (6140) mass spectrometer using ESI as the ionization source. The LC separation was done on a Phenomenex XB-C18, 1.7 μm, 50 × 2.1 mm column at a flow rate of 0.4 mL min<sup>–1</sup>. Mobile phase A was water with 0.1% formic acid, and mobile phase B was acetonitrile with 0.1% formic acid. The gradient started at 2% B, ended at 98% B over 7 min, and held at 98% B for 1.5 min following equilibration for 1.5 min. LC column temperature was 40 °C. UV absorbance was collected at 220 and 254 nm, and mass spectrometry full scan was applied to all experiments. (2) 30 min LCMS method: experiments were performed on an Agilent 1290 HPLC coupled with an Agilent MSD (6140) mass spectrometer using ESI as the ionization source. The LC separation was done on an Agilent Zorbax Eclipse XDB-C18, 3.5 μm, 100 × 3.0 mm column at a flow rate of 0.7 mL min<sup>–1</sup>. Mobile phase A was water with 0.1% formic acid, and mobile phase B was acetonitrile with 0.1% formic acid. The gradient started at 2% B, ended at 98% B over 25.5 min, and held at 98% B for 2.5 min following equilibration for 1.5 min. LC column temperature was 40 °C. UV absorbance was collected at 220 and 254 nm, and mass spectrometry full scan was applied to all experiments.</div><div id="sec5_1_8_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i24" class="anchor-spacer"></div><h5 class="article-section__title" id="_i24"> Methyl 5-Amino-4-fluoro-2-methylbenzoate (<b>8a</b>)</h5><div class="NLM_p last">Under a nitrogen atmosphere, palladium on carbon (4.99 g, 10 mol % [5 wt %, 50% wet]) and methyl 4-fluoro-2-methyl-5-nitrobenzoate (5.00 g, 23.5 mmol) were suspended in ethanol (78 mL). The atmosphere was evacuated and replaced with hydrogen gas balloon, and the mixture was stirred vigorously for 23 h. The mixture was filtered through Celite, rinsed with methanol, and then concentrated to a light purple solid (4.03 g, 94%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.41 (d, <i>J</i> = 9.3 Hz, 1H), 6.86 (d, <i>J</i> = 11.9 Hz, 1H), 3.86 (s, 3H), 3.67 (br s, 2H), 2.48 (s, 3H).</div></div><div id="sec5_1_8_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i25" class="anchor-spacer"></div><h5 class="article-section__title" id="_i25"> Methyl 5-(3-(3,3-Dimethylbutyl)ureido)-4-fluoro-2-methylbenzoate (<b>8b</b>)</h5><div class="NLM_p last">To a suspension of methyl 5-amino-4-fluoro-2-methylbenzoate (3.76 g, 20.5 mmol) and sodium bicarbonate (3.45 g, 41.1 mmol) in anhydrous tetrahydrofuran (103 mL) under a nitrogen atmosphere was added phenyl chloroformate (2.84 mL, 22.6 mmol), and the mixture was heated to 60 °C for 5 min. The mixture was then cooled to room temperature and filtered, and the solids were rinsed with dichloromethane. The mother liquor was concentrated to afford the crude carbamate as a white solid (1.42 g, 4.67 mmol). The solid was dissolved in anhydrous toluene (23 mL), and to this solution was added triethylamine (1.30 mL, 9.34 mmol) followed by 3,3-dimethylbutylamine (0.692 mL, 5.14 mmol). The solution was heated at 90 °C for 1.5 h and cooled to rt that afforded a white solid, which was filtered and rinsed with heptane and toluene to afford the title compound (1.29 g, 20% over two steps). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.68 (d, <i>J</i> = 8.6 Hz, 1H), 8.30 (d, <i>J</i> = 2.5 Hz, 1H), 7.17 (d, <i>J</i> = 12.3 Hz, 1H), 6.49 (t, <i>J</i> = 5.6 Hz, 1H), 3.80 (s, 3H), 3.14–3.05 (m, 2H), 2.44 (s, 3H), 1.40–1.29 (m, 2H), 0.91 (s, 9H).</div></div><div id="sec5_1_8_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i26" class="anchor-spacer"></div><h5 class="article-section__title" id="_i26"> 5-(3-(3,3-Dimethylbutyl)ureido)-4-fluoro-2-methylbenzoic Acid (<b>8c</b>)</h5><div class="NLM_p last">A solution of methyl 5-(3-(3,3-dimethylbutyl)ureido)-4-fluoro-2-methylbenzoate (400 mg, 1.29 mmol) and lithium hydroxide monohydrate (59.5 mg, 1.42 mmol) in tetrahydrofuran (6.4 mL) and water (1.3 mL) was stirred at 80 °C for 4 h. Tetrahydrofuran was carefully evaporated, and to the stirring aqueous solution was added hydrogen chloride (2.0 mL, 8.0 mmol, [4.0 M in 1,4-dioxane]). The solid precipitate was filtered and rinsed with water to afford the title compound as a white solid (371.8 mg, 97%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.58 (d, <i>J</i> = 8.8 Hz, 1H), 8.15 (d, <i>J</i> = 2.6 Hz, 1H), 7.07 (d, <i>J</i> = 12.2 Hz, 1H), 6.43 (t, <i>J</i> = 5.5 Hz, 1H), 3.12–3.08 (m, 2H), 2.43 (s, 3H), 1.40–1.32 (m, 2H), 0.91 (s, 9H).</div></div><div id="sec5_1_8_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i27" class="anchor-spacer"></div><h5 class="article-section__title" id="_i27"> 5-(3-(3,3-Dimethylbutyl)-2,4,5-trioxoimidazolidin-1-yl)-4-fluoro-<i>N</i>-(3-methoxy-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridin-5-yl)-2-methylbenzamide (<b>8d</b>)</h5><div class="NLM_p last">To a solution of 5-(3-(3,3-dimethylbutyl)ureido)-4-fluoro-2-methylbenzoic acid (60.0 mg, 0.203 mmol) in anhydrous tetrahydrofuran (1.0 mL) was added anhydrous DMF (0.003 mL, 0.04 mmol) followed by oxalyl chloride (52.8 μL, 0.606 mmol). After stirring for 5 min, the reaction mixture was concentrated to dryness and redissolved in anhydrous tetrahydrofuran (1.0 mL). To the solution was added 3-methoxy-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridin-5-amine (39.9 mg, 0.243 mmol) followed by triethylamine (56.4 μL, 0.405 mmol), and the mixture was heated at 55 °C for 66 h. The volatiles were removed, and the residue was subjected to flash column chromatography (dichloromethane/methanol, 100:0 to 90:10) to afford the title compound as a white solid (48.7 mg, 48%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 12.54 (s, 1H), 10.70 (s, 1H), 8.63 (d, <i>J</i> = 2.4 Hz, 1H), 8.46 (d, <i>J</i> = 2.4 Hz, 1H), 7.63 (d, <i>J</i> = 7.2 Hz, 1H), 7.49 (d, <i>J</i> = 10.9 Hz, 1H), 4.01 (s, 3H), 3.63–3.52 (m, 2H), 2.48 (s, 3H), 1.61–1.47 (m, 2H), 0.95 (s, 9H).</div></div><div id="sec5_1_8_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i28" class="anchor-spacer"></div><h5 class="article-section__title" id="_i28"> 5-(3-(3,3-Dimethylbutyl)ureido)-4-fluoro-<i>N</i>-(3-methoxy-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridin-5-yl)-2-methylbenzamide (<b>2</b>)</h5><div class="NLM_p last">To solid 5-(3-(3,3-dimethylbutyl)-2,4,5-trioxoimidazolidin-1-yl)-4-fluoro-<i>N</i>-(3-methoxy-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridin-5-yl)-2-methylbenzamide (18.2 mg, 0.0367 mmol) were added <i>N</i>,<i>N</i>-diisopropylethylamine (13 μL, 0.073 mmol), anhydrous <i>N</i>,<i>N</i>-dimethylformamide (70 μL), and aqueous 10% sodium hydroxide (0.18 mL), and the reaction mixture was stirred for 2.5 h. The mixture was concentrated and purified by preparative HPLC to afford the title compound as a white solid (11.6 mg, 72% yield, >99% HPLC purity). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 12.50 (s, 1H), 10.46 (s, 1H), 8.65 (d, <i>J</i> = 2.2 Hz, 1H), 8.47 (d, <i>J</i> = 2.5 Hz, 1H), 8.40–8.23 (m, 2H), 7.16 (d, <i>J</i> = 12.3 Hz, 1H), 6.52 (t, <i>J</i> = 5.6 Hz, 1H), 4.01 (s, 3H), 3.17–3.07 (m, 2H), 2.32 (s, 3H), 1.43–1.25 (m, 2H), 0.90 (s, 9H).</div></div><div id="sec5_1_8_6" class="NLM_sec NLM_sec_level_4"><div id="ac_i29" class="anchor-spacer"></div><h5 class="article-section__title" id="_i29"> 1-(5-Bromo-2-fluoro-4-methylphenyl)-3-(3,3-dimethylbutyl)urea (<b>9a</b>)</h5><div class="NLM_p last">To a mixture of 5-bromo-2-fluoro-4-methylaniline (10.00 g, 49.01 mmol) and sodium bicarbonate (8.23 g, 98.0 mmol) in anhydrous THF (196 mL) under nitrogen and at 0 °C was added phenyl chloroformate (6.8 mL, 54 mmol). After stirring for 15 min, the cooling bath was removed and the reaction mixture was allowed to stir for 2.5 h. The mixture was filtered, rinsed with anhydrous toluene, and then concentrated. The residue was taken up in anhydrous toluene (163 mL), and while stirring, triethylamine (13.7 mL, 98.0 mmol) and 3,3-dimethylbutylamine (7.9 mL, 59 mmol) were added sequentially. After 3 h, the mixture was filtered and the solid product was rinsed with heptane and toluene to afford the title compound as a white solid (15.16 g, 95%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.38 (d, <i>J</i> = 7.9 Hz, 1H), 8.32 (d, <i>J</i> = 2.2 Hz, 1H), 7.23 (d, <i>J</i> = 12.6 Hz, 1H), 6.52 (t, <i>J</i> = 5.5 Hz, 1H), 3.16–3.03 (m, 2H), 2.25 (s, 3H), 1.41–1.29 (m, 2H), 0.90 (s, 9H).</div></div><div id="sec5_1_8_7" class="NLM_sec NLM_sec_level_4"><div id="ac_i30" class="anchor-spacer"></div><h5 class="article-section__title" id="_i30"> 6-(2-Aminopyridin-3-yl)-<i>N</i>-methylpyrimidin-4-amine (<b>10a</b>)</h5><div class="NLM_p last">Into a vial were weighed 6-chloro-<i>N</i>-methylpyrimidin-4-amine (310 mg, 2.16 mmol), 2-aminopyridine-3-boronic acid pinacol ester (485 mg, 2.16 mmol), chloro(2-dicyclohexylphosphino-2′,4′,6′-triisopropyl-1,1′-biphenyl)[2-(2′-amino-1,1′-biphenyl)]palladium(II) (86.7 mg, 0.108 mmol), 2-dicyclohexylphosphino-2′,4′,6′-triisopropylbiphenyl (52.5 mg, 0.108 mmol), and potassium phosphate tribasic monohydrate (1.54 g, 6.48 mmol). The vial was purged with nitrogen gas, charged with degassed tetrahydrofuran (10.8 mL) and distilled water (1.1 mL), and then sealed, and the reaction mixture was stirred at 80 °C for 4 h. After cooling to rt, the mixture was concentrated to dryness. The reaction residue thus obtained was purified by flash column chromatography (100:0 to 20:80 CH<sub>2</sub>Cl<sub>2</sub>/90:9:1 CH<sub>2</sub>Cl<sub>2</sub>/MeOH/aq NH<sub>4</sub>OH) to afford the title compound as a white solid (346 mg, 80%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.49 (br s, 1H), 8.04 (dd, <i>J</i> = 4.7, 1.8 Hz, 1H), 7.85 (br s, 1H), 7.54–7.02 (m, 3H), 6.77 (d, <i>J</i> = 1.1 Hz, 1H), 6.64 (dd, <i>J</i> = 7.6, 5.0 Hz, 1H), 2.85 (d, <i>J</i> = 4.7 Hz, 3H).</div></div><div id="sec5_1_8_8" class="NLM_sec NLM_sec_level_4"><div id="ac_i31" class="anchor-spacer"></div><h5 class="article-section__title" id="_i31"> 1-(3,3-Dimethylbutyl)-3-(2-fluoro-4-methyl-5-((3-(6-(methylamino)pyrimidin-4-yl)pyridin-2-yl)amino)phenyl)urea (<b>3</b>)</h5><div class="NLM_p last">Into a vial were weighed 1-(5-bromo-2-fluoro-4-methylphenyl)-3-(3,3-dimethylbutyl)urea (80.0 mg, 0.242 mmol), tris(dibenzylideneacetone)dipalladium(0) (5.5 mg, 0.0060 mmol), 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (8.4 mg, 0.014 mmol), 6-(2-aminopyridin-3-yl)-<i>N</i>-methylpyrimidin-4-amine (48.6 mg, 0.242 mmol), and cesium carbonate (110 mg, 0.338 mmol). Under a stream of nitrogen gas, the vessel was charged with anhydrous 1,4-dioxane (1.2 mL) and the vial was sealed. The reaction mixture was stirred at 80 °C for 66 h. After cooling to rt, the mixture was filtered through Celite and rinsed with dichloromethane and methanol. The mother liquor was concentrated, and the residue was purified by preparative HPLC to afford the title compound as a yellow solid (66.0 mg, 61% yield, >99% HPLC purity). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.21 (br s, 1H), 8.67–8.48 (m, 2H), 8.16 (dd, <i>J</i> = 4.8, 1.8 Hz, 1H), 8.04 (d, <i>J</i> = 2.3 Hz, 1H), 8.00 (br s, 1H), 7.53 (br s, 1H), 7.03 (d, <i>J</i> = 11.9 Hz, 1H), 6.92 (d, <i>J</i> = 1.4 Hz, 1H), 6.84 (dd, <i>J</i> = 7.6, 5.0 Hz, 1H), 6.38 (t, <i>J</i> = 5.6 Hz, 1H), 3.13–3.00 (m, 2H), 2.88 (d, <i>J</i> = 4.6 Hz, 3H), 2.21 (s, 3H), 1.41–1.25 (m, 2H), 0.90 (s, 9H).</div></div><div id="sec5_1_8_9" class="NLM_sec NLM_sec_level_4"><div id="ac_i32" class="anchor-spacer"></div><h5 class="article-section__title" id="_i32"> 1-(5-Amino-2-fluoro-4-methylphenyl)-3-(3,3-dimethylbutyl)urea hydrochloride (<b>9c</b>)</h5><div class="NLM_p last">Into a pressure flask were weighed 1-(5-bromo-2-fluoro-4-methylphenyl)-3-(3,3-dimethylbutyl)urea (2.00 g, 6.04 mmol), chloro(2-dicyclohexylphosphino-2′,4′,6′-triisopropyl-1,1′-biphenyl)[2-(2′-amino-1,1′-biphenyl)]palladium(II) (225 mg, 0.302 mmol), 2-dicyclohexylphosphino-2′,4′,6′-triisopropylbiphenyl (294 mg, 0.604 mmol), <i>tert</i>-butyl carbamate (866 mg, 7.25 mmol), and cesium carbonate (2.75 g, 8.45 mmol). Under a stream of nitrogen gas, the vessel was charged with anhydrous 1,4-dioxane (60 mL) and the pressure flask was sealed. The reaction mixture was stirred at 110 °C for 18 h. After cooling to rt, the mixture was filtered through Celite and rinsed with dichloromethane. The mother liquor was concentrated, and the residue was dissolved in a solution of hydrochloric acid in isopropanol (30 mL, molarity unknown), stirred for 20 h, and then filtered. The solid was rinsed with isopropyl acetate to afford the title compound as a white solid (831 mg, 45% over two steps). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.23 (br s, 1H), 8.11 (d, <i>J</i> = 7.6 Hz, 1H), 7.07 (d, <i>J</i> = 11.9 Hz, 1H), 6.53 (br s, 1H), 3.14–3.06 (m, 2H), 2.19 (s, 3H), 1.39–1.32 (m, 2H), 0.91 (s, 9H).</div></div><div id="sec5_1_8_10" class="NLM_sec NLM_sec_level_4"><div id="ac_i33" class="anchor-spacer"></div><h5 class="article-section__title" id="_i33"> <i>tert</i>-Butyl (6-(Methylamino)pyrimidin-4-yl)carbamate (<b>11a</b>)</h5><div class="NLM_p last">To a mixture of methylamine hydrochloride (3.13 g, 46.4 mmol) and <i>tert</i>-butyl <i>N</i>-<i>tert</i>-butoxycarbonyl-<i>N</i>-(6-chloropyrimidin-4-yl)carbamate (4.00 g, 12.1 mmol) in dimethyl sulfoxide (50 mL) was added potassium carbonate (3.35 g, 24.3 mmol) at room temperature. The reaction mixture was stirred at 90 °C for 10 h, then cooled to rt, and concentrated under reduced pressure. The residue was purified by flash column chromatography (100:0 to 50:50 petroleum ether/EtOAc) to afford the title compound as a white solid (2.50 g, 92%). LCMS <i>m</i>/<i>z</i>: 225.1 (M + H<sup>+</sup>).</div></div><div id="sec5_1_8_11" class="NLM_sec NLM_sec_level_4"><div id="ac_i34" class="anchor-spacer"></div><h5 class="article-section__title" id="_i34"> Phenyl (6-Aminopyrimidin-4-yl)(methyl)carbamate (<b>11b</b>)</h5><div class="NLM_p last">To a mixture of <i>tert</i>-butyl (6-(methylamino)pyrimidin-4-yl)carbamate (650 mg, 2.90 mmol) and 4-dimethylaminopyridine (425 mg, 3.48 mmol) in <i>N</i>,<i>N</i>-dimethylformamide (5 mL) was added diphenyl carbonate (714 mg, 3.33 mmol) dropwise at room temperature. The resulting mixture was then stirred at 100 °C for 16 h. Thereafter, the reaction mixture was cooled to rt, diluted with water, and extracted with ethyl acetate. The organic layer was washed with water 2× and brine and dried over anhydrous sodium sulfate. Following concentration, the residue thus obtained was purified by flash chromatography (100:0 to 34:66 petroleum ether/EtOAc) to afford the title compound as a white solid (340 mg, 48%). LCMS <i>m</i>/<i>z</i>: 244.8 (M + H<sup>+</sup>).</div></div><div id="sec5_1_8_12" class="NLM_sec NLM_sec_level_4"><div id="ac_i35" class="anchor-spacer"></div><h5 class="article-section__title" id="_i35"> 1-(6-Aminopyrimidin-4-yl)-3-(5-(3-(3,3-dimethylbutyl)ureido)-4-fluoro-2-methylphenyl)-1-methylurea (<b>4</b>)</h5><div class="NLM_p last">To a mixture of 1-(5-amino-2-fluoro-4-methylphenyl)-3-(3,3-dimethylbutyl)urea (220 mg, 0.82 mmol) and phenyl (6-aminopyrimidin-4-yl)(methyl)carbamate (200 mg, 0.82 mmol) in <i>N</i>,<i>N</i>-dimethylformamide (5 mL) was added 4-dimethylaminopyridine (110 mg, 0.90 mmol) at rt. The resulting mixture was stirred at 90 °C for 16 h, cooled to rt, and concentrated to dryness. The residue thus obtained was purified by preparative HPLC to afford the title compound as a white solid (50 mg, 14% yield, 97% HPLC purity). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.46 (br s, 2H), 8.52 (d, <i>J</i> = 8.4 Hz, 1H), 8.19 (s, 1H), 8.09 (s, 1H), 7.27 (br s, 1H), 7.04 (d, <i>J</i> = 11.6 Hz, 1H), 6.43–6.40 (m, 1H), 3.36 (s, 3H), 3.11–3.06 (m, 2H), 2.18 (s, 3H), 1.36–1.32 (m, 2H), 0.90 (s, 9H).</div></div><div id="sec5_1_8_13" class="NLM_sec NLM_sec_level_4"><div id="ac_i36" class="anchor-spacer"></div><h5 class="article-section__title" id="_i36"> <i>tert</i>-Butyl (5-(3-(3,3-Dimethylbutyl)ureido)-4-fluoro-2-methylphenyl)carbamate (<b>9b</b>)</h5><div class="NLM_p last">Into a pressure flask were weighed 1-(5-bromo-2-fluoro-4-methylphenyl)-3-(3,3-dimethylbutyl)urea (2.00 g, 6.04 mmol), tris(dibenzylideneacetone)dipalladium(0) (138 mg, 0.151 mmol), 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (210 mg, 0.362 mmol), <i>tert</i>-butyl carbamate (8.66 g, 7.25 mmol), and cesium carbonate (5.90 g, 18.1 mmol). Under a stream of nitrogen gas, the vessel was charged with anhydrous tetrahydrofuran (30 mL) and the pressure flask was sealed. The reaction mixture was stirred at 90 °C for 18 h at which time HPLC indicated only minimal of conversion to product. Additional tris(dibenzylideneacetone)dipalladium(0) (138 mg, 0.151 mmol), 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (210 mg, 0.362 mmol), and <i>tert</i>-butyl carbamate (8.66 g, 7.25 mmol) were added, and the reaction was continued at 110 °C for a further 24 h. After cooling to rt, the mixture was filtered through Celite and rinsed with CH<sub>2</sub>Cl<sub>2</sub>. The mother liquor was concentrated, and the residue was purified by flash chromatography (100:0 to 50:50 heptane/EtOAc) to afford the title compound as a white solid (717 mg, 32%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.98 (d, <i>J</i> = 7.8 Hz, 1H), 6.83 (d, <i>J</i> = 11.2 Hz, 1H), 6.33 (br s, 1H), 6.14 (br s, 1H), 4.97–4.78 (m, 1H), 3.31–3.20 (m, 2H), 2.17 (s, 3H), 1.51 (s, 9H), 1.47–1.41 (m, 2H), 0.93 (s, 9H).</div></div><div id="sec5_1_8_14" class="NLM_sec NLM_sec_level_4"><div id="ac_i37" class="anchor-spacer"></div><h5 class="article-section__title" id="_i37"> 4-((2,4-Dimethoxybenzyl)amino)-<i>N</i>-(5-(3-(3,3-dimethylbutyl)ureido)-4-fluoro-2-methylphenyl)quinazoline-8-carboxamide (<b>12a</b>)</h5><div class="NLM_p last">A solution of <i>tert</i>-butyl (5-(3-(3,3-dimethylbutyl)ureido)-4-fluoro-2-methylphenyl)carbamate (99.0 mg, 0.269 mmol) in dichloromethane (1.3 mL) and trifluoroacetic acid (1.3 mL) was stirred for 45 min and then concentrated to dryness. Onto the solid residue were weighed HATU (209.0 mg, 0.539 mmol) and 4-((2,4-dimethoxybenzyl)amino)quinazoline-8-carboxylic acid (91.4 mg, 0.269 mmol), and then anhydrous <i>N</i>,<i>N</i>-dimethylformamide (1.3 mL) and triethylamine (0.263 mL, 1.89 mmol) were added. The reaction mixture was stirred for 18 h, then diluted with dichloromethane, and washed with 10% aqueous potassium carbonate and then brine. The organics were concentrated and purified by flash chromatography (dichloromethane/methanol, 100:0 to 95:5) to afford the title compound as a yellow solid (86.3 mg, 54%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 13.45 (s, 1H), 8.87 (dd, <i>J</i> = 7.5, 1.5 Hz, 1H), 8.69 (s, 1H), 8.45 (d, <i>J</i> = 8.0 Hz, 1H), 7.85 (dd, <i>J</i> = 8.1, 1.6 Hz, 1H), 7.58 (dd, <i>J</i> = 8.1 Hz, 1H), 7.32 (d, <i>J</i> = 8.4 Hz, 1H), 6.94 (d, <i>J</i> = 11.0 Hz, 1H), 6.59–6.40 (m, 3H), 6.29 (br s, 1H), 4.99 (t, <i>J</i> = 5.5 Hz, 1H), 4.82 (d, <i>J</i> = 5.4 Hz, 2H), 3.91 (s, 3H), 3.81 (s, 3H), 3.33–3.14 (m, 2H), 2.41 (s, 3H), 1.51–1.42 (m, 2H), 0.93 (s, 9H).</div></div><div id="sec5_1_8_15" class="NLM_sec NLM_sec_level_4"><div id="ac_i38" class="anchor-spacer"></div><h5 class="article-section__title" id="_i38"> 4-Amino-<i>N</i>-(5-(3-(3,3-dimethylbutyl)ureido)-4-fluoro-2-methylphenyl)quinazoline-8-carboxamide (<b>5</b>)</h5><div class="NLM_p last">A solution of 4-((2,4-dimethoxybenzyl)amino)-<i>N</i>-(5-(3-(3,3-dimethylbutyl)ureido)-4-fluoro-2-methylphenyl)quinazoline-8-carboxamide (41.0 mg, 0.0696 mmol) in trifluoroacetic acid (0.7 mL) was stirred at 70 °C for 3 h and then concentrated to dryness. The residue was purified by preparative HPLC to afford the title compound as a white solid (22.9 mg, 75% yield, >99% HPLC purity). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 13.43 (s, 1H), 8.93 (d, <i>J</i> = 8.5 Hz, 1H), 8.70 (dd, <i>J</i> = 7.5, 1.9 Hz, 1H), 8.60 (s, 1H), 8.48 (dd, <i>J</i> = 8.1, 1.5 Hz, 1H), 8.30 (br s, 2H), 8.12 (d, <i>J</i> = 2.3 Hz, 1H), 7.68 (dd, <i>J</i> = 7.9 Hz, 1H), 7.12 (d, <i>J</i> = 12.0 Hz, 1H), 6.43 (t, <i>J</i> = 5.6 Hz, 1H), 3.16–3.05 (m, 2H), 2.37 (s, 3H), 1.43–1.32 (m, 2H), 0.92 (s, 9H).</div></div><div id="sec5_1_8_16" class="NLM_sec NLM_sec_level_4"><div id="ac_i39" class="anchor-spacer"></div><h5 class="article-section__title" id="_i39"> <i>tert</i>-Butyl (3-Methyl-4-oxo-3,4-dihydroquinazolin-6-yl)carbamate (<b>13a</b>)</h5><div class="NLM_p last">Into a pressure flask were weighed 6-bromo-3-methyl-quinazolin-4-one (4.456 g, 18.64 mmol), tris(dibenzylideneacetone)dipalladium(0) (427 mg, 0.466 mmol), 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (539 mg, 0.932 mmol), <i>tert</i>-butyl carbamate (3.34 g, 28.0 mmol), and cesium carbonate (12.15 g, 37.28 mmol). Under a stream of nitrogen gas, the vessel was charged with anhydrous tetrahydrofuran (93 mL) and the pressure flask was sealed. The reaction mixture was stirred at 80 °C for 66 h. After cooling to rt, the mixture was filtered through Celite and rinsed with dichloromethane. The mother liquor was concentrated nearly to dryness and then filtered. The solid thus collected was rinsed with heptane and a small amount of isopropyl acetate to afford the title compound as a white solid (4.877 g, 95%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.75 (s, 1H), 8.35 (d, <i>J</i> = 2.5 Hz, 1H), 8.25 (s, 1H), 7.79 (dd, <i>J</i> = 8.9, 2.5 Hz, 1H), 7.59 (d, <i>J</i> = 8.9 Hz, 1H), 3.48 (s, 3H), 1.50 (s, 9H).</div></div><div id="sec5_1_8_17" class="NLM_sec NLM_sec_level_4"><div id="ac_i40" class="anchor-spacer"></div><h5 class="article-section__title" id="_i40"> 1-(3,3-Dimethylbutyl)-3-(2-fluoro-4-methyl-5-((3-methyl-4-oxo-3,4-dihydroquinazolin-6-yl)amino)phenyl)urea (<b>6</b>)</h5><div class="NLM_p last">A solution of <i>tert</i>-butyl (3-methyl-4-oxo-3,4-dihydroquinazolin-6-yl)carbamate (722 mg, 2.63 mmol) in trifluoroacetic acid (8.8 mL) was stirred for 1 h and then concentrated to a white solid. Onto this solid were weighed 1-(5-bromo-2-fluoro-4-methylphenyl)-3-(3,3-dimethylbutyl)urea (869 mg, 2.63 mmol), chloro[2-(dicyclohexylphosphino)-3,6-dimethoxy-2′,4′,6′-triisopropyl-1,1′-biphenyl][2-(2-aminoethyl)phenyl]palladium(II) methyl-<i>tert</i>-butyl ether adduct (107 mg, 0.131 mmol), 2-(dicyclohexylphosphino)-3,6-dimethoxy-2′,4′,6′-triisopropyl-1,1′-biphenyl (74.2 mg, 0.131 mmol), and sodium <i>tert</i>-butoxide (1.01 g, 10.5 mmol). Under a stream of nitrogen gas, the vessel was charged with anhydrous 1,4-dioxane (26 mL) and the pressure flask was sealed. The reaction mixture was stirred at 100 °C for 19 h before cooling to rt. After concentration, the crude residue was purified by flash chromatography (100:0 to 90:10 CH<sub>2</sub>Cl<sub>2</sub>/MeOH). The fractions containing the product were concentrated to dryness and then triturated with dichloromethane. After filtration, the white solid was washed with isopropyl acetate to afford the title compound as a white solid (889 mg, 80% over two steps, >99% HPLC purity). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.17 (d, <i>J</i> = 2.1 Hz, 1H), 8.11 (s, 1H), 8.03 (d, <i>J</i> = 8.0 Hz, 1H), 7.90 (br s, 1H), 7.50 (d, <i>J</i> = 8.8 Hz, 1H), 7.27 (dd, <i>J</i> = 8.8, 2.7 Hz, 1H), 7.21 (d, <i>J</i> = 2.6 Hz, 1H), 7.11 (d, <i>J</i> = 12.2 Hz, 1H), 6.46 (t, <i>J</i> = 5.5 Hz, 1H), 3.44 (s, 3H), 3.08–3.01 (m, 2H), 2.09 (s, 3H), 1.38–1.27 (m, 2H), 0.88 (s, 9H).</div></div><div id="sec5_1_8_18" class="NLM_sec NLM_sec_level_4"><div id="ac_i41" class="anchor-spacer"></div><h5 class="article-section__title" id="_i41"> 6-Amino-3-bromo-2-fluorobenzoic Acid Hydrobromide (<b>14a</b>)</h5><div class="NLM_p last">To a solution of 2-amino-6-fluorobenzoic acid (100 g, 0.640 mol) in methanol (1500 mL) at −78 °C was added bromine (103 g, 0.640 mol), and the reaction mixture was stirred for 2 h. The reaction was quenched with ice–water (800 mL) and aqueous sodium thiosulfate (670 mL), and the precipitate was collected by filtration to afford a brown solid. The brown solid was slurried in ethyl acetate (500 mL) and then filtered to afford the title compound (89 g, 44%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 7.40 (dd, <i>J</i> = 7.6, 9.2 Hz, 1H), 6.56 (dd, <i>J</i> = 1.2, 9.2 Hz, 1H).</div></div><div id="sec5_1_8_19" class="NLM_sec NLM_sec_level_4"><div id="ac_i42" class="anchor-spacer"></div><h5 class="article-section__title" id="_i42"> 6-Amino-3-bromo-2-fluoro-<i>N</i>-methylbenzamide (<b>14b</b>)</h5><div class="NLM_p last">To a solution of 6-amino-3-bromo-2-fluorobenzoic acid hydrobromide (80.6 g, 0.260 mol) and methylamine hydrochloride (86.3 g, 1.28 mol) in <i>N</i>,<i>N</i>-dimethylformamide (300 mL) were added triethylamine (258 g, 2.55 mol) and HATU (194 g, 0.510 mol). The reaction mixture was stirred overnight, then cooled to 0 °C, and quenched with saturated aqueous ammonium chloride (500 mL). The resulting mixture was extracted with dichloromethane (500 mL × 3), and the combined organic layers were washed with water (500 mL × 3), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (petroleum ether/EtOAc = 4:1) to afford the title compound as a white solid (36.5 g, 58%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.31 (d, <i>J</i> = 3.6 Hz, 1H), 7.30 (dd, <i>J</i> = 8.0, 8.8 Hz, 1H), 6.49 (dd, <i>J</i> = 1.2, 8.8 Hz, 1H), 5.95 (br s, 2H), 2.74 (d, <i>J</i> = 4.8 Hz, 3H).</div></div><div id="sec5_1_8_20" class="NLM_sec NLM_sec_level_4"><div id="ac_i43" class="anchor-spacer"></div><h5 class="article-section__title" id="_i43"> 6-Bromo-5-fluoro-3-methylquinazolin-4(3<i>H</i>)-one (<b>14c</b>)</h5><div class="NLM_p last">To a mixture of 6-amino-3-bromo-2-fluoro-<i>N</i>-methylbenzamide (75 g, 0.30 mol) in triethyl orthoformate (450 mL) was added hydrogen chloride (75 mL, 300 mmol, [4.0 M in 1,4-dioxane]). The reaction mixture was stirred at 110 °C for 3 h and then cooled to rt. The precipitate was collected by filtration and dried to afford the title compound (54 g, 69%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.05 (s, 1H), 7.87 (dd, <i>J</i> = 6.8, 8.8 Hz, 1H), 7.42 (dd, <i>J</i> = 1.6, 8.8 Hz, 1H), 3.58 (s, 3H).</div></div><div id="sec5_1_8_21" class="NLM_sec NLM_sec_level_4"><div id="ac_i44" class="anchor-spacer"></div><h5 class="article-section__title" id="_i44"> <i>tert</i>-Butyl 5-Fluoro-3-methyl-4-oxo-3,4-dihydroquinazolin-6-ylcarbamate (<b>14d</b>)</h5><div class="NLM_p last">To a nitrogen-sparged suspension of 6-bromo-5-fluoro-3-methylquinazolin-4(3<i>H</i>)-one (50 g, 0.19 mol) and <i>tert</i>-butyl carbamate (27.3 g, 0.230 mol) in toluene (1000 mL) were added tris(dibenzylideneacetone)dipalladium(0)-chloroform adduct (4.03 g, 3.90 mmol), 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (6.75 g, 11.7 mmol), and cesium carbonate (76.1 g, 0.230 mol). The reaction mixture was stirred at 90 °C overnight before being cooled to rt and filtered. The mother liquor was concentrated under reduced pressure, and the residue was purified by column chromatography on silica gel to afford the title compound (48.9 g, 86%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.24 (s, 1H), 8.31 (s, 1H), 8.01 (t, <i>J</i> = 8.4 Hz, 1H), 7.44 (dd, <i>J</i> = 1.2, 8.8 Hz, 1H), 3.44 (s, 3H), 1.48 (s, 9H).</div></div><div id="sec5_1_8_22" class="NLM_sec NLM_sec_level_4"><div id="ac_i45" class="anchor-spacer"></div><h5 class="article-section__title" id="_i45"> 6-Amino-5-fluoro-3-methylquinazolin-4(3<i>H</i>)-one (<b>14e</b>)</h5><div class="NLM_p last">To a solution of <i>tert</i>-butyl 5-fluoro-3-methyl-4-oxo-3,4-dihydroquinazolin-6-ylcarbamate (100 g, 0.340 mol) in ethyl acetate (1000 mL) was added hydrogen chloride (1000 mL, 4 mol, [4.0 M in ethyl acetate]). The reaction mixture was stirred for 12 h and then filtered. The solid was collected, suspended in water, and neutralized with aqueous sodium bicarbonate. The resulting solid was collected by filtration and dried to afford the title compound (57.6 g, 88%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.06 (s, 1H), 7.24–7.27 (m, 2H), 5.54 (br s, 2H), 3.41 (s, 3H).</div></div><div id="sec5_1_8_23" class="NLM_sec NLM_sec_level_4"><div id="ac_i46" class="anchor-spacer"></div><h5 class="article-section__title" id="_i46"> 1-(3,3-Dimethylbutyl)-3-(2-fluoro-5-((5-fluoro-3-methyl-4-oxo-3,4-dihydroquinazolin-6-yl)amino)-4-methylphenyl)urea (GNE-0749, <b>7</b>)</h5><div class="NLM_p last">Into a pressure flask were weighed 6-amino-5-fluoro-3-methylquinazolin-4(3<i>H</i>)-one (0.583 g, 3.02 mmol), palladium(II) acetate (34.0 mg, 0.151 mmol), 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (87.3 mg, 0.151 mmol), 1-(5-bromo-2-fluoro-4-methylphenyl)-3-(3,3-dimethylbutyl)urea (1.00 g, 3.02 mmol), cesium carbonate (2.95 g, 9.07 mmol), and 3 Å molecular sieves (2.50 g). Under a stream of nitrogen gas, the vessel was charged with anhydrous 1,4-dioxane (15 mL) and the pressure flask was sealed. The reaction mixture was stirred at 100 °C for 19 h. After cooling to rt, the mixture was filtered and rinsed with dichloromethane and methanol. The mother liquor was concentrated, and the residue was purified by flash chromatography (100:0 to 90:10 CH<sub>2</sub>Cl<sub>2</sub>/MeOH). This sequence was repeated with double the amount of reactants and without molecular sieves, and the two runs were combined for final purification via preparative HPLC to afford the title compound as a white solid (1.369 g, 34% yield, >99% HPLC purity). mp 215 °C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.17–8.13 (m, 2H), 7.89 (d, <i>J</i> = 7.9 Hz, 1H), 7.51 (d, <i>J</i> = 2.0 Hz, 1H), 7.31 (d, <i>J</i> = 8.7 Hz, 1H), 7.14–7.00 (m, 2H), 6.44 (t, <i>J</i> = 5.5 Hz, 1H), 3.44 (s, 3H), 3.11–2.98 (m, 2H), 2.09 (s, 3H), 1.38–1.24 (m, 2H), 0.88 (s, 9H). <sup>13</sup>C{<sup>1</sup>H} NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>): δ 157.7 (d, <i>J</i><sub>C–F</sub> = 3.0 Hz), 154.6, 148.2 (d, <i>J</i><sub>C–F</sub> = 237.4 Hz), 147.5 (d, <i>J</i><sub>C–F</sub> = 259.6 Hz), 145.6, 141.0, 135.6 (d, <i>J</i><sub>C–F</sub> = 3.0 Hz), 132.6 (d, <i>J</i><sub>C–F</sub> = 10.8 Hz), 126.3 (d, <i>J</i><sub>C–F</sub> = 11.4 Hz), 125.4 (d, <i>J</i><sub>C–F</sub> = 7.2 Hz), 122.9 (d, <i>J</i><sub>C–F</sub> = 4.0 Hz), 122.2 (d, <i>J</i><sub>C–F</sub> = 5.5 Hz), 116.3 (d, <i>J</i><sub>C–F</sub> = 18.5 Hz), 115.4, 111.3 (d, <i>J</i><sub>C–F</sub> = 2.8 Hz), 43.3, 35.5, 33.2, 29.4, 29.2, 16.9. <sup>19</sup>F NMR (377 MHz, DMSO-<i>d</i><sub>6</sub>): δ −130.8 (s, 1F), −136.1 (s, 1F). HRMS <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>23</sub>H<sub>27</sub>F<sub>2</sub>N<sub>5</sub>O<sub>2</sub>, 444.2206; found, 444.2212.</div></div></div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i47"><a href="/doi/suppl/10.1021/acs.jmedchem.0c02085" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_61033" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_61033" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.0c02085?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c02085</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Molecular formula strings of compounds <b>1</b>–<b>14</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.0c02085/suppl_file/jm0c02085_si_001.csv" class="ext-link">CSV</a>)</p></li><li><p class="inline">Crystallographic data of compound <b>6</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.0c02085/suppl_file/jm0c02085_si_002.cif" class="ext-link">CIF</a>)</p></li><li><p class="inline">Crystallographic data of compound <b>7</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.0c02085/suppl_file/jm0c02085_si_003.cif" class="ext-link">CIF</a>)</p></li><li><p class="inline">Detailed synthetic chemistry schemes, NMR and HPLC spectra for compound <b>7</b>, small-molecule X-ray crystal structures and statistics for compounds <b>6</b> and <b>7</b>, detailed kinase selectivity panel data for compounds <b>1</b>–<b>7</b>, crystallographic statistics for protein cocrystal structure of <b>7</b>, data on synergistic effects of GNE-0749 + cobimetinib and nonsynergistic effects of vemurafenib + cobimetinib in KRAS mutant cell line, HCT116 (<a href="/doi/suppl/10.1021/acs.jmedchem.0c02085/suppl_file/jm0c02085_si_004.pdf" class="ext-link">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c02085/suppl_file/jm0c02085_si_001.csv">jm0c02085_si_001.csv (1.58 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c02085/suppl_file/jm0c02085_si_002.cif">jm0c02085_si_002.cif (438.96 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c02085/suppl_file/jm0c02085_si_003.cif">jm0c02085_si_003.cif (496.34 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c02085/suppl_file/jm0c02085_si_004.pdf">jm0c02085_si_004.pdf (1.04 MB)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.0c02085" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_82152" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_82152" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michael Siu</span> - <span class="hlFld-Affiliation affiliation">Discovery
Chemistry, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-2822-6584" title="Orcid link">http://orcid.org/0000-0002-2822-6584</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#e89b819dc685818b80898d84a88f8d868dc68b8785"><span class="__cf_email__" data-cfemail="95e6fce0bbf8fcf6fdf4f0f9d5f2f0fbf0bbf6faf8">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Joachim Rudolph</span> - <span class="hlFld-Affiliation affiliation">Discovery
Chemistry, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#90e2e5f4fffce0f8befafff1f3f8f9fdd0f7f5fef5bef3fffd"><span class="__cf_email__" data-cfemail="9be9eefff4f7ebf3b5f1f4faf8f3f2f6dbfcfef5feb5f8f4f6">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Malcolm P. Huestis</span> - <span class="hlFld-Affiliation affiliation">Discovery
Chemistry, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-6038-3838" title="Orcid link">http://orcid.org/0000-0002-6038-3838</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Darlene Dela Cruz</span> - <span class="hlFld-Affiliation affiliation">Translational
Oncology, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Antonio G. DiPasquale</span> - <span class="hlFld-Affiliation affiliation">Small
Molecule Pharmaceutical Sciences, Genentech,
Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Matthew R. Durk</span> - <span class="hlFld-Affiliation affiliation">Drug
Metabolism and Pharmacokinetics, Genentech,
Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Charles Eigenbrot</span> - <span class="hlFld-Affiliation affiliation">Structural
Biology, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Paul Gibbons</span> - <span class="hlFld-Affiliation affiliation">Discovery
Chemistry, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Alberto Gobbi</span> - <span class="hlFld-Affiliation affiliation">Discovery
Chemistry, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Thomas L. Hunsaker</span> - <span class="hlFld-Affiliation affiliation">Translational
Oncology, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hank La</span> - <span class="hlFld-Affiliation affiliation">Drug
Metabolism and Pharmacokinetics, Genentech,
Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Dennis H. Leung</span> - <span class="hlFld-Affiliation affiliation">Small
Molecule Pharmaceutical Sciences, Genentech,
Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Wendy Liu</span> - <span class="hlFld-Affiliation affiliation">Discovery
Chemistry, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Shiva Malek</span> - <span class="hlFld-Affiliation affiliation">Molecular
Oncology, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mark Merchant</span> - <span class="hlFld-Affiliation affiliation">Translational
Oncology, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">John G. Moffat</span> - <span class="hlFld-Affiliation affiliation">Biochemical
and Cellular Pharmacology, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Christine S. Muli</span> - <span class="hlFld-Affiliation affiliation">Small
Molecule Pharmaceutical Sciences, Genentech,
Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Christine J. Orr</span> - <span class="hlFld-Affiliation affiliation">Translational
Oncology, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Brendan T. Parr</span> - <span class="hlFld-Affiliation affiliation">Discovery
Chemistry, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Frances Shanahan</span> - <span class="hlFld-Affiliation affiliation">Molecular
Oncology, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Christopher J. Sneeringer</span> - <span class="hlFld-Affiliation affiliation">Biochemical
and Cellular Pharmacology, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Weiru Wang</span> - <span class="hlFld-Affiliation affiliation">Structural
Biology, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ivana Yen</span> - <span class="hlFld-Affiliation affiliation">Molecular
Oncology, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jianping Yin</span> - <span class="hlFld-Affiliation affiliation">Structural
Biology, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare the following competing financial interest(s): All authors are employees/former employees of Genentech, Inc. and may hold stock in Roche Holding AG. All studies were funded by Genentech, Inc.<br /></br><p class="inlineNote">Coordinates and structure factors for the BRAF domain complex are available in the PDB with accession code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7K0V">7K0V</a> (<b>7</b>). The authors will release the atomic coordinates and experimental data upon article publication.</p></div></li></ul></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i49">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_64602" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_64602" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">M.P.H. thanks Kim Huard for support and encouragement. Kinase selectivity data courtesy of SelectScreen service from Life Technologies, a Thermo Fisher company, Madison, WI, USA. We thank the staff at beamline 5.0.2 of the Advanced Light Source for assistance during data collection and Xiaolin Zhang (Genentech, Inc.) for BA analysis.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">ASD</td><td class="NLM_def"><p class="first last">amorphous spray-dried dispersion</p></td></tr><tr><td class="NLM_term">CL</td><td class="NLM_def"><p class="first last">clearance</p></td></tr><tr><td class="NLM_term">DELFIA</td><td class="NLM_def"><p class="first last">dissociation-enhanced lanthanide fluorescence immunoassay</p></td></tr><tr><td class="NLM_term">DFG</td><td class="NLM_def"><p class="first last">Asp–Phe–Gly</p></td></tr><tr><td class="NLM_term">ERK</td><td class="NLM_def"><p class="first last">extracellular signal-regulated kinase</p></td></tr><tr><td class="NLM_term">F</td><td class="NLM_def"><p class="first last">bioavailability</p></td></tr><tr><td class="NLM_term">HCT</td><td class="NLM_def"><p class="first last">human colorectal cancer cells</p></td></tr><tr><td class="NLM_term">IV</td><td class="NLM_def"><p class="first last">intravenous</p></td></tr><tr><td class="NLM_term">KRAS</td><td class="NLM_def"><p class="first last">Kirsten rat sarcoma</p></td></tr><tr><td class="NLM_term">log <i>D</i></td><td class="NLM_def"><p class="first last">log of distribution coefficient</p></td></tr><tr><td class="NLM_term">MDCK</td><td class="NLM_def"><p class="first last">Madin–Darby canine kidney cell</p></td></tr><tr><td class="NLM_term">MEK</td><td class="NLM_def"><p class="first last">mitogen-activated protein kinase kinase</p></td></tr><tr><td class="NLM_term">MAPK</td><td class="NLM_def"><p class="first last">mitogen-activated protein kinase</p></td></tr><tr><td class="NLM_term">MCT</td><td class="NLM_def"><p class="first last">methylcellulose-tween</p></td></tr><tr><td class="NLM_term">mp</td><td class="NLM_def"><p class="first last">melting point</p></td></tr><tr><td class="NLM_term">MS</td><td class="NLM_def"><p class="first last">mass spectrometry</p></td></tr><tr><td class="NLM_term">Ni-NTA</td><td class="NLM_def"><p class="first last">nickel-nitrilotriacetic acid</p></td></tr><tr><td class="NLM_term"><i>P</i><sub>app</sub></td><td class="NLM_def"><p class="first last">permeability coefficient</p></td></tr><tr><td class="NLM_term">PBS</td><td class="NLM_def"><p class="first last">phosphate-buffered saline</p></td></tr><tr><td class="NLM_term">PEG</td><td class="NLM_def"><p class="first last">polyethylene glycol</p></td></tr><tr><td class="NLM_term">PK</td><td class="NLM_def"><p class="first last">pharmacokinetic</p></td></tr><tr><td class="NLM_term">PKPD</td><td class="NLM_def"><p class="first last">pharmacokinetic/pharmacodynamic</p></td></tr><tr><td class="NLM_term">PO</td><td class="NLM_def"><p class="first last">per os (oral)</p></td></tr><tr><td class="NLM_term">RAF</td><td class="NLM_def"><p class="first last">rapidly accelerated fibrosarcoma</p></td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">structure–activity relationship</p></td></tr><tr><td class="NLM_term">TCEP</td><td class="NLM_def"><p class="first last">tris(2-carboxyethyl)phosphine</p></td></tr><tr><td class="NLM_term">TGI</td><td class="NLM_def"><p class="first last">tumor growth inhibition</p></td></tr><tr><td class="NLM_term">TPSA</td><td class="NLM_def"><p class="first last">topological polar surface area</p></td></tr><tr><td class="NLM_term"><i>V</i><sub>dss</sub></td><td class="NLM_def"><p class="first last">volume of distribution</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i51">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_62446" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_62446" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 40 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Samatar, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poulikakos, P. I.</span></span> <span> </span><span class="NLM_article-title">Targeting RAS–ERK signalling in cancer: Promises and challenges</span>. <i>Nat. Rev. Drug Discov.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">928</span>– <span class="NLM_lpage">942</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=10.1038%2Fnrd4281" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=25435214" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvF2lsrrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=928-942&author=A.+A.+Samatarauthor=P.+I.+Poulikakos&title=Targeting+RAS%E2%80%93ERK+signalling+in+cancer%3A+Promises+and+challenges"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1aR"><div class="casContent"><span class="casTitleNuber">1a</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting RAS-ERK signalling in cancer: promises and challenges</span></div><div class="casAuthors">Samatar, Ahmed A.; Poulikakos, Poulikos I.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">928-942</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The RAS-RAF-MEK-ERK signalling pathway is hyperactivated in a high percentage of tumors, most frequently owing to activating mutations of the KRAS, NRAS and BRAF genes.  Recently, the use of compds. targeting components of ERK signalling, such as RAF or MEK inhibitors, has led to substantial improvement in clin. outcome in metastatic melanoma and has shown promising clin. activity in addnl. tumor types.  However, response rates are highly variable and the efficacy of these drugs is primarily limited by the development of resistance.  Both intrinsic and acquired resistance to RAF and MEK inhibitors are frequently assocd. with the persistence of ERK signalling in the presence of the drug, implying the need for more innovative approaches to target the pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrL4UeXNUJnYbVg90H21EOLACvtfcHk0lgM3hKzkcEUJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvF2lsrrI&md5=ab4038893612f438cf4406680ab2e4f4</span></div><a href="/servlet/linkout?suffix=cit1a&amp;dbid=16384&amp;doi=10.1038%2Fnrd4281&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4281%26sid%3Dliteratum%253Aachs%26aulast%3DSamatar%26aufirst%3DA.%2BA.%26aulast%3DPoulikakos%26aufirst%3DP.%2BI.%26atitle%3DTargeting%2520RAS%25E2%2580%2593ERK%2520signalling%2520in%2520cancer%253A%2520Promises%2520and%2520challenges%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discov.%26date%3D2014%26volume%3D13%26spage%3D928%26epage%3D942" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit1b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, H.</span></span> <span> </span><span class="NLM_article-title">Current development status of MEK inhibitors</span>. <i>Molecules</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">1551</span>– <span class="NLM_lpage">1571</span>, <span class="refDoi"> DOI: 10.3390/molecules22101551</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=10.3390%2Fmolecules22101551" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhs1Wjsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2017&pages=1551-1571&author=Y.+Chengauthor=H.+Tian&title=Current+development+status+of+MEK+inhibitors&doi=10.3390%2Fmolecules22101551"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1bR"><div class="casContent"><span class="casTitleNuber">1b</span><div class="casTitle"><span class="NLM_cas:atitle">Current development status of MEK inhibitors</span></div><div class="casAuthors">Cheng, Ying; Tian, Hongqi</div><div class="citationInfo"><span class="NLM_cas:title">Molecules</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1551/1-1551/20</span>CODEN:
                <span class="NLM_cas:coden">MOLEFW</span>;
        ISSN:<span class="NLM_cas:issn">1420-3049</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">The current development status of mitogen-activated protein kinase kinase (MEK) inhibitors, including the preclin. data and clin. study progress, has been summarized in this review.  Different MEK inhibitors, possessing specific physicochem. properties and bioactivity characteristics, may provide different options for patients seeking treatment for cancer.  Moreover, the combination of the MEK inhibitors with other therapies-such as chemotherapy, targeted therapy, and immunotherapy-may be a promising approach for clin. use.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGosd6s1Lx6dYbVg90H21EOLACvtfcHk0lgM3hKzkcEUJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhs1Wjsrk%253D&md5=0210d125f8a46468d67adb4f9aaf6cf3</span></div><a href="/servlet/linkout?suffix=cit1b&amp;dbid=16384&amp;doi=10.3390%2Fmolecules22101551&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmolecules22101551%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DY.%26aulast%3DTian%26aufirst%3DH.%26atitle%3DCurrent%2520development%2520status%2520of%2520MEK%2520inhibitors%26jtitle%3DMolecules%26date%3D2017%26volume%3D22%26spage%3D1551%26epage%3D1571%26doi%3D10.3390%2Fmolecules22101551" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit1c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Agianian, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gavathiotis, E.</span></span> <span> </span><span class="NLM_article-title">Current insights of BRAF inhibitors in cancer</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">5775</span>– <span class="NLM_lpage">5793</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01306</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01306" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref1/cit1c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=1%3ACAS%3A528%3ADC%252BC1cXivFChu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=5775-5793&author=B.+Agianianauthor=E.+Gavathiotis&title=Current+insights+of+BRAF+inhibitors+in+cancer&doi=10.1021%2Facs.jmedchem.7b01306"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1cR"><div class="casContent"><span class="casTitleNuber">1c</span><div class="casTitle"><span class="NLM_cas:atitle">Current Insights of BRAF Inhibitors in Cancer</span></div><div class="casAuthors">Agianian, Bogos; Gavathiotis, Evripidis</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">5775-5793</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Oncogenic BRAF kinase deregulates the ERK signaling pathway in a large no. of human tumors.  FDA-approved BRAF inhibitors for BRAFV600E/K tumors have provided impressive clin. responses extending survival of melanoma patients.  However, these drugs display paradoxical activation in normal tissue with BRAFWT due to RAF transactivation and priming, acquired drug resistance, and limited clin. effectiveness in non-V600 BRAF-dependent tumors, underscoring the urgent need to develop improved BRAF inhibitors.  This review provides an overview of recent structural and biochem. insights into the mechanisms of BRAF regulation by BRAF inhibitors that are linked to their clin. activity, clin. liabilities, and medicinal chem. properties.  The effectiveness and challenges of structurally diverse next generation RAF inhibitors currently in preclin. and clin. development are discussed, along with mechanistic insights for developing more effective RAF inhibitors targeting different oncogenic BRAF conformations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbFSsceLmTALVg90H21EOLACvtfcHk0lgM3hKzkcEUJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXivFChu70%253D&md5=7dcd6ce731bb591ecfac244b3b2b9b32</span></div><a href="/servlet/linkout?suffix=cit1c&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01306%26sid%3Dliteratum%253Aachs%26aulast%3DAgianian%26aufirst%3DB.%26aulast%3DGavathiotis%26aufirst%3DE.%26atitle%3DCurrent%2520insights%2520of%2520BRAF%2520inhibitors%2520in%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D5775%26epage%3D5793%26doi%3D10.1021%2Facs.jmedchem.7b01306" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit1d"><span><span class="NLM_label">(d) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Sammons, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghose, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsai, K. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalby, K. N.</span></span> <span> </span><span class="NLM_article-title">Targeting ERK beyond the boundaries of the kinase active site in melanoma</span>. <i>Mol. Carcinog.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">1551</span>– <span class="NLM_lpage">1570</span>, <span class="refDoi"> DOI: 10.1002/mc.23047</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=10.1002%2Fmc.23047" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=31190430" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtFGhsrjO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2019&pages=1551-1570&author=R.+M.+Sammonsauthor=R.+Ghoseauthor=K.+Y.+Tsaiauthor=K.+N.+Dalby&title=Targeting+ERK+beyond+the+boundaries+of+the+kinase+active+site+in+melanoma&doi=10.1002%2Fmc.23047"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1dR"><div class="casContent"><span class="casTitleNuber">1d</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting ERK beyond the boundaries of the kinase active site in melanoma</span></div><div class="casAuthors">Sammons, Rachel M.; Ghose, Ranajeet; Tsai, Kenneth Y.; Dalby, Kevin N.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Carcinogenesis</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1551-1570</span>CODEN:
                <span class="NLM_cas:coden">MOCAE8</span>;
        ISSN:<span class="NLM_cas:issn">0899-1987</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Extracellular signal-regulated kinase 1/2 (ERK1/2) constitute a point of convergence for complex signaling events that regulate essential cellular processes, including proliferation and survival.  As such, dysregulation of the ERK signaling pathway is prevalent in many cancers.  In the case of BRAF-V600E mutant melanoma, ERK inhibition has emerged as a viable clin. approach to abrogate signaling through the ERK pathway, even in cases where MEK and Raf inhibitor treatments fail to induce tumor regression due to resistance mechanisms.  Several ERK inhibitors that target the active site of ERK have reached clin. trials, however, many crit. ERK interactions occur at other potentially druggable sites on the protein.  Here we discuss the role of ERK signaling in cell fate, in driving melanoma, and in resistance mechanisms to current BRAF-V600E melanoma treatments.  We explore targeting ERK via a distinct site of protein-protein interaction, known as the D-recruitment site (DRS), as an alternative or supplementary mode of ERK pathway inhibition in BRAF-V600E melanoma.  Targeting the DRS with inhibitors in melanoma has the potential to not only disrupt the catalytic app. of ERK but also its noncatalytic functions, which have significant impacts on spatiotemporal signaling dynamics and cell fate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFpdwGW-bv6rVg90H21EOLACvtfcHk0ljjZPcsR68YAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtFGhsrjO&md5=24c27606b2302730c94a64521c82962f</span></div><a href="/servlet/linkout?suffix=cit1d&amp;dbid=16384&amp;doi=10.1002%2Fmc.23047&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmc.23047%26sid%3Dliteratum%253Aachs%26aulast%3DSammons%26aufirst%3DR.%2BM.%26aulast%3DGhose%26aufirst%3DR.%26aulast%3DTsai%26aufirst%3DK.%2BY.%26aulast%3DDalby%26aufirst%3DK.%2BN.%26atitle%3DTargeting%2520ERK%2520beyond%2520the%2520boundaries%2520of%2520the%2520kinase%2520active%2520site%2520in%2520melanoma%26jtitle%3DMol.%2520Carcinog.%26date%3D2019%26volume%3D58%26spage%3D1551%26epage%3D1570%26doi%3D10.1002%2Fmc.23047" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Tsai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mamo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bremer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillette, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haass, N. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sproesser, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smalley, K. S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fong, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Y.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marimuthu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheung, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rice, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Settachatgul, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shellooe, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantwell, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlessinger, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, K. Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">West, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powell, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Habets, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ibrahim, P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirth, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Artis, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herlyn, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bollag, G.</span></span> <span> </span><span class="NLM_article-title">Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>105</i></span>,  <span class="NLM_fpage">3041</span>– <span class="NLM_lpage">3046</span>, <span class="refDoi"> DOI: 10.1073/pnas.0711741105</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=10.1073%2Fpnas.0711741105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=18287029" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=1%3ACAS%3A528%3ADC%252BD1cXjtVSitrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2008&pages=3041-3046&author=J.+Tsaiauthor=J.+T.+Leeauthor=W.+Wangauthor=J.+Zhangauthor=H.+Choauthor=S.+Mamoauthor=R.+Bremerauthor=S.+Gilletteauthor=J.+Kongauthor=N.+K.+Haassauthor=K.+Sproesserauthor=L.+Liauthor=K.+S.+M.+Smalleyauthor=D.+Fongauthor=Y.-L.+Zhuauthor=A.+Marimuthuauthor=H.+Nguyenauthor=B.+Lamauthor=J.+Liuauthor=I.+Cheungauthor=J.+Riceauthor=Y.+Suzukiauthor=C.+Luuauthor=C.+Settachatgulauthor=R.+Shellooeauthor=J.+Cantwellauthor=S.-H.+Kimauthor=J.+Schlessingerauthor=K.+Y.+L.+Zhangauthor=B.+L.+Westauthor=B.+Powellauthor=G.+Habetsauthor=C.+Zhangauthor=P.+N.+Ibrahimauthor=P.+Hirthauthor=D.+R.+Artisauthor=M.+Herlynauthor=G.+Bollag&title=Discovery+of+a+selective+inhibitor+of+oncogenic+B-Raf+kinase+with+potent+antimelanoma+activity&doi=10.1073%2Fpnas.0711741105"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2aR"><div class="casContent"><span class="casTitleNuber">2a</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity</span></div><div class="casAuthors">Tsai, James; Lee, John T.; Wang, Weiru; Zhang, Jiazhong; Cho, Hanna; Mamo, Shumeye; Bremer, Ryan; Gillette, Sam; Kong, Jun; Haass, Nikolas K.; Sproesser, Katrin; Li, Ling; Smalley, Keiran S. M.; Fong, Daniel; Zhu, Yong-Liang; Marimuthu, Adhirai; Nguyen, Hoa; Lam, Billy; Liu, Jennifer; Cheung, Ivana; Rice, Julie; Suzuki, Yoshihisa; Luu, Catherine; Settachatgul, Calvin; Shellooe, Rafe; Cantwell, John; Kim, Sung-Hou; Schlessinger, Joseph; Zhang, Kam Y. J.; West, Brian L.; Powell, Ben; Habets, Gaston; Zhang, Chao; Ibrahim, Prabha N.; Hirth, Peter; Artis, Dean R.; Herlyn, Meenhard; Bollag, Gideon</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3041-3046</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">BRAFV600E is the most frequent oncogenic protein kinase mutation known.  Furthermore, inhibitors targeting "active" protein kinases have demonstrated significant utility in the therapeutic repertoire against cancer.  Therefore, the authors pursued the development of specific kinase inhibitors targeting B-Raf, and the V600E allele in particular.  By using a structure-guided discovery approach, a potent and selective inhibitor of active B-Raf has been discovered.  PLX4720, a 7-azaindole deriv. that inhibits B-RafV600E with an IC50 of 13 nM, defines a class of kinase inhibitor with marked selectivity in both biochem. and cellular assays.  PLX4720 preferentially inhibits the active B-RafV600E kinase compared with a broad spectrum of other kinases, and potent cytotoxic effects are also exclusive to cells bearing the V600E allele.  Consistent with the high degree of selectivity, ERK phosphorylation is potently inhibited by PLX4720 in B-RafV600E-bearing tumor cell lines but not in cells lacking oncogenic B-Raf.  In melanoma models, PLX4720 induces cell cycle arrest and apoptosis exclusively in B-RafV600E-pos. cells.  In B-RafV600E-dependent tumor xenograft models, orally dosed PLX4720 causes significant tumor growth delays, including tumor regressions, without evidence of toxicity.  The work described here represents the entire discovery process, from initial identification through structural and biol. studies in animal models to a promising therapeutic for testing in cancer patients bearing B-RafV600E-driven tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPX53IQCbDJ7Vg90H21EOLACvtfcHk0ljjZPcsR68YAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXjtVSitrk%253D&md5=273b94202f99984e6eb24723d0c6141f</span></div><a href="/servlet/linkout?suffix=cit2a&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0711741105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0711741105%26sid%3Dliteratum%253Aachs%26aulast%3DTsai%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DJ.%2BT.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DCho%26aufirst%3DH.%26aulast%3DMamo%26aufirst%3DS.%26aulast%3DBremer%26aufirst%3DR.%26aulast%3DGillette%26aufirst%3DS.%26aulast%3DKong%26aufirst%3DJ.%26aulast%3DHaass%26aufirst%3DN.%2BK.%26aulast%3DSproesser%26aufirst%3DK.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DSmalley%26aufirst%3DK.%2BS.%2BM.%26aulast%3DFong%26aufirst%3DD.%26aulast%3DZhu%26aufirst%3DY.-L.%26aulast%3DMarimuthu%26aufirst%3DA.%26aulast%3DNguyen%26aufirst%3DH.%26aulast%3DLam%26aufirst%3DB.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DCheung%26aufirst%3DI.%26aulast%3DRice%26aufirst%3DJ.%26aulast%3DSuzuki%26aufirst%3DY.%26aulast%3DLuu%26aufirst%3DC.%26aulast%3DSettachatgul%26aufirst%3DC.%26aulast%3DShellooe%26aufirst%3DR.%26aulast%3DCantwell%26aufirst%3DJ.%26aulast%3DKim%26aufirst%3DS.-H.%26aulast%3DSchlessinger%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DK.%2BY.%2BL.%26aulast%3DWest%26aufirst%3DB.%2BL.%26aulast%3DPowell%26aufirst%3DB.%26aulast%3DHabets%26aufirst%3DG.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DIbrahim%26aufirst%3DP.%2BN.%26aulast%3DHirth%26aufirst%3DP.%26aulast%3DArtis%26aufirst%3DD.%2BR.%26aulast%3DHerlyn%26aufirst%3DM.%26aulast%3DBollag%26aufirst%3DG.%26atitle%3DDiscovery%2520of%2520a%2520selective%2520inhibitor%2520of%2520oncogenic%2520B-Raf%2520kinase%2520with%2520potent%2520antimelanoma%2520activity%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2008%26volume%3D105%26spage%3D3041%26epage%3D3046%26doi%3D10.1073%2Fpnas.0711741105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit2b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Chapman, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hauschild, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robert, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haanen, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ascierto, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larkin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dummer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garbe, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Testori, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maio, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hogg, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lorigan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lebbe, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jouary, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schadendorf, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ribas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Day, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sosman, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirkwood, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eggermont, A. M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dreno, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nolop, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flaherty, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McArthur, G. A.</span></span> <span> </span><span class="NLM_article-title">Improved survival with vemurafenib in melanoma with BRAF V600E mutation</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>364</i></span>,  <span class="NLM_fpage">2507</span>– <span class="NLM_lpage">2516</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1103782</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=10.1056%2FNEJMoa1103782" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=21639808" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=1%3ACAS%3A528%3ADC%252BC3MXosVeitbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=364&publication_year=2011&pages=2507-2516&author=P.+B.+Chapmanauthor=A.+Hauschildauthor=C.+Robertauthor=J.+B.+Haanenauthor=P.+Asciertoauthor=J.+Larkinauthor=R.+Dummerauthor=C.+Garbeauthor=A.+Testoriauthor=M.+Maioauthor=D.+Hoggauthor=P.+Loriganauthor=C.+Lebbeauthor=T.+Jouaryauthor=D.+Schadendorfauthor=A.+Ribasauthor=S.+J.+O%E2%80%99Dayauthor=J.+A.+Sosmanauthor=J.+M.+Kirkwoodauthor=A.+M.+M.+Eggermontauthor=B.+Drenoauthor=K.+Nolopauthor=J.+Liauthor=B.+Nelsonauthor=J.+Houauthor=R.+J.+Leeauthor=K.+T.+Flahertyauthor=G.+A.+McArthur&title=Improved+survival+with+vemurafenib+in+melanoma+with+BRAF+V600E+mutation&doi=10.1056%2FNEJMoa1103782"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2bR"><div class="casContent"><span class="casTitleNuber">2b</span><div class="casTitle"><span class="NLM_cas:atitle">Improved survival with vemurafenib in melanoma with BRAF V600E mutation</span></div><div class="casAuthors">Chapman, Paul B.; Hauschild, Axel; Robert, Caroline; Haanen, John B.; Ascierto, Paolo; Larkin, James; Dummer, Reinhard; Garbe, Claus; Testori, Alessandro; Maio, Michele; Hogg, David; Lorigan, Paul; Lebbe, Celeste; Jouary, Thomas; Schadendorf, Dirk; Ribas, Antoni; O'Day, Steven J.; Sosman, Jeffrey A.; Kirkwood, John M.; Eggermont, Alexander M. M.; Dreno, Brigitte; Nolop, Keith; Li, Jiang; Nelson, Betty; Hou, Jeannie; Lee, Richard J.; Flaherty, Keith T.; McArthur, Grant A.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">364</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">2507-2516</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: Phase 1 and 2 clin. trials of the BRAF kinase inhibitor vemurafenib (PLX4032) have shown response rates of more than 50% in patients with metastatic melanoma with the BRAF V600E mutation.  METHODS: We conducted a phase 3 randomized clin. trial comparing vemurafenib with dacarbazine in 675 patients with previously untreated, metastatic melanoma with the BRAF V600E mutation.  Patients were randomly assigned to receive either vemurafenib (960 mg orally twice daily) or dacarbazine (1000 mg per square meter of body-surface area i.v. every 3 wk).  Coprimary end points were rates of overall and progression-free survival.  Secondary end points included the response rate, response duration, and safety.  A final anal. was planned after 196 deaths and an interim anal. after 98 deaths.  RESULTS: At 6 mo, overall survival was 840/ (95% confidence interval [CI], 78 to 89) in the vemurafenib group and 64% (95% CI, 56 to 73) in the dacarbazine group.  In the interim anal. for overall survival and final anal. for progression-free survival, vemurafenib was assocd. with a relative redn. of 63% in the risk of death and of 74% in the risk of either death or disease progression, as compared with dacarbazine (P < 0.001 for both comparisons).  After review of the interim anal. by an independent data and safety monitoring board, crossover from dacarbazine to vemurafenib was recommended.  Response rates were 48% for vemurafenib and 5% for dacarbazine.  Common adverse events assocd. with vemurafenib were arthralgia, rash, fatigue, alopecia, keratoacanthoma or squamous-cell carcinoma, photosensitivity, nausea, and diarrhea; 38% of patients required dose modification because of toxic effects.  CONCLUSIONS: Vemurafenib produced improved rates of overall and progression-free survival in patients with previously untreated melanoma with the BRAF V600E mutation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4NFxmTaDz97Vg90H21EOLACvtfcHk0ljgx69gA_IH4w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXosVeitbs%253D&md5=1a4b4f963221888dc63f620e87408070</span></div><a href="/servlet/linkout?suffix=cit2b&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1103782&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1103782%26sid%3Dliteratum%253Aachs%26aulast%3DChapman%26aufirst%3DP.%2BB.%26aulast%3DHauschild%26aufirst%3DA.%26aulast%3DRobert%26aufirst%3DC.%26aulast%3DHaanen%26aufirst%3DJ.%2BB.%26aulast%3DAscierto%26aufirst%3DP.%26aulast%3DLarkin%26aufirst%3DJ.%26aulast%3DDummer%26aufirst%3DR.%26aulast%3DGarbe%26aufirst%3DC.%26aulast%3DTestori%26aufirst%3DA.%26aulast%3DMaio%26aufirst%3DM.%26aulast%3DHogg%26aufirst%3DD.%26aulast%3DLorigan%26aufirst%3DP.%26aulast%3DLebbe%26aufirst%3DC.%26aulast%3DJouary%26aufirst%3DT.%26aulast%3DSchadendorf%26aufirst%3DD.%26aulast%3DRibas%26aufirst%3DA.%26aulast%3DO%25E2%2580%2599Day%26aufirst%3DS.%2BJ.%26aulast%3DSosman%26aufirst%3DJ.%2BA.%26aulast%3DKirkwood%26aufirst%3DJ.%2BM.%26aulast%3DEggermont%26aufirst%3DA.%2BM.%2BM.%26aulast%3DDreno%26aufirst%3DB.%26aulast%3DNolop%26aufirst%3DK.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DNelson%26aufirst%3DB.%26aulast%3DHou%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DR.%2BJ.%26aulast%3DFlaherty%26aufirst%3DK.%2BT.%26aulast%3DMcArthur%26aufirst%3DG.%2BA.%26atitle%3DImproved%2520survival%2520with%2520vemurafenib%2520in%2520melanoma%2520with%2520BRAF%2520V600E%2520mutation%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2011%26volume%3D364%26spage%3D2507%26epage%3D2516%26doi%3D10.1056%2FNEJMoa1103782" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit2c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Sosman, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuchter, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pavlick, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weber, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McArthur, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hutson, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moschos, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flaherty, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herset, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kefford, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawrence, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puzanov, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amaravadi, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chmielowski, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawrence, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shyr, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nolop, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joe, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ribas, A.</span></span> <span> </span><span class="NLM_article-title">Survival in BRAF V600–mutant advanced melanoma treated with vemurafenib</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>366</i></span>,  <span class="NLM_fpage">707</span>– <span class="NLM_lpage">714</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1112302</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=10.1056%2FNEJMoa1112302" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=22356324" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=1%3ACAS%3A528%3ADC%252BC38XjtFOqtr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=366&publication_year=2012&pages=707-714&author=J.+A.+Sosmanauthor=K.+B.+Kimauthor=L.+Schuchterauthor=R.+Gonzalezauthor=A.+C.+Pavlickauthor=J.+S.+Weberauthor=G.+A.+McArthurauthor=T.+E.+Hutsonauthor=S.+J.+Moschosauthor=K.+T.+Flahertyauthor=P.+Hersetauthor=R.+Keffordauthor=D.+Lawrenceauthor=I.+Puzanovauthor=K.+D.+Lewisauthor=R.+K.+Amaravadiauthor=B.+Chmielowskiauthor=H.+J.+Lawrenceauthor=Y.+Shyrauthor=F.+Yeauthor=J.+Liauthor=K.+B.+Nolopauthor=R.+J.+Leeauthor=A.+K.+Joeauthor=A.+Ribas&title=Survival+in+BRAF+V600%E2%80%93mutant+advanced+melanoma+treated+with+vemurafenib&doi=10.1056%2FNEJMoa1112302"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2cR"><div class="casContent"><span class="casTitleNuber">2c</span><div class="casTitle"><span class="NLM_cas:atitle">Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib</span></div><div class="casAuthors">Sosman, Jeffrey A.; Kim, Kevin B.; Schuchter, Lynn; Gonzalez, Rene; Pavlick, Anna C.; Weber, Jeffrey S.; McArthur, Grant A.; Hutson, Thomas E.; Moschos, Stergios J.; Flaherty, Keith T.; Hersey, Peter; Kefford, Richard; Lawrence, Donald; Puzanov, Igor; Lewis, Karl D.; Amaravadi, Ravi K.; Chmielowski, Bartosz; Lawrence, H. Jeffrey; Shyr, Yu; Ye, Fei; Li, Jiang; Nolop, Keith B.; Lee, Richard J.; Joe, Andrew K.; Ribas, Antoni</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">366</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">707-714</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND Approx. 50% of melanomas harbor activating (V600) mutations in the serine-threonine protein kinase B-RAF (BRAF).  The oral BRAF inhibitor vemurafenib (PLX4032) frequently produced tumor regressions in patients with BRAF V600-mutant metastatic melanoma in a phase 1 trial and improved overall survival in a phase 3 trial.  METHODS We designed a multicenter phase 2 trial of vemurafenib in patients with previously treated BRAF V600-mutant metastatic melanoma to investigate the efficacy of vem urafenib with respect to overall response rate (percentage of treated patients with a tumor response), duration of response, and overall survival.  The primary end point was the overall response rate as ascertained by the independent review committee; overall survival was a secondary end point.  RESULTS A total of 132 patients had a median follow-up of 12.9 mo (range, 0.6 to 20.1).  The confirmed overall response rate was 53% (95% confidence interval [CI], 44 to 62; 6% with a complete response and 47% with a partial response), the median duration of response was 6.7 mo (95% CI, 5.6 to 8.6), and the median progression-free survival was 6.8 mo (95% CI, 5.6 to 8.1).  Primary progression was obsd.,in only 14% of patients.  Some patients had a response after receiving vemurafenib for more than 6' months.  The median overall survival was 15.9 mo (95% CI, 11.6 to 18.3).  The most common adverse events were grade 1 or 2 arthralgia, rash, photosensitivity, fatigue, and alopecia.  Cutaneous squamous-cell carcinomas (the majority, keratoacanthoma type) were diagnosed in 26% of patients.  CONCLUSIONS Vemurafenib induces clin. responses in more than half of patients with previously treated BRAF V600-mutant metastatic melanoma.  In this study with a long follow-up, the median overall survival was approx. 16 mo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0-17UBZyghrVg90H21EOLACvtfcHk0ljgx69gA_IH4w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XjtFOqtr0%253D&md5=74da93cc5ac6497207f12dd0461d9414</span></div><a href="/servlet/linkout?suffix=cit2c&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1112302&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1112302%26sid%3Dliteratum%253Aachs%26aulast%3DSosman%26aufirst%3DJ.%2BA.%26aulast%3DKim%26aufirst%3DK.%2BB.%26aulast%3DSchuchter%26aufirst%3DL.%26aulast%3DGonzalez%26aufirst%3DR.%26aulast%3DPavlick%26aufirst%3DA.%2BC.%26aulast%3DWeber%26aufirst%3DJ.%2BS.%26aulast%3DMcArthur%26aufirst%3DG.%2BA.%26aulast%3DHutson%26aufirst%3DT.%2BE.%26aulast%3DMoschos%26aufirst%3DS.%2BJ.%26aulast%3DFlaherty%26aufirst%3DK.%2BT.%26aulast%3DHerset%26aufirst%3DP.%26aulast%3DKefford%26aufirst%3DR.%26aulast%3DLawrence%26aufirst%3DD.%26aulast%3DPuzanov%26aufirst%3DI.%26aulast%3DLewis%26aufirst%3DK.%2BD.%26aulast%3DAmaravadi%26aufirst%3DR.%2BK.%26aulast%3DChmielowski%26aufirst%3DB.%26aulast%3DLawrence%26aufirst%3DH.%2BJ.%26aulast%3DShyr%26aufirst%3DY.%26aulast%3DYe%26aufirst%3DF.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DNolop%26aufirst%3DK.%2BB.%26aulast%3DLee%26aufirst%3DR.%2BJ.%26aulast%3DJoe%26aufirst%3DA.%2BK.%26aulast%3DRibas%26aufirst%3DA.%26atitle%3DSurvival%2520in%2520BRAF%2520V600%25E2%2580%2593mutant%2520advanced%2520melanoma%2520treated%2520with%2520vemurafenib%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2012%26volume%3D366%26spage%3D707%26epage%3D714%26doi%3D10.1056%2FNEJMoa1112302" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rheault, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stellwagen, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adjabeng, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hornberger, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petrov, K. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waterson, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dickerson, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mook, R. A.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laquerre, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">King, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rossanese, O. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnone, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smitheman, K. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kane-Carson, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moorthy, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moss, K. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uehling, D. E.</span></span> <span> </span><span class="NLM_article-title">Discovery of Dabrafenib: A selective inhibitor of Raf kinases with antitumor activity against B-Raf-driven tumors</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">358</span>– <span class="NLM_lpage">362</span>, <span class="refDoi"> DOI: 10.1021/ml4000063</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml4000063" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=1%3ACAS%3A528%3ADC%252BC3sXit1Sqtr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=358-362&author=T.+R.+Rheaultauthor=J.+C.+Stellwagenauthor=G.+M.+Adjabengauthor=K.+R.+Hornbergerauthor=K.+G.+Petrovauthor=A.+G.+Watersonauthor=S.+H.+Dickersonauthor=R.+A.+Mookauthor=S.+G.+Laquerreauthor=A.+J.+Kingauthor=O.+W.+Rossaneseauthor=M.+R.+Arnoneauthor=K.+N.+Smithemanauthor=L.+S.+Kane-Carsonauthor=C.+Hanauthor=G.+S.+Moorthyauthor=K.+G.+Mossauthor=D.+E.+Uehling&title=Discovery+of+Dabrafenib%3A+A+selective+inhibitor+of+Raf+kinases+with+antitumor+activity+against+B-Raf-driven+tumors&doi=10.1021%2Fml4000063"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Dabrafenib: A Selective Inhibitor of Raf Kinases with Antitumor Activity against B-Raf-Driven Tumors</span></div><div class="casAuthors">Rheault, Tara R.; Stellwagen, John C.; Adjabeng, George M.; Hornberger, Keith R.; Petrov, Kimberly G.; Waterson, Alex G.; Dickerson, Scott H.; Mook, Robert A.; Laquerre, Sylvie G.; King, Alastair J.; Rossanese, Olivia W.; Arnone, Marc R.; Smitheman, Kimberly N.; Kane-Carson, Laurie S.; Han, Chao; Moorthy, Ganesh S.; Moss, Katherine G.; Uehling, David E.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">358-362</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Hyperactive signaling of the MAP kinase pathway resulting from the constitutively active B-RafV600E mutated enzyme has been obsd. in a no. of human tumors, including melanomas.  Herein, we report the discovery and biol. evaluation of GSK2118436 (dabrafenib, I), a selective inhibitor of Raf kinases with potent in vitro activity in oncogenic B-Raf-driven melanoma and colorectal carcinoma cells and robust in vivo antitumor and pharmacodynamic activity in mouse models of B-RafV600E human melanoma.  GSK2118436 was identified as a development candidate, and early clin. results have shown significant activity in patients with B-Raf mutant melanoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq97lPGF-Yb8bVg90H21EOLACvtfcHk0lja1mPEExwt8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXit1Sqtr4%253D&md5=4b26187120192c298ca89283e2871fe4</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1021%2Fml4000063&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml4000063%26sid%3Dliteratum%253Aachs%26aulast%3DRheault%26aufirst%3DT.%2BR.%26aulast%3DStellwagen%26aufirst%3DJ.%2BC.%26aulast%3DAdjabeng%26aufirst%3DG.%2BM.%26aulast%3DHornberger%26aufirst%3DK.%2BR.%26aulast%3DPetrov%26aufirst%3DK.%2BG.%26aulast%3DWaterson%26aufirst%3DA.%2BG.%26aulast%3DDickerson%26aufirst%3DS.%2BH.%26aulast%3DMook%26aufirst%3DR.%2BA.%26aulast%3DLaquerre%26aufirst%3DS.%2BG.%26aulast%3DKing%26aufirst%3DA.%2BJ.%26aulast%3DRossanese%26aufirst%3DO.%2BW.%26aulast%3DArnone%26aufirst%3DM.%2BR.%26aulast%3DSmitheman%26aufirst%3DK.%2BN.%26aulast%3DKane-Carson%26aufirst%3DL.%2BS.%26aulast%3DHan%26aufirst%3DC.%26aulast%3DMoorthy%26aufirst%3DG.%2BS.%26aulast%3DMoss%26aufirst%3DK.%2BG.%26aulast%3DUehling%26aufirst%3DD.%2BE.%26atitle%3DDiscovery%2520of%2520Dabrafenib%253A%2520A%2520selective%2520inhibitor%2520of%2520Raf%2520kinases%2520with%2520antitumor%2520activity%2520against%2520B-Raf-driven%2520tumors%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D4%26spage%3D358%26epage%3D362%26doi%3D10.1021%2Fml4000063" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Abe, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kikuchi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayakawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iida, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagahashi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maeda, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakamoto, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsumoto, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miura, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsumura, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seki, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inaba, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawasaki, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamaguchi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kakefuda, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nanayama, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurachi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hori, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshida, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kakegawa, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilmartin, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richter, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moss, K. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laquerre, S. L.</span></span> <span> </span><span class="NLM_article-title">Discovery of a highly potent and selective MEK inhibitor: GSK1120212 (JTP-74057 DMSO solvate)</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">320</span>– <span class="NLM_lpage">324</span>, <span class="refDoi"> DOI: 10.1021/ml200004g</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml200004g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=1%3ACAS%3A528%3ADC%252BC3MXisFeksb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2011&pages=320-324&author=H.+Abeauthor=S.+Kikuchiauthor=K.+Hayakawaauthor=T.+Iidaauthor=N.+Nagahashiauthor=K.+Maedaauthor=J.+Sakamotoauthor=N.+Matsumotoauthor=T.+Miuraauthor=K.+Matsumuraauthor=N.+Sekiauthor=T.+Inabaauthor=H.+Kawasakiauthor=T.+Yamaguchiauthor=R.+Kakefudaauthor=T.+Nanayamaauthor=H.+Kurachiauthor=Y.+Horiauthor=T.+Yoshidaauthor=J.+Kakegawaauthor=Y.+Watanabeauthor=A.+G.+Gilmartinauthor=M.+C.+Richterauthor=K.+G.+Mossauthor=S.+L.+Laquerre&title=Discovery+of+a+highly+potent+and+selective+MEK+inhibitor%3A+GSK1120212+%28JTP-74057+DMSO+solvate%29&doi=10.1021%2Fml200004g"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4aR"><div class="casContent"><span class="casTitleNuber">4a</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Highly Potent and Selective MEK Inhibitor: GSK1120212 (JTP-74057 DMSO Solvate)</span></div><div class="casAuthors">Abe, Hiroyuki; Kikuchi, Shinichi; Hayakawa, Kazuhide; Iida, Tetsuya; Nagahashi, Noboru; Maeda, Katsuya; Sakamoto, Johei; Matsumoto, Noriaki; Miura, Tomoya; Matsumura, Koji; Seki, Noriyoshi; Inaba, Takashi; Kawasaki, Hisashi; Yamaguchi, Takayuki; Kakefuda, Reina; Nanayama, Toyomichi; Kurachi, Hironori; Hori, Yoshikazu; Yoshida, Takayuki; Kakegawa, Junya; Watanabe, Yoshihiro; Gilmartin, Aidan G.; Richter, Mark C.; Moss, Katherine G.; Laquerre, Sylvie G.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">320-324</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Inhibition of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase (MEK) represents a promising strategy for the discovery of a new generation of anticancer chemotherapeutics.  Our synthetic efforts, beginning from the lead compd. 2, were directed at improving antiproliferative activity against cancer cells as well as various drug properties.  These efforts led to the discovery of N-{3-[3-cyclopropyl-5-(2-fluoro-4-iodophenylamino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydro-2H-pyrido[4,3-d]pyrimidin-1-yl]phenyl}acetamide dimethylsulfoxide solvate (GSK1120212, JTP-74057 DMSO solvate; 1), a selective and highly potent MEK inhibitor with improved drug properties.  We further confirmed that the antiproliferative activity correlates with cellular MEK inhibition and obsd. significant antitumor activity with daily oral dosing of 1 in a tumor xenograft model.  These qualities led to the selection of 1 for clin. development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpxCuItdsb_1bVg90H21EOLACvtfcHk0lja1mPEExwt8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXisFeksb0%253D&md5=0cb3bfa4e142b8d5ecc591e6792cd692</span></div><a href="/servlet/linkout?suffix=cit4a&amp;dbid=16384&amp;doi=10.1021%2Fml200004g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml200004g%26sid%3Dliteratum%253Aachs%26aulast%3DAbe%26aufirst%3DH.%26aulast%3DKikuchi%26aufirst%3DS.%26aulast%3DHayakawa%26aufirst%3DK.%26aulast%3DIida%26aufirst%3DT.%26aulast%3DNagahashi%26aufirst%3DN.%26aulast%3DMaeda%26aufirst%3DK.%26aulast%3DSakamoto%26aufirst%3DJ.%26aulast%3DMatsumoto%26aufirst%3DN.%26aulast%3DMiura%26aufirst%3DT.%26aulast%3DMatsumura%26aufirst%3DK.%26aulast%3DSeki%26aufirst%3DN.%26aulast%3DInaba%26aufirst%3DT.%26aulast%3DKawasaki%26aufirst%3DH.%26aulast%3DYamaguchi%26aufirst%3DT.%26aulast%3DKakefuda%26aufirst%3DR.%26aulast%3DNanayama%26aufirst%3DT.%26aulast%3DKurachi%26aufirst%3DH.%26aulast%3DHori%26aufirst%3DY.%26aulast%3DYoshida%26aufirst%3DT.%26aulast%3DKakegawa%26aufirst%3DJ.%26aulast%3DWatanabe%26aufirst%3DY.%26aulast%3DGilmartin%26aufirst%3DA.%2BG.%26aulast%3DRichter%26aufirst%3DM.%2BC.%26aulast%3DMoss%26aufirst%3DK.%2BG.%26aulast%3DLaquerre%26aufirst%3DS.%2BL.%26atitle%3DDiscovery%2520of%2520a%2520highly%2520potent%2520and%2520selective%2520MEK%2520inhibitor%253A%2520GSK1120212%2520%2528JTP-74057%2520DMSO%2520solvate%2529%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D2%26spage%3D320%26epage%3D324%26doi%3D10.1021%2Fml200004g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit4b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Flaherty, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Infante, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daud, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kefford, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sosman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamid, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuchter, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cebon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ibrahim, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kudchadkar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burris, H. A.,  III</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Falchook, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Algazi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, G. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puzanov, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lebowitz, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Little, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allred, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ouellet, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weber, J.</span></span> <span> </span><span class="NLM_article-title">Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>367</i></span>,  <span class="NLM_fpage">1694</span>– <span class="NLM_lpage">1703</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1210093</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=10.1056%2FNEJMoa1210093" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=23020132" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1eksLrJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=367&publication_year=2012&pages=1694-1703&author=K.+T.+Flahertyauthor=J.+R.+Infanteauthor=A.+Daudauthor=R.+Gonzalezauthor=R.+F.+Keffordauthor=J.+Sosmanauthor=O.+Hamidauthor=L.+Schuchterauthor=J.+Cebonauthor=N.+Ibrahimauthor=R.+Kudchadkarauthor=H.+A.+Burrisauthor=G.+Falchookauthor=A.+Algaziauthor=K.+Lewisauthor=G.+V.+Longauthor=I.+Puzanovauthor=P.+Lebowitzauthor=A.+Singhauthor=S.+Littleauthor=P.+Sunauthor=A.+Allredauthor=D.+Ouelletauthor=K.+B.+Kimauthor=K.+Patelauthor=J.+Weber&title=Combined+BRAF+and+MEK+inhibition+in+melanoma+with+BRAF+V600+mutations&doi=10.1056%2FNEJMoa1210093"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4bR"><div class="casContent"><span class="casTitleNuber">4b</span><div class="casTitle"><span class="NLM_cas:atitle">Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations</span></div><div class="casAuthors">Flaherty, Keith T.; Infante, Jeffery R.; Daud, Adil; Gonzalez, Rene; Kefford, Richard F.; Sosman, Jeffrey; Hamid, Omid; Schuchter, Lynn; Cebon, Jonathan; Ibrahim, Nageatte; Kudchadkar, Ragini; Burris, Howard A., III; Falchook, Gerald; Algazi, Alain; Lewis, Karl; Long, Georgina V.; Puzanov, Igor; Lebowitz, Peter; Singh, Ajay; Little, Shonda; Sun, Peng; Allred, Alicia; Ouellet, Daniele; Kim, Kevin B.; Patel, Kiran; Weber, Jeffrey</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">367</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">1694-1703</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND Resistance to therapy with BRAF kinase inhibitors is assocd. with reactivation of the mitogen-activated protein kinase (MAPK) pathway.  To address this problem, we conducted a phase 1 and 2 trial of combined treatment with dabrafenib, a selective BRAF inhibitor, and trametinib, a selective MAPK kinase (MEK) inhibitor.  METHODS In this open-label study involving 247 patients with metastatic melanoma and BRAF V600 mutations, we evaluated the pharmacokinetic activity and safety of oral dabrafenib (75 or 150 mg twice daily) and trametinib (1, 1.5, or 2 mg daily) in 85 patients and then randomly assigned 162 patients to receive combination therapy with dabrafenib (150 mg) plus trametinib (1 or 2 mg) or dabrafenib monotherapy.  The primary end points were the incidence of cutaneous squamous-cell carcinoma, survival free of melanoma progression, and response.  Secondary end points were overall survival and pharmacokinetic activity.  RESULTS Dose-limiting toxic effects were infrequently obsd. in patients receiving combination therapy with 150 mg of dabrafenib and 2 mg of trametinib (combination 150/2).  Cutaneous squamous-cell carcinoma was seen in 7% of patients receiving combination 150/2 and in 19% receiving monotherapy (P = 0.09), whereas pyrexia was more common in the combination 150/2 group than in the monotherapy group (71% vs. 26%).  Median progression-free survival in the combination 150/2 group was 9.4 mo, as compared with 5.8 mo in the monotherapy group (hazard ratio for progression or death, 0.39; 95% confidence interval, 0.25 to 0.62; P<0.001).  The rate of complete or partial response with combination 150/2 therapy was 76%, as compared with 54% with monotherapy (P = 0.03).  CONCLUSIONS Dabrafenib and trametinib were safely combined at full monotherapy doses.  The rate of pyrexia was increased with combination therapy, whereas the rate of proliferative skin lesions was nonsignificantly reduced.  Progression-free survival was significantly improved.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhk7I8zrGTVbVg90H21EOLACvtfcHk0lja1mPEExwt8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1eksLrJ&md5=199ae281d44c3b41309b934d88674cd3</span></div><a href="/servlet/linkout?suffix=cit4b&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1210093&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1210093%26sid%3Dliteratum%253Aachs%26aulast%3DFlaherty%26aufirst%3DK.%2BT.%26aulast%3DInfante%26aufirst%3DJ.%2BR.%26aulast%3DDaud%26aufirst%3DA.%26aulast%3DGonzalez%26aufirst%3DR.%26aulast%3DKefford%26aufirst%3DR.%2BF.%26aulast%3DSosman%26aufirst%3DJ.%26aulast%3DHamid%26aufirst%3DO.%26aulast%3DSchuchter%26aufirst%3DL.%26aulast%3DCebon%26aufirst%3DJ.%26aulast%3DIbrahim%26aufirst%3DN.%26aulast%3DKudchadkar%26aufirst%3DR.%26aulast%3DBurris%26aufirst%3DH.%2BA.%26aulast%3DFalchook%26aufirst%3DG.%26aulast%3DAlgazi%26aufirst%3DA.%26aulast%3DLewis%26aufirst%3DK.%26aulast%3DLong%26aufirst%3DG.%2BV.%26aulast%3DPuzanov%26aufirst%3DI.%26aulast%3DLebowitz%26aufirst%3DP.%26aulast%3DSingh%26aufirst%3DA.%26aulast%3DLittle%26aufirst%3DS.%26aulast%3DSun%26aufirst%3DP.%26aulast%3DAllred%26aufirst%3DA.%26aulast%3DOuellet%26aufirst%3DD.%26aulast%3DKim%26aufirst%3DK.%2BB.%26aulast%3DPatel%26aufirst%3DK.%26aulast%3DWeber%26aufirst%3DJ.%26atitle%3DCombined%2520BRAF%2520and%2520MEK%2520inhibition%2520in%2520melanoma%2520with%2520BRAF%2520V600%2520mutations%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2012%26volume%3D367%26spage%3D1694%26epage%3D1703%26doi%3D10.1056%2FNEJMoa1210093" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit4c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Robert, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karaszewska, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schachter, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rutkowski, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mackiewicz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stroiakovski, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lichinitser, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dummer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grange, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mortier, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiarion-Sileni, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drucis, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krajsova, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hauschild, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lorigan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolter, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, G. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flaherty, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nathan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ribas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, A.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crist, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Legos, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubin, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Little, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schadendorf, D.</span></span> <span> </span><span class="NLM_article-title">Improved overall survival in melanoma with combined dabrafenib and trametinib</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>372</i></span>,  <span class="NLM_fpage">30</span>– <span class="NLM_lpage">39</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1412690</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=10.1056%2FNEJMoa1412690" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=25399551" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFSqsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=372&publication_year=2015&pages=30-39&author=C.+Robertauthor=B.+Karaszewskaauthor=J.+Schachterauthor=P.+Rutkowskiauthor=A.+Mackiewiczauthor=D.+Stroiakovskiauthor=M.+Lichinitserauthor=R.+Dummerauthor=F.+Grangeauthor=L.+Mortierauthor=V.+Chiarion-Sileniauthor=K.+Drucisauthor=I.+Krajsovaauthor=A.+Hauschildauthor=P.+Loriganauthor=P.+Wolterauthor=G.+V.+Longauthor=K.+Flahertyauthor=P.+Nathanauthor=A.+Ribasauthor=A.-M.+Martinauthor=P.+Sunauthor=W.+Cristauthor=J.+Legosauthor=S.+D.+Rubinauthor=S.+M.+Littleauthor=D.+Schadendorf&title=Improved+overall+survival+in+melanoma+with+combined+dabrafenib+and+trametinib&doi=10.1056%2FNEJMoa1412690"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4cR"><div class="casContent"><span class="casTitleNuber">4c</span><div class="casTitle"><span class="NLM_cas:atitle">Improved overall survival in melanoma with combined dabrafenib and trametinib</span></div><div class="casAuthors">Robert, Caroline; Karaszewska, Boguslawa; Schachter, Jacob; Rutkowski, Piotr; Mackiewicz, Andrzej; Stroiakovski, Daniil; Lichinitser, Michael; Dummer, Reinhard; Grange, Florent; Mortier, Laurent; Chiarion-Sileni, Vanna; Drucis, Kamil; Krajsova, Ivana; Hauschild, Axel; Lorigan, Paul; Wolter, Pascal; Long, Georgina V.; Flaherty, Keith; Nathan, Paul; Ribas, Antoni; Martin, Anne-Marie; Sun, Peng; Crist, Wendy; Legos, Jeff; Rubin, Stephen D.; Little, Shonda M.; Schadendorf, Dirk</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">372</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">30-39/1-30-39/10, 10 pp.</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: The BRAF inhibitors vemurafenib and dabrafenib have shown efficacy as monotherapies in patients with previously untreated metastatic melanoma with BRAF V600E or V600K mutations.  Combining dabrafenib and the MEK inhibitor trametinib, as compared with dabrafenib alone, enhanced antitumor activity in this population of patients.  Methods: In this open-label, phase 3 trial, we randomly assigned 704 patients with metastatic melanoma with a BRAF V600 mutation to receive either a combination of dabrafenib (150 mg twice daily) and trametinib (2 mg once daily) or vemurafenib (960 mg twice daily) orally as first-line therapy.  The primary end point was overall survival.  Results: At the preplanned interim overall survival anal., which was performed after 77% of the total no. of expected events occurred, the overall survival rate at 12 mo was 72% (95% confidence interval [CI], 67 to 77) in the combination-therapy group and 65% (95% CI, 59 to 70) in the vemurafenib group (hazard ratio for death in the combination-therapy group, 0.69; 95% CI, 0.53 to 0.89; P = 0.005).  The prespecified interim stopping boundary was crossed, and the study was stopped for efficacy in July 2014.  Median progression-free survival was 11.4 mo in the combination therapy group and 7.3 mo in the vemurafenib group (hazard ratio, 0.56; 95% CI, 0.46 to 0.69; P<0.001).  The objective response rate was 64% in the combination therapy group and 51% in the vemurafenib group (P<0.001).  Rates of severe adverse events and study-drug discontinuations were similar in the two groups.  Cutaneous squamous-cell carcinoma and keratoacanthoma occurred in 1% of patients in the combination-therapy group and 18% of those in the vemurafenib group.  Conclusions: Dabrafenib plus trametinib, as compared with vemurafenib monotherapy, significantly improved overall survival in previously untreated patients with metastatic melanoma with BRAF V600E or V600K mutations, without increased overall toxicity. (Funded by GlaxoSmithKline; ClinicalTrials.gov no., NCT01597908.).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5of4j14YrP7Vg90H21EOLACvtfcHk0lh8yB0taQeljQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFSqsb0%253D&md5=9d6a8f49bbd196f9463ec15958eb15d1</span></div><a href="/servlet/linkout?suffix=cit4c&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1412690&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1412690%26sid%3Dliteratum%253Aachs%26aulast%3DRobert%26aufirst%3DC.%26aulast%3DKaraszewska%26aufirst%3DB.%26aulast%3DSchachter%26aufirst%3DJ.%26aulast%3DRutkowski%26aufirst%3DP.%26aulast%3DMackiewicz%26aufirst%3DA.%26aulast%3DStroiakovski%26aufirst%3DD.%26aulast%3DLichinitser%26aufirst%3DM.%26aulast%3DDummer%26aufirst%3DR.%26aulast%3DGrange%26aufirst%3DF.%26aulast%3DMortier%26aufirst%3DL.%26aulast%3DChiarion-Sileni%26aufirst%3DV.%26aulast%3DDrucis%26aufirst%3DK.%26aulast%3DKrajsova%26aufirst%3DI.%26aulast%3DHauschild%26aufirst%3DA.%26aulast%3DLorigan%26aufirst%3DP.%26aulast%3DWolter%26aufirst%3DP.%26aulast%3DLong%26aufirst%3DG.%2BV.%26aulast%3DFlaherty%26aufirst%3DK.%26aulast%3DNathan%26aufirst%3DP.%26aulast%3DRibas%26aufirst%3DA.%26aulast%3DMartin%26aufirst%3DA.-M.%26aulast%3DSun%26aufirst%3DP.%26aulast%3DCrist%26aufirst%3DW.%26aulast%3DLegos%26aufirst%3DJ.%26aulast%3DRubin%26aufirst%3DS.%2BD.%26aulast%3DLittle%26aufirst%3DS.%2BM.%26aulast%3DSchadendorf%26aufirst%3DD.%26atitle%3DImproved%2520overall%2520survival%2520in%2520melanoma%2520with%2520combined%2520dabrafenib%2520and%2520trametinib%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2015%26volume%3D372%26spage%3D30%26epage%3D39%26doi%3D10.1056%2FNEJMoa1412690" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit4d"><span><span class="NLM_label">(d) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Robert, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grob, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stroyakovskiy, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karaszewska, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hauschild, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levchenko, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiarion Sileni, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schachter, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garbe, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bondarenko, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gogas, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mandalá, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haanen, J. B. A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lebbé, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mackiewicz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rutkowski, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nathan, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ribas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flaherty, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burgess, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gasal, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schadendorf, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, G. V.</span></span> <span> </span><span class="NLM_article-title">Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>381</i></span>,  <span class="NLM_fpage">626</span>– <span class="NLM_lpage">636</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1904059</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=10.1056%2FNEJMoa1904059" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=31166680" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhs1GqsbbO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=381&publication_year=2019&pages=626-636&author=C.+Robertauthor=J.+J.+Grobauthor=D.+Stroyakovskiyauthor=B.+Karaszewskaauthor=A.+Hauschildauthor=E.+Levchenkoauthor=V.+Chiarion+Sileniauthor=J.+Schachterauthor=C.+Garbeauthor=I.+Bondarenkoauthor=H.+Gogasauthor=M.+Mandal%C3%A1author=J.+B.+A.+G.+Haanenauthor=C.+Lebb%C3%A9author=A.+Mackiewiczauthor=P.+Rutkowskiauthor=P.+D.+Nathanauthor=A.+Ribasauthor=M.+A.+Daviesauthor=K.+T.+Flahertyauthor=P.+Burgessauthor=M.+Tanauthor=E.+Gasalauthor=M.+Voiauthor=D.+Schadendorfauthor=G.+V.+Long&title=Five-year+outcomes+with+dabrafenib+plus+trametinib+in+metastatic+melanoma&doi=10.1056%2FNEJMoa1904059"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4dR"><div class="casContent"><span class="casTitleNuber">4d</span><div class="casTitle"><span class="NLM_cas:atitle">Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma</span></div><div class="casAuthors">Robert, C.; Grob, J. J.; Stroyakovskiy, D.; Karaszewska, B.; Hauschild, A.; Levchenko, E.; Sileni, V. Chiarion; Schachter, J.; Garbe, C.; Bondarenko, I.; Gogas, H.; Mandala, M.; Haanen, J. B. A. G.; Lebbe, C.; Mackiewicz, A.; Rutkowski, P.; Nathan, P. D.; Ribas, A.; Davies, M. A.; Flaherty, K. T.; Burgess, P.; Tan, M.; Gasal, E.; Voi, M.; Schadendorf, D.; Long, G. V.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">381</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">626-636</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">A review.  Background Patients who have unresectable or metastatic melanoma with a BRAF V600E or V600K mutation have prolonged progression-free survival and overall survival when receiving treatment with BRAF inhibitors plus MEK inhibitors.  However, long-term clin. outcomes in these patients remain undefined.  To det. 5-yr survival rates and clin. characteristics of the patients with durable benefit, we sought to review long-term data from randomized trials of combination therapy with BRAF and MEK inhibitors. methods We analyzed pooled extended-survival data from two trials involving previously untreated patients who had received BRAF inhibitor dabrafenib (at a dose of 150 mg twice daily) plus MEK inhibitor trametinib (2 mg once daily) in the COMBI-d and COMBI-v trials.  The median duration of follow-up was 22 mo (range, 0 to 76).  The primary end points in the COMBI-d and COMBI-v trials were progression-free survival and overall survival, resp. results A total of 563 patients were randomly assigned to receive dabrafenib plus trametinib (211 in the COMBI-d trial and 352 in the COMBI-v trial).  The progression-free survival rates were 21% (95% confidence interval [CI], 17 to 24) at 4 years and 19% (95% CI, 15 to 22) at 5 years.  The overall survival rates were 37% (95% CI, 33 to 42) at 4 years and 34% (95% CI, 30 to 38) at 5 years.  In multivariate anal., several baseline factors (e.g., performance status, age, sex, no. of organ sites with metastasis, and lactate dehydrogenase level) were significantly assocd. with both progression-free survival and overall survival.  A complete response occurred in 109 patients (19%) and was assocd. with an improved long-term outcome, with an overall survival rate of 71% (95% CI, 62 to 79) at 5 years. conclusions First-line treatment with dabrafenib plus trametinib led to long-term benefit in approx. one third of the patients who had unresectable or metastatic melanoma with a BRAF V600E or V600K mutation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo3AT72ajVerrVg90H21EOLACvtfcHk0lh8yB0taQeljQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhs1GqsbbO&md5=4aef2f5bbda3d7a8863a0c084bce61b1</span></div><a href="/servlet/linkout?suffix=cit4d&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1904059&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1904059%26sid%3Dliteratum%253Aachs%26aulast%3DRobert%26aufirst%3DC.%26aulast%3DGrob%26aufirst%3DJ.%2BJ.%26aulast%3DStroyakovskiy%26aufirst%3DD.%26aulast%3DKaraszewska%26aufirst%3DB.%26aulast%3DHauschild%26aufirst%3DA.%26aulast%3DLevchenko%26aufirst%3DE.%26aulast%3DChiarion%2BSileni%26aufirst%3DV.%26aulast%3DSchachter%26aufirst%3DJ.%26aulast%3DGarbe%26aufirst%3DC.%26aulast%3DBondarenko%26aufirst%3DI.%26aulast%3DGogas%26aufirst%3DH.%26aulast%3DMandal%25C3%25A1%26aufirst%3DM.%26aulast%3DHaanen%26aufirst%3DJ.%2BB.%2BA.%2BG.%26aulast%3DLebb%25C3%25A9%26aufirst%3DC.%26aulast%3DMackiewicz%26aufirst%3DA.%26aulast%3DRutkowski%26aufirst%3DP.%26aulast%3DNathan%26aufirst%3DP.%2BD.%26aulast%3DRibas%26aufirst%3DA.%26aulast%3DDavies%26aufirst%3DM.%2BA.%26aulast%3DFlaherty%26aufirst%3DK.%2BT.%26aulast%3DBurgess%26aufirst%3DP.%26aulast%3DTan%26aufirst%3DM.%26aulast%3DGasal%26aufirst%3DE.%26aulast%3DVoi%26aufirst%3DM.%26aulast%3DSchadendorf%26aufirst%3DD.%26aulast%3DLong%26aufirst%3DG.%2BV.%26atitle%3DFive-year%2520outcomes%2520with%2520dabrafenib%2520plus%2520trametinib%2520in%2520metastatic%2520melanoma%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2019%26volume%3D381%26spage%3D626%26epage%3D636%26doi%3D10.1056%2FNEJMoa1904059" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Rice, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aay, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anand, N. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blazey, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowles, O. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bussenius, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Costanzo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curtis, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Defina, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubenko, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engst, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joshi, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kennedy, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, A. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koltun, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lougheed, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manalo, J.-C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martini, J.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nuss, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peto, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsang, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnston, S.</span></span> <span> </span><span class="NLM_article-title">Novel carboxamide-based allosteric MEK inhibitors: Discovery and optimization efforts toward XL518 (GDC-0973)</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">416</span>– <span class="NLM_lpage">421</span>, <span class="refDoi"> DOI: 10.1021/ml300049d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml300049d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref5/cit5a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=1%3ACAS%3A528%3ADC%252BC38Xlt1eit7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=416-421&author=K.+D.+Riceauthor=N.+Aayauthor=N.+K.+Anandauthor=C.+M.+Blazeyauthor=O.+J.+Bowlesauthor=J.+Busseniusauthor=S.+Costanzoauthor=J.+K.+Curtisauthor=S.+C.+Definaauthor=L.+Dubenkoauthor=S.+Engstauthor=A.+A.+Joshiauthor=A.+R.+Kennedyauthor=A.+I.+Kimauthor=E.+S.+Koltunauthor=J.+C.+Lougheedauthor=J.-C.+L.+Manaloauthor=J.-F.+Martiniauthor=J.+M.+Nussauthor=C.+J.+Petoauthor=T.+H.+Tsangauthor=P.+Yuauthor=S.+Johnston&title=Novel+carboxamide-based+allosteric+MEK+inhibitors%3A+Discovery+and+optimization+efforts+toward+XL518+%28GDC-0973%29&doi=10.1021%2Fml300049d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5aR"><div class="casContent"><span class="casTitleNuber">5a</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Carboxamide-Based Allosteric MEK Inhibitors: Discovery and Optimization Efforts toward XL518 (GDC-0973)</span></div><div class="casAuthors">Rice, Kenneth D.; Aay, Naing; Anand, Neel K.; Blazey, Charles M.; Bowles, Owen J.; Bussenius, Joerg; Costanzo, Simona; Curtis, Jeffry K.; Defina, Steven C.; Dubenko, Larisa; Engst, Stefan; Joshi, Anagha A.; Kennedy, Abigail R.; Kim, Angie I.; Koltun, Elena S.; Lougheed, Julie C.; Manalo, Jean-Claire L.; Martini, Jean-Francois; Nuss, John M.; Peto, Csaba J.; Tsang, Tsze H.; Yu, Peiwen; Johnston, Stuart</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">416-421</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The ERK/MAP kinase cascade is a key mechanism subject to dysregulation in cancer and is constitutively activated or highly upregulated in many tumor types.  Mutations assocd. with upstream pathway components RAS and Raf occur frequently and contribute to the oncogenic phenotype through activation of MEK and then ERK.  Inhibitors of MEK have been shown to effectively block upregulated ERK/MAPK signaling in a range of cancer cell lines and have further demonstrated early evidence of efficacy in the clinic for the treatment of cancer.  Guided by structural insight, a strategy aimed at the identification of an optimal diphenylamine-based MEK inhibitor with an improved metab. and safety profile vs. PD-0325901 led to the discovery of development candidate 1-({3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]phenyl}carbonyl)-3-[(2S)-piperidin-2-yl]azetidin-3-ol (XL518, GDC-0973) (I).  I exhibits robust in vitro and in vivo potency and efficacy in preclin. models with sustained duration of action and is currently in early stage clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOx-Upr00b8LVg90H21EOLACvtfcHk0lj_gpuyn5n9pA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xlt1eit7k%253D&md5=04aa82afd24efe83a3b888140781bfc6</span></div><a href="/servlet/linkout?suffix=cit5a&amp;dbid=16384&amp;doi=10.1021%2Fml300049d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml300049d%26sid%3Dliteratum%253Aachs%26aulast%3DRice%26aufirst%3DK.%2BD.%26aulast%3DAay%26aufirst%3DN.%26aulast%3DAnand%26aufirst%3DN.%2BK.%26aulast%3DBlazey%26aufirst%3DC.%2BM.%26aulast%3DBowles%26aufirst%3DO.%2BJ.%26aulast%3DBussenius%26aufirst%3DJ.%26aulast%3DCostanzo%26aufirst%3DS.%26aulast%3DCurtis%26aufirst%3DJ.%2BK.%26aulast%3DDefina%26aufirst%3DS.%2BC.%26aulast%3DDubenko%26aufirst%3DL.%26aulast%3DEngst%26aufirst%3DS.%26aulast%3DJoshi%26aufirst%3DA.%2BA.%26aulast%3DKennedy%26aufirst%3DA.%2BR.%26aulast%3DKim%26aufirst%3DA.%2BI.%26aulast%3DKoltun%26aufirst%3DE.%2BS.%26aulast%3DLougheed%26aufirst%3DJ.%2BC.%26aulast%3DManalo%26aufirst%3DJ.-C.%2BL.%26aulast%3DMartini%26aufirst%3DJ.-F.%26aulast%3DNuss%26aufirst%3DJ.%2BM.%26aulast%3DPeto%26aufirst%3DC.%2BJ.%26aulast%3DTsang%26aufirst%3DT.%2BH.%26aulast%3DYu%26aufirst%3DP.%26aulast%3DJohnston%26aufirst%3DS.%26atitle%3DNovel%2520carboxamide-based%2520allosteric%2520MEK%2520inhibitors%253A%2520Discovery%2520and%2520optimization%2520efforts%2520toward%2520XL518%2520%2528GDC-0973%2529%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D3%26spage%3D416%26epage%3D421%26doi%3D10.1021%2Fml300049d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit5b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Larkin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ascierto, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dréno, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atkinson, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liszkay, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maio, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mandalà, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demidov, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stroyakovskiy, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de la Cruz-Merino, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dutriaux, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garbe, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sovak, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choong, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hack, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McArthur, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ribas, A.</span></span> <span> </span><span class="NLM_article-title">Combined vemurafenib and cobimetinib in <i>BRAF</i>-mutated melanoma</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>371</i></span>,  <span class="NLM_fpage">1867</span>– <span class="NLM_lpage">1876</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1408868</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=10.1056%2FNEJMoa1408868" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=25265494" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=1%3ACAS%3A528%3ADC%252BC2MXlslGgsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=371&publication_year=2014&pages=1867-1876&author=J.+Larkinauthor=P.+A.+Asciertoauthor=B.+Dr%C3%A9noauthor=V.+Atkinsonauthor=G.+Liszkayauthor=M.+Maioauthor=M.+Mandal%C3%A0author=L.+Demidovauthor=D.+Stroyakovskiyauthor=L.+Thomasauthor=L.+de+la+Cruz-Merinoauthor=C.+Dutriauxauthor=C.+Garbeauthor=M.+A.+Sovakauthor=I.+Changauthor=N.+Choongauthor=S.+P.+Hackauthor=G.+A.+McArthurauthor=A.+Ribas&title=Combined+vemurafenib+and+cobimetinib+in+BRAF-mutated+melanoma&doi=10.1056%2FNEJMoa1408868"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5bR"><div class="casContent"><span class="casTitleNuber">5b</span><div class="casTitle"><span class="NLM_cas:atitle">Combined vemurafenib and cobimetinib in BRAF-mutated melanoma</span></div><div class="casAuthors">Larkin, James; Ascierto, Paolo A.; Dreno, Brigitte; Atkinson, Victoria; Liszkay, Gabriella; Maio, Michele; Mandala, Mario; Demidov, Lev; Stroyakovskiy, Daniil; Thomas, Luc; de la Cruz-Merino, Luis; Dutriaux, Caroline; Garbe, Claus; Sovak, Mika A.; Chang, Ilsung; Choong, Nicholas; Hack, Stephen P.; McArthur, Grant A.; Ribas, Antoni</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">371</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">1867-1876, 10 pp.</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background The combined inhibition of BRAF and MEK is hypothesized to improve clin. outcomes in patients with melanoma by preventing or delaying the onset of resistance obsd. with BRAF inhibitors alone.  This randomized phase 3 study evaluated the combination of the BRAF inhibitor vemurafenib and the MEK inhibitor cobimetinib.  We randomly assigned 495 patients with previously untreated unresectable locally advanced or metastatic BRAF V600 mutation-pos. melanoma to receive vemurafenib and cobimetinib (combination group) or vemurafenib and placebo (control group).  The primary end point was investigator-assessed progression-free survival.  The median progression-free survival was 9.9 mo in the combination group and 6.2 mo in the control group (hazard ratio for death or disease progression, 0.51; 95% confidence interval [CI], 0.39 to 0.68; P<0.001).  The rate of complete or partial response in the combination group was 68%, as compared with 45% in the control group (P<0.001), including rates of complete response of 10% in the combination group and 4% in the control group.  Progression-free survival as assessed by independent review was similar to investigator-assessed progression-free survival.  Interim analyses of overall survival showed 9-mo survival rates of 81% (95% CI, 75 to 87) in the combination group and 73% (95% CI, 65 to 80) in the control group.  Vemurafenib and cobimetinib was assocd. with a nonsignificantly higher incidence of adverse events of grade 3 or higher, as compared with vemurafenib and placebo (65% vs. 59%), and there was no significant difference in the rate of study-drug discontinuation.  The no. of secondary cutaneous cancers decreased with the combination therapy.  The addn. of cobimetinib to vemurafenib was assocd. with a significant improvement in progression-free survival among patients with BRAF V600-mutated metastatic melanoma, at the cost of some increase in toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpErdkeTyZ9rVg90H21EOLACvtfcHk0lj_gpuyn5n9pA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXlslGgsQ%253D%253D&md5=9b6fb4f9ea883da579d6435ccb5742eb</span></div><a href="/servlet/linkout?suffix=cit5b&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1408868&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1408868%26sid%3Dliteratum%253Aachs%26aulast%3DLarkin%26aufirst%3DJ.%26aulast%3DAscierto%26aufirst%3DP.%2BA.%26aulast%3DDr%25C3%25A9no%26aufirst%3DB.%26aulast%3DAtkinson%26aufirst%3DV.%26aulast%3DLiszkay%26aufirst%3DG.%26aulast%3DMaio%26aufirst%3DM.%26aulast%3DMandal%25C3%25A0%26aufirst%3DM.%26aulast%3DDemidov%26aufirst%3DL.%26aulast%3DStroyakovskiy%26aufirst%3DD.%26aulast%3DThomas%26aufirst%3DL.%26aulast%3Dde%2Bla%2BCruz-Merino%26aufirst%3DL.%26aulast%3DDutriaux%26aufirst%3DC.%26aulast%3DGarbe%26aufirst%3DC.%26aulast%3DSovak%26aufirst%3DM.%2BA.%26aulast%3DChang%26aufirst%3DI.%26aulast%3DChoong%26aufirst%3DN.%26aulast%3DHack%26aufirst%3DS.%2BP.%26aulast%3DMcArthur%26aufirst%3DG.%2BA.%26aulast%3DRibas%26aufirst%3DA.%26atitle%3DCombined%2520vemurafenib%2520and%2520cobimetinib%2520in%2520BRAF-mutated%2520melanoma%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2014%26volume%3D371%26spage%3D1867%26epage%3D1876%26doi%3D10.1056%2FNEJMoa1408868" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, S.</span>; <span class="NLM_string-name">Jin, X.</span>; <span class="NLM_string-name">Liu, Z.</span>; <span class="NLM_string-name">Poon, D.</span>; <span class="NLM_string-name">Tellew, J.</span>; <span class="NLM_string-name">Wan, Y.</span>; <span class="NLM_string-name">Wang, X.</span>; <span class="NLM_string-name">Xie, Y.</span></span> <span> </span><span class="NLM_article-title">Compounds and compositions as protein kinase inhibitors</span>. <i>PCT Int. Appl.</i> <span class="NLM_patent">WO2011025927</span>, <span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=S.+Huang&author=X.+Jin&author=Z.+Liu&author=D.+Poon&author=J.+Tellew&author=Y.+Wan&author=X.+Wang&author=Y.+Xie&title=Compounds+and+compositions+as+protein+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DS.%26atitle%3DCompounds%2520and%2520compositions%2520as%2520protein%2520kinase%2520inhibitors%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit6b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Dummer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ascierto, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gogas, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arance, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mandala, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liszkay, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garbe, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schadendorf, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krajsova, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gutzmer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiarion-Sileni, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dutriaux, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Groot, J. W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamazaki, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loquai, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moutouh-de Parseval, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pickard, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sandor, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robert, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flaherty, K. T.</span></span> <span> </span><span class="NLM_article-title">Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): A multicentre, open-label, randomized phase 3 trial</span>. <i>Lancet Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">603</span>– <span class="NLM_lpage">615</span>, <span class="refDoi"> DOI: 10.1016/S1470-2045(18)30142-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=10.1016%2FS1470-2045%2818%2930142-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=29573941" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=1%3ACAS%3A528%3ADC%252BC1cXlslKltr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2018&pages=603-615&author=R.+Dummerauthor=P.+A.+Asciertoauthor=H.+J.+Gogasauthor=A.+Aranceauthor=M.+Mandalaauthor=G.+Liszkayauthor=C.+Garbeauthor=D.+Schadendorfauthor=I.+Krajsovaauthor=R.+Gutzmerauthor=V.+Chiarion-Sileniauthor=C.+Dutriauxauthor=J.+W.+B.+de+Grootauthor=N.+Yamazakiauthor=C.+Loquaiauthor=L.+A.+Moutouh-de+Parsevalauthor=M.+D.+Pickardauthor=V.+Sandorauthor=C.+Robertauthor=K.+T.+Flaherty&title=Encorafenib+plus+binimetinib+versus+vemurafenib+or+encorafenib+in+patients+with+BRAF-mutant+melanoma+%28COLUMBUS%29%3A+A+multicentre%2C+open-label%2C+randomized+phase+3+trial&doi=10.1016%2FS1470-2045%2818%2930142-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6bR"><div class="casContent"><span class="casTitleNuber">6b</span><div class="casTitle"><span class="NLM_cas:atitle">Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicenter, open-label, randomized phase 3 trial</span></div><div class="casAuthors">Dummer, Reinhard; Ascierto, Paolo A.; Gogas, Helen J.; Arance, Ana; Mandala, Mario; Liszkay, Gabriella; Garbe, Claus; Schadendorf, Dirk; Krajsova, Ivana; Gutzmer, Ralf; Chiarion-Sileni, Vanna; Dutriaux, Caroline; de Groot, Jan Willem B.; Yamazaki, Naoya; Loquai, Carmen; Moutouh-de Parseval, Laure A.; Pickard, Michael D.; Sandor, Victor; Robert, Caroline; Flaherty, Keith T.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">603-615</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Combined BRAF-MEK inhibitor therapy is the std. of care for BRAFV600-mutant advanced melanoma.  We investigated encorafenib, a BRAF inhibitor with unique target-binding properties, alone or in combination with the MEK inhibitor binimetinib, vs. vemurafenib in patients with advanced BRAFV600-mutant melanoma.  COLUMBUS was conducted as a two-part, randomized, open-label phase 3 study at 162 hospitals in 28 countries.  Eligible patients were aged 18 years or older and had histol. confirmed locally advanced (American Joint Committee on Cancer [AJCC] stage IIIB, IIIC, or IV), unresectable or metastatic cutaneous melanoma, or unknown primary melanoma; a BRAFV600E or BRAFV600K mutation; an Eastern Cooperative Oncol. Group (ECOG) performance status of 0 or 1; and were treatment naive or had progressed on or after previous first-line immunotherapy.  In part 1 of the study, patients were randomly assigned (1:1:1) via interactive response technol. to receive either oral encorafenib 450 mg once daily plus oral binimetinib 45 mg twice daily (encorafenib plus binimetinib group), oral encorafenib 300 mg once daily (encorafenib group), or oral vemurafenib 960 mg twice daily (vemurafenib group).  The primary endpoint was progression-free survival by blinded independent central review for encorafenib plus binimetinib vs. vemurafenib.  Efficacy analyses were by intention-to-treat.  Safety was analyzed in patients who received at least one dose of study drug and one post-baseline safety assessment.  The results of part 2 will be published sep.  This study is registered with ClinicalTrials.gov, no. NCT01909453, and EudraCT, no. 2013-001176-38.  Between Dec 30, 2013, and Apr. 10, 2015, 577 of 1345 screened patients were randomly assigned to either the encorafenib plus binimetinib group (n=192), the encorafenib group (n=194), or the vemurafenib group (n=191).  With a median follow-up of 16·6 mo (95% CI 14·8-16·9), median progression-free survival was 14·9 mo (95% CI 11·0-18·5) in the encorafenib plus binimetinib group and 7·3 mo (5·6-8·2) in the vemurafenib group (hazard ratio [HR] 0·54, 95% CI 0·41-0·71; two-sided p<0·0001).  The most common grade 3-4 adverse events seen in more than 5% of patients in the encorafenib plus binimetinib group were increased γ-glutamyltransferase (18 [9%] of 192 patients), increased creatine phosphokinase (13 [7%]), and hypertension (11 [6%]); in the encorafenib group they were palmoplantar erythrodysaesthesia syndrome (26 [14%] of 192 patients), myalgia (19 [10%]), and arthralgia (18 [9%]); and in the vemurafenib group it was arthralgia (11 [6%] of 186 patients).  There were no treatment-related deaths except for one death in the combination group, which was considered possibly related to treatment by the investigator.  Encorafenib plus binimetinib and encorafenib monotherapy showed favorable efficacy compared with vemurafenib.  Overall, encorafenib plus binimetinib appears to have an improved tolerability profile compared with encorafenib or vemurafenib.  Encorafenib plus binimetinib could represent a new treatment option for patients with BRAF-mutant melanoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjPYLzOZ57s7Vg90H21EOLACvtfcHk0ljA7bX5VBPJ-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXlslKltr4%253D&md5=4570e5b6091c5683a5f8a2d09110d541</span></div><a href="/servlet/linkout?suffix=cit6b&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2818%2930142-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252818%252930142-6%26sid%3Dliteratum%253Aachs%26aulast%3DDummer%26aufirst%3DR.%26aulast%3DAscierto%26aufirst%3DP.%2BA.%26aulast%3DGogas%26aufirst%3DH.%2BJ.%26aulast%3DArance%26aufirst%3DA.%26aulast%3DMandala%26aufirst%3DM.%26aulast%3DLiszkay%26aufirst%3DG.%26aulast%3DGarbe%26aufirst%3DC.%26aulast%3DSchadendorf%26aufirst%3DD.%26aulast%3DKrajsova%26aufirst%3DI.%26aulast%3DGutzmer%26aufirst%3DR.%26aulast%3DChiarion-Sileni%26aufirst%3DV.%26aulast%3DDutriaux%26aufirst%3DC.%26aulast%3Dde%2BGroot%26aufirst%3DJ.%2BW.%2BB.%26aulast%3DYamazaki%26aufirst%3DN.%26aulast%3DLoquai%26aufirst%3DC.%26aulast%3DMoutouh-de%2BParseval%26aufirst%3DL.%2BA.%26aulast%3DPickard%26aufirst%3DM.%2BD.%26aulast%3DSandor%26aufirst%3DV.%26aulast%3DRobert%26aufirst%3DC.%26aulast%3DFlaherty%26aufirst%3DK.%2BT.%26atitle%3DEncorafenib%2520plus%2520binimetinib%2520versus%2520vemurafenib%2520or%2520encorafenib%2520in%2520patients%2520with%2520BRAF-mutant%2520melanoma%2520%2528COLUMBUS%2529%253A%2520A%2520multicentre%252C%2520open-label%252C%2520randomized%2520phase%25203%2520trial%26jtitle%3DLancet%2520Oncol.%26date%3D2018%26volume%3D19%26spage%3D603%26epage%3D615%26doi%3D10.1016%2FS1470-2045%2818%2930142-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Hatzivassiliou, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yen, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brandhuber, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alvarado, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ludlam, M. J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stokoe, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gloor, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vigers, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morales, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aliagas, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sideris, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoeflich, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaiswal, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seshagiri, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koeppen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belvin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedman, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malek, S.</span></span> <span> </span><span class="NLM_article-title">RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>464</i></span>,  <span class="NLM_fpage">431</span>– <span class="NLM_lpage">435</span>, <span class="refDoi"> DOI: 10.1038/nature08833</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=10.1038%2Fnature08833" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=20130576" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVygtb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=464&publication_year=2010&pages=431-435&author=G.+Hatzivassiliouauthor=K.+Songauthor=I.+Yenauthor=B.+J.+Brandhuberauthor=D.+J.+Andersonauthor=R.+Alvaradoauthor=M.+J.+C.+Ludlamauthor=D.+Stokoeauthor=S.+L.+Gloorauthor=G.+Vigersauthor=T.+Moralesauthor=I.+Aliagasauthor=B.+Liuauthor=S.+Siderisauthor=K.+P.+Hoeflichauthor=B.+S.+Jaiswalauthor=S.+Seshagiriauthor=H.+Koeppenauthor=M.+Belvinauthor=L.+S.+Friedmanauthor=S.+Malek&title=RAF+inhibitors+prime+wild-type+RAF+to+activate+the+MAPK+pathway+and+enhance+growth&doi=10.1038%2Fnature08833"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7aR"><div class="casContent"><span class="casTitleNuber">7a</span><div class="casTitle"><span class="NLM_cas:atitle">RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth</span></div><div class="casAuthors">Hatzivassiliou, Georgia; Song, Kyung; Yen, Ivana; Brandhuber, Barbara J.; Anderson, Daniel J.; Alvarado, Ryan; Ludlam, Mary J. C.; Stokoe, David; Gloor, Susan L.; Vigers, Guy; Morales, Tony; Aliagas, Ignacio; Liu, Bonnie; Sideris, Steve; Hoeflich, Klaus P.; Jaiswal, Bijay S.; Seshagiri, Somasekar; Koeppen, Hartmut; Belvin, Marcia; Friedman, Lori S.; Malek, Shiva</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">464</span>
        (<span class="NLM_cas:issue">7287</span>),
    <span class="NLM_cas:pages">431-435</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Activating mutations in KRAS and BRAF are found in more than 30% of all human tumors and 40% of melanoma, resp., thus targeting this pathway could have broad therapeutic effects.  Small mol. ATP-competitive RAF kinase inhibitors have potent antitumor effects on mutant BRAF(V600E) tumors but, in contrast to mitogen-activated protein kinase kinase (MEK) inhibitors, are not potent against RAS mutant tumor models, despite RAF functioning as a key effector downstream of RAS and upstream of MEK.  Here we show that ATP-competitive RAF inhibitors have two opposing mechanisms of action depending on the cellular context.  In BRAF(V600E) tumors, RAF inhibitors effectively block the mitogen-activated protein kinase (MAPK) signalling pathway and decrease tumor growth.  Notably, in KRAS mutant and RAS/RAF wild-type tumors, RAF inhibitors activate the RAF-MEK-ERK pathway in a RAS-dependent manner, thus enhancing tumor growth in some xenograft models.  Inhibitor binding activates wild-type RAF isoforms by inducing dimerization, membrane localization and interaction with RAS-GTP.  These events occur independently of kinase inhibition and are, instead, linked to direct conformational effects of inhibitors on the RAF kinase domain.  On the basis of these findings, we demonstrate that ATP-competitive kinase inhibitors can have opposing functions as inhibitors or activators of signalling pathways, depending on the cellular context.  Furthermore, this work provides new insights into the therapeutic use of ATP-competitive RAF inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGounpcMETzVoLVg90H21EOLACvtfcHk0ljA7bX5VBPJ-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVygtb8%253D&md5=eb48bdf352ee9c9e182e63e38fd820a5</span></div><a href="/servlet/linkout?suffix=cit7a&amp;dbid=16384&amp;doi=10.1038%2Fnature08833&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature08833%26sid%3Dliteratum%253Aachs%26aulast%3DHatzivassiliou%26aufirst%3DG.%26aulast%3DSong%26aufirst%3DK.%26aulast%3DYen%26aufirst%3DI.%26aulast%3DBrandhuber%26aufirst%3DB.%2BJ.%26aulast%3DAnderson%26aufirst%3DD.%2BJ.%26aulast%3DAlvarado%26aufirst%3DR.%26aulast%3DLudlam%26aufirst%3DM.%2BJ.%2BC.%26aulast%3DStokoe%26aufirst%3DD.%26aulast%3DGloor%26aufirst%3DS.%2BL.%26aulast%3DVigers%26aufirst%3DG.%26aulast%3DMorales%26aufirst%3DT.%26aulast%3DAliagas%26aufirst%3DI.%26aulast%3DLiu%26aufirst%3DB.%26aulast%3DSideris%26aufirst%3DS.%26aulast%3DHoeflich%26aufirst%3DK.%2BP.%26aulast%3DJaiswal%26aufirst%3DB.%2BS.%26aulast%3DSeshagiri%26aufirst%3DS.%26aulast%3DKoeppen%26aufirst%3DH.%26aulast%3DBelvin%26aufirst%3DM.%26aulast%3DFriedman%26aufirst%3DL.%2BS.%26aulast%3DMalek%26aufirst%3DS.%26atitle%3DRAF%2520inhibitors%2520prime%2520wild-type%2520RAF%2520to%2520activate%2520the%2520MAPK%2520pathway%2520and%2520enhance%2520growth%26jtitle%3DNature%26date%3D2010%26volume%3D464%26spage%3D431%26epage%3D435%26doi%3D10.1038%2Fnature08833" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit7b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Poulikakos, P. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Persaud, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janakiraman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ng, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moriceau, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atefi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Titz, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gabay, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salton, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dahlman, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tadi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wargo, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flaherty, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelley, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Misteli, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chapman, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sosman, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graeber, T. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ribas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lo, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosen, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solit, D. B.</span></span> <span> </span><span class="NLM_article-title">RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>480</i></span>,  <span class="NLM_fpage">387</span>– <span class="NLM_lpage">390</span>, <span class="refDoi"> DOI: 10.1038/nature10662</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=10.1038%2Fnature10662" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=22113612" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsFWqtL%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=480&publication_year=2011&pages=387-390&author=P.+I.+Poulikakosauthor=Y.+Persaudauthor=M.+Janakiramanauthor=X.+Kongauthor=C.+Ngauthor=G.+Moriceauauthor=H.+Shiauthor=M.+Atefiauthor=B.+Titzauthor=M.+T.+Gabayauthor=M.+Saltonauthor=K.+B.+Dahlmanauthor=M.+Tadiauthor=J.+A.+Wargoauthor=K.+T.+Flahertyauthor=M.+C.+Kelleyauthor=T.+Misteliauthor=P.+B.+Chapmanauthor=J.+A.+Sosmanauthor=T.+G.+Graeberauthor=A.+Ribasauthor=R.+S.+Loauthor=N.+Rosenauthor=D.+B.+Solit&title=RAF+inhibitor+resistance+is+mediated+by+dimerization+of+aberrantly+spliced+BRAF%28V600E%29&doi=10.1038%2Fnature10662"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7bR"><div class="casContent"><span class="casTitleNuber">7b</span><div class="casTitle"><span class="NLM_cas:atitle">RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)</span></div><div class="casAuthors">Poulikakos, Poulikos I.; Persaud, Yogindra; Janakiraman, Manickam; Kong, Xiangju; Ng, Charles; Moriceau, Gatien; Shi, Hubing; Atefi, Mohammad; Titz, Bjoern; Gabay, May Tal; Salton, Maayan; Dahlman, Kimberly B.; Tadi, Madhavi; Wargo, Jennifer A.; Flaherty, Keith T.; Kelley, Mark C.; Misteli, Tom; Chapman, Paul B.; Sosman, Jeffrey A.; Graeber, Thomas G.; Ribas, Antoni; Lo, Roger S.; Rosen, Neal; Solit, David B.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">480</span>
        (<span class="NLM_cas:issue">7377</span>),
    <span class="NLM_cas:pages">387-390</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Although clin. trials have shown that RAF inhibitors prolong the survival of patients with BRAF-mutant melanoma, resistance inevitably develops; resistance is shown here to be frequently mediated by the expression of splicing variants of mutant BRAF.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0XPUFDxeK5rVg90H21EOLACvtfcHk0lgFcK_yZidCGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsFWqtL%252FN&md5=b239591d5efd1d965deabf0527c3b9a6</span></div><a href="/servlet/linkout?suffix=cit7b&amp;dbid=16384&amp;doi=10.1038%2Fnature10662&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature10662%26sid%3Dliteratum%253Aachs%26aulast%3DPoulikakos%26aufirst%3DP.%2BI.%26aulast%3DPersaud%26aufirst%3DY.%26aulast%3DJanakiraman%26aufirst%3DM.%26aulast%3DKong%26aufirst%3DX.%26aulast%3DNg%26aufirst%3DC.%26aulast%3DMoriceau%26aufirst%3DG.%26aulast%3DShi%26aufirst%3DH.%26aulast%3DAtefi%26aufirst%3DM.%26aulast%3DTitz%26aufirst%3DB.%26aulast%3DGabay%26aufirst%3DM.%2BT.%26aulast%3DSalton%26aufirst%3DM.%26aulast%3DDahlman%26aufirst%3DK.%2BB.%26aulast%3DTadi%26aufirst%3DM.%26aulast%3DWargo%26aufirst%3DJ.%2BA.%26aulast%3DFlaherty%26aufirst%3DK.%2BT.%26aulast%3DKelley%26aufirst%3DM.%2BC.%26aulast%3DMisteli%26aufirst%3DT.%26aulast%3DChapman%26aufirst%3DP.%2BB.%26aulast%3DSosman%26aufirst%3DJ.%2BA.%26aulast%3DGraeber%26aufirst%3DT.%2BG.%26aulast%3DRibas%26aufirst%3DA.%26aulast%3DLo%26aufirst%3DR.%2BS.%26aulast%3DRosen%26aufirst%3DN.%26aulast%3DSolit%26aufirst%3DD.%2BB.%26atitle%3DRAF%2520inhibitor%2520resistance%2520is%2520mediated%2520by%2520dimerization%2520of%2520aberrantly%2520spliced%2520BRAF%2528V600E%2529%26jtitle%3DNature%26date%3D2011%26volume%3D480%26spage%3D387%26epage%3D390%26doi%3D10.1038%2Fnature10662" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit7c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Heidorn, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milagre, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whittaker, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nourry, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niculescu-Duvas, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhomen, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hussain, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reis-Filho, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Springer, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pritchard, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marais, R.</span></span> <span> </span><span class="NLM_article-title">Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>140</i></span>,  <span class="NLM_fpage">209</span>– <span class="NLM_lpage">221</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2009.12.040</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=10.1016%2Fj.cell.2009.12.040" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=20141835" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=1%3ACAS%3A528%3ADC%252BC3cXkvVWitL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=140&publication_year=2010&pages=209-221&author=S.+J.+Heidornauthor=C.+Milagreauthor=S.+Whittakerauthor=A.+Nourryauthor=I.+Niculescu-Duvasauthor=N.+Dhomenauthor=J.+Hussainauthor=J.+S.+Reis-Filhoauthor=C.+J.+Springerauthor=C.+Pritchardauthor=R.+Marais&title=Kinase-dead+BRAF+and+oncogenic+RAS+cooperate+to+drive+tumor+progression+through+CRAF&doi=10.1016%2Fj.cell.2009.12.040"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7cR"><div class="casContent"><span class="casTitleNuber">7c</span><div class="casTitle"><span class="NLM_cas:atitle">Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF</span></div><div class="casAuthors">Heidorn, Sonja J.; Milagre, Carla; Whittaker, Steven; Nourry, Arnaud; Niculescu-Duvas, Ion; Dhomen, Nathalie; Hussain, Jahan; Reis-Filho, Jorge S.; Springer, Caroline J.; Pritchard, Catrin; Marais, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">140</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">209-221</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">We describe a mechanism of tumorigenesis mediated by kinase-dead BRAF in the presence of oncogenic RAS.  We show that drugs that selectively inhibit BRAF drive RAS-dependent BRAF binding to CRAF, CRAF activation, and MEK-ERK signaling.  This does not occur when oncogenic BRAF is inhibited, demonstrating that BRAF inhibition per se does not drive pathway activation; it only occurs when BRAF is inhibited in the presence of oncogenic RAS.  Kinase-dead BRAF mimics the effects of the BRAF-selective drugs and kinase-dead Braf and oncogenic Ras cooperate to induce melanoma in mice.  Our data reveal another paradigm of BRAF-mediated signaling that promotes tumor progression.  They highlight the importance of understanding pathway signaling in clin. practice and of genotyping tumors prior to administering BRAF-selective drugs, to identify patients who are likely to respond and also to identify patients who may experience adverse effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpMSb6ckHpR07Vg90H21EOLACvtfcHk0lgFcK_yZidCGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXkvVWitL0%253D&md5=80af840cb978f5956b3d998b185115f4</span></div><a href="/servlet/linkout?suffix=cit7c&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2009.12.040&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2009.12.040%26sid%3Dliteratum%253Aachs%26aulast%3DHeidorn%26aufirst%3DS.%2BJ.%26aulast%3DMilagre%26aufirst%3DC.%26aulast%3DWhittaker%26aufirst%3DS.%26aulast%3DNourry%26aufirst%3DA.%26aulast%3DNiculescu-Duvas%26aufirst%3DI.%26aulast%3DDhomen%26aufirst%3DN.%26aulast%3DHussain%26aufirst%3DJ.%26aulast%3DReis-Filho%26aufirst%3DJ.%2BS.%26aulast%3DSpringer%26aufirst%3DC.%2BJ.%26aulast%3DPritchard%26aufirst%3DC.%26aulast%3DMarais%26aufirst%3DR.%26atitle%3DKinase-dead%2520BRAF%2520and%2520oncogenic%2520RAS%2520cooperate%2520to%2520drive%2520tumor%2520progression%2520through%2520CRAF%26jtitle%3DCell%26date%3D2010%26volume%3D140%26spage%3D209%26epage%3D221%26doi%3D10.1016%2Fj.cell.2009.12.040" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit7d"><span><span class="NLM_label">(d) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heynen, G. J. J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prahallad, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robert, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haanen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blank, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wesseling, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willems, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zecchin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hobor, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bajpe, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lieftink, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mateus, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vagner, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grernrum, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hofland, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlicker, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wessels, L. F. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beijersbergen, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bardelli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Nicolantonio, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eggermont, A. M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernards, R.</span></span> <span> </span><span class="NLM_article-title">Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>508</i></span>,  <span class="NLM_fpage">118</span>– <span class="NLM_lpage">122</span>, <span class="refDoi"> DOI: 10.1038/nature13121</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=10.1038%2Fnature13121" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=24670642" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=1%3ACAS%3A528%3ADC%252BC2cXlsFyjs7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=508&publication_year=2014&pages=118-122&author=C.+Sunauthor=L.+Wangauthor=S.+Huangauthor=G.+J.+J.+E.+Heynenauthor=A.+Prahalladauthor=C.+Robertauthor=J.+Haanenauthor=C.+Blankauthor=J.+Wesselingauthor=S.+M.+Willemsauthor=D.+Zecchinauthor=S.+Hoborauthor=P.+K.+Bajpeauthor=C.+Lieftinkauthor=C.+Mateusauthor=S.+Vagnerauthor=W.+Grernrumauthor=I.+Hoflandauthor=A.+Schlickerauthor=L.+F.+A.+Wesselsauthor=R.+L.+Beijersbergenauthor=A.+Bardelliauthor=F.+Di+Nicolantonioauthor=A.+M.+M.+Eggermontauthor=R.+Bernards&title=Reversible+and+adaptive+resistance+to+BRAF%28V600E%29+inhibition+in+melanoma&doi=10.1038%2Fnature13121"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7dR"><div class="casContent"><span class="casTitleNuber">7d</span><div class="casTitle"><span class="NLM_cas:atitle">Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma</span></div><div class="casAuthors">Sun, Chong; Wang, Liqin; Huang, Sidong; Heynen, Guus J. J. E.; Prahallad, Anirudh; Robert, Caroline; Haanen, John; Blank, Christian; Wesseling, Jelle; Willems, Stefan M.; Zecchin, Davide; Hobor, Sebastijan; Bajpe, Prashanth K.; Lieftink, Cor; Mateus, Christina; Vagner, Stephan; Grernrum, Wipawadee; Hofland, Ingrid; Schlicker, Andreas; Wessels, Lodewyk F. A.; Beijersbergen, Roderick L.; Bardelli, Alberto; Di Nicolantonio, Federica; Eggermont, Alexander M. M.; Bernards, Rene</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">508</span>
        (<span class="NLM_cas:issue">7494</span>),
    <span class="NLM_cas:pages">118-122</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Treatment of BRAF(V600E) mutant melanoma by small mol. drugs that target the BRAF or MEK kinases can be effective, but resistance develops invariably.  In contrast, colon cancers that harbor the same BRAF(V600E) mutation are intrinsically resistant to BRAF inhibitors, due to feedback activation of the epidermal growth factor receptor (EGFR).  Here we show that 6 out of 16 melanoma tumors analyzed acquired EGFR expression after the development of resistance to BRAF or MEK inhibitors.  Using a chromatin-regulator-focused short hairpin RNA (shRNA) library, we find that suppression of sex detg. region Y-box 10 (SOX10) in melanoma causes activation of TGF-β signalling, thus leading to upregulation of EGFR and platelet-derived growth factor receptor-β (PDGFRB), which confer resistance to BRAF and MEK inhibitors.  Expression of EGFR in melanoma or treatment with TGF-β results in a slow-growth phenotype with cells displaying hallmarks of oncogene-induced senescence.  However, EGFR expression or exposure to TGF-β becomes beneficial for proliferation in the presence of BRAF or MEK inhibitors.  In a heterogeneous population of melanoma cells having varying levels of SOX10 suppression, cells with low SOX10 and consequently high EGFR expression are rapidly enriched in the presence of drug, but this is reversed when the drug treatment is discontinued.  We find evidence for SOX10 loss and/or activation of TGF-β signalling in 4 of the 6 EGFR-pos. drug-resistant melanoma patient samples.  Our findings provide a rationale for why some BRAF or MEK inhibitor-resistant melanoma patients may regain sensitivity to these drugs after a 'drug holiday' and identify patients with EGFR-pos. melanoma as a group that may benefit from re-treatment after a drug holiday.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0kATZtT3jcbVg90H21EOLACvtfcHk0lgqnDOse5rTKg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXlsFyjs7Y%253D&md5=837e0c482c78e7fab31778c98ecec5d6</span></div><a href="/servlet/linkout?suffix=cit7d&amp;dbid=16384&amp;doi=10.1038%2Fnature13121&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature13121%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DHuang%26aufirst%3DS.%26aulast%3DHeynen%26aufirst%3DG.%2BJ.%2BJ.%2BE.%26aulast%3DPrahallad%26aufirst%3DA.%26aulast%3DRobert%26aufirst%3DC.%26aulast%3DHaanen%26aufirst%3DJ.%26aulast%3DBlank%26aufirst%3DC.%26aulast%3DWesseling%26aufirst%3DJ.%26aulast%3DWillems%26aufirst%3DS.%2BM.%26aulast%3DZecchin%26aufirst%3DD.%26aulast%3DHobor%26aufirst%3DS.%26aulast%3DBajpe%26aufirst%3DP.%2BK.%26aulast%3DLieftink%26aufirst%3DC.%26aulast%3DMateus%26aufirst%3DC.%26aulast%3DVagner%26aufirst%3DS.%26aulast%3DGrernrum%26aufirst%3DW.%26aulast%3DHofland%26aufirst%3DI.%26aulast%3DSchlicker%26aufirst%3DA.%26aulast%3DWessels%26aufirst%3DL.%2BF.%2BA.%26aulast%3DBeijersbergen%26aufirst%3DR.%2BL.%26aulast%3DBardelli%26aufirst%3DA.%26aulast%3DDi%2BNicolantonio%26aufirst%3DF.%26aulast%3DEggermont%26aufirst%3DA.%2BM.%2BM.%26aulast%3DBernards%26aufirst%3DR.%26atitle%3DReversible%2520and%2520adaptive%2520resistance%2520to%2520BRAF%2528V600E%2529%2520inhibition%2520in%2520melanoma%26jtitle%3DNature%26date%3D2014%26volume%3D508%26spage%3D118%26epage%3D122%26doi%3D10.1038%2Fnature13121" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Karoulia, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmed, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xin, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bollard, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krepler, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bollag, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herlyn, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fagin, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lujambio, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gavathiotis, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poulikakos, P. I.</span></span> <span> </span><span class="NLM_article-title">An integrated model of RAF inhibitor action predicts inhibitor activity against oncogenic BRAF signaling</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">485</span>– <span class="NLM_lpage">498</span>, <span class="refDoi"> DOI: 10.1016/j.ccell.2016.06.024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=10.1016%2Fj.ccell.2016.06.024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=27523909" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhtleis77I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2016&pages=485-498&author=Z.+Karouliaauthor=Y.+Wuauthor=T.+A.+Ahmedauthor=Q.+Xinauthor=J.+Bollardauthor=C.+Kreplerauthor=X.+Wuauthor=C.+Zhangauthor=G.+Bollagauthor=M.+Herlynauthor=J.+A.+Faginauthor=A.+Lujambioauthor=E.+Gavathiotisauthor=P.+I.+Poulikakos&title=An+integrated+model+of+RAF+inhibitor+action+predicts+inhibitor+activity+against+oncogenic+BRAF+signaling&doi=10.1016%2Fj.ccell.2016.06.024"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling</span></div><div class="casAuthors">Karoulia, Zoi; Wu, Yang; Ahmed, Tamer A.; Xin, Qisheng; Bollard, Julien; Krepler, Clemens; Wu, Xuewei; Zhang, Chao; Bollag, Gideon; Herlyn, Meenhard; Fagin, James A.; Lujambio, Amaia; Gavathiotis, Evripidis; Poulikakos, Poulikos I.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">485-498</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">The complex biochem. effects of RAF inhibitors account for both the effectiveness and mechanisms of resistance to these drugs, but a unified mechanistic model has been lacking.  Here we show that RAF inhibitors exert their effects via two distinct allosteric mechanisms.  Drug resistance due to dimerization is detd. by the position of the αC helix stabilized by inhibitor, whereas inhibitor-induced RAF priming and dimerization are the result of inhibitor-induced formation of the RAF/RAS-GTP complex.  The biochem. effect of RAF inhibitor in cells is the combined outcome of the two mechanisms.  Therapeutic strategies including αC-helix-IN inhibitors are more effective in multiple mutant BRAF-driven tumor models, including colorectal and thyroid BRAFV600E cancers, in which first-generation RAF inhibitors have been ineffective.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9VLWvQ7ojJrVg90H21EOLACvtfcHk0lgqnDOse5rTKg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhtleis77I&md5=197711577048b889ea1dac8c87049a01</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2Fj.ccell.2016.06.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccell.2016.06.024%26sid%3Dliteratum%253Aachs%26aulast%3DKaroulia%26aufirst%3DZ.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DAhmed%26aufirst%3DT.%2BA.%26aulast%3DXin%26aufirst%3DQ.%26aulast%3DBollard%26aufirst%3DJ.%26aulast%3DKrepler%26aufirst%3DC.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DBollag%26aufirst%3DG.%26aulast%3DHerlyn%26aufirst%3DM.%26aulast%3DFagin%26aufirst%3DJ.%2BA.%26aulast%3DLujambio%26aufirst%3DA.%26aulast%3DGavathiotis%26aufirst%3DE.%26aulast%3DPoulikakos%26aufirst%3DP.%2BI.%26atitle%3DAn%2520integrated%2520model%2520of%2520RAF%2520inhibitor%2520action%2520predicts%2520inhibitor%2520activity%2520against%2520oncogenic%2520BRAF%2520signaling%26jtitle%3DCancer%2520Cell%26date%3D2016%26volume%3D30%26spage%3D485%26epage%3D498%26doi%3D10.1016%2Fj.ccell.2016.06.024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Cotto-Rios, X. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agianian, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gitego, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zacharioudakis, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giricz, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verma, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poulikakos, P. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gavathiotis, E.</span></span> <span> </span><span class="NLM_article-title">Inhibitors of BRAF dimers using an allosteric site</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">4370</span>, <span class="refDoi"> DOI: 10.1038/s41467-020-18123-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=10.1038%2Fs41467-020-18123-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=32873792" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhsl2isLjE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2020&pages=4370&author=X.+M.+Cotto-Riosauthor=B.+Agianianauthor=N.+Gitegoauthor=E.+Zacharioudakisauthor=O.+Giriczauthor=Y.+Wuauthor=Y.+Zouauthor=A.+Vermaauthor=P.+I.+Poulikakosauthor=E.+Gavathiotis&title=Inhibitors+of+BRAF+dimers+using+an+allosteric+site&doi=10.1038%2Fs41467-020-18123-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9aR"><div class="casContent"><span class="casTitleNuber">9a</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitors of BRAF dimers using an allosteric site</span></div><div class="casAuthors">Cotto-Rios, Xiomaris M.; Agianian, Bogos; Gitego, Nadege; Zacharioudakis, Emmanouil; Giricz, Orsi; Wu, Yang; Zou, Yiyu; Verma, Amit; Poulikakos, Poulikos I.; Gavathiotis, Evripidis</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">4370</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">BRAF kinase, a crit. effector of the ERK signaling pathway, is hyperactivated in many cancers.  Oncogenic BRAFV600E signals as an active monomer in the absence of active RAS, however, in many tumors BRAF dimers mediate ERK signaling.  FDA-approved RAF inhibitors poorly inhibit BRAF dimers, which leads to tumor resistance.  We found that Ponatinib, an FDA-approved drug, is an effective inhibitor of BRAF monomers and dimers.  Ponatinib binds the BRAF dimer and stabilizes a distinct αC-helix conformation through interaction with a previously unrevealed allosteric site.  Using these structural insights, we developed PHI1, a BRAF inhibitor that fully uncovers the allosteric site.  PHI1 exhibits discrete cellular selectivity for BRAF dimers, with enhanced inhibition of the second protomer when the first protomer is occupied, comprising a novel class of dimer selective inhibitors.  This work shows that Ponatinib and BRAF dimer selective inhibitors will be useful in treating BRAF-dependent tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrp3pYoP75dj7Vg90H21EOLACvtfcHk0li55Q6ljPZshw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhsl2isLjE&md5=cbac9561e74cc6ef85724302925218b8</span></div><a href="/servlet/linkout?suffix=cit9a&amp;dbid=16384&amp;doi=10.1038%2Fs41467-020-18123-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-020-18123-2%26sid%3Dliteratum%253Aachs%26aulast%3DCotto-Rios%26aufirst%3DX.%2BM.%26aulast%3DAgianian%26aufirst%3DB.%26aulast%3DGitego%26aufirst%3DN.%26aulast%3DZacharioudakis%26aufirst%3DE.%26aulast%3DGiricz%26aufirst%3DO.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DZou%26aufirst%3DY.%26aulast%3DVerma%26aufirst%3DA.%26aulast%3DPoulikakos%26aufirst%3DP.%2BI.%26aulast%3DGavathiotis%26aufirst%3DE.%26atitle%3DInhibitors%2520of%2520BRAF%2520dimers%2520using%2520an%2520allosteric%2520site%26jtitle%3DNat.%2520Commun.%26date%3D2020%26volume%3D11%26spage%3D4370%26doi%3D10.1038%2Fs41467-020-18123-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="note"><p class="first last">Other data put the monomeric signaling hypothesis into question:</p></div><div class="NLM_citation" id="cit9b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ng, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, P. Y. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xia, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yap, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guan, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, A. S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baccarini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, J.</span></span> <span> </span><span class="NLM_article-title">The dimer-dependent catalytic activity of RAF family kinases is revealed through characterizing their oncogenic mutants</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">5719</span>– <span class="NLM_lpage">5734</span>, <span class="refDoi"> DOI: 10.1038/s41388-018-0365-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=10.1038%2Fs41388-018-0365-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=29930381" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtFyjurnE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2018&pages=5719-5734&author=J.+Yuanauthor=W.+H.+Ngauthor=P.+Y.+P.+Lamauthor=Y.+Wangauthor=H.+Xiaauthor=J.+Yapauthor=S.+P.+Guanauthor=A.+S.+G.+Leeauthor=M.+Wangauthor=M.+Baccariniauthor=J.+Hu&title=The+dimer-dependent+catalytic+activity+of+RAF+family+kinases+is+revealed+through+characterizing+their+oncogenic+mutants&doi=10.1038%2Fs41388-018-0365-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9bR"><div class="casContent"><span class="casTitleNuber">9b</span><div class="casTitle"><span class="NLM_cas:atitle">The dimer-dependent catalytic activity of RAF family kinases is revealed through characterizing their oncogenic mutants</span></div><div class="casAuthors">Yuan, Jimin; Ng, Wan Hwa; Lam, Paula Y. P.; Wang, Yu; Xia, Hongping; Yap, Jiajun; Guan, Shou Ping; Lee, Ann S. G.; Wang, Mei; Baccarini, Manuela; Hu, Jiancheng</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">43</span>),
    <span class="NLM_cas:pages">5719-5734</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Although extensively studied for three decades, the mol. mechanisms that regulate the RAF/MEK/ERK kinase cascade remain ambiguous.  Recent studies identified the dimerization of RAF as a key event in the activation of this cascade.  Here, we show that in-frame deletions in the β3-αC loop activate ARAF as well as BRAF and other oncogenic kinases by enforcing homodimerization.  By characterizing these RAF mutants, we find that ARAF has less allosteric and catalytic activity than the other two RAF isoforms, which arises from its non-canonical APE motif.  Further, these RAF mutants exhibit a strong oncogenic potential, and a differential inhibitor resistance that correlates with their dimer affinity.  Using these unique mutants, we demonstrate that active RAFs, including the BRAF(V600E) mutant, phosphorylate MEK in a dimer-dependent manner.  This study characterizes a special category of oncogenic kinase mutations, and elucidates the mol. basis that underlies the differential ability of RAF isoforms to stimulate MEK-ERK pathway.  Further, this study reveals a unique catalytic feature of RAF family kinases that can be exploited to control their activities for cancer therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrLNAwHWAX5e7Vg90H21EOLACvtfcHk0li55Q6ljPZshw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtFyjurnE&md5=95743660b4d91f1fce7236f4c90c21df</span></div><a href="/servlet/linkout?suffix=cit9b&amp;dbid=16384&amp;doi=10.1038%2Fs41388-018-0365-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41388-018-0365-2%26sid%3Dliteratum%253Aachs%26aulast%3DYuan%26aufirst%3DJ.%26aulast%3DNg%26aufirst%3DW.%2BH.%26aulast%3DLam%26aufirst%3DP.%2BY.%2BP.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DXia%26aufirst%3DH.%26aulast%3DYap%26aufirst%3DJ.%26aulast%3DGuan%26aufirst%3DS.%2BP.%26aulast%3DLee%26aufirst%3DA.%2BS.%2BG.%26aulast%3DWang%26aufirst%3DM.%26aulast%3DBaccarini%26aufirst%3DM.%26aulast%3DHu%26aufirst%3DJ.%26atitle%3DThe%2520dimer-dependent%2520catalytic%2520activity%2520of%2520RAF%2520family%2520kinases%2520is%2520revealed%2520through%2520characterizing%2520their%2520oncogenic%2520mutants%26jtitle%3DOncogene%26date%3D2018%26volume%3D37%26spage%3D5719%26epage%3D5734%26doi%3D10.1038%2Fs41388-018-0365-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Arora, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Michele, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stes, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vandermarliere, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martens, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gevaert, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Heerde, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Linders, J. T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brehmer, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacoby, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonnet, P.</span></span> <span> </span><span class="NLM_article-title">Structural investigation of B-Raf paradox breaker and inducer inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">1818</span>– <span class="NLM_lpage">1831</span>, <span class="refDoi"> DOI: 10.1021/jm501667n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501667n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVWgtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=1818-1831&author=R.+Aroraauthor=M.+Di+Micheleauthor=E.+Stesauthor=E.+Vandermarliereauthor=L.+Martensauthor=K.+Gevaertauthor=E.+Van+Heerdeauthor=J.+T.+M.+Lindersauthor=D.+Brehmerauthor=E.+Jacobyauthor=P.+Bonnet&title=Structural+investigation+of+B-Raf+paradox+breaker+and+inducer+inhibitors&doi=10.1021%2Fjm501667n"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Investigation of B-Raf Paradox Breaker and Inducer Inhibitors</span></div><div class="casAuthors">Arora, Rohit; Di Michele, Michela; Stes, Elisabeth; Vandermarliere, Elien; Martens, Lennart; Gevaert, Kris; Van Heerde, Erika; Linders, Joannes T. M.; Brehmer, Dirk; Jacoby, Edgar; Bonnet, Pascal</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1818-1831</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The V600E missense mutation in B-Raf kinase leads to an anomalous regulation of the MAPK pathway, uncontrolled cell proliferation, and initiation of tumorigenesis.  While the ATP-competitive B-Raf inhibitors block the MAPK pathway in B-Raf mutant cells, they induce conformational changes to wild-type B-Raf kinase domain leading to heterodimerization with C-Raf causing a paradoxical hyperactivation of MAPK pathway.  A new class of inhibitors (paradox breakers) has been developed that inhibit B-RafV600E activity without agonistically affecting the MAPK pathway in wild-type B-Raf cells.  In this study, we explore the structural, conformational, and cellular effects on the B-Raf kinase domain upon binding of paradox breakers and inducers.  Our results indicate that a subtle structural difference between paradox inducers and breakers leads to significant conformational differences when complexed with B-Raf.  This study provides a novel insight into the activation of B-Raf by ATP-competitive inhibitors and can aid in the design of more potent and selective inhibitors without agonistic function.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDJw-VSU5CabVg90H21EOLACvtfcHk0li55Q6ljPZshw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVWgtr8%253D&md5=c79cfd000d525f553a5247b9e917b3e7</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1021%2Fjm501667n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501667n%26sid%3Dliteratum%253Aachs%26aulast%3DArora%26aufirst%3DR.%26aulast%3DDi%2BMichele%26aufirst%3DM.%26aulast%3DStes%26aufirst%3DE.%26aulast%3DVandermarliere%26aufirst%3DE.%26aulast%3DMartens%26aufirst%3DL.%26aulast%3DGevaert%26aufirst%3DK.%26aulast%3DVan%2BHeerde%26aufirst%3DE.%26aulast%3DLinders%26aufirst%3DJ.%2BT.%2BM.%26aulast%3DBrehmer%26aufirst%3DD.%26aulast%3DJacoby%26aufirst%3DE.%26aulast%3DBonnet%26aufirst%3DP.%26atitle%3DStructural%2520investigation%2520of%2520B-Raf%2520paradox%2520breaker%2520and%2520inducer%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D1818%26epage%3D1831%26doi%3D10.1021%2Fjm501667n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Peng, S.-B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henry, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaufman, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, W.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vogeti, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rutkoski, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wise, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chun, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Horn, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yadav, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webster, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchanan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mochalkin, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huber, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kays, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donoho, G. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walgren, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCann, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conti, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plowman, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Starling, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flynn, D. L.</span></span> <span> </span><span class="NLM_article-title">Inhibition of RAF isoforms and active dimers by LY3009120 leads to anti-tumor activities in RAS or BRAF mutant cancers</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">384</span>– <span class="NLM_lpage">398</span>, <span class="refDoi"> DOI: 10.1016/j.ccell.2015.08.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=10.1016%2Fj.ccell.2015.08.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=26343583" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVKgsr7O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2015&pages=384-398&author=S.-B.+Pengauthor=J.+R.+Henryauthor=M.+D.+Kaufmanauthor=W.-P.+Luauthor=B.+D.+Smithauthor=S.+Vogetiauthor=T.+J.+Rutkoskiauthor=S.+Wiseauthor=L.+Chunauthor=Y.+Zhangauthor=R.+D.+Van+Hornauthor=T.+Yinauthor=X.+Zhangauthor=V.+Yadavauthor=S.-H.+Chenauthor=X.+Gongauthor=X.+Maauthor=Y.+Websterauthor=S.+Buchananauthor=I.+Mochalkinauthor=L.+Huberauthor=L.+Kaysauthor=G.+P.+Donohoauthor=J.+Walgrenauthor=D.+McCannauthor=P.+Patelauthor=I.+Contiauthor=G.+D.+Plowmanauthor=J.+J.+Starlingauthor=D.+L.+Flynn&title=Inhibition+of+RAF+isoforms+and+active+dimers+by+LY3009120+leads+to+anti-tumor+activities+in+RAS+or+BRAF+mutant+cancers&doi=10.1016%2Fj.ccell.2015.08.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers</span></div><div class="casAuthors">Peng, Sheng-Bin; Henry, James R.; Kaufman, Michael D.; Lu, Wei-Ping; Smith, Bryan D.; Vogeti, Subha; Rutloski, Thomas J.; Wise, Scott; Chun, Lawrence; Zhang, Youyan; Van Horn, Robert D.; Yin, Tinggui; Zhang, Xiaoyi; Yadav, Vipin; Chen, Shih-Hsun; Gong, Xueqian; Ma, Xiwen; Webster, Yue; Buchanan, Sean; Mochalkin, Igor; Huber, Lysiane; Kays, Lisa; Donoho, Gregory P.; Walgren, Jennie; McCann, Denis; Patel, Phenil; Conti, Ilaria; Plowman, Gregory D.; Starling, James J.; Flynn, Daniel L.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">384-398</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">LY3009120 is a pan-RAF and RAF dimer inhibitor that inhibits all RAF isoforms and occupies both protomers in RAF dimers.  Biochem. and cellular analyses revealed that LY3009120 inhibits ARAF, BRAF, and CRAF isoforms with similar affinity, while vemurafenib or dabrafenib have little or modest CRAF activity compared to their BRAF activities.  LY3009120 induces BRAF-CRAF dimerization but inhibits the phosphorylation of downstream MEK and ERK, suggesting that it effectively inhibits the kinase activity of BRAF-CRAF heterodimers.  Further analyses demonstrated that LY3009120 also inhibits various forms of RAF dimers including BRAF or CRAF homodimers.  Due to these unique properties, LY3009120 demonstrates minimal paradoxical activation, inhibits MEK1/2 phosphorylation, and exhibits anti-tumor activities across multiple models carrying KRAS, NRAS, or BRAF mutation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJMiHK-Gub5bVg90H21EOLACvtfcHk0lhvMshEZVxatg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVKgsr7O&md5=c167caa6e5a9b47a6ec1ee2ab6d9e0d1</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2Fj.ccell.2015.08.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccell.2015.08.002%26sid%3Dliteratum%253Aachs%26aulast%3DPeng%26aufirst%3DS.-B.%26aulast%3DHenry%26aufirst%3DJ.%2BR.%26aulast%3DKaufman%26aufirst%3DM.%2BD.%26aulast%3DLu%26aufirst%3DW.-P.%26aulast%3DSmith%26aufirst%3DB.%2BD.%26aulast%3DVogeti%26aufirst%3DS.%26aulast%3DRutkoski%26aufirst%3DT.%2BJ.%26aulast%3DWise%26aufirst%3DS.%26aulast%3DChun%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DVan%2BHorn%26aufirst%3DR.%2BD.%26aulast%3DYin%26aufirst%3DT.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DYadav%26aufirst%3DV.%26aulast%3DChen%26aufirst%3DS.-H.%26aulast%3DGong%26aufirst%3DX.%26aulast%3DMa%26aufirst%3DX.%26aulast%3DWebster%26aufirst%3DY.%26aulast%3DBuchanan%26aufirst%3DS.%26aulast%3DMochalkin%26aufirst%3DI.%26aulast%3DHuber%26aufirst%3DL.%26aulast%3DKays%26aufirst%3DL.%26aulast%3DDonoho%26aufirst%3DG.%2BP.%26aulast%3DWalgren%26aufirst%3DJ.%26aulast%3DMcCann%26aufirst%3DD.%26aulast%3DPatel%26aufirst%3DP.%26aulast%3DConti%26aufirst%3DI.%26aulast%3DPlowman%26aufirst%3DG.%2BD.%26aulast%3DStarling%26aufirst%3DJ.%2BJ.%26aulast%3DFlynn%26aufirst%3DD.%2BL.%26atitle%3DInhibition%2520of%2520RAF%2520isoforms%2520and%2520active%2520dimers%2520by%2520LY3009120%2520leads%2520to%2520anti-tumor%2520activities%2520in%2520RAS%2520or%2520BRAF%2520mutant%2520cancers%26jtitle%3DCancer%2520Cell%26date%3D2015%26volume%3D28%26spage%3D384%26epage%3D398%26doi%3D10.1016%2Fj.ccell.2015.08.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Durrant, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrison, D. K.</span></span> <span> </span><span class="NLM_article-title">Targeting the Raf kinases in human cancer: The Raf dimer dilemma</span>. <i>Br. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>118</i></span>,  <span class="NLM_fpage">3</span>– <span class="NLM_lpage">8</span>, <span class="refDoi"> DOI: 10.1038/bjc.2017.399</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=10.1038%2Fbjc.2017.399" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=29235562" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvFKhu7vL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=118&publication_year=2018&pages=3-8&author=D.+E.+Durrantauthor=D.+K.+Morrison&title=Targeting+the+Raf+kinases+in+human+cancer%3A+The+Raf+dimer+dilemma&doi=10.1038%2Fbjc.2017.399"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the Raf kinases in human cancer: the Raf dimer dilemma</span></div><div class="casAuthors">Durrant, David E.; Morrison, Deborah K.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">118</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">3-8</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">The Raf protein kinases are key intermediates in cellular signal transduction, functioning as direct effectors of the Ras GTPases and as the initiating kinases in the ERK cascade.  In human cancer, Raf activity is frequently dysregulated due to mutations in the Raf family member B-Raf or to alterations in upstream Raf regulators, including Ras and receptor tyrosine kinases.  First-generation Raf inhibitors, such as vemurafenib and dabrafenib, have yielded dramatic responses in malignant melanomas contg. B-Raf mutations; however, their overall usefulness has been limited by both intrinsic and acquired drug resistance.  In particular, issues related to the dimerization of the Raf kinases can impact the efficacy of these compds. and are a primary cause of drug resistance.  Here, we will review the importance of Raf dimerization in cell signalling as well as its effects on Raf inhibitor therapy, and we will present the new strategies that are being pursued to overcome the 'Raf Dimer Dilemma'.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpHTShTLpMLiLVg90H21EOLACvtfcHk0lhvMshEZVxatg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvFKhu7vL&md5=186dbe3ee9006a384d9b50831000e144</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1038%2Fbjc.2017.399&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fbjc.2017.399%26sid%3Dliteratum%253Aachs%26aulast%3DDurrant%26aufirst%3DD.%2BE.%26aulast%3DMorrison%26aufirst%3DD.%2BK.%26atitle%3DTargeting%2520the%2520Raf%2520kinases%2520in%2520human%2520cancer%253A%2520The%2520Raf%2520dimer%2520dilemma%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2018%26volume%3D118%26spage%3D3%26epage%3D8%26doi%3D10.1038%2Fbjc.2017.399" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Shen, M.</span>; <span class="NLM_string-name">Lyne, P.</span>; <span class="NLM_string-name">Aquila, B.</span>; <span class="NLM_string-name">Drew, L.</span></span> <i>Abstracts of Papers, 98th American Association for Cancer Research Annual Meeting, Los Angeles, CA, United States, April 14–18, 2007</i>; <span class="NLM_publisher-name">American Association for Cancer Research</span>: <span class="NLM_publisher-loc">Philadelphia, PA</span>, <span class="NLM_year">2007</span>; Abstract  <span class="NLM_fpage">5249</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&pages=5249&author=M.+Shen&author=P.+Lyne&author=B.+Aquila&author=L.+Drew&title=Abstracts+of+Papers%2C+98th+American+Association+for+Cancer+Research+Annual+Meeting%2C+Los+Angeles%2C+CA%2C+United+States%2C+April+14%E2%80%9318%2C+2007"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DShen%26aufirst%3DM.%26btitle%3DAbstracts%2520of%2520Papers%252C%252098th%2520American%2520Association%2520for%2520Cancer%2520Research%2520Annual%2520Meeting%252C%2520Los%2520Angeles%252C%2520CA%252C%2520United%2520States%252C%2520April%252014%25E2%2580%259318%252C%25202007%26pub%3DAmerican%2520Association%2520for%2520Cancer%2520Research%26date%3D2007%26spage%3D5249" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit13b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Aquila, B.</span>; <span class="NLM_string-name">Dakin, L.</span>; <span class="NLM_string-name">Ezhuthachan, J.</span>; <span class="NLM_string-name">Lee, S.</span>; <span class="NLM_string-name">Lyne, P.</span>; <span class="NLM_string-name">Pontz, T.</span>; <span class="NLM_string-name">Zheng, X.</span></span> <span> </span><span class="NLM_article-title">Quinazolinone derivatives and their use as B-raf inhibitors</span>. <i>PCT Int. Appl.</i> <span class="NLM_patent">WO2006024834</span>, <span class="NLM_year">2006</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&author=B.+Aquila&author=L.+Dakin&author=J.+Ezhuthachan&author=S.+Lee&author=P.+Lyne&author=T.+Pontz&author=X.+Zheng&title=Quinazolinone+derivatives+and+their+use+as+B-raf+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DAquila%26aufirst%3DB.%26atitle%3DQuinazolinone%2520derivatives%2520and%2520their%2520use%2520as%2520B-raf%2520inhibitors%26date%3D2006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Henry, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaufman, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, S.-B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, Y. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caldwell, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vogeti, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Telikepalli, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, W.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hood, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rutkoski, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vogeti, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wise, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chun, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kays, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hipskind, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wrobleski, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lobb, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clay, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walgren, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCann, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clawson, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manglicmot, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groshong, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Logan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Starling, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flynn, D. L.</span></span> <span> </span><span class="NLM_article-title">Discovery of 1-(3,3-dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2,3-<i>d</i>]pyrimidin-6-yl)phenyl)urea (LY3009120) as a pan-RAF inhibitor with minimal paradoxical activation and activity against BRAF or RAS mutant tumor cells</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">4165</span>– <span class="NLM_lpage">4179</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00067</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00067" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref14/cit14a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=1%3ACAS%3A528%3ADC%252BC2MXotlCisL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=4165-4179&author=J.+R.+Henryauthor=M.+D.+Kaufmanauthor=S.-B.+Pengauthor=Y.+M.+Ahnauthor=T.+M.+Caldwellauthor=L.+Vogetiauthor=H.+Telikepalliauthor=W.-P.+Luauthor=M.+M.+Hoodauthor=T.+J.+Rutkoskiauthor=B.+D.+Smithauthor=S.+Vogetiauthor=D.+Millerauthor=S.+C.+Wiseauthor=L.+Chunauthor=X.+Zhangauthor=Y.+Zhangauthor=L.+Kaysauthor=P.+A.+Hipskindauthor=A.+D.+Wrobleskiauthor=K.+L.+Lobbauthor=J.+M.+Clayauthor=J.+D.+Cohenauthor=J.+L.+Walgrenauthor=D.+McCannauthor=P.+Patelauthor=D.+K.+Clawsonauthor=S.+Guoauthor=D.+Manglicmotauthor=C.+Groshongauthor=C.+Loganauthor=J.+J.+Starlingauthor=D.+L.+Flynn&title=Discovery+of+1-%283%2C3-dimethylbutyl%29-3-%282-fluoro-4-methyl-5-%287-methyl-2-%28methylamino%29pyrido%5B2%2C3-d%5Dpyrimidin-6-yl%29phenyl%29urea+%28LY3009120%29+as+a+pan-RAF+inhibitor+with+minimal+paradoxical+activation+and+activity+against+BRAF+or+RAS+mutant+tumor+cells&doi=10.1021%2Facs.jmedchem.5b00067"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14aR"><div class="casContent"><span class="casTitleNuber">14a</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 1-(3,3-Dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2,3-d]pyrimidin-6-yl)phenyl)urea (LY3009120) as a Pan-RAF Inhibitor with Minimal Paradoxical Activation and Activity against BRAF or RAS Mutant Tumor Cells</span></div><div class="casAuthors">Henry, James R.; Kaufman, Michael D.; Peng, Sheng-Bin; Ahn, Yu Mi; Caldwell, Timothy M.; Vogeti, Lakshminarayana; Telikepalli, Hanumaiah; Lu, Wei-Ping; Hood, Molly M.; Rutkoski, Thomas J.; Smith, Bryan D.; Vogeti, Subha; Miller, David; Wise, Scott C.; Chun, Lawrence; Zhang, Xiaoyi; Zhang, Youyan; Kays, Lisa; Hipskind, Philip A.; Wrobleski, Aaron D.; Lobb, Karen L.; Clay, Julia M.; Cohen, Jeffrey D.; Walgren, Jennie L.; McCann, Denis; Patel, Phenil; Clawson, David K.; Guo, Sherry; Manglicmot, Danalyn; Groshong, Chris; Logan, Cheyenne; Starling, James J.; Flynn, Daniel L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4165-4179</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The RAS-RAF-MEK-MAPK cascade is an essential signaling pathway, with activation typically mediated through cell surface receptors.  The kinase inhibitors vemurafenib and dabrafenib, which target oncogenic BRAF V600E, have shown significant clin. efficacy in melanoma patients harboring this mutation.  Because of paradoxical pathway activation, both agents were demonstrated to promote growth and metastasis of tumor cells with RAS mutations in preclin. models and are contraindicated for treatment of cancer patients with BRAF WT background, including patients with KRAS or NRAS mutations.  To eliminate the issues assocd. with paradoxical MAPK pathway activation and to provide therapeutic benefit to patients with RAS mutant cancers, we sought to identify a compd. not only active against BRAF V600E but also wild type BRAF and CRAF.  On the basis of its superior in vitro and in vivo profile, compd. 13 was selected for further development and is currently being evaluated in phase I clin. studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXIUwbnhct2rVg90H21EOLACvtfcHk0liYbH2MWqXkKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXotlCisL0%253D&md5=9e5bc7ee7f45d238e2fa40e1d5cfc739</span></div><a href="/servlet/linkout?suffix=cit14a&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00067&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00067%26sid%3Dliteratum%253Aachs%26aulast%3DHenry%26aufirst%3DJ.%2BR.%26aulast%3DKaufman%26aufirst%3DM.%2BD.%26aulast%3DPeng%26aufirst%3DS.-B.%26aulast%3DAhn%26aufirst%3DY.%2BM.%26aulast%3DCaldwell%26aufirst%3DT.%2BM.%26aulast%3DVogeti%26aufirst%3DL.%26aulast%3DTelikepalli%26aufirst%3DH.%26aulast%3DLu%26aufirst%3DW.-P.%26aulast%3DHood%26aufirst%3DM.%2BM.%26aulast%3DRutkoski%26aufirst%3DT.%2BJ.%26aulast%3DSmith%26aufirst%3DB.%2BD.%26aulast%3DVogeti%26aufirst%3DS.%26aulast%3DMiller%26aufirst%3DD.%26aulast%3DWise%26aufirst%3DS.%2BC.%26aulast%3DChun%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DKays%26aufirst%3DL.%26aulast%3DHipskind%26aufirst%3DP.%2BA.%26aulast%3DWrobleski%26aufirst%3DA.%2BD.%26aulast%3DLobb%26aufirst%3DK.%2BL.%26aulast%3DClay%26aufirst%3DJ.%2BM.%26aulast%3DCohen%26aufirst%3DJ.%2BD.%26aulast%3DWalgren%26aufirst%3DJ.%2BL.%26aulast%3DMcCann%26aufirst%3DD.%26aulast%3DPatel%26aufirst%3DP.%26aulast%3DClawson%26aufirst%3DD.%2BK.%26aulast%3DGuo%26aufirst%3DS.%26aulast%3DManglicmot%26aufirst%3DD.%26aulast%3DGroshong%26aufirst%3DC.%26aulast%3DLogan%26aufirst%3DC.%26aulast%3DStarling%26aufirst%3DJ.%2BJ.%26aulast%3DFlynn%26aufirst%3DD.%2BL.%26atitle%3DDiscovery%2520of%25201-%25283%252C3-dimethylbutyl%2529-3-%25282-fluoro-4-methyl-5-%25287-methyl-2-%2528methylamino%2529pyrido%255B2%252C3-d%255Dpyrimidin-6-yl%2529phenyl%2529urea%2520%2528LY3009120%2529%2520as%2520a%2520pan-RAF%2520inhibitor%2520with%2520minimal%2520paradoxical%2520activation%2520and%2520activity%2520against%2520BRAF%2520or%2520RAS%2520mutant%2520tumor%2520cells%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D4165%26epage%3D4179%26doi%3D10.1021%2Facs.jmedchem.5b00067" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit14b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Horn, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huber, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, T. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manro, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iversen, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhagwat, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beckmann, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tiu, R. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchanan, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, S.-B.</span></span> <span> </span><span class="NLM_article-title">RAF inhibitor LY3009120 sensitizes RAS or BRAF mutant cancer to CDK4/6 inhibition by abemaciclib via superior inhibition of phospho-RB and suppression of cyclin D1</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">821</span>– <span class="NLM_lpage">832</span>, <span class="refDoi"> DOI: 10.1038/onc.2017.384</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=10.1038%2Fonc.2017.384" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=29059158" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=1%3ACAS%3A280%3ADC%252BC1M7jsVSmsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2018&pages=821-832&author=S.-H.+Chenauthor=X.+Gongauthor=Y.+Zhangauthor=R.+D.+Van+Hornauthor=T.+Yinauthor=L.+Huberauthor=T.+F.+Burkeauthor=J.+Manroauthor=P.+W.+Iversenauthor=W.+Wuauthor=S.+V.+Bhagwatauthor=R.+P.+Beckmannauthor=R.+V.+Tiuauthor=S.+G.+Buchananauthor=S.-B.+Peng&title=RAF+inhibitor+LY3009120+sensitizes+RAS+or+BRAF+mutant+cancer+to+CDK4%2F6+inhibition+by+abemaciclib+via+superior+inhibition+of+phospho-RB+and+suppression+of+cyclin+D1&doi=10.1038%2Fonc.2017.384"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14bR"><div class="casContent"><span class="casTitleNuber">14b</span><div class="casTitle"><span class="NLM_cas:atitle">RAF inhibitor LY3009120 sensitizes RAS or BRAF mutant cancer to CDK4/6 inhibition by abemaciclib via superior inhibition of phospho-RB and suppression of cyclin D1</span></div><div class="casAuthors">Chen S-H; Gong X; Zhang Y; Van Horn R D; Yin T; Huber L; Burke T F; Wu W; Bhagwat S V; Beckmann R P; Buchanan S G; Peng S-B; Manro J; Iversen P W; Tiu R V</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">821-832</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">KRAS, NRAS and BRAF mutations are among the most important oncogenic drivers in many major cancer types, such as melanoma, lung, colorectal and pancreatic cancer.  There is currently no effective therapy for the treatment of RAS mutant cancers.  LY3009120, a pan-RAF and RAF dimer inhibitor advanced to clinical study has been shown to inhibit both RAS and BRAF mutant cell proliferation in vitro and xenograft tumor growth in vivo.  Abemaciclib, a CDK4/6-selective inhibitor, is currently in phase III studies for ER-positive breast cancer and KRAS mutant lung cancer.  In this study, we found that combinatory treatment with LY3009120 and abemaciclib synergistically inhibited proliferation of tumor cells in vitro and led to tumor growth regression in xenograft models with a KRAS, NRAS or BRAF mutation at the doses of two drugs that were well tolerated in combination.  Further in vitro screen in 328 tumor cell lines revealed that tumor cells with KRAS, NRAS or BRAF mutation, or cyclin D activation are more sensitive, whereas tumor cells with PTEN, PIK3CA, PIK3R1 or retinoblastoma (Rb) mutation are more resistant to this combination treatment.  Molecular analysis revealed that abemaciclib alone inhibited Rb phosphorylation partially and caused an increase of cyclin D1.  The combinatory treatment cooperatively demonstrated more complete inhibition of Rb phosphorylation, and LY3009120 suppressed the cyclin D1 upregulation mediated by abemaciclib.  These results were further verified by CDK4/6 siRNA knockdown.  Importantly, the more complete phospho-Rb inhibition and cyclin D1 suppression by LY3009120 and abemaciclib combination led to more significant cell cycle G0/G1 arrest of tumor cells.  These preclinical findings suggest that combined inhibition of RAF and d-cyclin-dependent kinases might provide an effective approach to treat patients with tumors harboring mutations in RAS or RAF genes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSejUtYs4tFGEh5eUSa2oe_fW6udTcc2eYR27qe8WGMP7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1M7jsVSmsQ%253D%253D&md5=b7d3e64c63e0c6e9e4f6fcda729584ee</span></div><a href="/servlet/linkout?suffix=cit14b&amp;dbid=16384&amp;doi=10.1038%2Fonc.2017.384&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fonc.2017.384%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DS.-H.%26aulast%3DGong%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DVan%2BHorn%26aufirst%3DR.%2BD.%26aulast%3DYin%26aufirst%3DT.%26aulast%3DHuber%26aufirst%3DL.%26aulast%3DBurke%26aufirst%3DT.%2BF.%26aulast%3DManro%26aufirst%3DJ.%26aulast%3DIversen%26aufirst%3DP.%2BW.%26aulast%3DWu%26aufirst%3DW.%26aulast%3DBhagwat%26aufirst%3DS.%2BV.%26aulast%3DBeckmann%26aufirst%3DR.%2BP.%26aulast%3DTiu%26aufirst%3DR.%2BV.%26aulast%3DBuchanan%26aufirst%3DS.%2BG.%26aulast%3DPeng%26aufirst%3DS.-B.%26atitle%3DRAF%2520inhibitor%2520LY3009120%2520sensitizes%2520RAS%2520or%2520BRAF%2520mutant%2520cancer%2520to%2520CDK4%252F6%2520inhibition%2520by%2520abemaciclib%2520via%2520superior%2520inhibition%2520of%2520phospho-RB%2520and%2520suppression%2520of%2520cyclin%2520D1%26jtitle%3DOncogene%26date%3D2018%26volume%3D37%26spage%3D821%26epage%3D832%26doi%3D10.1038%2Fonc.2017.384" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rebocho, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marais, R.</span></span> <span> </span><span class="NLM_article-title">New insight puts CRAF in sight as a therapeutic target</span>. <i>Cancer Discov.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">98</span>– <span class="NLM_lpage">99</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-11-0118</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=10.1158%2F2159-8290.CD-11-0118" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=22318779" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=1%3ACAS%3A528%3ADC%252BC3MXovFalt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2011&pages=98-99&author=A.+P.+Rebochoauthor=R.+Marais&title=New+insight+puts+CRAF+in+sight+as+a+therapeutic+target&doi=10.1158%2F2159-8290.CD-11-0118"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">New Insight Puts CRAF in Sight as a Therapeutic Target</span></div><div class="casAuthors">Rebocho, Ana Paula; Marais, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">98-99</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research, Inc.</span>)
        </div><div class="casAbstract">A review.  By selectively depleting components of the RAF-MEK-ERK pathway in transgenic mice, it is now shown in 2 studies that CRAF is crit. for signaling to MEK downstream of oncogenic Kras and that BRAF is not required.  Cancer Discovery; 1(2); 98-9.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGown_LK1MCqvbVg90H21EOLACvtfcHk0lgskcUFgytx7w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXovFalt7g%253D&md5=fc2cd219ee60d00cb7d32a3a83a05e86</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-11-0118&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-11-0118%26sid%3Dliteratum%253Aachs%26aulast%3DRebocho%26aufirst%3DA.%2BP.%26aulast%3DMarais%26aufirst%3DR.%26atitle%3DNew%2520insight%2520puts%2520CRAF%2520in%2520sight%2520as%2520a%2520therapeutic%2520target%26jtitle%3DCancer%2520Discov.%26date%3D2011%26volume%3D1%26spage%3D98%26epage%3D99%26doi%3D10.1158%2F2159-8290.CD-11-0118" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Nishiguchi, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rico, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanner, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aversa, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taft, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Subramanian, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Setti, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burger, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamez, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barsanti, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Appleton, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mamo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tandeske, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dix, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tellew, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathews Griner, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooke, V. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Abbema, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merritt, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gampa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haling, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaziri, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hekmat-Nejad, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jansen, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polyakov, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sethuraman, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amiri, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lees, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stuart, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dillon, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramurthy, S.</span></span> <span> </span><span class="NLM_article-title">Design and discovery of <i>N</i>-(2-methyl-5′-morpholino-6′-((tetrahydro-2<i>H</i>-pyran-4-yl)oxy)-[3,3′-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide (RAF709): A potent, selective, and efficacious RAF inhibitor targeting RAS mutant cancers</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">4869</span>– <span class="NLM_lpage">4881</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01862</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01862" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref16/cit16a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=1%3ACAS%3A528%3ADC%252BC2sXos1Sgt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=4869-4881&author=G.+A.+Nishiguchiauthor=A.+Ricoauthor=H.+Tannerauthor=R.+J.+Aversaauthor=B.+R.+Taftauthor=S.+Subramanianauthor=L.+Settiauthor=M.+T.+Burgerauthor=L.+Wanauthor=V.+Tamezauthor=A.+Smithauthor=Y.+Louauthor=P.+A.+Barsantiauthor=B.+A.+Appletonauthor=M.+Mamoauthor=L.+Tandeskeauthor=I.+Dixauthor=J.+E.+Tellewauthor=S.+Huangauthor=L.+A.+Mathews+Grinerauthor=V.+G.+Cookeauthor=A.+Van+Abbemaauthor=H.+Merrittauthor=S.+Maauthor=K.+Gampaauthor=F.+Fengauthor=J.+Yuanauthor=Y.+Wangauthor=J.+R.+Halingauthor=S.+Vaziriauthor=M.+Hekmat-Nejadauthor=J.+M.+Jansenauthor=V.+Polyakovauthor=R.+Zangauthor=V.+Sethuramanauthor=P.+Amiriauthor=M.+Singhauthor=E.+Leesauthor=W.+Shaoauthor=D.+D.+Stuartauthor=M.+P.+Dillonauthor=S.+Ramurthy&title=Design+and+discovery+of+N-%282-methyl-5%E2%80%B2-morpholino-6%E2%80%B2-%28%28tetrahydro-2H-pyran-4-yl%29oxy%29-%5B3%2C3%E2%80%B2-bipyridin%5D-5-yl%29-3-%28trifluoromethyl%29benzamide+%28RAF709%29%3A+A+potent%2C+selective%2C+and+efficacious+RAF+inhibitor+targeting+RAS+mutant+cancers&doi=10.1021%2Facs.jmedchem.6b01862"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16aR"><div class="casContent"><span class="casTitleNuber">16a</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Discovery of N-(2-Methyl-5'-morpholino-6'-((tetrahydro-2H-pyran-4-yl)oxy)-[3,3'-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide (RAF709): A Potent, Selective, and Efficacious RAF Inhibitor Targeting RAS Mutant Cancers</span></div><div class="casAuthors">Nishiguchi, Gisele A.; Rico, Alice; Tanner, Huw; Aversa, Robert J.; Taft, Benjamin R.; Subramanian, Sharadha; Setti, Lina; Burger, Matthew T.; Wan, Lifeng; Tamez, Victoriano; Smith, Aaron; Lou, Yan; Barsanti, Paul A.; Appleton, Brent A.; Mamo, Mulugeta; Tandeske, Laura; Dix, Ina; Tellew, John E.; Huang, Shenlin; Mathews Griner, Lesley A.; Cooke, Vesselina G.; Van Abbema, Anne; Merritt, Hanne; Ma, Sylvia; Gampa, Kalyani; Feng, Fei; Yuan, Jing; Wang, Yingyun; Haling, Jacob R.; Vaziri, Sepideh; Hekmat-Nejad, Mohammad; Jansen, Johanna M.; Polyakov, Valery; Zang, Richard; Sethuraman, Vijay; Amiri, Payman; Singh, Mallika; Lees, Emma; Shao, Wenlin; Stuart, Darrin D.; Dillon, Michael P.; Ramurthy, Savithri</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">4869-4881</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">RAS oncogenes have been implicated in >30% of human cancers, all representing high unmet medical need.  The exquisite dependency on CRAF kinase in KRAS mutant tumors has been established in genetically engineered mouse models and human tumor cells.  To date, many small mol. approaches are under investigation to target CRAF, yet kinase-selective and cellular potent inhibitors remain challenging to identify.  Herein, we describe 14 (RAF709) [Aversa, Biaryl amide compds. as kinase inhibitors and their prepn. WO 2014151616, 2014], a selective B/C RAF inhibitor, which was developed through a hypothesis-driven approach focusing on drug-like properties.  A key challenge encountered in the medicinal chem. campaign was maintaining a balance between good soly. and potent cellular activity (suppression of pMEK and proliferation) in KRAS mutant tumor cell lines.  We investigated the small mol. crystal structure of lead mol. 7 and hypothesized that disruption of the crystal packing would improve soly., which led to a change from N-methylpyridone to a tetrahydropyranyl oxy-pyridine deriv. 14 proved to be sol., kinase selective, and efficacious in a KRAS mutant xenograft model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmcZ2Rl42uP7Vg90H21EOLACvtfcHk0lgskcUFgytx7w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXos1Sgt7s%253D&md5=ed35a93d83b721a8e639a992bee43f04</span></div><a href="/servlet/linkout?suffix=cit16a&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01862&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01862%26sid%3Dliteratum%253Aachs%26aulast%3DNishiguchi%26aufirst%3DG.%2BA.%26aulast%3DRico%26aufirst%3DA.%26aulast%3DTanner%26aufirst%3DH.%26aulast%3DAversa%26aufirst%3DR.%2BJ.%26aulast%3DTaft%26aufirst%3DB.%2BR.%26aulast%3DSubramanian%26aufirst%3DS.%26aulast%3DSetti%26aufirst%3DL.%26aulast%3DBurger%26aufirst%3DM.%2BT.%26aulast%3DWan%26aufirst%3DL.%26aulast%3DTamez%26aufirst%3DV.%26aulast%3DSmith%26aufirst%3DA.%26aulast%3DLou%26aufirst%3DY.%26aulast%3DBarsanti%26aufirst%3DP.%2BA.%26aulast%3DAppleton%26aufirst%3DB.%2BA.%26aulast%3DMamo%26aufirst%3DM.%26aulast%3DTandeske%26aufirst%3DL.%26aulast%3DDix%26aufirst%3DI.%26aulast%3DTellew%26aufirst%3DJ.%2BE.%26aulast%3DHuang%26aufirst%3DS.%26aulast%3DMathews%2BGriner%26aufirst%3DL.%2BA.%26aulast%3DCooke%26aufirst%3DV.%2BG.%26aulast%3DVan%2BAbbema%26aufirst%3DA.%26aulast%3DMerritt%26aufirst%3DH.%26aulast%3DMa%26aufirst%3DS.%26aulast%3DGampa%26aufirst%3DK.%26aulast%3DFeng%26aufirst%3DF.%26aulast%3DYuan%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DHaling%26aufirst%3DJ.%2BR.%26aulast%3DVaziri%26aufirst%3DS.%26aulast%3DHekmat-Nejad%26aufirst%3DM.%26aulast%3DJansen%26aufirst%3DJ.%2BM.%26aulast%3DPolyakov%26aufirst%3DV.%26aulast%3DZang%26aufirst%3DR.%26aulast%3DSethuraman%26aufirst%3DV.%26aulast%3DAmiri%26aufirst%3DP.%26aulast%3DSingh%26aufirst%3DM.%26aulast%3DLees%26aufirst%3DE.%26aulast%3DShao%26aufirst%3DW.%26aulast%3DStuart%26aufirst%3DD.%2BD.%26aulast%3DDillon%26aufirst%3DM.%2BP.%26aulast%3DRamurthy%26aufirst%3DS.%26atitle%3DDesign%2520and%2520discovery%2520of%2520N-%25282-methyl-5%25E2%2580%25B2-morpholino-6%25E2%2580%25B2-%2528%2528tetrahydro-2H-pyran-4-yl%2529oxy%2529-%255B3%252C3%25E2%2580%25B2-bipyridin%255D-5-yl%2529-3-%2528trifluoromethyl%2529benzamide%2520%2528RAF709%2529%253A%2520A%2520potent%252C%2520selective%252C%2520and%2520efficacious%2520RAF%2520inhibitor%2520targeting%2520RAS%2520mutant%2520cancers%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D4869%26epage%3D4881%26doi%3D10.1021%2Facs.jmedchem.6b01862" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit16b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Ramurthy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taft, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aversa, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barsanti, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burger, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishiguchi, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rico, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Setti, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Subramanian, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamez, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanner, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Appleton, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mamo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tandeske, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tellew, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yue, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaudhary, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iyer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hassan, A. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathews
Griner, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">La Bonte, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooke, V. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Abbema, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merritt, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gampa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mishina, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haling, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaziri, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hekmat-Nejad, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polyakov, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sethuraman, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amiri, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sellers, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lees, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dillon, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stuart, D. D.</span></span> <span> </span><span class="NLM_article-title">Design and discovery of <i>N</i>-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamide, a selective, efficacious, and well-tolerated RAF inhibitor targeting RAS mutant cancers: The path to the clinic</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">2013</span>– <span class="NLM_lpage">2027</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00161</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00161" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref16/cit16b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=1%3ACAS%3A528%3ADC%252BC1MXovVKnu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=2013-2027&author=S.+Ramurthyauthor=B.+R.+Taftauthor=R.+J.+Aversaauthor=P.+A.+Barsantiauthor=M.+T.+Burgerauthor=Y.+Louauthor=G.+A.+Nishiguchiauthor=A.+Ricoauthor=L.+Settiauthor=A.+Smithauthor=S.+Subramanianauthor=V.+Tamezauthor=H.+Tannerauthor=W.+Wanauthor=C.+Huauthor=B.+A.+Appletonauthor=M.+Mamoauthor=L.+Tandeskeauthor=J.+E.+Tellewauthor=S.+Huangauthor=Q.+Yueauthor=A.+Chaudharyauthor=H.+Tianauthor=R.+Iyerauthor=A.+Q.+Hassanauthor=L.+A.+Mathews%0AGrinerauthor=L.+R.+La+Bonteauthor=V.+G.+Cookeauthor=A.+Van+Abbemaauthor=H.+Merrittauthor=K.+Gampaauthor=F.+Fengauthor=J.+Yuanauthor=Y.+Mishinaauthor=Y.+Wangauthor=J.+R.+Halingauthor=S.+Vaziriauthor=M.+Hekmat-Nejadauthor=V.+Polyakovauthor=R.+Zangauthor=V.+Sethuramanauthor=P.+Amiriauthor=M.+Singhauthor=W.+R.+Sellersauthor=E.+Leesauthor=W.+Shaoauthor=M.+P.+Dillonauthor=D.+D.+Stuart&title=Design+and+discovery+of+N-%283-%282-%282-hydroxyethoxy%29-6-morpholinopyridin-4-yl%29-4-methylphenyl%29-2-%28trifluoromethyl%29isonicotinamide%2C+a+selective%2C+efficacious%2C+and+well-tolerated+RAF+inhibitor+targeting+RAS+mutant+cancers%3A+The+path+to+the+clinic&doi=10.1021%2Facs.jmedchem.9b00161"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16bR"><div class="casContent"><span class="casTitleNuber">16b</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Discovery of N-(3-(2-(2-Hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamide, a Selective, Efficacious, and Well-Tolerated RAF Inhibitor Targeting RAS Mutant Cancers: The Path to the Clinic</span></div><div class="casAuthors">Ramurthy, Savithri; Taft, Benjamin R.; Aversa, Robert J.; Barsanti, Paul A.; Burger, Matthew T.; Lou, Yan; Nishiguchi, Gisele A.; Rico, Alice; Setti, Lina; Smith, Aaron; Subramanian, Sharadha; Tamez, Victoriano; Tanner, Huw; Wan, Lifeng; Hu, Cheng; Appleton, Brent A.; Mamo, Mulugeta; Tandeske, Laura; Tellew, John E.; Huang, Shenlin; Yue, Qin; Chaudhary, Apurva; Tian, Hung; Iyer, Raman; Hassan, A. Quamrul; Mathews Griner, Lesley A.; La Bonte, Laura R.; Cooke, Vesselina G.; Van Abbema, Anne; Merritt, Hanne; Gampa, Kalyani; Feng, Fei; Yuan, Jing; Mishina, Yuji; Wang, Yingyun; Haling, Jacob R.; Vaziri, Sepideh; Hekmat-Nejad, Mohammad; Polyakov, Valery; Zang, Richard; Sethuraman, Vijay; Amiri, Payman; Singh, Mallika; Sellers, William R.; Lees, Emma; Shao, Wenlin; Dillon, Michael P.; Stuart, Darrin D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2013-2027</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Direct pharmacol. inhibition of RAS has remained elusive, and efforts to target CRAF have been challenging due to the complex nature of RAF signaling, downstream of activated RAS, and the poor overall kinase selectivity of putative RAF inhibitors.  Herein, we describe 15, a selective B/C RAF inhibitor, which was developed by focusing on drug-like properties and selectivity.  Our previous tool compd., 3, was potent, selective, efficacious, and well tolerated in preclin. models, but the high human intrinsic clearance precluded further development and prompted further investigation of close analogs.  A structure-based approach led to a pyridine series with an alc. side chain that could interact with the DFG loop and significantly improved cell potency.  Further mitigation of human intrinsic clearance and time-dependent inhibition led to the discovery of 15.  Due to its excellent properties, it was progressed through toxicol. studies and is being tested in phase 1 clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRb3eMaZSvx7Vg90H21EOLACvtfcHk0lghHQ6dtCyCyg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXovVKnu74%253D&md5=8afaef4860ed341c0c80e1fd3e2138b5</span></div><a href="/servlet/linkout?suffix=cit16b&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00161&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00161%26sid%3Dliteratum%253Aachs%26aulast%3DRamurthy%26aufirst%3DS.%26aulast%3DTaft%26aufirst%3DB.%2BR.%26aulast%3DAversa%26aufirst%3DR.%2BJ.%26aulast%3DBarsanti%26aufirst%3DP.%2BA.%26aulast%3DBurger%26aufirst%3DM.%2BT.%26aulast%3DLou%26aufirst%3DY.%26aulast%3DNishiguchi%26aufirst%3DG.%2BA.%26aulast%3DRico%26aufirst%3DA.%26aulast%3DSetti%26aufirst%3DL.%26aulast%3DSmith%26aufirst%3DA.%26aulast%3DSubramanian%26aufirst%3DS.%26aulast%3DTamez%26aufirst%3DV.%26aulast%3DTanner%26aufirst%3DH.%26aulast%3DWan%26aufirst%3DW.%26aulast%3DHu%26aufirst%3DC.%26aulast%3DAppleton%26aufirst%3DB.%2BA.%26aulast%3DMamo%26aufirst%3DM.%26aulast%3DTandeske%26aufirst%3DL.%26aulast%3DTellew%26aufirst%3DJ.%2BE.%26aulast%3DHuang%26aufirst%3DS.%26aulast%3DYue%26aufirst%3DQ.%26aulast%3DChaudhary%26aufirst%3DA.%26aulast%3DTian%26aufirst%3DH.%26aulast%3DIyer%26aufirst%3DR.%26aulast%3DHassan%26aufirst%3DA.%2BQ.%26aulast%3DMathews%2BGriner%26aufirst%3DL.%2BA.%26aulast%3DLa%2BBonte%26aufirst%3DL.%2BR.%26aulast%3DCooke%26aufirst%3DV.%2BG.%26aulast%3DVan%2BAbbema%26aufirst%3DA.%26aulast%3DMerritt%26aufirst%3DH.%26aulast%3DGampa%26aufirst%3DK.%26aulast%3DFeng%26aufirst%3DF.%26aulast%3DYuan%26aufirst%3DJ.%26aulast%3DMishina%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DHaling%26aufirst%3DJ.%2BR.%26aulast%3DVaziri%26aufirst%3DS.%26aulast%3DHekmat-Nejad%26aufirst%3DM.%26aulast%3DPolyakov%26aufirst%3DV.%26aulast%3DZang%26aufirst%3DR.%26aulast%3DSethuraman%26aufirst%3DV.%26aulast%3DAmiri%26aufirst%3DP.%26aulast%3DSingh%26aufirst%3DM.%26aulast%3DSellers%26aufirst%3DW.%2BR.%26aulast%3DLees%26aufirst%3DE.%26aulast%3DShao%26aufirst%3DW.%26aulast%3DDillon%26aufirst%3DM.%2BP.%26aulast%3DStuart%26aufirst%3DD.%2BD.%26atitle%3DDesign%2520and%2520discovery%2520of%2520N-%25283-%25282-%25282-hydroxyethoxy%2529-6-morpholinopyridin-4-yl%2529-4-methylphenyl%2529-2-%2528trifluoromethyl%2529isonicotinamide%252C%2520a%2520selective%252C%2520efficacious%252C%2520and%2520well-tolerated%2520RAF%2520inhibitor%2520targeting%2520RAS%2520mutant%2520cancers%253A%2520The%2520path%2520to%2520the%2520clinic%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D2013%26epage%3D2027%26doi%3D10.1021%2Facs.jmedchem.9b00161" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bae, I. H.</span>; <span class="NLM_string-name">Son, J. B.</span>; <span class="NLM_string-name">Han, S. M.</span>; <span class="NLM_string-name">Kwak, E. J.</span>; <span class="NLM_string-name">Kim, H. S.</span>; <span class="NLM_string-name">Song, J. Y.</span>; <span class="NLM_string-name">Byun, E. Y.</span>; <span class="NLM_string-name">Jun, S. A.</span>; <span class="NLM_string-name">Ahn, Y. G.</span>; <span class="NLM_string-name">Suh, K. H.</span></span> <span> </span><span class="NLM_article-title">Thieno[3,2-<i>d</i>]pyrimidine derivatives having inhibitory activity for protein kinases</span>.  <i>PCT Int. Appl.</i> <span class="NLM_patent">WO2013100632</span>, <span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=I.+H.+Bae&author=J.+B.+Son&author=S.+M.+Han&author=E.+J.+Kwak&author=H.+S.+Kim&author=J.+Y.+Song&author=E.+Y.+Byun&author=S.+A.+Jun&author=Y.+G.+Ahn&author=K.+H.+Suh&title=Thieno%5B3%2C2-d%5Dpyrimidine+derivatives+having+inhibitory+activity+for+protein+kinases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBae%26aufirst%3DI.%2BH.%26atitle%3DThieno%255B3%252C2-d%255Dpyrimidine%2520derivatives%2520having%2520inhibitory%2520activity%2520for%2520protein%2520kinases%26jtitle%3DPCT%2520Int.%2520Appl.%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span> </span><span class="NLM_article-title">Clinical development
of LY3009120 (<b>1</b>) was terminated in 2018</span>. <a href="https://clinicaltrials.gov/ct2/show/NCT02014116" class="extLink">https://clinicaltrials.gov/ct2/show/NCT02014116</a> (accessed 6–18-<span class="NLM_year">2020</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Clinical+development%0Aof+LY3009120+%281%29+was+terminated+in+2018.+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT02014116+%28accessed+6%E2%80%9318-2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26atitle%3DClinical%2520development%250Aof%2520LY3009120%2520%25281%2529%2520was%2520terminated%2520in%25202018%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Hatzivassiliou, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haling, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Price, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heald, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hewitt, J. F. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zak, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peck, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orr, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merchant, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoeflich, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luoh, S.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ludlam, M. J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiesmann, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ultsch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedman, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malek, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belvin, M.</span></span> <span> </span><span class="NLM_article-title">Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>501</i></span>,  <span class="NLM_fpage">232</span>– <span class="NLM_lpage">236</span>, <span class="refDoi"> DOI: 10.1038/nature12441</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=10.1038%2Fnature12441" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=23934108" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1Cgtr3N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=501&publication_year=2013&pages=232-236&author=G.+Hatzivassiliouauthor=J.+R.+Halingauthor=H.+Chenauthor=K.+Songauthor=S.+Priceauthor=R.+Healdauthor=J.+F.+M.+Hewittauthor=M.+Zakauthor=A.+Peckauthor=C.+Orrauthor=M.+Merchantauthor=K.+P.+Hoeflichauthor=J.+Chanauthor=S.-M.+Luohauthor=D.+J.+Andersonauthor=M.+J.+C.+Ludlamauthor=C.+Wiesmannauthor=M.+Ultschauthor=L.+S.+Friedmanauthor=S.+Malekauthor=M.+Belvin&title=Mechanism+of+MEK+inhibition+determines+efficacy+in+mutant+KRAS-+versus+BRAF-driven+cancers&doi=10.1038%2Fnature12441"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19aR"><div class="casContent"><span class="casTitleNuber">19a</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers</span></div><div class="casAuthors">Hatzivassiliou, Georgia; Haling, Jacob R.; Chen, Huifen; Song, Kyung; Price, Steve; Heald, Robert; Hewitt, Joanne F. M.; Zak, Mark; Peck, Ariana; Orr, Christine; Merchant, Mark; Hoeflich, Klaus P.; Chan, Jocelyn; Luoh, Shiuh-Ming; Anderson, Daniel J.; Ludlam, Mary J. C.; Wiesmann, Christian; Ultsch, Mark; Friedman, Lori S.; Malek, Shiva; Belvin, Marcia</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">501</span>
        (<span class="NLM_cas:issue">7466</span>),
    <span class="NLM_cas:pages">232-236</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">KRAS and BRAF activating mutations drive tumorigenesis through constitutive activation of the MAPK pathway.  As these tumors represent an area of high unmet medical need, multiple allosteric MEK inhibitors, which inhibit MAPK signaling in both genotypes, are being tested in clin. trials.  Impressive single-agent activity in BRAF-mutant melanoma has been obsd.; however, efficacy has been far less robust in KRAS-mutant disease.  Owing to distinct mechanisms regulating MEK activation in KRAS- vs. BRAF-driven tumors, different mechanisms of inhibition are required for optimal antitumor activity in each genotype.  Structural and functional anal. illustrates that MEK inhibitors with superior efficacy in KRAS-driven tumors (GDC-0623 and G-573, the former currently in phase I clin. trials) form a strong hydrogen-bond interaction with S212 in MEK that is crit. for blocking MEK feedback phosphorylation by wild-type RAF.  Conversely, potent inhibition of active, phosphorylated MEK is required for strong inhibition of the MAPK pathway in BRAF-mutant tumors, resulting in superior efficacy in this genotype with GDC-0973 (also known as cobimetinib), a MEK inhibitor currently in phase III clin. trials.  The authors' study highlights that differences in the activation state of MEK in KRAS-mutant tumors vs. BRAF-mutant tumors can be exploited through the design of inhibitors that uniquely target these distinct activation states of MEK.  These inhibitors are currently being evaluated in clin. trials to det. whether improvements in therapeutic index within KRAS vs. BRAF preclin. models translate to improved clin. responses in patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQUdtElnPqJLVg90H21EOLACvtfcHk0lgQT68QB9znNg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1Cgtr3N&md5=12ceb67132291cbaff64c20c67b61b32</span></div><a href="/servlet/linkout?suffix=cit19a&amp;dbid=16384&amp;doi=10.1038%2Fnature12441&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature12441%26sid%3Dliteratum%253Aachs%26aulast%3DHatzivassiliou%26aufirst%3DG.%26aulast%3DHaling%26aufirst%3DJ.%2BR.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DSong%26aufirst%3DK.%26aulast%3DPrice%26aufirst%3DS.%26aulast%3DHeald%26aufirst%3DR.%26aulast%3DHewitt%26aufirst%3DJ.%2BF.%2BM.%26aulast%3DZak%26aufirst%3DM.%26aulast%3DPeck%26aufirst%3DA.%26aulast%3DOrr%26aufirst%3DC.%26aulast%3DMerchant%26aufirst%3DM.%26aulast%3DHoeflich%26aufirst%3DK.%2BP.%26aulast%3DChan%26aufirst%3DJ.%26aulast%3DLuoh%26aufirst%3DS.-M.%26aulast%3DAnderson%26aufirst%3DD.%2BJ.%26aulast%3DLudlam%26aufirst%3DM.%2BJ.%2BC.%26aulast%3DWiesmann%26aufirst%3DC.%26aulast%3DUltsch%26aufirst%3DM.%26aulast%3DFriedman%26aufirst%3DL.%2BS.%26aulast%3DMalek%26aufirst%3DS.%26aulast%3DBelvin%26aufirst%3DM.%26atitle%3DMechanism%2520of%2520MEK%2520inhibition%2520determines%2520efficacy%2520in%2520mutant%2520KRAS-%2520versus%2520BRAF-driven%2520cancers%26jtitle%3DNature%26date%3D2013%26volume%3D501%26spage%3D232%26epage%3D236%26doi%3D10.1038%2Fnature12441" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit19b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Yen, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shanahan, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merchant, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orr, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunsaker, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Durk, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">La, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neve, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gustafson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venkatanarayan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foster, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rudolph, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klijn, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malek, S.</span></span> <span> </span><span class="NLM_article-title">Pharmacological induction of RAS-GTP confers RAF inhibitor sensitivity in KRAS mutant tumors</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">611</span>– <span class="NLM_lpage">625</span>, <span class="refDoi"> DOI: 10.1016/j.ccell.2018.09.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=10.1016%2Fj.ccell.2018.09.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=30300582" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvVOgsr%252FF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2018&pages=611-625&author=I.+Yenauthor=F.+Shanahanauthor=M.+Merchantauthor=C.+Orrauthor=T.+Hunsakerauthor=M.+Durkauthor=H.+Laauthor=X.+Zhangauthor=S.+E.+Martinauthor=E.+Linauthor=J.+Chanauthor=Y.+Yuauthor=D.+Aminauthor=R.+M.+Neveauthor=A.+Gustafsonauthor=A.+Venkatanarayanauthor=S.+A.+Fosterauthor=J.+Rudolphauthor=C.+Klijnauthor=S.+Malek&title=Pharmacological+induction+of+RAS-GTP+confers+RAF+inhibitor+sensitivity+in+KRAS+mutant+tumors&doi=10.1016%2Fj.ccell.2018.09.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19bR"><div class="casContent"><span class="casTitleNuber">19b</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological Induction of RAS-GTP Confers RAF Inhibitor Sensitivity in KRAS Mutant Tumors</span></div><div class="casAuthors">Yen, Ivana; Shanahan, Frances; Merchant, Mark; Orr, Christine; Hunsaker, Thomas; Durk, Matthew; La, Hank; Zhang, Xiaolin; Martin, Scott E.; Lin, Eva; Chan, John; Yu, Yihong; Amin, Dhara; Neve, Richard M.; Gustafson, Amy; Venkatanarayan, Avinashnarayan; Foster, Scott A.; Rudolph, Joachim; Klijn, Christiaan; Malek, Shiva</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">611-625.e7</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Targeting KRAS mutant tumors through inhibition of individual downstream pathways has had limited clin. success.  Here we report that RAF inhibitors exhibit little efficacy in KRAS mutant tumors.  In combination drug screens, MEK and PI3K inhibitors synergized with pan-RAF inhibitors through an RAS-GTP-dependent mechanism.  Broad cell line profiling with RAF/MEK inhibitor combinations revealed synergistic efficacy in KRAS mutant and wild-type tumors, with KRASG13D mutants exhibiting greater synergy vs. KRASG12 mutant tumors.  Mechanistic studies demonstrate that MEK inhibition induced RAS-GTP levels, RAF dimerization and RAF kinase activity resulting in MEK phosphorylation in synergistic tumor lines regardless of KRAS status.  Taken together, our studies uncover a strategy to rewire KRAS mutant tumors to confer sensitivity to RAF kinase inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFoaNP8uQOe7Vg90H21EOLACvtfcHk0lgQT68QB9znNg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvVOgsr%252FF&md5=7f68e31356ca67eb93c5c0ef88d707e3</span></div><a href="/servlet/linkout?suffix=cit19b&amp;dbid=16384&amp;doi=10.1016%2Fj.ccell.2018.09.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccell.2018.09.002%26sid%3Dliteratum%253Aachs%26aulast%3DYen%26aufirst%3DI.%26aulast%3DShanahan%26aufirst%3DF.%26aulast%3DMerchant%26aufirst%3DM.%26aulast%3DOrr%26aufirst%3DC.%26aulast%3DHunsaker%26aufirst%3DT.%26aulast%3DDurk%26aufirst%3DM.%26aulast%3DLa%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DMartin%26aufirst%3DS.%2BE.%26aulast%3DLin%26aufirst%3DE.%26aulast%3DChan%26aufirst%3DJ.%26aulast%3DYu%26aufirst%3DY.%26aulast%3DAmin%26aufirst%3DD.%26aulast%3DNeve%26aufirst%3DR.%2BM.%26aulast%3DGustafson%26aufirst%3DA.%26aulast%3DVenkatanarayan%26aufirst%3DA.%26aulast%3DFoster%26aufirst%3DS.%2BA.%26aulast%3DRudolph%26aufirst%3DJ.%26aulast%3DKlijn%26aufirst%3DC.%26aulast%3DMalek%26aufirst%3DS.%26atitle%3DPharmacological%2520induction%2520of%2520RAS-GTP%2520confers%2520RAF%2520inhibitor%2520sensitivity%2520in%2520KRAS%2520mutant%2520tumors%26jtitle%3DCancer%2520Cell%26date%3D2018%26volume%3D34%26spage%3D611%26epage%3D625%26doi%3D10.1016%2Fj.ccell.2018.09.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wenglowsky, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreno, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laird, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gloor, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Risom, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rudolph, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sturgis, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voegtli, W. C.</span></span> <span> </span><span class="NLM_article-title">Pyrazolopyridine inhibitors of B-Raf<sup>V600E</sup>. Part 4: Rational design and kinase selectivity profile of cell potent type II inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">6237</span>– <span class="NLM_lpage">6241</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2012.08.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=10.1016%2Fj.bmcl.2012.08.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=22954737" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhtlajsb7L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=6237-6241&author=S.+Wenglowskyauthor=D.+Morenoauthor=E.+R.+Lairdauthor=S.+L.+Gloorauthor=L.+Renauthor=T.+Risomauthor=J.+Rudolphauthor=H.+L.+Sturgisauthor=W.+C.+Voegtli&title=Pyrazolopyridine+inhibitors+of+B-RafV600E.+Part+4%3A+Rational+design+and+kinase+selectivity+profile+of+cell+potent+type+II+inhibitors&doi=10.1016%2Fj.bmcl.2012.08.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Pyrazolopyridine inhibitors of B-RafV600E. Part 4: Rational design and kinase selectivity profile of cell potent type II inhibitors</span></div><div class="casAuthors">Wenglowsky, Steve; Moreno, David; Laird, Ellen R.; Gloor, Susan L.; Ren, Li; Risom, Tyler; Rudolph, Joachim; Sturgis, Hillary L.; Voegtli, Walter C.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">6237-6241</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Cell potent inhibitors of B-RafV600E that bind to the kinase in the DFG-out conformation are reported.  These compds. utilize the hinge-binding group and lipophilic linker from a previously disclosed series of B-RafV600E inhibitors that bind to the kinase in an atypical DFG-in, αC-helix-out conformation.  This new series demonstrates that DFG-out kinase inhibitors can be rationally designed from related inhibitors which utilize an unconventional binding mode.  Kinase selectivity profiles are compared.  The pattern of kinase selectivity was found to be detd. by the feature of the inhibitor which extends into the back pocket of the kinase and leads to the kinase conformation, rather than by the hinge-binding group or other minor modifications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfijQ1ttxu5LVg90H21EOLACvtfcHk0lgQT68QB9znNg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhtlajsb7L&md5=d02430d27f3103572a52009eeec246ec</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2012.08.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2012.08.007%26sid%3Dliteratum%253Aachs%26aulast%3DWenglowsky%26aufirst%3DS.%26aulast%3DMoreno%26aufirst%3DD.%26aulast%3DLaird%26aufirst%3DE.%2BR.%26aulast%3DGloor%26aufirst%3DS.%2BL.%26aulast%3DRen%26aufirst%3DL.%26aulast%3DRisom%26aufirst%3DT.%26aulast%3DRudolph%26aufirst%3DJ.%26aulast%3DSturgis%26aufirst%3DH.%2BL.%26aulast%3DVoegtli%26aufirst%3DW.%2BC.%26atitle%3DPyrazolopyridine%2520inhibitors%2520of%2520B-RafV600E.%2520Part%25204%253A%2520Rational%2520design%2520and%2520kinase%2520selectivity%2520profile%2520of%2520cell%2520potent%2520type%2520II%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D6237%26epage%3D6241%26doi%3D10.1016%2Fj.bmcl.2012.08.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Furet, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caravatti, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guagnano, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schoepfer, J.</span></span> <span> </span><span class="NLM_article-title">Entry into a new class of protein kinase inhibitors by pseudo ring design</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">897</span>– <span class="NLM_lpage">900</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2007.12.041</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=10.1016%2Fj.bmcl.2007.12.041" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=18248988" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsFWksb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=897-900&author=P.+Furetauthor=G.+Caravattiauthor=V.+Guagnanoauthor=M.+Langauthor=T.+Meyerauthor=J.+Schoepfer&title=Entry+into+a+new+class+of+protein+kinase+inhibitors+by+pseudo+ring+design&doi=10.1016%2Fj.bmcl.2007.12.041"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21aR"><div class="casContent"><span class="casTitleNuber">21a</span><div class="casTitle"><span class="NLM_cas:atitle">Entry into a new class of protein kinase inhibitors by pseudo ring design</span></div><div class="casAuthors">Furet, Pascal; Caravatti, Giorgio; Guagnano, Vito; Lang, Marc; Meyer, Thomas; Schoepfer, Joseph</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">897-900</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A pyrimidin-4-yl-urea motif forming a pseudo ring by intramol. hydrogen bonding has been designed to mimic the pyrido[2,3-d]pyrimidin-7-one core structure of a well-established class of protein kinase inhibitors.  Potent inhibition of a no. of protein kinases was obtained with the first prototype compd. synthesized to probe the design concept.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5MZZKS4I03LVg90H21EOLACvtfcHk0lg2rV8LjB8ang"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsFWksb0%253D&md5=989b4bb7f1d5177be45d4edf31290de5</span></div><a href="/servlet/linkout?suffix=cit21a&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2007.12.041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2007.12.041%26sid%3Dliteratum%253Aachs%26aulast%3DFuret%26aufirst%3DP.%26aulast%3DCaravatti%26aufirst%3DG.%26aulast%3DGuagnano%26aufirst%3DV.%26aulast%3DLang%26aufirst%3DM.%26aulast%3DMeyer%26aufirst%3DT.%26aulast%3DSchoepfer%26aufirst%3DJ.%26atitle%3DEntry%2520into%2520a%2520new%2520class%2520of%2520protein%2520kinase%2520inhibitors%2520by%2520pseudo%2520ring%2520design%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D897%26epage%3D900%26doi%3D10.1016%2Fj.bmcl.2007.12.041" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit21b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Mathieu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gradl, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aliagas, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunzner-Toste, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pulk, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alicke, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boggs, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buckmelter, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choo, E. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dinkel, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gloor, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gould, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansen, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hastings, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hatzivassiliou, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laird, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreno, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ran, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voegtli, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wenglowsky, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grina, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rudolph, J.</span></span> <span> </span><span class="NLM_article-title">Potent and selective aminopyrimidine-based B-Raf inhibitors with favorable physicochemical and pharmacokinetic properties</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">2869</span>– <span class="NLM_lpage">2881</span>, <span class="refDoi"> DOI: 10.1021/jm300016v</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300016v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref21/cit21b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=1%3ACAS%3A528%3ADC%252BC38XitlGjtbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=2869-2881&author=S.+Mathieuauthor=S.+N.+Gradlauthor=L.+Renauthor=Z.+Wenauthor=I.+Aliagasauthor=J.+Gunzner-Tosteauthor=W.+Leeauthor=R.+Pulkauthor=G.+Zhaoauthor=B.+Alickeauthor=J.+W.+Boggsauthor=A.+J.+Buckmelterauthor=E.+F.+Chooauthor=V.+Dinkelauthor=S.+L.+Gloorauthor=S.+E.+Gouldauthor=J.+D.+Hansenauthor=G.+Hastingsauthor=G.+Hatzivassiliouauthor=E.+R.+Lairdauthor=D.+Morenoauthor=Y.+Ranauthor=W.+C.+Voegtliauthor=S.+Wenglowskyauthor=J.+Grinaauthor=J.+Rudolph&title=Potent+and+selective+aminopyrimidine-based+B-Raf+inhibitors+with+favorable+physicochemical+and+pharmacokinetic+properties&doi=10.1021%2Fjm300016v"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21bR"><div class="casContent"><span class="casTitleNuber">21b</span><div class="casTitle"><span class="NLM_cas:atitle">Potent and Selective Aminopyrimidine-Based B-Raf Inhibitors with Favorable Physicochemical and Pharmacokinetic Properties</span></div><div class="casAuthors">Mathieu, Simon; Gradl, Stefan N.; Ren, Li; Wen, Zhaoyang; Aliagas, Ignacio; Gunzner-Toste, Janet; Lee, Wendy; Pulk, Rebecca; Zhao, Guiling; Alicke, Bruno; Boggs, Jason W.; Buckmelter, Alex J.; Choo, Edna F.; Dinkel, Victoria; Gloor, Susan L.; Gould, Stephen E.; Hansen, Joshua D.; Hastings, Gregg; Hatzivassiliou, Georgia; Laird, Ellen R.; Moreno, David; Ran, Yingqing; Voegtli, Walter C.; Wenglowsky, Steve; Grina, Jonas; Rudolph, Joachim</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2869-2881</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Recent clin. data provided proof-of-concept for selective B-Raf inhibitors in treatment of B-RafV600E mutant melanoma.  Pyrazolopyridine-type B-Raf inhibitors previously described by the authors are potent and selective but exhibit low soly. requiring the use of amorphous dispersion-based formulation for achieving efficacious drug exposures.  Through structure-based design, a new class of highly potent aminopyrimidine-based B-Raf inhibitors was discovered with improved soly. and pharmacokinetic profiles.  The hinge binding moiety possesses a basic center imparting high soly. at gastric pH, addressing the dissoln. limitation obsd. with the previous series.  In our search for an optimal linker-hinge binding moiety system, amide-linked thieno[3,2-d]pyrimidine analogs I and II (G945), mols. with desirable physicochem. properties, emerged as lead compds. with strong efficacy in a B-RafV600E mutant mouse xenograft model.  Synthesis, SAR, lead selection, and evaluation of key compds. in animal studies will be described.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGos8je6g5RG6LVg90H21EOLACvtfcHk0lg2rV8LjB8ang"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XitlGjtbw%253D&md5=53373bfc102c5dfa271c4f429d11139a</span></div><a href="/servlet/linkout?suffix=cit21b&amp;dbid=16384&amp;doi=10.1021%2Fjm300016v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300016v%26sid%3Dliteratum%253Aachs%26aulast%3DMathieu%26aufirst%3DS.%26aulast%3DGradl%26aufirst%3DS.%2BN.%26aulast%3DRen%26aufirst%3DL.%26aulast%3DWen%26aufirst%3DZ.%26aulast%3DAliagas%26aufirst%3DI.%26aulast%3DGunzner-Toste%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DW.%26aulast%3DPulk%26aufirst%3DR.%26aulast%3DZhao%26aufirst%3DG.%26aulast%3DAlicke%26aufirst%3DB.%26aulast%3DBoggs%26aufirst%3DJ.%2BW.%26aulast%3DBuckmelter%26aufirst%3DA.%2BJ.%26aulast%3DChoo%26aufirst%3DE.%2BF.%26aulast%3DDinkel%26aufirst%3DV.%26aulast%3DGloor%26aufirst%3DS.%2BL.%26aulast%3DGould%26aufirst%3DS.%2BE.%26aulast%3DHansen%26aufirst%3DJ.%2BD.%26aulast%3DHastings%26aufirst%3DG.%26aulast%3DHatzivassiliou%26aufirst%3DG.%26aulast%3DLaird%26aufirst%3DE.%2BR.%26aulast%3DMoreno%26aufirst%3DD.%26aulast%3DRan%26aufirst%3DY.%26aulast%3DVoegtli%26aufirst%3DW.%2BC.%26aulast%3DWenglowsky%26aufirst%3DS.%26aulast%3DGrina%26aufirst%3DJ.%26aulast%3DRudolph%26aufirst%3DJ.%26atitle%3DPotent%2520and%2520selective%2520aminopyrimidine-based%2520B-Raf%2520inhibitors%2520with%2520favorable%2520physicochemical%2520and%2520pharmacokinetic%2520properties%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D2869%26epage%3D2881%26doi%3D10.1021%2Fjm300016v" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit21c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group"><span class="NLM_string-name">De Morin, F. F.</span>; <span class="NLM_string-name">Chen, J. J.</span>; <span class="NLM_string-name">Hitchcock, S.</span>; <span class="NLM_string-name">Liu, G.</span>; <span class="NLM_string-name">Paras, N. A.</span>; <span class="NLM_string-name">Petkus, J.</span>; <span class="NLM_string-name">Smith, A. L.</span>; <span class="NLM_string-name">Tasker, A.</span>; <span class="NLM_string-name">Zhu, J.</span></span> <span> </span><span class="NLM_article-title">Preparation of nitrogen-containing bicyclic heteroaryl compounds as antitumor agents</span>. US Patent <span class="NLM_patent">7989461</span>, <span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=F.+F.+De+Morin&author=J.+J.+Chen&author=S.+Hitchcock&author=G.+Liu&author=N.+A.+Paras&author=J.+Petkus&author=A.+L.+Smith&author=A.+Tasker&author=J.+Zhu&title=Preparation+of+nitrogen-containing+bicyclic+heteroaryl+compounds+as+antitumor+agents"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BMorin%26aufirst%3DF.%2BF.%26atitle%3DPreparation%2520of%2520nitrogen-containing%2520bicyclic%2520heteroaryl%2520compounds%2520as%2520antitumor%2520agents%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="note"><p class="first last">A focused kinase panel (including RAF kinases) was created from a broad kinome panel in order to routinely measure selectivity of kinases which were relevant in terms of homology and pathway, and monitor critical off-targets. The list of kinases is presented in <a href="/doi/suppl/10.1021/acs.jmedchem.0c02085/suppl_file/jm0c02085_si_004.pdf" class="ext-link">Table S2</a>, and RAF kinases are not included in the totals in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xing, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klug-Mcleod, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rai, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lunney, E. A.</span></span> <span> </span><span class="NLM_article-title">Kinase Hinge binding scaffolds and their hydrogen bond patterns</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">6520</span>– <span class="NLM_lpage">6527</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2015.08.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=10.1016%2Fj.bmc.2015.08.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=26358279" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVentr3L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2015&pages=6520-6527&author=L.+Xingauthor=J.+Klug-Mcleodauthor=B.+Raiauthor=E.+A.+Lunney&title=Kinase+Hinge+binding+scaffolds+and+their+hydrogen+bond+patterns&doi=10.1016%2Fj.bmc.2015.08.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Kinase hinge binding scaffolds and their hydrogen bond patterns</span></div><div class="casAuthors">Xing, Li; Klug-Mcleod, Jacquelyn; Rai, Brajesh; Lunney, Elizabeth A.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">6520-6527</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Protein kinases constitute a major class of intracellular signaling mols., and describe some of the most prominent drug targets.  Kinase inhibitors commonly employ small chem. scaffolds that form hydrogen bonds with the kinase hinge residues connecting the N- and C-terminal lobes of the catalytic domain.  In general the satisfied hydrogen bonds are required for potent inhibition, therefore constituting a conserved feature in the majority of inhibitor-kinase interactions.  From systematically analyzing the kinase scaffolds extd. from Pfizer crystal structure database (CSDb) the authors recognize that large no. of kinase inhibitors of diverse chem. structures are derived from a relatively small no. of common scaffolds.  Depending on specific substitution patterns, scaffolds may demonstrate versatile binding capacities to interact with kinase hinge.  Afforded by thousands of ligand-protein binary complexes, the hinge hydrogen bond patterns were analyzed with a focus on their three-dimensional configurations.  Most of the compds. engage H6 NH for hinge recognition.  Dual hydrogen bonds are commonly obsd. with addnl. recruitment of H4 CO upstream and/or H6 CO downstream.  Triple hydrogen bonds accounts for small no. of binary complexes.  An unusual hydrogen bond with a non-canonical H5 conformation is obsd., requiring a peptide bond flip by a glycine residue at the H6 position.  Addnl. hydrogen bonds to kinase hinge do not necessarily correlate with an increase in potency; conversely they appear to compromise kinase selectivity.  Such learnings could enhance the prospect of successful therapy design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRC-xiTiNvELVg90H21EOLACvtfcHk0lg0D04sblx4SQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVentr3L&md5=048b4b99628c6e1ae273b00a47ab2377</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2015.08.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2015.08.006%26sid%3Dliteratum%253Aachs%26aulast%3DXing%26aufirst%3DL.%26aulast%3DKlug-Mcleod%26aufirst%3DJ.%26aulast%3DRai%26aufirst%3DB.%26aulast%3DLunney%26aufirst%3DE.%2BA.%26atitle%3DKinase%2520Hinge%2520binding%2520scaffolds%2520and%2520their%2520hydrogen%2520bond%2520patterns%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2015%26volume%3D23%26spage%3D6520%26epage%3D6527%26doi%3D10.1016%2Fj.bmc.2015.08.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="note"><p class="first last">A larger panel of 218 kinases found no kinases that were inhibited to a degree of greater than 50% at 10 nM (<a href="/doi/suppl/10.1021/acs.jmedchem.0c02085/suppl_file/jm0c02085_si_004.pdf" class="ext-link">Table S3</a>).</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="note"><p class="first last">Example of <i>N</i>-methyl-polarized CH protein interactions:</p></div><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hanan, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Abbema, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrett, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blair, W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blaney, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eigenbrot, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flynn, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibbons, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurley, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kenny, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kulagowski, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magnuson, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morris, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pastor, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rawson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ultsch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sampath, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyssikatos, J. P.</span></span> <span> </span><span class="NLM_article-title">Discovery of potent and selective pyrazolopyrimidine janus kinase 2 inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">10090</span>– <span class="NLM_lpage">10107</span>, <span class="refDoi"> DOI: 10.1021/jm3012239</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm3012239" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFSgs7vO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=10090-10107&author=E.+J.+Hananauthor=A.+van+Abbemaauthor=K.+Barrettauthor=W.+S.+Blairauthor=J.+Blaneyauthor=C.+Changauthor=C.+Eigenbrotauthor=S.+Flynnauthor=P.+Gibbonsauthor=C.+A.+Hurleyauthor=J.+R.+Kennyauthor=J.+Kulagowskiauthor=L.+Leeauthor=S.+M.+Magnusonauthor=C.+Morrisauthor=J.+Murrayauthor=R.+M.+Pastorauthor=T.+Rawsonauthor=M.+Siuauthor=M.+Ultschauthor=A.+Zhouauthor=D.+Sampathauthor=J.+P.+Lyssikatos&title=Discovery+of+potent+and+selective+pyrazolopyrimidine+janus+kinase+2+inhibitors&doi=10.1021%2Fjm3012239"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Potent and Selective Pyrazolopyrimidine Janus Kinase 2 Inhibitors</span></div><div class="casAuthors">Hanan, Emily J.; van Abbema, Anne; Barrett, Kathy; Blair, Wade S.; Blaney, Jeff; Chang, Christine; Eigenbrot, Charles; Flynn, Sean; Gibbons, Paul; Hurley, Christopher A.; Kenny, Jane R.; Kulagowski, Janusz; Lee, Leslie; Magnuson, Steven R.; Morris, Claire; Murray, Jeremy; Pastor, Richard M.; Rawson, Tom; Siu, Michael; Ultsch, Mark; Zhou, Aihe; Sampath, Deepak; Lyssikatos, Joseph P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">10090-10107</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The discovery of somatic Jak2 mutations in patients with chronic myeloproliferative neoplasms has led to significant interest in discovering selective Jak2 inhibitors for use in treating these disorders.  A high-throughput screening effort identified the pyrazolo[1,5-a]pyrimidine scaffold as a potent inhibitor of Jak2.  Optimization of lead compds. in this chem. series for activity against Jak2, selectivity against other Jak family kinases, and good in vivo pharmacokinetic properties led to the discovery of (I).  In a SET2 xenograft model that is dependent on Jak2 for growth, I demonstrated a time-dependent knock-down of pSTAT5, a downstream target of Jak2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqLsbJk8ilR07Vg90H21EOLACvtfcHk0lg0D04sblx4SQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFSgs7vO&md5=b08cc250ae2498a164c6ce416743c968</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Fjm3012239&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm3012239%26sid%3Dliteratum%253Aachs%26aulast%3DHanan%26aufirst%3DE.%2BJ.%26aulast%3Dvan%2BAbbema%26aufirst%3DA.%26aulast%3DBarrett%26aufirst%3DK.%26aulast%3DBlair%26aufirst%3DW.%2BS.%26aulast%3DBlaney%26aufirst%3DJ.%26aulast%3DChang%26aufirst%3DC.%26aulast%3DEigenbrot%26aufirst%3DC.%26aulast%3DFlynn%26aufirst%3DS.%26aulast%3DGibbons%26aufirst%3DP.%26aulast%3DHurley%26aufirst%3DC.%2BA.%26aulast%3DKenny%26aufirst%3DJ.%2BR.%26aulast%3DKulagowski%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DL.%26aulast%3DMagnuson%26aufirst%3DS.%2BM.%26aulast%3DMorris%26aufirst%3DC.%26aulast%3DMurray%26aufirst%3DJ.%26aulast%3DPastor%26aufirst%3DR.%2BM.%26aulast%3DRawson%26aufirst%3DT.%26aulast%3DSiu%26aufirst%3DM.%26aulast%3DUltsch%26aufirst%3DM.%26aulast%3DZhou%26aufirst%3DA.%26aulast%3DSampath%26aufirst%3DD.%26aulast%3DLyssikatos%26aufirst%3DJ.%2BP.%26atitle%3DDiscovery%2520of%2520potent%2520and%2520selective%2520pyrazolopyrimidine%2520janus%2520kinase%25202%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D10090%26epage%3D10107%26doi%3D10.1021%2Fjm3012239" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="note"><p class="first last">Given that the biochemical potencies of <b>6</b> and <b>7</b> are at the lower limits of detection, we cannot exclude the possibility that the observed cellular potency improvement of <b>7</b> may be due to greater permeability.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Greco, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bravo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parsons, J. C.</span></span> <span> </span><span class="NLM_article-title">The search for synergy: A critical review from a response surface perspective</span>. <i>Pharmacol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">331</span>– <span class="NLM_lpage">385</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=7568331" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=1%3ACAS%3A280%3ADyaK28%252FjsFSgtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=1995&pages=331-385&author=W.+R.+Grecoauthor=G.+Bravoauthor=J.+C.+Parsons&title=The+search+for+synergy%3A+A+critical+review+from+a+response+surface+perspective"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27aR"><div class="casContent"><span class="casTitleNuber">27a</span><div class="casTitle"><span class="NLM_cas:atitle">The search for synergy: a critical review from a response surface perspective</span></div><div class="casAuthors">Greco W R; Bravo G; Parsons J C</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological reviews</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">331-85</span>
        ISSN:<span class="NLM_cas:issn">0031-6997</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRXywHk-SVAkdenUz0lpNqnfW6udTcc2eZGxDA1ic8WV7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK28%252FjsFSgtQ%253D%253D&md5=80f1b0c8e20e587625a5d68339d30709</span></div><a href="/servlet/linkout?suffix=cit27a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGreco%26aufirst%3DW.%2BR.%26aulast%3DBravo%26aufirst%3DG.%26aulast%3DParsons%26aufirst%3DJ.%2BC.%26atitle%3DThe%2520search%2520for%2520synergy%253A%2520A%2520critical%2520review%2520from%2520a%2520response%2520surface%2520perspective%26jtitle%3DPharmacol.%2520Rev.%26date%3D1995%26volume%3D47%26spage%3D331%26epage%3D385" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit27b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, G. K. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moffat, J. G.</span></span> <span> </span><span class="NLM_article-title">Unlocking the potential of high-throughput drug combination assays using acoustic dispensing</span>. <i>J. Lab. Autom.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">125</span>– <span class="NLM_lpage">132</span>, <span class="refDoi"> DOI: 10.1177/2211068215593759</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=10.1177%2F2211068215593759" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=26160862" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVaitb%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2016&pages=125-132&author=G.+K.+Y.+Chanauthor=S.+Wilsonauthor=S.+Schmidtauthor=J.+G.+Moffat&title=Unlocking+the+potential+of+high-throughput+drug+combination+assays+using+acoustic+dispensing&doi=10.1177%2F2211068215593759"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27bR"><div class="casContent"><span class="casTitleNuber">27b</span><div class="casTitle"><span class="NLM_cas:atitle">Unlocking the potential of high-throughput drug combination assays using acoustic dispensing</span></div><div class="casAuthors">Chan, Grace Ka Yan; Wilson, Stacy; Schmidt, Stephen; Moffat, John G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Laboratory Automation</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">125-132</span>CODEN:
                <span class="NLM_cas:coden">JLAOBH</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">Assessment of synergistic effects of drug combinations in vitro is a crit. part of anticancer drug research.  However, the complexities of dosing and analyzing two drugs over the appropriate range of doses have generally led to compromises in exptl. design that restrict the quality and robustness of the data.  In particular, the use of a single dose response of combined drugs, rather than a full two-way matrix of varying doses, has predominated in higher-throughput studies.  Acoustic dispensing unlocks the potential of high-throughput dose matrix anal.  We have developed acoustic dispensing protocols that enable compd. synergy assays in a 384-well format.  This exptl. design is considerably more efficient and flexible with respect to time, reagent usage, and labware than is achievable using traditional serial-diln. approaches.  Data anal. tools integrated in Genedata Screener were used to efficiently deconvolute the combination compd. mapping scheme and calc. compd. potency and synergy metrics.  We have applied this workflow to evaluate interactions among drugs targeting different nodes of the mitogen-activated protein kinase pathway in a panel of cancer cell lines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6qXA6OcoF1rVg90H21EOLACvtfcHk0li5WETcjb8J0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVaitb%252FO&md5=d88b45023c8e90f772035f4b952f8391</span></div><a href="/servlet/linkout?suffix=cit27b&amp;dbid=16384&amp;doi=10.1177%2F2211068215593759&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F2211068215593759%26sid%3Dliteratum%253Aachs%26aulast%3DChan%26aufirst%3DG.%2BK.%2BY.%26aulast%3DWilson%26aufirst%3DS.%26aulast%3DSchmidt%26aufirst%3DS.%26aulast%3DMoffat%26aufirst%3DJ.%2BG.%26atitle%3DUnlocking%2520the%2520potential%2520of%2520high-throughput%2520drug%2520combination%2520assays%2520using%2520acoustic%2520dispensing%26jtitle%3DJ.%2520Lab.%2520Autom.%26date%3D2016%26volume%3D21%26spage%3D125%26epage%3D132%26doi%3D10.1177%2F2211068215593759" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="note"><p class="first last">Detailed synthetic schemes are provided in the Supporting Information (<a href="/doi/suppl/10.1021/acs.jmedchem.0c02085/suppl_file/jm0c02085_si_004.pdf" class="ext-link">Scheme S1</a>).</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Qin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span> <span> </span><span class="NLM_article-title">Pd-catalyzed amidation of aryl(het) halides with <i>tert</i>-butyl carbamate</span>. <i>Tetrahedron Lett.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">4445</span>– <span class="NLM_lpage">4448</span>, <span class="refDoi"> DOI: 10.1016/j.tetlet.2010.06.083</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=10.1016%2Fj.tetlet.2010.06.083" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=1%3ACAS%3A528%3ADC%252BC3cXptVagtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2010&pages=4445-4448&author=L.+Qinauthor=H.+Cuiauthor=D.+Zouauthor=J.+Liauthor=Y.+Wuauthor=Z.+Zhuauthor=Y.+Wu&title=Pd-catalyzed+amidation+of+aryl%28het%29+halides+with+tert-butyl+carbamate&doi=10.1016%2Fj.tetlet.2010.06.083"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Pd-catalyzed amidation of aryl(Het) halides with tert-butyl carbamate</span></div><div class="casAuthors">Qin, Lijin; Cui, Hongmeng; Zou, Dapeng; Li, Jingya; Wu, Yangjie; Zhu, Zhiwu; Wu, Yusheng</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron Letters</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">33</span>),
    <span class="NLM_cas:pages">4445-4448</span>CODEN:
                <span class="NLM_cas:coden">TELEAY</span>;
        ISSN:<span class="NLM_cas:issn">0040-4039</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Pd-catalyzed cross-coupling reaction of tert-Bu carbamate with various aryl(Het) halides with Cs2CO3 as base in 1,4-dioxane as solvent was investigated, which resulted in the formation of the desired compds. in moderate to excellent yields.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqUf_uWurXB37Vg90H21EOLACvtfcHk0li5WETcjb8J0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXptVagtbo%253D&md5=ab2e56cea9014a08ebaa0cf175dc3994</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1016%2Fj.tetlet.2010.06.083&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tetlet.2010.06.083%26sid%3Dliteratum%253Aachs%26aulast%3DQin%26aufirst%3DL.%26aulast%3DCui%26aufirst%3DH.%26aulast%3DZou%26aufirst%3DD.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DZhu%26aufirst%3DZ.%26aulast%3DWu%26aufirst%3DY.%26atitle%3DPd-catalyzed%2520amidation%2520of%2520aryl%2528het%2529%2520halides%2520with%2520tert-butyl%2520carbamate%26jtitle%3DTetrahedron%2520Lett.%26date%3D2010%26volume%3D51%26spage%3D4445%26epage%3D4448%26doi%3D10.1016%2Fj.tetlet.2010.06.083" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bogolubsky, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryabukhin, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pakhomov, G. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ostapchuk, E. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shivanyuk, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tolmachev, A. A.</span></span> <span> </span><span class="NLM_article-title">A facile synthesis of <i>N</i>-carbamoylamino acids</span>. <i>Synlett</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_fpage">2279</span>– <span class="NLM_lpage">2282</span>, <span class="refDoi"> DOI: 10.1055/s-2008-1078017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=10.1055%2Fs-2008-1078017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=1%3ACAS%3A528%3ADC%252BD1cXht1amsL3F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&pages=2279-2282&author=A.+V.+Bogolubskyauthor=S.+V.+Ryabukhinauthor=G.+G.+Pakhomovauthor=E.+N.+Ostapchukauthor=A.+N.+Shivanyukauthor=A.+A.+Tolmachev&title=A+facile+synthesis+of+N-carbamoylamino+acids&doi=10.1055%2Fs-2008-1078017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">A facile synthesis of N-carbamoylamino acids</span></div><div class="casAuthors">Bogolubsky, Andrey V.; Ryabukhin, Sergey V.; Pakhomov, Gennadiy G.; Ostapchuk, Eugeniy N.; Shivanyuk, Alexander N.; Tolmachev, Andrey A.</div><div class="citationInfo"><span class="NLM_cas:title">Synlett</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume"></span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">2279-2282</span>CODEN:
                <span class="NLM_cas:coden">SYNLES</span>;
        ISSN:<span class="NLM_cas:issn">0936-5214</span>.
    
            (<span class="NLM_cas:orgname">Georg Thieme Verlag</span>)
        </div><div class="casAbstract">N-Carbamoyl amino acids were obtained through the alkylation of monosubstituted parabanates and subsequent hydrolysis.  This new methodol. furnishes structurally and functionally diverse N-carbamoyl amino acids in high preparative yields and excellent purity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpNK4re9LM3VbVg90H21EOLACvtfcHk0li5WETcjb8J0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXht1amsL3F&md5=d9367b1e64f96a90705489c5e35bd3e6</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1055%2Fs-2008-1078017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-2008-1078017%26sid%3Dliteratum%253Aachs%26aulast%3DBogolubsky%26aufirst%3DA.%2BV.%26aulast%3DRyabukhin%26aufirst%3DS.%2BV.%26aulast%3DPakhomov%26aufirst%3DG.%2BG.%26aulast%3DOstapchuk%26aufirst%3DE.%2BN.%26aulast%3DShivanyuk%26aufirst%3DA.%2BN.%26aulast%3DTolmachev%26aufirst%3DA.%2BA.%26atitle%3DA%2520facile%2520synthesis%2520of%2520N-carbamoylamino%2520acids%26jtitle%3DSynlett%26date%3D2008%26spage%3D2279%26epage%3D2282%26doi%3D10.1055%2Fs-2008-1078017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Kinzel, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchwald, S. L.</span></span> <span> </span><span class="NLM_article-title">A new palladium precatalyst allows for the fast Suzuki-Miyaura coupling reactions of unstable polyfluorophenyl and 2-heteroaryl boronic acids</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>132</i></span>,  <span class="NLM_fpage">14073</span>– <span class="NLM_lpage">14075</span>, <span class="refDoi"> DOI: 10.1021/ja1073799</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja1073799" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref31/cit31a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtF2nu7vP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=132&publication_year=2010&pages=14073-14075&author=T.+Kinzelauthor=Y.+Zhangauthor=S.+L.+Buchwald&title=A+new+palladium+precatalyst+allows+for+the+fast+Suzuki-Miyaura+coupling+reactions+of+unstable+polyfluorophenyl+and+2-heteroaryl+boronic+acids&doi=10.1021%2Fja1073799"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31aR"><div class="casContent"><span class="casTitleNuber">31a</span><div class="casTitle"><span class="NLM_cas:atitle">A New Palladium Precatalyst Allows for the Fast Suzuki-Miyaura Coupling Reactions of Unstable Polyfluorophenyl and 2-Heteroaryl Boronic Acids</span></div><div class="casAuthors">Kinzel, Tom; Zhang, Yong; Buchwald, Stephen L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">132</span>
        (<span class="NLM_cas:issue">40</span>),
    <span class="NLM_cas:pages">14073-14075</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Boronic acids which quickly deboronate under basic conditions, such as polyfluorophenylboronic acid and five-membered 2-heteroarom. boronic acids, are esp. challenging coupling partners for Suzuki-Miyaura reactions.  Nevertheless, being able to use these substrates is highly desirable for a no. of applications.  Having found that monodentate biarylphosphine ligands can promote these coupling processes, we developed a precatalyst that forms the catalytically active species under conditions where boronic acid decompn. is slow.  With this precatalyst, Suzuki-Miyaura reactions of a wide range of (hetero)aryl chlorides, bromides, and triflates with polyfluorophenyl, 2-furan, 2-thiophene, and 2-pyrroleboronic acids and their analogs proceed at room temp. or 40 °C in short reaction times to give the desired products in excellent yields.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQcxyqTMX_GLVg90H21EOLACvtfcHk0lgdfX42XkF9RQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtF2nu7vP&md5=1022a0f192fb806ea9d567bf0c2d739a</span></div><a href="/servlet/linkout?suffix=cit31a&amp;dbid=16384&amp;doi=10.1021%2Fja1073799&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja1073799%26sid%3Dliteratum%253Aachs%26aulast%3DKinzel%26aufirst%3DT.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DBuchwald%26aufirst%3DS.%2BL.%26atitle%3DA%2520new%2520palladium%2520precatalyst%2520allows%2520for%2520the%2520fast%2520Suzuki-Miyaura%2520coupling%2520reactions%2520of%2520unstable%2520polyfluorophenyl%2520and%25202-heteroaryl%2520boronic%2520acids%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2010%26volume%3D132%26spage%3D14073%26epage%3D14075%26doi%3D10.1021%2Fja1073799" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit31b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Düfert, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Billingsley, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchwald, S. L.</span></span> <span> </span><span class="NLM_article-title">Suzuki-Miyaura cross-coupling of unprotected, nitrogen-rich heterocycles: Substrate scope and mechanistic investigation</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>135</i></span>,  <span class="NLM_fpage">12877</span>– <span class="NLM_lpage">12885</span>, <span class="refDoi"> DOI: 10.1021/ja4064469</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja4064469" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref31/cit31b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1WltrjE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=135&publication_year=2013&pages=12877-12885&author=M.+A.+D%C3%BCfertauthor=K.+L.+Billingsleyauthor=S.+L.+Buchwald&title=Suzuki-Miyaura+cross-coupling+of+unprotected%2C+nitrogen-rich+heterocycles%3A+Substrate+scope+and+mechanistic+investigation&doi=10.1021%2Fja4064469"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31bR"><div class="casContent"><span class="casTitleNuber">31b</span><div class="casTitle"><span class="NLM_cas:atitle">Suzuki-Miyaura Cross-Coupling of Unprotected, Nitrogen-Rich Heterocycles: Substrate Scope and Mechanistic Investigation</span></div><div class="casAuthors">Dufert, M. Alexander; Billingsley, Kelvin L.; Buchwald, Stephen L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">135</span>
        (<span class="NLM_cas:issue">34</span>),
    <span class="NLM_cas:pages">12877-12885</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The Suzuki-Miyaura cross-coupling of unprotected, nitrogen-rich heterocycles using precatalysts P1 or P2 is reported.  The procedure allows for the reaction of variously substituted indazole, benzimidazole, pyrazole, indole, oxindole, and azaindole halides under mild conditions in good to excellent yields.  Addnl., the mechanism behind the inhibitory effect of unprotected azoles on Pd-catalyzed cross-coupling reactions is described based on evidence gained through exptl., crystallog., and theor. investigations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGE4glX6IYJrVg90H21EOLACvtfcHk0lgdfX42XkF9RQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1WltrjE&md5=54d0f5fab5732a011a35412cc580406e</span></div><a href="/servlet/linkout?suffix=cit31b&amp;dbid=16384&amp;doi=10.1021%2Fja4064469&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja4064469%26sid%3Dliteratum%253Aachs%26aulast%3DD%25C3%25BCfert%26aufirst%3DM.%2BA.%26aulast%3DBillingsley%26aufirst%3DK.%2BL.%26aulast%3DBuchwald%26aufirst%3DS.%2BL.%26atitle%3DSuzuki-Miyaura%2520cross-coupling%2520of%2520unprotected%252C%2520nitrogen-rich%2520heterocycles%253A%2520Substrate%2520scope%2520and%2520mechanistic%2520investigation%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2013%26volume%3D135%26spage%3D12877%26epage%3D12885%26doi%3D10.1021%2Fja4064469" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huffman, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNamara, J. M.</span></span> <span> </span><span class="NLM_article-title">Pd-catalyzed <i>N</i>-arylation of heteroarylamines</span>. <i>Org. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">3481</span>– <span class="NLM_lpage">3484</span>, <span class="refDoi"> DOI: 10.1021/ol0265923</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ol0265923" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=1%3ACAS%3A528%3ADC%252BD38Xms1Omur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2002&pages=3481-3484&author=J.+Yinauthor=M.+M.+Zhaoauthor=M.+A.+Huffmanauthor=J.+M.+McNamara&title=Pd-catalyzed+N-arylation+of+heteroarylamines&doi=10.1021%2Fol0265923"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Pd-Catalyzed N-Arylation of Heteroarylamines</span></div><div class="casAuthors">Yin, Jingjun; Zhao, Matthew M.; Huffman, Mark A.; McNamara, James M.</div><div class="citationInfo"><span class="NLM_cas:title">Organic Letters</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">3481-3484</span>CODEN:
                <span class="NLM_cas:coden">ORLEF7</span>;
        ISSN:<span class="NLM_cas:issn">1523-7060</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The palladium-catalyzed N-(hetero)arylation of a no. of heteroarylamines including 2-aminopyridines, 2-aminothiazoles, and their analogs has been realized using Xantphos as the ligand.  Weak bases such as Cs2CO3, Na2CO3, and K3PO4 were used in most cases to allow for the introduction of functional groups.  Choice of the base and solvent was crit. for the success of these reactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpto0A1OmazwbVg90H21EOLACvtfcHk0lgdfX42XkF9RQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xms1Omur8%253D&md5=95f39b69250ce41d7c97d66ecc7f1ae8</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1021%2Fol0265923&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fol0265923%26sid%3Dliteratum%253Aachs%26aulast%3DYin%26aufirst%3DJ.%26aulast%3DZhao%26aufirst%3DM.%2BM.%26aulast%3DHuffman%26aufirst%3DM.%2BA.%26aulast%3DMcNamara%26aufirst%3DJ.%2BM.%26atitle%3DPd-catalyzed%2520N-arylation%2520of%2520heteroarylamines%26jtitle%3DOrg.%2520Lett.%26date%3D2002%26volume%3D4%26spage%3D3481%26epage%3D3484%26doi%3D10.1021%2Fol0265923" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fors, B. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watson, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biscoe, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchwald, S. L.</span></span> <span> </span><span class="NLM_article-title">A highly active catalyst for Pd-catalyzed amination reactions: Cross-coupling reactions using aryl mesylates and the highly selective monoarylation of primary amines using aryl chlorides</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>130</i></span>,  <span class="NLM_fpage">13552</span>– <span class="NLM_lpage">13554</span>, <span class="refDoi"> DOI: 10.1021/ja8055358</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja8055358" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtFeqs77L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=130&publication_year=2008&pages=13552-13554&author=B.+P.+Forsauthor=D.+A.+Watsonauthor=M.+R.+Biscoeauthor=S.+L.+Buchwald&title=A+highly+active+catalyst+for+Pd-catalyzed+amination+reactions%3A+Cross-coupling+reactions+using+aryl+mesylates+and+the+highly+selective+monoarylation+of+primary+amines+using+aryl+chlorides&doi=10.1021%2Fja8055358"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">A Highly Active Catalyst for Pd-Catalyzed Amination Reactions: Cross-Coupling Reactions Using Aryl Mesylates and the Highly Selective Monoarylation of Primary Amines Using Aryl Chlorides</span></div><div class="casAuthors">Fors, Brett P.; Watson, Donald A.; Biscoe, Mark R.; Buchwald, Stephen L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">130</span>
        (<span class="NLM_cas:issue">41</span>),
    <span class="NLM_cas:pages">13552-13554</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A catalyst system based on a new biarylmonophosphine ligand (BrettPhos, I) that shows excellent reactivity for C-N cross-coupling reactions is reported.  This catalyst system enables the use of aryl mesylates as a coupling partner in C-N bond-forming reactions.  Addnl., the use of BrettPhos permits the highly selective monoarylation of an array of primary aliph. amines and anilines at low catalyst loadings and with fast reaction times, including the first monoarylation of methylamine.  Lastly, oxidative addn. complexes of BrettPhos are included, which provide insight into the origin of reactivity for this system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq1Noy8GnOtfrVg90H21EOLACvtfcHk0ljTPItz-5JN7A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtFeqs77L&md5=f1e43af9fe1a21426ca3d408ab1c4779</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1021%2Fja8055358&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja8055358%26sid%3Dliteratum%253Aachs%26aulast%3DFors%26aufirst%3DB.%2BP.%26aulast%3DWatson%26aufirst%3DD.%2BA.%26aulast%3DBiscoe%26aufirst%3DM.%2BR.%26aulast%3DBuchwald%26aufirst%3DS.%2BL.%26atitle%3DA%2520highly%2520active%2520catalyst%2520for%2520Pd-catalyzed%2520amination%2520reactions%253A%2520Cross-coupling%2520reactions%2520using%2520aryl%2520mesylates%2520and%2520the%2520highly%2520selective%2520monoarylation%2520of%2520primary%2520amines%2520using%2520aryl%2520chlorides%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2008%26volume%3D130%26spage%3D13552%26epage%3D13554%26doi%3D10.1021%2Fja8055358" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kabsch, W.</span></span> <span> </span><span class="NLM_article-title">Integration, scaling, space-group assignment and post-refinement</span>. <i>Acta Crystallogr. D Biol. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">133</span>– <span class="NLM_lpage">144</span>, <span class="refDoi"> DOI: 10.1107/S0907444909047374</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=10.1107%2FS0907444909047374" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=20124693" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhs1Sisb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2010&pages=133-144&author=W.+Kabsch&title=Integration%2C+scaling%2C+space-group+assignment+and+post-refinement&doi=10.1107%2FS0907444909047374"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Integration, scaling, space-group assignment and post-refinement</span></div><div class="casAuthors">Kabsch, Wolfgang</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">133-144</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">Important steps in the processing of rotation data are described that are common to most software packages.  These programs differ in the details and in the methods implemented to carry out the tasks.  Here, the working principles underlying the data-redn. package XDS are explained, including the new features of automatic detn. of spot size and reflecting range, recognition and assignment of crystal symmetry and a highly efficient algorithm for the detn. of correction/scaling factors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGW7t3Bb1P_rVg90H21EOLACvtfcHk0ljTPItz-5JN7A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhs1Sisb4%253D&md5=eb1db34f3c959b4921771eb9f57b2159</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1107%2FS0907444909047374&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444909047374%26sid%3Dliteratum%253Aachs%26aulast%3DKabsch%26aufirst%3DW.%26atitle%3DIntegration%252C%2520scaling%252C%2520space-group%2520assignment%2520and%2520post-refinement%26jtitle%3DActa%2520Crystallogr.%2520D%2520Biol.%2520Crystallogr.%26date%3D2010%26volume%3D66%26spage%3D133%26epage%3D144%26doi%3D10.1107%2FS0907444909047374" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Winn, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballard, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowtan, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dodson, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emsley, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evans, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keegan, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krissinel, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leslie, A. G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCoy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNicholas, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murshudov, G. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pannu, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potterton, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powell, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Read, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vagin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, K. S.</span></span> <span> </span><span class="NLM_article-title">Overview of the <i>CCP</i>4 suite and current developments</span>. <i>Acta Crystallogr. D Biol. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>67</i></span>,  <span class="NLM_fpage">235</span>– <span class="NLM_lpage">242</span>, <span class="refDoi"> DOI: 10.1107/S0907444910045749</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=10.1107%2FS0907444910045749" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=21460441" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=1%3ACAS%3A528%3ADC%252BC3MXktFWqt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2011&pages=235-242&author=M.+D.+Winnauthor=C.+C.+Ballardauthor=K.+D.+Cowtanauthor=E.+J.+Dodsonauthor=P.+Emsleyauthor=P.+R.+Evansauthor=R.+M.+Keeganauthor=E.+B.+Krissinelauthor=A.+G.+W.+Leslieauthor=A.+McCoyauthor=S.+J.+McNicholasauthor=G.+N.+Murshudovauthor=N.+S.+Pannuauthor=E.+A.+Pottertonauthor=H.+R.+Powellauthor=R.+J.+Readauthor=A.+Vaginauthor=K.+S.+Wilson&title=Overview+of+the+CCP4+suite+and+current+developments&doi=10.1107%2FS0907444910045749"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Overview of the CCP4 suite and current developments</span></div><div class="casAuthors">Winn, Martyn D.; Ballard, Charles C.; Cowtan, Kevin D.; Dodson, Eleanor J.; Emsley, Paul; Evans, Phil R.; Keegan, Ronan M.; Krissinel, Eugene B.; Leslie, Andrew G. W.; McCoy, Airlie; McNicholas, Stuart J.; Murshudov, Garib N.; Pannu, Navraj S.; Potterton, Elizabeth A.; Powell, Harold R.; Read, Randy J.; Vagin, Alexei; Wilson, Keith S.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">235-242</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">A review.  The CCP4 (Collaborative Computational Project, No. 4) software suite is a collection of programs and assocd. data and software libraries which can be used for macromol. structure detn. by X-ray crystallog.  The suite is designed to be flexible, allowing users a no. of methods of achieving their aims.  The programs are from a wide variety of sources but are connected by a common infrastructure provided by std. file formats, data objects and graphical interfaces.  Structure soln. by macromol. crystallog. is becoming increasingly automated and the CCP4 suite includes several automation pipelines.  After giving a brief description of the evolution of CCP4 over the last 30 years, an overview of the current suite is given.  While detailed descriptions are given in the accompanying articles, here it is shown how the individual programs contribute to a complete software package.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_wWMMIol6UrVg90H21EOLACvtfcHk0ljTPItz-5JN7A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXktFWqt70%253D&md5=c407e4d47bef46864be336d60147c17d</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1107%2FS0907444910045749&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444910045749%26sid%3Dliteratum%253Aachs%26aulast%3DWinn%26aufirst%3DM.%2BD.%26aulast%3DBallard%26aufirst%3DC.%2BC.%26aulast%3DCowtan%26aufirst%3DK.%2BD.%26aulast%3DDodson%26aufirst%3DE.%2BJ.%26aulast%3DEmsley%26aufirst%3DP.%26aulast%3DEvans%26aufirst%3DP.%2BR.%26aulast%3DKeegan%26aufirst%3DR.%2BM.%26aulast%3DKrissinel%26aufirst%3DE.%2BB.%26aulast%3DLeslie%26aufirst%3DA.%2BG.%2BW.%26aulast%3DMcCoy%26aufirst%3DA.%26aulast%3DMcNicholas%26aufirst%3DS.%2BJ.%26aulast%3DMurshudov%26aufirst%3DG.%2BN.%26aulast%3DPannu%26aufirst%3DN.%2BS.%26aulast%3DPotterton%26aufirst%3DE.%2BA.%26aulast%3DPowell%26aufirst%3DH.%2BR.%26aulast%3DRead%26aufirst%3DR.%2BJ.%26aulast%3DVagin%26aufirst%3DA.%26aulast%3DWilson%26aufirst%3DK.%2BS.%26atitle%3DOverview%2520of%2520the%2520CCP4%2520suite%2520and%2520current%2520developments%26jtitle%3DActa%2520Crystallogr.%2520D%2520Biol.%2520Crystallogr.%26date%3D2011%26volume%3D67%26spage%3D235%26epage%3D242%26doi%3D10.1107%2FS0907444910045749" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McCoy, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grosse-Kunstleve, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winn, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Storoni, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Read, R. J.</span></span> <span> </span><span class="NLM_article-title"><i>Phaser</i> crystallographic software</span>. <i>J. Appl. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">658</span>– <span class="NLM_lpage">674</span>, <span class="refDoi"> DOI: 10.1107/S0021889807021206</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=10.1107%2FS0021889807021206" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=19461840" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=1%3ACAS%3A528%3ADC%252BD2sXnslWqsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2007&pages=658-674&author=A.+J.+McCoyauthor=R.+W.+Grosse-Kunstleveauthor=P.+D.+Adamsauthor=M.+D.+Winnauthor=L.+C.+Storoniauthor=R.+J.+Read&title=Phaser+crystallographic+software&doi=10.1107%2FS0021889807021206"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Phaser crystallographic software</span></div><div class="casAuthors">McCoy, Airlie J.; Grosse-Kunstleve, Ralf W.; Adams, Paul D.; Winn, Martyn D.; Storoni, Laurent C.; Read, Randy J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Applied Crystallography</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">658-674</span>CODEN:
                <span class="NLM_cas:coden">JACGAR</span>;
        ISSN:<span class="NLM_cas:issn">0021-8898</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">Phaser is a program for phasing macromol. crystal structures by both mol. replacement and exptl. phasing methods.  The novel phasing algorithms implemented in Phaser have been developed using max. likelihood and multivariate statistics.  For mol. replacement, the new algorithms have proved to be significantly better than traditional methods in discriminating correct solns. from noise, and for single-wavelength anomalous dispersion exptl. phasing, the new algorithms, which account for correlations between F+ and F-, give better phases (lower mean phase error with respect to the phases given by the refined structure) than those that use mean F and anomalous differences ΔF.  One of the design concepts of Phaser was that it be capable of a high degree of automation.  To this end, Phaser (written in C++) can be called directly from Python, although it can also be called using traditional CCP4 keyword-style input.  Phaser is a platform for future development of improved phasing methods and their release, including source code, to the crystallog. community.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPeVyjN_FMGbVg90H21EOLACvtfcHk0lhPoNDKdBxHOA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXnslWqsLk%253D&md5=c63b722ae97e0a74e6a5a079d388f09f</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1107%2FS0021889807021206&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0021889807021206%26sid%3Dliteratum%253Aachs%26aulast%3DMcCoy%26aufirst%3DA.%2BJ.%26aulast%3DGrosse-Kunstleve%26aufirst%3DR.%2BW.%26aulast%3DAdams%26aufirst%3DP.%2BD.%26aulast%3DWinn%26aufirst%3DM.%2BD.%26aulast%3DStoroni%26aufirst%3DL.%2BC.%26aulast%3DRead%26aufirst%3DR.%2BJ.%26atitle%3DPhaser%2520crystallographic%2520software%26jtitle%3DJ.%2520Appl.%2520Crystallogr.%26date%3D2007%26volume%3D40%26spage%3D658%26epage%3D674%26doi%3D10.1107%2FS0021889807021206" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Emsley, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowtan, K.</span></span> <span> </span><span class="NLM_article-title"><i>Coot</i>: Model-building tools for molecular graphics</span>. <i>Acta Crystallogr. D Biol. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">2126</span>– <span class="NLM_lpage">2132</span>, <span class="refDoi"> DOI: 10.1107/S0907444904019158</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=10.1107%2FS0907444904019158" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=15572765" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVars73P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2004&pages=2126-2132&author=P.+Emsleyauthor=K.+Cowtan&title=Coot%3A+Model-building+tools+for+molecular+graphics&doi=10.1107%2FS0907444904019158"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Coot: model-building tools for molecular graphics</span></div><div class="casAuthors">Emsley, Paul; Cowtan, Kevin</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">D60</span>
        (<span class="NLM_cas:issue">12, Pt. 1</span>),
    <span class="NLM_cas:pages">2126-2132</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">CCP4mg is a project that aims to provide a general-purpose tool for structural biologists, providing tools for x-ray structure soln., structure comparison and anal., and publication-quality graphics.  The map-fitting tools are available as a stand-alone package, distributed as 'Coot'.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMisM42468k7Vg90H21EOLACvtfcHk0lhPoNDKdBxHOA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVars73P&md5=1be390f3bb6fd584468499ad0921161e</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1107%2FS0907444904019158&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444904019158%26sid%3Dliteratum%253Aachs%26aulast%3DEmsley%26aufirst%3DP.%26aulast%3DCowtan%26aufirst%3DK.%26atitle%3DCoot%253A%2520Model-building%2520tools%2520for%2520molecular%2520graphics%26jtitle%3DActa%2520Crystallogr.%2520D%2520Biol.%2520Crystallogr.%26date%3D2004%26volume%3D60%26spage%3D2126%26epage%3D2132%26doi%3D10.1107%2FS0907444904019158" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Murshudov, G. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vagin, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dodson, E. J.</span></span> <span> </span><span class="NLM_article-title">Refinement of macromolecular structures by the maximum-likelihood method</span>. <i>Acta Crystallogr. D Biol. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">240</span>– <span class="NLM_lpage">255</span>, <span class="refDoi"> DOI: 10.1107/S0907444996012255</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=10.1107%2FS0907444996012255" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=15299926" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=1%3ACAS%3A528%3ADyaK2sXjs1Gnsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=1997&pages=240-255&author=G.+N.+Murshudovauthor=A.+A.+Vaginauthor=E.+J.+Dodson&title=Refinement+of+macromolecular+structures+by+the+maximum-likelihood+method&doi=10.1107%2FS0907444996012255"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Refinement of macromolecular structures by the maximum-likelihood method</span></div><div class="casAuthors">Murshudov, Garib N.; Vagin, Alexei A.; Dodson, Eleanor J.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">D53</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">240-255</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">Munksgaard</span>)
        </div><div class="casAbstract">A review with many refs. on the math. basis of max. likelihood.  The likelihood function for macromol. structures is extended to include prior phase information and exptl. std. uncertainties.  The assumption that different parts of a structure might have different errors is considered.  A method for estg. σA using "free" reflections is described and its effects analyzed.  The derived equations have been implemented in the program REFMAC.  This has been tested on several proteins at different stages of refinement (bacterial α-amylase, cytochrome c', cross-linked insulin and oligopeptide binding protein).  The results derived using the max.-likelihood residual are consistently better than those obtained from least-squares refinement.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWg7mzQRNBhbVg90H21EOLACvtfcHk0lhPoNDKdBxHOA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXjs1Gnsb4%253D&md5=ec7f141ce1542f7ff458b98ecfe3f8af</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1107%2FS0907444996012255&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444996012255%26sid%3Dliteratum%253Aachs%26aulast%3DMurshudov%26aufirst%3DG.%2BN.%26aulast%3DVagin%26aufirst%3DA.%2BA.%26aulast%3DDodson%26aufirst%3DE.%2BJ.%26atitle%3DRefinement%2520of%2520macromolecular%2520structures%2520by%2520the%2520maximum-likelihood%2520method%26jtitle%3DActa%2520Crystallogr.%2520D%2520Biol.%2520Crystallogr.%26date%3D1997%26volume%3D53%26spage%3D240%26epage%3D255%26doi%3D10.1107%2FS0907444996012255" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Adams, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Afonine, P. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bunkóczi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, V. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, I. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Echols, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Headd, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hung, L.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kapral, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grosse-Kunstleve, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCoy, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moriarty, N. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oeffner, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Read, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terwilliger, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zwart, P. H.</span></span> <span> </span><span class="NLM_article-title"><i>PHENIX</i>: A comprehensive python-based system for macromolecular structure solution</span>. <i>Acta Crystallogr. D Biol. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">213</span>– <span class="NLM_lpage">221</span>, <span class="refDoi"> DOI: 10.1107/S0907444909052925</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=10.1107%2FS0907444909052925" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=20124702" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhs1Sisbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2010&pages=213-221&author=P.+D.+Adamsauthor=P.+V.+Afonineauthor=G.+Bunk%C3%B3cziauthor=V.+B.+Chenauthor=I.+W.+Davisauthor=N.+Echolsauthor=J.+J.+Headdauthor=L.-W.+Hungauthor=G.+J.+Kapralauthor=R.+W.+Grosse-Kunstleveauthor=A.+J.+McCoyauthor=N.+W.+Moriartyauthor=R.+Oeffnerauthor=R.+J.+Readauthor=D.+C.+Richardsonauthor=J.+S.+Richardsonauthor=T.+C.+Terwilligerauthor=P.+H.+Zwart&title=PHENIX%3A+A+comprehensive+python-based+system+for+macromolecular+structure+solution&doi=10.1107%2FS0907444909052925"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">PHENIX: a comprehensive Python-based system for macromolecular structure solution</span></div><div class="casAuthors">Adams, Paul D.; Afonine, Pavel V.; Bunkoczi, Gabor; Chen, Vincent B.; Davis, Ian W.; Echols, Nathaniel; Headd, Jeffrey J.; Hung, Li Wei; Kapral, Gary J.; Grosse-Kunstleve, Ralf W.; McCoy, Airlie J.; Moriarty, Nigel W.; Oeffner, Robert; Read, Randy J.; Richardson, David C.; Richardson, Jane S.; Terwilliger, Thomas C.; Zwart, Peter H.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">213-221</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">A review.  Macromol. X-ray crystallog. is routinely applied to understand biol. processes at a mol. level.  However, significant time and effort are still required to solve and complete many of these structures because of the need for manual interpretation of complex numerical data using many software packages and the repeated use of interactive three-dimensional graphics.  PHENIX has been developed to provide a comprehensive system for macromol. crystallog. structure soln. with an emphasis on the automation of all procedures.  This has relied on the development of algorithms that minimize or eliminate subjective input, the development of algorithms that automate procedures that are traditionally performed by hand and, finally, the development of a framework that allows a tight integration between the algorithms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpm_HgKRpa-ObVg90H21EOLACvtfcHk0lhPoNDKdBxHOA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhs1Sisbc%253D&md5=67b439ff4bd61c659cae37ca4209b7bc</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1107%2FS0907444909052925&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444909052925%26sid%3Dliteratum%253Aachs%26aulast%3DAdams%26aufirst%3DP.%2BD.%26aulast%3DAfonine%26aufirst%3DP.%2BV.%26aulast%3DBunk%25C3%25B3czi%26aufirst%3DG.%26aulast%3DChen%26aufirst%3DV.%2BB.%26aulast%3DDavis%26aufirst%3DI.%2BW.%26aulast%3DEchols%26aufirst%3DN.%26aulast%3DHeadd%26aufirst%3DJ.%2BJ.%26aulast%3DHung%26aufirst%3DL.-W.%26aulast%3DKapral%26aufirst%3DG.%2BJ.%26aulast%3DGrosse-Kunstleve%26aufirst%3DR.%2BW.%26aulast%3DMcCoy%26aufirst%3DA.%2BJ.%26aulast%3DMoriarty%26aufirst%3DN.%2BW.%26aulast%3DOeffner%26aufirst%3DR.%26aulast%3DRead%26aufirst%3DR.%2BJ.%26aulast%3DRichardson%26aufirst%3DD.%2BC.%26aulast%3DRichardson%26aufirst%3DJ.%2BS.%26aulast%3DTerwilliger%26aufirst%3DT.%2BC.%26aulast%3DZwart%26aufirst%3DP.%2BH.%26atitle%3DPHENIX%253A%2520A%2520comprehensive%2520python-based%2520system%2520for%2520macromolecular%2520structure%2520solution%26jtitle%3DActa%2520Crystallogr.%2520D%2520Biol.%2520Crystallogr.%26date%3D2010%26volume%3D66%26spage%3D213%26epage%3D221%26doi%3D10.1107%2FS0907444909052925" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hoeflich, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merchant, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orr, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otter, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berry, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kasman, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koeppen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rice, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, N.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engst, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnston, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedman, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belvin, M.</span></span> <span> </span><span class="NLM_article-title">Intermittent administration of MEK inhibitor GDC-0973 plus PI3K inhibitor GDC-0941 triggers robust apoptosis and tumor growth inhibition</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>72</i></span>,  <span class="NLM_fpage">210</span>– <span class="NLM_lpage">219</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-11-1515</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=10.1158%2F0008-5472.CAN-11-1515" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=22084396" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvVCltA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2012&pages=210-219&author=K.+P.+Hoeflichauthor=M.+Merchantauthor=C.+Orrauthor=J.+Chanauthor=D.+D.+Otterauthor=L.+Berryauthor=I.+Kasmanauthor=H.+Koeppenauthor=K.+Riceauthor=N.-Y.+Yangauthor=S.+Engstauthor=S.+Johnstonauthor=L.+S.+Friedmanauthor=M.+Belvin&title=Intermittent+administration+of+MEK+inhibitor+GDC-0973+plus+PI3K+inhibitor+GDC-0941+triggers+robust+apoptosis+and+tumor+growth+inhibition&doi=10.1158%2F0008-5472.CAN-11-1515"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Intermittent Administration of MEK Inhibitor GDC-0973 plus PI3K Inhibitor GDC-0941 Triggers Robust Apoptosis and Tumor Growth Inhibition</span></div><div class="casAuthors">Hoeflich, Klaus P.; Merchant, Mark; Orr, Christine; Chan, Jocelyn; Den Otter, Doug; Berry, Leanne; Kasman, Ian; Koeppen, Hartmut; Rice, Ken; Yang, Nai-Ying; Engst, Stefan; Johnston, Stuart; Friedman, Lori S.; Belvin, Marcia</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">210-219</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Combinations of MAP/ERK kinase (MEK) and phosphoinositide 3-kinase (PI3K) inhibitors have shown promise in preclin. cancer models, leading to the initiation of clin. trials cotargeting these two key cancer signaling pathways.  GDC-0973, a novel selective MEK inhibitor, and GDC-0941, a class I PI3K inhibitor, are in early stage clin. trials as both single agents and in combination.  The discovery of these selective inhibitors has allowed investigation into the precise effects of combining inhibitors of two major signaling branches downstream of RAS.  Here, we investigated multiple biomarkers in the mitogen-activated protein kinase (MAPK) and PI3K pathway to search for points of convergence that explain the increased apoptosis seen in combination.  Using washout studies in vitro and alternate dosing schedules in mice, we showed that intermittent inhibition of the PI3K and MAPK pathway is sufficient for efficacy in BRAF and KRAS mutant cancer cells.  The combination of GDC-0973 with the PI3K inhibitor GDC-0941 resulted in combination efficacy in vitro and in vivo via induction of biomarkers assocd. with apoptosis, including Bcl-2 family proapoptotic regulators.  Therefore, these data suggest that continuous exposure of MEK and PI3K inhibitors in combination is not required for efficacy in preclin. cancer models and that sustained effects on downstream apoptosis biomarkers can be obsd. in response to intermittent dosing.  Cancer Res; 72(1); 210-9.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokHbA7g6hLGrVg90H21EOLACvtfcHk0ljj4vMdwQXhUg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvVCltA%253D%253D&md5=40032bf35d5e6335856a645d5c331df8</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-11-1515&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-11-1515%26sid%3Dliteratum%253Aachs%26aulast%3DHoeflich%26aufirst%3DK.%2BP.%26aulast%3DMerchant%26aufirst%3DM.%26aulast%3DOrr%26aufirst%3DC.%26aulast%3DChan%26aufirst%3DJ.%26aulast%3DOtter%26aufirst%3DD.%2BD.%26aulast%3DBerry%26aufirst%3DL.%26aulast%3DKasman%26aufirst%3DI.%26aulast%3DKoeppen%26aufirst%3DH.%26aulast%3DRice%26aufirst%3DK.%26aulast%3DYang%26aufirst%3DN.-Y.%26aulast%3DEngst%26aufirst%3DS.%26aulast%3DJohnston%26aufirst%3DS.%26aulast%3DFriedman%26aufirst%3DL.%2BS.%26aulast%3DBelvin%26aufirst%3DM.%26atitle%3DIntermittent%2520administration%2520of%2520MEK%2520inhibitor%2520GDC-0973%2520plus%2520PI3K%2520inhibitor%2520GDC-0941%2520triggers%2520robust%2520apoptosis%2520and%2520tumor%2520growth%2520inhibition%26jtitle%3DCancer%2520Res.%26date%3D2012%26volume%3D72%26spage%3D210%26epage%3D219%26doi%3D10.1158%2F0008-5472.CAN-11-1515" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1a','cit1b','cit1c','cit1d'],'ref2':['cit2a','cit2b','cit2c'],'ref3':['cit3'],'ref4':['cit4a','cit4b','cit4c','cit4d'],'ref5':['cit5a','cit5b'],'ref6':['cit6a','cit6b'],'ref7':['cit7a','cit7b','cit7c','cit7d'],'ref8':['cit8'],'ref9':['cit9a','cit9b'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13a','cit13b'],'ref14':['cit14a','cit14b'],'ref15':['cit15'],'ref16':['cit16a','cit16b'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19a','cit19b'],'ref20':['cit20'],'ref21':['cit21a','cit21b','cit21c'],'ref22':[],'ref23':['cit23'],'ref24':[],'ref25':['cit25'],'ref26':[],'ref27':['cit27a','cit27b'],'ref28':[],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31a','cit31b'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 1 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Malcolm P. Huestis, Matthew R. Durk, Charles Eigenbrot, Paul Gibbons, Thomas L. Hunsaker, Hank La, Dennis H. Leung, Wendy Liu, Shiva Malek, Mark Merchant, John G. Moffat, Christine S. Muli, Christine J. Orr, Brendan T. Parr, Frances Shanahan, Christopher J. Sneeringer, Weiru Wang, Ivana Yen, Jianping Yin, Joachim Rudolph, <span class="NLM_string-name hlFld-ContribAuthor">Michael Siu</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting KRAS Mutant Cancers via Combination Treatment: Discovery of a Pyridopyridazinone pan-RAF Kinase Inhibitor. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2021,</strong> <em>12 </em>
                                    (5)
                                     , 791-797. <a href="https://doi.org/10.1021/acsmedchemlett.1c00063" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.1c00063</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.1c00063&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.1c00063%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DTargeting%252BKRAS%252BMutant%252BCancers%252Bvia%252BCombination%252BTreatment%25253A%252BDiscovery%252Bof%252Ba%252BPyridopyridazinone%252Bpan-RAF%252BKinase%252BInhibitor%26aulast%3DHuestis%26aufirst%3DMalcolm%2BP.%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D27012021%26date%3D31032021%26date%3D21042021%26volume%3D12%26issue%3D5%26spage%3D791%26epage%3D797" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02085/20210331/images/medium/jm0c02085_0013.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02085/20210331/images/large/jm0c02085_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02085&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02085/20210331/images/medium/jm0c02085_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02085/20210331/images/large/jm0c02085_0002.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Marketed BRAF<sup>V600E</sup> inhibitors and MEK inhibitor combination partners.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02085/20210331/images/large/jm0c02085_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02085&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02085/20210331/images/medium/jm0c02085_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02085/20210331/images/large/jm0c02085_0003.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Recently disclosed pan-RAF inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02085/20210331/images/large/jm0c02085_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02085&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02085/20210331/images/medium/jm0c02085_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02085/20210331/images/large/jm0c02085_0004.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Kinome tree for <b>7</b>, tested against 222 kinases at a concentration of 0.1 μM. Red circles represent BRAF and CRAF.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02085/20210331/images/large/jm0c02085_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02085&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02085/20210331/images/medium/jm0c02085_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02085/20210331/images/large/jm0c02085_0005.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. X-ray crystal structure of <b>7</b> bound in a mutant BRAF construct (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7K0V">7K0V</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02085/20210331/images/large/jm0c02085_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02085&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02085/20210331/images/medium/jm0c02085_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02085/20210331/images/large/jm0c02085_0006.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Conformations of <b>6</b> (yellow) and <b>7</b> (orange) determined by small-molecule X-ray crystallography and overlay with protein ligand conformation of <b>7</b> (gray). The largest difference between the conformations of <b>6</b> and <b>7</b> is an ∼170° rotation around <i>T</i><sub>1</sub> (indicated). In the overlay, the urea side chain is hidden for clarity.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02085/20210331/images/large/jm0c02085_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02085&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02085/20210331/images/medium/jm0c02085_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02085/20210331/images/large/jm0c02085_0007.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Quantum mechanical (B3LYP-D3/6-311+g**) torsion scan for model compounds representing <b>6</b> and <b>7</b>. Torsion <i>T</i><sub>1</sub> was scanned from −180 to 180° in steps of 30°. <i>T</i><sub>2</sub> was kept constant at −120°, the angle found in the protein ligand crystal structure. The gray line indicates the torsion angle of <i>T</i><sub>1</sub> found in the protein ligand crystal structure, and the blue and orange lines denote the torsion angles of <i>T</i><sub>1</sub> in the small-molecule X-ray structures of <b>6</b> and <b>7</b>, respectively. <i>T</i><sub>2</sub> in the small-molecule crystal structures is approximately −60°; however, the change accounts for just 0.3 kcal mol<sup>–1</sup> energy difference.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02085/20210331/images/large/jm0c02085_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02085&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02085/20210331/images/medium/jm0c02085_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02085/20210331/images/large/jm0c02085_0008.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Synergistic activity of <b>7</b> combined with cobimetinib. (A) Proliferation of A549 cells, determined by incorporation of 5-ethynyl-2′-deoxyuridine (EdU) into newly synthesized DNA, is inhibited in a dose-dependent manner by each agent separately (green curves), and potency is strongly enhanced by increasing concentrations of the second compound. (B) Isobologram plot of fractional EdU uptake inhibition at different dose combinations shows that the doses required to attain 50% inhibition (blue line) are significantly lower than predicted by a simple additivity model (red line). (C) Difference between the observed percent effect and expected fractional effect according to the Loewe additivity model plotted for each dose combination.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02085/20210331/images/large/jm0c02085_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02085&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02085/20210331/images/medium/jm0c02085_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02085/20210331/images/large/jm0c02085_0009.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. (A) In vivo tumor growth inhibition study over 21 days using HCT116 tumor-bearing mice treated with cobimetinib (5 mg kg<sup>–1</sup> PO, QD), GNE-0749 (<b>7</b>) (10 mg kg<sup>–1</sup> PO, BID), or a combination. (B) In vivo PK/PD study over 4 days using HCT116 tumor-bearing mice treated with cobimetinib (5 mg kg<sup>–1</sup> PO, QD), GNE-0749 (<b>7</b>) (10 mg kg<sup>–1</sup> PO, BID), or a combination.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02085/20210331/images/large/jm0c02085_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02085&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02085/20210331/images/medium/jm0c02085_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02085/20210331/images/large/jm0c02085_0010.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Common Intermediates for Hinge Binder Analysis<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02085/20210331/images/large/jm0c02085_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02085&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Conditions: (a) 10% Pd/C (50% w/w), H<sub>2</sub> (1 atm), EtOH, 23 °C, 94%; (b) PhOCOCl (1.1 equiv), NaHCO<sub>3</sub> (2 equiv), THF, 23–60 °C; then, NEt<sub>3</sub> (2 equiv), 3,3-dimethylbutylamine (1.1 equiv), toluene, 23–90 °C, 20% (two steps); (c) LiOH·H<sub>2</sub>O (1.1 equiv), THF/H<sub>2</sub>O (5:1), 80 °C, 97%; (d) PhOCOCl (1.1 equiv), NaHCO<sub>3</sub> (2 equiv), THF, 0–23 °C; then, NEt<sub>3</sub> (2 equiv), 3,3-dimethylbutylamine (1.2 equiv), toluene, 23 °C, 95% (two steps); (e) <i>tert</i>-butyl carbamate (2 × 1.2 equiv), Pd<sub>2</sub>(dba)<sub>3</sub> (2 × 0.025 equiv), Xantphos (2 × 0.06 equiv), Cs<sub>2</sub>CO<sub>3</sub> (3 equiv), THF, 90–110 °C, 32%; (f) <i>tert</i>-butyl carbamate (1.2 equiv), X-Phos Pd G2 (0.05 equiv), X-Phos (0.10 equiv), Cs<sub>2</sub>CO<sub>3</sub> (1.4 equiv), 1,4-dioxane, 110 °C; then, HCl in isopropanol, 23 °C, 45% (two steps).</p></p></figure><figure data-id="sch2" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02085/20210331/images/medium/jm0c02085_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02085/20210331/images/large/jm0c02085_0011.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Compounds in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.0c02085/20210331/images/large/jm0c02085_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02085&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Conditions: (a) DMF (0.2 equiv), oxalyl chloride (3 equiv), THF, 23 °C; then, 3-methoxy-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridin-5-amine (1.2 equiv), NEt<sub>3</sub> (2 equiv), 55 °C, 48%; (b) Hunig’s base (2 equiv), 10% aq NaOH/DMF (2:1), 23 °C, 72%; (c) 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-amine (1 equiv), X-Phos Pd G2 (0.05 equiv), X-Phos (0.05 equiv), K<sub>3</sub>PO<sub>4</sub>·H<sub>2</sub>O (3 equiv), THF/H<sub>2</sub>O (10:1), 80 °C, 80%; (d) <b>9a</b> (1 equiv), <b>10a</b> (1.4 equiv), Pd<sub>2</sub>(dba)<sub>3</sub> (0.02 equiv), Xantphos (0.06 equiv), Cs<sub>2</sub>CO<sub>3</sub> (1.4 equiv), 1,4-dioxane, 80 °C, 61%; (e) methylamine hydrochloride (3.8 equiv), K<sub>2</sub>CO<sub>3</sub> (2 equiv), DMSO, 90 °C, 92%; (f) diphenyl carbonate (1.15 equiv), DMAP (1.2 equiv), DMF, 100 °C, 48%; (g) <b>9c</b> (1 equiv), DMAP (1.1 equiv), DMF, 90 °C, 14%; (h) TFA/CH<sub>2</sub>Cl<sub>2</sub> (1:1), 23 °C; then, 4-((2,4-dimethoxybenzyl)amino)quinazoline-8-carboxylic acid (1 equiv), HATU (2 equiv), NEt<sub>3</sub> (7 equiv), DMF, 23 °C, 54% (two steps); (i) TFA, 70 °C, 75%; (j) <i>tert</i>-butyl carbamate (1.5 equiv), Pd<sub>2</sub>(dba)<sub>3</sub> (0.025 equiv), Xantphos (0.05 equiv), Cs<sub>2</sub>CO<sub>3</sub> (2 equiv), THF, 80 °C, 95%; (k) TFA 23 °C; then, <b>9a</b> (1 equiv), BrettPhos Pd G1 (0.05 equiv), BrettPhos (0.05 equiv), NaO<i>t</i>Bu (4 equiv), 1,4-dioxane, 100 °C, 80% (two steps); (l) 4.0 M HCl in 1,4-dioxane/(EtO)<sub>3</sub>CH (1:6), 110 °C, 69%; (m) <i>tert</i>-butyl carbamate (1.2 equiv), Pd<sub>2</sub>(dba)<sub>3</sub> (0.02 equiv), Xantphos (0.06 equiv), Cs<sub>2</sub>CO<sub>3</sub> (1.2 equiv), toluene, 90 °C, 86%; (n) 4.0 M HCl in 1,4-dioxane (12 equiv), EtOAc, 23 °C, 88%; (o) <b>9a</b> (1 equiv), Pd(OAc)<sub>2</sub> (0.05 equiv), Xantphos (0.05 equiv), Cs<sub>2</sub>CO<sub>3</sub> (3 equiv), 3 Å molecular sieves, 1,4-dioxane, 100 °C, 34%.</p></p></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i51">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_42187" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_42187" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 40 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Samatar, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poulikakos, P. I.</span></span> <span> </span><span class="NLM_article-title">Targeting RAS–ERK signalling in cancer: Promises and challenges</span>. <i>Nat. Rev. Drug Discov.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">928</span>– <span class="NLM_lpage">942</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=10.1038%2Fnrd4281" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=25435214" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvF2lsrrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=928-942&author=A.+A.+Samatarauthor=P.+I.+Poulikakos&title=Targeting+RAS%E2%80%93ERK+signalling+in+cancer%3A+Promises+and+challenges"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1aR"><div class="casContent"><span class="casTitleNuber">1a</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting RAS-ERK signalling in cancer: promises and challenges</span></div><div class="casAuthors">Samatar, Ahmed A.; Poulikakos, Poulikos I.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">928-942</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The RAS-RAF-MEK-ERK signalling pathway is hyperactivated in a high percentage of tumors, most frequently owing to activating mutations of the KRAS, NRAS and BRAF genes.  Recently, the use of compds. targeting components of ERK signalling, such as RAF or MEK inhibitors, has led to substantial improvement in clin. outcome in metastatic melanoma and has shown promising clin. activity in addnl. tumor types.  However, response rates are highly variable and the efficacy of these drugs is primarily limited by the development of resistance.  Both intrinsic and acquired resistance to RAF and MEK inhibitors are frequently assocd. with the persistence of ERK signalling in the presence of the drug, implying the need for more innovative approaches to target the pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrL4UeXNUJnYbVg90H21EOLACvtfcHk0lhZU7VNBjtDKg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvF2lsrrI&md5=ab4038893612f438cf4406680ab2e4f4</span></div><a href="/servlet/linkout?suffix=cit1a&amp;dbid=16384&amp;doi=10.1038%2Fnrd4281&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4281%26sid%3Dliteratum%253Aachs%26aulast%3DSamatar%26aufirst%3DA.%2BA.%26aulast%3DPoulikakos%26aufirst%3DP.%2BI.%26atitle%3DTargeting%2520RAS%25E2%2580%2593ERK%2520signalling%2520in%2520cancer%253A%2520Promises%2520and%2520challenges%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discov.%26date%3D2014%26volume%3D13%26spage%3D928%26epage%3D942" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit1b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, H.</span></span> <span> </span><span class="NLM_article-title">Current development status of MEK inhibitors</span>. <i>Molecules</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">1551</span>– <span class="NLM_lpage">1571</span>, <span class="refDoi"> DOI: 10.3390/molecules22101551</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=10.3390%2Fmolecules22101551" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhs1Wjsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2017&pages=1551-1571&author=Y.+Chengauthor=H.+Tian&title=Current+development+status+of+MEK+inhibitors&doi=10.3390%2Fmolecules22101551"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1bR"><div class="casContent"><span class="casTitleNuber">1b</span><div class="casTitle"><span class="NLM_cas:atitle">Current development status of MEK inhibitors</span></div><div class="casAuthors">Cheng, Ying; Tian, Hongqi</div><div class="citationInfo"><span class="NLM_cas:title">Molecules</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1551/1-1551/20</span>CODEN:
                <span class="NLM_cas:coden">MOLEFW</span>;
        ISSN:<span class="NLM_cas:issn">1420-3049</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">The current development status of mitogen-activated protein kinase kinase (MEK) inhibitors, including the preclin. data and clin. study progress, has been summarized in this review.  Different MEK inhibitors, possessing specific physicochem. properties and bioactivity characteristics, may provide different options for patients seeking treatment for cancer.  Moreover, the combination of the MEK inhibitors with other therapies-such as chemotherapy, targeted therapy, and immunotherapy-may be a promising approach for clin. use.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGosd6s1Lx6dYbVg90H21EOLACvtfcHk0lisoejWa6tLdA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhs1Wjsrk%253D&md5=0210d125f8a46468d67adb4f9aaf6cf3</span></div><a href="/servlet/linkout?suffix=cit1b&amp;dbid=16384&amp;doi=10.3390%2Fmolecules22101551&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmolecules22101551%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DY.%26aulast%3DTian%26aufirst%3DH.%26atitle%3DCurrent%2520development%2520status%2520of%2520MEK%2520inhibitors%26jtitle%3DMolecules%26date%3D2017%26volume%3D22%26spage%3D1551%26epage%3D1571%26doi%3D10.3390%2Fmolecules22101551" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit1c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Agianian, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gavathiotis, E.</span></span> <span> </span><span class="NLM_article-title">Current insights of BRAF inhibitors in cancer</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">5775</span>– <span class="NLM_lpage">5793</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01306</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01306" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref1/cit1c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=1%3ACAS%3A528%3ADC%252BC1cXivFChu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=5775-5793&author=B.+Agianianauthor=E.+Gavathiotis&title=Current+insights+of+BRAF+inhibitors+in+cancer&doi=10.1021%2Facs.jmedchem.7b01306"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1cR"><div class="casContent"><span class="casTitleNuber">1c</span><div class="casTitle"><span class="NLM_cas:atitle">Current Insights of BRAF Inhibitors in Cancer</span></div><div class="casAuthors">Agianian, Bogos; Gavathiotis, Evripidis</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">5775-5793</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Oncogenic BRAF kinase deregulates the ERK signaling pathway in a large no. of human tumors.  FDA-approved BRAF inhibitors for BRAFV600E/K tumors have provided impressive clin. responses extending survival of melanoma patients.  However, these drugs display paradoxical activation in normal tissue with BRAFWT due to RAF transactivation and priming, acquired drug resistance, and limited clin. effectiveness in non-V600 BRAF-dependent tumors, underscoring the urgent need to develop improved BRAF inhibitors.  This review provides an overview of recent structural and biochem. insights into the mechanisms of BRAF regulation by BRAF inhibitors that are linked to their clin. activity, clin. liabilities, and medicinal chem. properties.  The effectiveness and challenges of structurally diverse next generation RAF inhibitors currently in preclin. and clin. development are discussed, along with mechanistic insights for developing more effective RAF inhibitors targeting different oncogenic BRAF conformations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbFSsceLmTALVg90H21EOLACvtfcHk0lisoejWa6tLdA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXivFChu70%253D&md5=7dcd6ce731bb591ecfac244b3b2b9b32</span></div><a href="/servlet/linkout?suffix=cit1c&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01306&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01306%26sid%3Dliteratum%253Aachs%26aulast%3DAgianian%26aufirst%3DB.%26aulast%3DGavathiotis%26aufirst%3DE.%26atitle%3DCurrent%2520insights%2520of%2520BRAF%2520inhibitors%2520in%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D5775%26epage%3D5793%26doi%3D10.1021%2Facs.jmedchem.7b01306" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit1d"><span><span class="NLM_label">(d) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Sammons, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghose, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsai, K. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalby, K. N.</span></span> <span> </span><span class="NLM_article-title">Targeting ERK beyond the boundaries of the kinase active site in melanoma</span>. <i>Mol. Carcinog.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">1551</span>– <span class="NLM_lpage">1570</span>, <span class="refDoi"> DOI: 10.1002/mc.23047</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=10.1002%2Fmc.23047" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=31190430" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtFGhsrjO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2019&pages=1551-1570&author=R.+M.+Sammonsauthor=R.+Ghoseauthor=K.+Y.+Tsaiauthor=K.+N.+Dalby&title=Targeting+ERK+beyond+the+boundaries+of+the+kinase+active+site+in+melanoma&doi=10.1002%2Fmc.23047"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1dR"><div class="casContent"><span class="casTitleNuber">1d</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting ERK beyond the boundaries of the kinase active site in melanoma</span></div><div class="casAuthors">Sammons, Rachel M.; Ghose, Ranajeet; Tsai, Kenneth Y.; Dalby, Kevin N.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Carcinogenesis</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1551-1570</span>CODEN:
                <span class="NLM_cas:coden">MOCAE8</span>;
        ISSN:<span class="NLM_cas:issn">0899-1987</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Extracellular signal-regulated kinase 1/2 (ERK1/2) constitute a point of convergence for complex signaling events that regulate essential cellular processes, including proliferation and survival.  As such, dysregulation of the ERK signaling pathway is prevalent in many cancers.  In the case of BRAF-V600E mutant melanoma, ERK inhibition has emerged as a viable clin. approach to abrogate signaling through the ERK pathway, even in cases where MEK and Raf inhibitor treatments fail to induce tumor regression due to resistance mechanisms.  Several ERK inhibitors that target the active site of ERK have reached clin. trials, however, many crit. ERK interactions occur at other potentially druggable sites on the protein.  Here we discuss the role of ERK signaling in cell fate, in driving melanoma, and in resistance mechanisms to current BRAF-V600E melanoma treatments.  We explore targeting ERK via a distinct site of protein-protein interaction, known as the D-recruitment site (DRS), as an alternative or supplementary mode of ERK pathway inhibition in BRAF-V600E melanoma.  Targeting the DRS with inhibitors in melanoma has the potential to not only disrupt the catalytic app. of ERK but also its noncatalytic functions, which have significant impacts on spatiotemporal signaling dynamics and cell fate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFpdwGW-bv6rVg90H21EOLACvtfcHk0liOYS3AsrQYog"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtFGhsrjO&md5=24c27606b2302730c94a64521c82962f</span></div><a href="/servlet/linkout?suffix=cit1d&amp;dbid=16384&amp;doi=10.1002%2Fmc.23047&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmc.23047%26sid%3Dliteratum%253Aachs%26aulast%3DSammons%26aufirst%3DR.%2BM.%26aulast%3DGhose%26aufirst%3DR.%26aulast%3DTsai%26aufirst%3DK.%2BY.%26aulast%3DDalby%26aufirst%3DK.%2BN.%26atitle%3DTargeting%2520ERK%2520beyond%2520the%2520boundaries%2520of%2520the%2520kinase%2520active%2520site%2520in%2520melanoma%26jtitle%3DMol.%2520Carcinog.%26date%3D2019%26volume%3D58%26spage%3D1551%26epage%3D1570%26doi%3D10.1002%2Fmc.23047" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Tsai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mamo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bremer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillette, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haass, N. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sproesser, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smalley, K. S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fong, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Y.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marimuthu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheung, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rice, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Settachatgul, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shellooe, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantwell, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlessinger, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, K. Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">West, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powell, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Habets, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ibrahim, P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirth, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Artis, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herlyn, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bollag, G.</span></span> <span> </span><span class="NLM_article-title">Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>105</i></span>,  <span class="NLM_fpage">3041</span>– <span class="NLM_lpage">3046</span>, <span class="refDoi"> DOI: 10.1073/pnas.0711741105</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=10.1073%2Fpnas.0711741105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=18287029" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=1%3ACAS%3A528%3ADC%252BD1cXjtVSitrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2008&pages=3041-3046&author=J.+Tsaiauthor=J.+T.+Leeauthor=W.+Wangauthor=J.+Zhangauthor=H.+Choauthor=S.+Mamoauthor=R.+Bremerauthor=S.+Gilletteauthor=J.+Kongauthor=N.+K.+Haassauthor=K.+Sproesserauthor=L.+Liauthor=K.+S.+M.+Smalleyauthor=D.+Fongauthor=Y.-L.+Zhuauthor=A.+Marimuthuauthor=H.+Nguyenauthor=B.+Lamauthor=J.+Liuauthor=I.+Cheungauthor=J.+Riceauthor=Y.+Suzukiauthor=C.+Luuauthor=C.+Settachatgulauthor=R.+Shellooeauthor=J.+Cantwellauthor=S.-H.+Kimauthor=J.+Schlessingerauthor=K.+Y.+L.+Zhangauthor=B.+L.+Westauthor=B.+Powellauthor=G.+Habetsauthor=C.+Zhangauthor=P.+N.+Ibrahimauthor=P.+Hirthauthor=D.+R.+Artisauthor=M.+Herlynauthor=G.+Bollag&title=Discovery+of+a+selective+inhibitor+of+oncogenic+B-Raf+kinase+with+potent+antimelanoma+activity&doi=10.1073%2Fpnas.0711741105"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2aR"><div class="casContent"><span class="casTitleNuber">2a</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity</span></div><div class="casAuthors">Tsai, James; Lee, John T.; Wang, Weiru; Zhang, Jiazhong; Cho, Hanna; Mamo, Shumeye; Bremer, Ryan; Gillette, Sam; Kong, Jun; Haass, Nikolas K.; Sproesser, Katrin; Li, Ling; Smalley, Keiran S. M.; Fong, Daniel; Zhu, Yong-Liang; Marimuthu, Adhirai; Nguyen, Hoa; Lam, Billy; Liu, Jennifer; Cheung, Ivana; Rice, Julie; Suzuki, Yoshihisa; Luu, Catherine; Settachatgul, Calvin; Shellooe, Rafe; Cantwell, John; Kim, Sung-Hou; Schlessinger, Joseph; Zhang, Kam Y. J.; West, Brian L.; Powell, Ben; Habets, Gaston; Zhang, Chao; Ibrahim, Prabha N.; Hirth, Peter; Artis, Dean R.; Herlyn, Meenhard; Bollag, Gideon</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3041-3046</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">BRAFV600E is the most frequent oncogenic protein kinase mutation known.  Furthermore, inhibitors targeting "active" protein kinases have demonstrated significant utility in the therapeutic repertoire against cancer.  Therefore, the authors pursued the development of specific kinase inhibitors targeting B-Raf, and the V600E allele in particular.  By using a structure-guided discovery approach, a potent and selective inhibitor of active B-Raf has been discovered.  PLX4720, a 7-azaindole deriv. that inhibits B-RafV600E with an IC50 of 13 nM, defines a class of kinase inhibitor with marked selectivity in both biochem. and cellular assays.  PLX4720 preferentially inhibits the active B-RafV600E kinase compared with a broad spectrum of other kinases, and potent cytotoxic effects are also exclusive to cells bearing the V600E allele.  Consistent with the high degree of selectivity, ERK phosphorylation is potently inhibited by PLX4720 in B-RafV600E-bearing tumor cell lines but not in cells lacking oncogenic B-Raf.  In melanoma models, PLX4720 induces cell cycle arrest and apoptosis exclusively in B-RafV600E-pos. cells.  In B-RafV600E-dependent tumor xenograft models, orally dosed PLX4720 causes significant tumor growth delays, including tumor regressions, without evidence of toxicity.  The work described here represents the entire discovery process, from initial identification through structural and biol. studies in animal models to a promising therapeutic for testing in cancer patients bearing B-RafV600E-driven tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPX53IQCbDJ7Vg90H21EOLACvtfcHk0liCU_SFmzNA0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXjtVSitrk%253D&md5=273b94202f99984e6eb24723d0c6141f</span></div><a href="/servlet/linkout?suffix=cit2a&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0711741105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0711741105%26sid%3Dliteratum%253Aachs%26aulast%3DTsai%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DJ.%2BT.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DCho%26aufirst%3DH.%26aulast%3DMamo%26aufirst%3DS.%26aulast%3DBremer%26aufirst%3DR.%26aulast%3DGillette%26aufirst%3DS.%26aulast%3DKong%26aufirst%3DJ.%26aulast%3DHaass%26aufirst%3DN.%2BK.%26aulast%3DSproesser%26aufirst%3DK.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DSmalley%26aufirst%3DK.%2BS.%2BM.%26aulast%3DFong%26aufirst%3DD.%26aulast%3DZhu%26aufirst%3DY.-L.%26aulast%3DMarimuthu%26aufirst%3DA.%26aulast%3DNguyen%26aufirst%3DH.%26aulast%3DLam%26aufirst%3DB.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DCheung%26aufirst%3DI.%26aulast%3DRice%26aufirst%3DJ.%26aulast%3DSuzuki%26aufirst%3DY.%26aulast%3DLuu%26aufirst%3DC.%26aulast%3DSettachatgul%26aufirst%3DC.%26aulast%3DShellooe%26aufirst%3DR.%26aulast%3DCantwell%26aufirst%3DJ.%26aulast%3DKim%26aufirst%3DS.-H.%26aulast%3DSchlessinger%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DK.%2BY.%2BL.%26aulast%3DWest%26aufirst%3DB.%2BL.%26aulast%3DPowell%26aufirst%3DB.%26aulast%3DHabets%26aufirst%3DG.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DIbrahim%26aufirst%3DP.%2BN.%26aulast%3DHirth%26aufirst%3DP.%26aulast%3DArtis%26aufirst%3DD.%2BR.%26aulast%3DHerlyn%26aufirst%3DM.%26aulast%3DBollag%26aufirst%3DG.%26atitle%3DDiscovery%2520of%2520a%2520selective%2520inhibitor%2520of%2520oncogenic%2520B-Raf%2520kinase%2520with%2520potent%2520antimelanoma%2520activity%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2008%26volume%3D105%26spage%3D3041%26epage%3D3046%26doi%3D10.1073%2Fpnas.0711741105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit2b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Chapman, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hauschild, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robert, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haanen, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ascierto, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larkin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dummer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garbe, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Testori, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maio, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hogg, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lorigan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lebbe, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jouary, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schadendorf, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ribas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Day, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sosman, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirkwood, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eggermont, A. M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dreno, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nolop, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flaherty, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McArthur, G. A.</span></span> <span> </span><span class="NLM_article-title">Improved survival with vemurafenib in melanoma with BRAF V600E mutation</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>364</i></span>,  <span class="NLM_fpage">2507</span>– <span class="NLM_lpage">2516</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1103782</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=10.1056%2FNEJMoa1103782" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=21639808" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=1%3ACAS%3A528%3ADC%252BC3MXosVeitbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=364&publication_year=2011&pages=2507-2516&author=P.+B.+Chapmanauthor=A.+Hauschildauthor=C.+Robertauthor=J.+B.+Haanenauthor=P.+Asciertoauthor=J.+Larkinauthor=R.+Dummerauthor=C.+Garbeauthor=A.+Testoriauthor=M.+Maioauthor=D.+Hoggauthor=P.+Loriganauthor=C.+Lebbeauthor=T.+Jouaryauthor=D.+Schadendorfauthor=A.+Ribasauthor=S.+J.+O%E2%80%99Dayauthor=J.+A.+Sosmanauthor=J.+M.+Kirkwoodauthor=A.+M.+M.+Eggermontauthor=B.+Drenoauthor=K.+Nolopauthor=J.+Liauthor=B.+Nelsonauthor=J.+Houauthor=R.+J.+Leeauthor=K.+T.+Flahertyauthor=G.+A.+McArthur&title=Improved+survival+with+vemurafenib+in+melanoma+with+BRAF+V600E+mutation&doi=10.1056%2FNEJMoa1103782"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2bR"><div class="casContent"><span class="casTitleNuber">2b</span><div class="casTitle"><span class="NLM_cas:atitle">Improved survival with vemurafenib in melanoma with BRAF V600E mutation</span></div><div class="casAuthors">Chapman, Paul B.; Hauschild, Axel; Robert, Caroline; Haanen, John B.; Ascierto, Paolo; Larkin, James; Dummer, Reinhard; Garbe, Claus; Testori, Alessandro; Maio, Michele; Hogg, David; Lorigan, Paul; Lebbe, Celeste; Jouary, Thomas; Schadendorf, Dirk; Ribas, Antoni; O'Day, Steven J.; Sosman, Jeffrey A.; Kirkwood, John M.; Eggermont, Alexander M. M.; Dreno, Brigitte; Nolop, Keith; Li, Jiang; Nelson, Betty; Hou, Jeannie; Lee, Richard J.; Flaherty, Keith T.; McArthur, Grant A.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">364</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">2507-2516</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: Phase 1 and 2 clin. trials of the BRAF kinase inhibitor vemurafenib (PLX4032) have shown response rates of more than 50% in patients with metastatic melanoma with the BRAF V600E mutation.  METHODS: We conducted a phase 3 randomized clin. trial comparing vemurafenib with dacarbazine in 675 patients with previously untreated, metastatic melanoma with the BRAF V600E mutation.  Patients were randomly assigned to receive either vemurafenib (960 mg orally twice daily) or dacarbazine (1000 mg per square meter of body-surface area i.v. every 3 wk).  Coprimary end points were rates of overall and progression-free survival.  Secondary end points included the response rate, response duration, and safety.  A final anal. was planned after 196 deaths and an interim anal. after 98 deaths.  RESULTS: At 6 mo, overall survival was 840/ (95% confidence interval [CI], 78 to 89) in the vemurafenib group and 64% (95% CI, 56 to 73) in the dacarbazine group.  In the interim anal. for overall survival and final anal. for progression-free survival, vemurafenib was assocd. with a relative redn. of 63% in the risk of death and of 74% in the risk of either death or disease progression, as compared with dacarbazine (P < 0.001 for both comparisons).  After review of the interim anal. by an independent data and safety monitoring board, crossover from dacarbazine to vemurafenib was recommended.  Response rates were 48% for vemurafenib and 5% for dacarbazine.  Common adverse events assocd. with vemurafenib were arthralgia, rash, fatigue, alopecia, keratoacanthoma or squamous-cell carcinoma, photosensitivity, nausea, and diarrhea; 38% of patients required dose modification because of toxic effects.  CONCLUSIONS: Vemurafenib produced improved rates of overall and progression-free survival in patients with previously untreated melanoma with the BRAF V600E mutation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4NFxmTaDz97Vg90H21EOLACvtfcHk0liCU_SFmzNA0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXosVeitbs%253D&md5=1a4b4f963221888dc63f620e87408070</span></div><a href="/servlet/linkout?suffix=cit2b&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1103782&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1103782%26sid%3Dliteratum%253Aachs%26aulast%3DChapman%26aufirst%3DP.%2BB.%26aulast%3DHauschild%26aufirst%3DA.%26aulast%3DRobert%26aufirst%3DC.%26aulast%3DHaanen%26aufirst%3DJ.%2BB.%26aulast%3DAscierto%26aufirst%3DP.%26aulast%3DLarkin%26aufirst%3DJ.%26aulast%3DDummer%26aufirst%3DR.%26aulast%3DGarbe%26aufirst%3DC.%26aulast%3DTestori%26aufirst%3DA.%26aulast%3DMaio%26aufirst%3DM.%26aulast%3DHogg%26aufirst%3DD.%26aulast%3DLorigan%26aufirst%3DP.%26aulast%3DLebbe%26aufirst%3DC.%26aulast%3DJouary%26aufirst%3DT.%26aulast%3DSchadendorf%26aufirst%3DD.%26aulast%3DRibas%26aufirst%3DA.%26aulast%3DO%25E2%2580%2599Day%26aufirst%3DS.%2BJ.%26aulast%3DSosman%26aufirst%3DJ.%2BA.%26aulast%3DKirkwood%26aufirst%3DJ.%2BM.%26aulast%3DEggermont%26aufirst%3DA.%2BM.%2BM.%26aulast%3DDreno%26aufirst%3DB.%26aulast%3DNolop%26aufirst%3DK.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DNelson%26aufirst%3DB.%26aulast%3DHou%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DR.%2BJ.%26aulast%3DFlaherty%26aufirst%3DK.%2BT.%26aulast%3DMcArthur%26aufirst%3DG.%2BA.%26atitle%3DImproved%2520survival%2520with%2520vemurafenib%2520in%2520melanoma%2520with%2520BRAF%2520V600E%2520mutation%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2011%26volume%3D364%26spage%3D2507%26epage%3D2516%26doi%3D10.1056%2FNEJMoa1103782" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit2c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Sosman, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuchter, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pavlick, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weber, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McArthur, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hutson, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moschos, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flaherty, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herset, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kefford, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawrence, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puzanov, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amaravadi, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chmielowski, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawrence, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shyr, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nolop, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joe, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ribas, A.</span></span> <span> </span><span class="NLM_article-title">Survival in BRAF V600–mutant advanced melanoma treated with vemurafenib</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>366</i></span>,  <span class="NLM_fpage">707</span>– <span class="NLM_lpage">714</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1112302</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=10.1056%2FNEJMoa1112302" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=22356324" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=1%3ACAS%3A528%3ADC%252BC38XjtFOqtr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=366&publication_year=2012&pages=707-714&author=J.+A.+Sosmanauthor=K.+B.+Kimauthor=L.+Schuchterauthor=R.+Gonzalezauthor=A.+C.+Pavlickauthor=J.+S.+Weberauthor=G.+A.+McArthurauthor=T.+E.+Hutsonauthor=S.+J.+Moschosauthor=K.+T.+Flahertyauthor=P.+Hersetauthor=R.+Keffordauthor=D.+Lawrenceauthor=I.+Puzanovauthor=K.+D.+Lewisauthor=R.+K.+Amaravadiauthor=B.+Chmielowskiauthor=H.+J.+Lawrenceauthor=Y.+Shyrauthor=F.+Yeauthor=J.+Liauthor=K.+B.+Nolopauthor=R.+J.+Leeauthor=A.+K.+Joeauthor=A.+Ribas&title=Survival+in+BRAF+V600%E2%80%93mutant+advanced+melanoma+treated+with+vemurafenib&doi=10.1056%2FNEJMoa1112302"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2cR"><div class="casContent"><span class="casTitleNuber">2c</span><div class="casTitle"><span class="NLM_cas:atitle">Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib</span></div><div class="casAuthors">Sosman, Jeffrey A.; Kim, Kevin B.; Schuchter, Lynn; Gonzalez, Rene; Pavlick, Anna C.; Weber, Jeffrey S.; McArthur, Grant A.; Hutson, Thomas E.; Moschos, Stergios J.; Flaherty, Keith T.; Hersey, Peter; Kefford, Richard; Lawrence, Donald; Puzanov, Igor; Lewis, Karl D.; Amaravadi, Ravi K.; Chmielowski, Bartosz; Lawrence, H. Jeffrey; Shyr, Yu; Ye, Fei; Li, Jiang; Nolop, Keith B.; Lee, Richard J.; Joe, Andrew K.; Ribas, Antoni</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">366</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">707-714</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND Approx. 50% of melanomas harbor activating (V600) mutations in the serine-threonine protein kinase B-RAF (BRAF).  The oral BRAF inhibitor vemurafenib (PLX4032) frequently produced tumor regressions in patients with BRAF V600-mutant metastatic melanoma in a phase 1 trial and improved overall survival in a phase 3 trial.  METHODS We designed a multicenter phase 2 trial of vemurafenib in patients with previously treated BRAF V600-mutant metastatic melanoma to investigate the efficacy of vem urafenib with respect to overall response rate (percentage of treated patients with a tumor response), duration of response, and overall survival.  The primary end point was the overall response rate as ascertained by the independent review committee; overall survival was a secondary end point.  RESULTS A total of 132 patients had a median follow-up of 12.9 mo (range, 0.6 to 20.1).  The confirmed overall response rate was 53% (95% confidence interval [CI], 44 to 62; 6% with a complete response and 47% with a partial response), the median duration of response was 6.7 mo (95% CI, 5.6 to 8.6), and the median progression-free survival was 6.8 mo (95% CI, 5.6 to 8.1).  Primary progression was obsd.,in only 14% of patients.  Some patients had a response after receiving vemurafenib for more than 6' months.  The median overall survival was 15.9 mo (95% CI, 11.6 to 18.3).  The most common adverse events were grade 1 or 2 arthralgia, rash, photosensitivity, fatigue, and alopecia.  Cutaneous squamous-cell carcinomas (the majority, keratoacanthoma type) were diagnosed in 26% of patients.  CONCLUSIONS Vemurafenib induces clin. responses in more than half of patients with previously treated BRAF V600-mutant metastatic melanoma.  In this study with a long follow-up, the median overall survival was approx. 16 mo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0-17UBZyghrVg90H21EOLACvtfcHk0lgVNU4YHvf91Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XjtFOqtr0%253D&md5=74da93cc5ac6497207f12dd0461d9414</span></div><a href="/servlet/linkout?suffix=cit2c&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1112302&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1112302%26sid%3Dliteratum%253Aachs%26aulast%3DSosman%26aufirst%3DJ.%2BA.%26aulast%3DKim%26aufirst%3DK.%2BB.%26aulast%3DSchuchter%26aufirst%3DL.%26aulast%3DGonzalez%26aufirst%3DR.%26aulast%3DPavlick%26aufirst%3DA.%2BC.%26aulast%3DWeber%26aufirst%3DJ.%2BS.%26aulast%3DMcArthur%26aufirst%3DG.%2BA.%26aulast%3DHutson%26aufirst%3DT.%2BE.%26aulast%3DMoschos%26aufirst%3DS.%2BJ.%26aulast%3DFlaherty%26aufirst%3DK.%2BT.%26aulast%3DHerset%26aufirst%3DP.%26aulast%3DKefford%26aufirst%3DR.%26aulast%3DLawrence%26aufirst%3DD.%26aulast%3DPuzanov%26aufirst%3DI.%26aulast%3DLewis%26aufirst%3DK.%2BD.%26aulast%3DAmaravadi%26aufirst%3DR.%2BK.%26aulast%3DChmielowski%26aufirst%3DB.%26aulast%3DLawrence%26aufirst%3DH.%2BJ.%26aulast%3DShyr%26aufirst%3DY.%26aulast%3DYe%26aufirst%3DF.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DNolop%26aufirst%3DK.%2BB.%26aulast%3DLee%26aufirst%3DR.%2BJ.%26aulast%3DJoe%26aufirst%3DA.%2BK.%26aulast%3DRibas%26aufirst%3DA.%26atitle%3DSurvival%2520in%2520BRAF%2520V600%25E2%2580%2593mutant%2520advanced%2520melanoma%2520treated%2520with%2520vemurafenib%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2012%26volume%3D366%26spage%3D707%26epage%3D714%26doi%3D10.1056%2FNEJMoa1112302" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rheault, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stellwagen, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adjabeng, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hornberger, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petrov, K. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waterson, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dickerson, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mook, R. A.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laquerre, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">King, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rossanese, O. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnone, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smitheman, K. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kane-Carson, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moorthy, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moss, K. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uehling, D. E.</span></span> <span> </span><span class="NLM_article-title">Discovery of Dabrafenib: A selective inhibitor of Raf kinases with antitumor activity against B-Raf-driven tumors</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">358</span>– <span class="NLM_lpage">362</span>, <span class="refDoi"> DOI: 10.1021/ml4000063</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml4000063" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=1%3ACAS%3A528%3ADC%252BC3sXit1Sqtr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=358-362&author=T.+R.+Rheaultauthor=J.+C.+Stellwagenauthor=G.+M.+Adjabengauthor=K.+R.+Hornbergerauthor=K.+G.+Petrovauthor=A.+G.+Watersonauthor=S.+H.+Dickersonauthor=R.+A.+Mookauthor=S.+G.+Laquerreauthor=A.+J.+Kingauthor=O.+W.+Rossaneseauthor=M.+R.+Arnoneauthor=K.+N.+Smithemanauthor=L.+S.+Kane-Carsonauthor=C.+Hanauthor=G.+S.+Moorthyauthor=K.+G.+Mossauthor=D.+E.+Uehling&title=Discovery+of+Dabrafenib%3A+A+selective+inhibitor+of+Raf+kinases+with+antitumor+activity+against+B-Raf-driven+tumors&doi=10.1021%2Fml4000063"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Dabrafenib: A Selective Inhibitor of Raf Kinases with Antitumor Activity against B-Raf-Driven Tumors</span></div><div class="casAuthors">Rheault, Tara R.; Stellwagen, John C.; Adjabeng, George M.; Hornberger, Keith R.; Petrov, Kimberly G.; Waterson, Alex G.; Dickerson, Scott H.; Mook, Robert A.; Laquerre, Sylvie G.; King, Alastair J.; Rossanese, Olivia W.; Arnone, Marc R.; Smitheman, Kimberly N.; Kane-Carson, Laurie S.; Han, Chao; Moorthy, Ganesh S.; Moss, Katherine G.; Uehling, David E.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">358-362</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Hyperactive signaling of the MAP kinase pathway resulting from the constitutively active B-RafV600E mutated enzyme has been obsd. in a no. of human tumors, including melanomas.  Herein, we report the discovery and biol. evaluation of GSK2118436 (dabrafenib, I), a selective inhibitor of Raf kinases with potent in vitro activity in oncogenic B-Raf-driven melanoma and colorectal carcinoma cells and robust in vivo antitumor and pharmacodynamic activity in mouse models of B-RafV600E human melanoma.  GSK2118436 was identified as a development candidate, and early clin. results have shown significant activity in patients with B-Raf mutant melanoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq97lPGF-Yb8bVg90H21EOLACvtfcHk0lgVNU4YHvf91Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXit1Sqtr4%253D&md5=4b26187120192c298ca89283e2871fe4</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1021%2Fml4000063&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml4000063%26sid%3Dliteratum%253Aachs%26aulast%3DRheault%26aufirst%3DT.%2BR.%26aulast%3DStellwagen%26aufirst%3DJ.%2BC.%26aulast%3DAdjabeng%26aufirst%3DG.%2BM.%26aulast%3DHornberger%26aufirst%3DK.%2BR.%26aulast%3DPetrov%26aufirst%3DK.%2BG.%26aulast%3DWaterson%26aufirst%3DA.%2BG.%26aulast%3DDickerson%26aufirst%3DS.%2BH.%26aulast%3DMook%26aufirst%3DR.%2BA.%26aulast%3DLaquerre%26aufirst%3DS.%2BG.%26aulast%3DKing%26aufirst%3DA.%2BJ.%26aulast%3DRossanese%26aufirst%3DO.%2BW.%26aulast%3DArnone%26aufirst%3DM.%2BR.%26aulast%3DSmitheman%26aufirst%3DK.%2BN.%26aulast%3DKane-Carson%26aufirst%3DL.%2BS.%26aulast%3DHan%26aufirst%3DC.%26aulast%3DMoorthy%26aufirst%3DG.%2BS.%26aulast%3DMoss%26aufirst%3DK.%2BG.%26aulast%3DUehling%26aufirst%3DD.%2BE.%26atitle%3DDiscovery%2520of%2520Dabrafenib%253A%2520A%2520selective%2520inhibitor%2520of%2520Raf%2520kinases%2520with%2520antitumor%2520activity%2520against%2520B-Raf-driven%2520tumors%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D4%26spage%3D358%26epage%3D362%26doi%3D10.1021%2Fml4000063" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Abe, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kikuchi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayakawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iida, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagahashi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maeda, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakamoto, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsumoto, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miura, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsumura, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seki, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inaba, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawasaki, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamaguchi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kakefuda, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nanayama, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurachi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hori, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshida, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kakegawa, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilmartin, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richter, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moss, K. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laquerre, S. L.</span></span> <span> </span><span class="NLM_article-title">Discovery of a highly potent and selective MEK inhibitor: GSK1120212 (JTP-74057 DMSO solvate)</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">320</span>– <span class="NLM_lpage">324</span>, <span class="refDoi"> DOI: 10.1021/ml200004g</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml200004g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=1%3ACAS%3A528%3ADC%252BC3MXisFeksb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2011&pages=320-324&author=H.+Abeauthor=S.+Kikuchiauthor=K.+Hayakawaauthor=T.+Iidaauthor=N.+Nagahashiauthor=K.+Maedaauthor=J.+Sakamotoauthor=N.+Matsumotoauthor=T.+Miuraauthor=K.+Matsumuraauthor=N.+Sekiauthor=T.+Inabaauthor=H.+Kawasakiauthor=T.+Yamaguchiauthor=R.+Kakefudaauthor=T.+Nanayamaauthor=H.+Kurachiauthor=Y.+Horiauthor=T.+Yoshidaauthor=J.+Kakegawaauthor=Y.+Watanabeauthor=A.+G.+Gilmartinauthor=M.+C.+Richterauthor=K.+G.+Mossauthor=S.+L.+Laquerre&title=Discovery+of+a+highly+potent+and+selective+MEK+inhibitor%3A+GSK1120212+%28JTP-74057+DMSO+solvate%29&doi=10.1021%2Fml200004g"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4aR"><div class="casContent"><span class="casTitleNuber">4a</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Highly Potent and Selective MEK Inhibitor: GSK1120212 (JTP-74057 DMSO Solvate)</span></div><div class="casAuthors">Abe, Hiroyuki; Kikuchi, Shinichi; Hayakawa, Kazuhide; Iida, Tetsuya; Nagahashi, Noboru; Maeda, Katsuya; Sakamoto, Johei; Matsumoto, Noriaki; Miura, Tomoya; Matsumura, Koji; Seki, Noriyoshi; Inaba, Takashi; Kawasaki, Hisashi; Yamaguchi, Takayuki; Kakefuda, Reina; Nanayama, Toyomichi; Kurachi, Hironori; Hori, Yoshikazu; Yoshida, Takayuki; Kakegawa, Junya; Watanabe, Yoshihiro; Gilmartin, Aidan G.; Richter, Mark C.; Moss, Katherine G.; Laquerre, Sylvie G.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">320-324</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Inhibition of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase (MEK) represents a promising strategy for the discovery of a new generation of anticancer chemotherapeutics.  Our synthetic efforts, beginning from the lead compd. 2, were directed at improving antiproliferative activity against cancer cells as well as various drug properties.  These efforts led to the discovery of N-{3-[3-cyclopropyl-5-(2-fluoro-4-iodophenylamino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydro-2H-pyrido[4,3-d]pyrimidin-1-yl]phenyl}acetamide dimethylsulfoxide solvate (GSK1120212, JTP-74057 DMSO solvate; 1), a selective and highly potent MEK inhibitor with improved drug properties.  We further confirmed that the antiproliferative activity correlates with cellular MEK inhibition and obsd. significant antitumor activity with daily oral dosing of 1 in a tumor xenograft model.  These qualities led to the selection of 1 for clin. development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpxCuItdsb_1bVg90H21EOLACvtfcHk0lizqF1AdInquw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXisFeksb0%253D&md5=0cb3bfa4e142b8d5ecc591e6792cd692</span></div><a href="/servlet/linkout?suffix=cit4a&amp;dbid=16384&amp;doi=10.1021%2Fml200004g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml200004g%26sid%3Dliteratum%253Aachs%26aulast%3DAbe%26aufirst%3DH.%26aulast%3DKikuchi%26aufirst%3DS.%26aulast%3DHayakawa%26aufirst%3DK.%26aulast%3DIida%26aufirst%3DT.%26aulast%3DNagahashi%26aufirst%3DN.%26aulast%3DMaeda%26aufirst%3DK.%26aulast%3DSakamoto%26aufirst%3DJ.%26aulast%3DMatsumoto%26aufirst%3DN.%26aulast%3DMiura%26aufirst%3DT.%26aulast%3DMatsumura%26aufirst%3DK.%26aulast%3DSeki%26aufirst%3DN.%26aulast%3DInaba%26aufirst%3DT.%26aulast%3DKawasaki%26aufirst%3DH.%26aulast%3DYamaguchi%26aufirst%3DT.%26aulast%3DKakefuda%26aufirst%3DR.%26aulast%3DNanayama%26aufirst%3DT.%26aulast%3DKurachi%26aufirst%3DH.%26aulast%3DHori%26aufirst%3DY.%26aulast%3DYoshida%26aufirst%3DT.%26aulast%3DKakegawa%26aufirst%3DJ.%26aulast%3DWatanabe%26aufirst%3DY.%26aulast%3DGilmartin%26aufirst%3DA.%2BG.%26aulast%3DRichter%26aufirst%3DM.%2BC.%26aulast%3DMoss%26aufirst%3DK.%2BG.%26aulast%3DLaquerre%26aufirst%3DS.%2BL.%26atitle%3DDiscovery%2520of%2520a%2520highly%2520potent%2520and%2520selective%2520MEK%2520inhibitor%253A%2520GSK1120212%2520%2528JTP-74057%2520DMSO%2520solvate%2529%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D2%26spage%3D320%26epage%3D324%26doi%3D10.1021%2Fml200004g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit4b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Flaherty, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Infante, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daud, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kefford, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sosman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamid, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuchter, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cebon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ibrahim, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kudchadkar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burris, H. A.,  III</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Falchook, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Algazi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, G. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puzanov, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lebowitz, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Little, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allred, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ouellet, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weber, J.</span></span> <span> </span><span class="NLM_article-title">Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>367</i></span>,  <span class="NLM_fpage">1694</span>– <span class="NLM_lpage">1703</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1210093</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=10.1056%2FNEJMoa1210093" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=23020132" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1eksLrJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=367&publication_year=2012&pages=1694-1703&author=K.+T.+Flahertyauthor=J.+R.+Infanteauthor=A.+Daudauthor=R.+Gonzalezauthor=R.+F.+Keffordauthor=J.+Sosmanauthor=O.+Hamidauthor=L.+Schuchterauthor=J.+Cebonauthor=N.+Ibrahimauthor=R.+Kudchadkarauthor=H.+A.+Burrisauthor=G.+Falchookauthor=A.+Algaziauthor=K.+Lewisauthor=G.+V.+Longauthor=I.+Puzanovauthor=P.+Lebowitzauthor=A.+Singhauthor=S.+Littleauthor=P.+Sunauthor=A.+Allredauthor=D.+Ouelletauthor=K.+B.+Kimauthor=K.+Patelauthor=J.+Weber&title=Combined+BRAF+and+MEK+inhibition+in+melanoma+with+BRAF+V600+mutations&doi=10.1056%2FNEJMoa1210093"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4bR"><div class="casContent"><span class="casTitleNuber">4b</span><div class="casTitle"><span class="NLM_cas:atitle">Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations</span></div><div class="casAuthors">Flaherty, Keith T.; Infante, Jeffery R.; Daud, Adil; Gonzalez, Rene; Kefford, Richard F.; Sosman, Jeffrey; Hamid, Omid; Schuchter, Lynn; Cebon, Jonathan; Ibrahim, Nageatte; Kudchadkar, Ragini; Burris, Howard A., III; Falchook, Gerald; Algazi, Alain; Lewis, Karl; Long, Georgina V.; Puzanov, Igor; Lebowitz, Peter; Singh, Ajay; Little, Shonda; Sun, Peng; Allred, Alicia; Ouellet, Daniele; Kim, Kevin B.; Patel, Kiran; Weber, Jeffrey</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">367</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">1694-1703</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND Resistance to therapy with BRAF kinase inhibitors is assocd. with reactivation of the mitogen-activated protein kinase (MAPK) pathway.  To address this problem, we conducted a phase 1 and 2 trial of combined treatment with dabrafenib, a selective BRAF inhibitor, and trametinib, a selective MAPK kinase (MEK) inhibitor.  METHODS In this open-label study involving 247 patients with metastatic melanoma and BRAF V600 mutations, we evaluated the pharmacokinetic activity and safety of oral dabrafenib (75 or 150 mg twice daily) and trametinib (1, 1.5, or 2 mg daily) in 85 patients and then randomly assigned 162 patients to receive combination therapy with dabrafenib (150 mg) plus trametinib (1 or 2 mg) or dabrafenib monotherapy.  The primary end points were the incidence of cutaneous squamous-cell carcinoma, survival free of melanoma progression, and response.  Secondary end points were overall survival and pharmacokinetic activity.  RESULTS Dose-limiting toxic effects were infrequently obsd. in patients receiving combination therapy with 150 mg of dabrafenib and 2 mg of trametinib (combination 150/2).  Cutaneous squamous-cell carcinoma was seen in 7% of patients receiving combination 150/2 and in 19% receiving monotherapy (P = 0.09), whereas pyrexia was more common in the combination 150/2 group than in the monotherapy group (71% vs. 26%).  Median progression-free survival in the combination 150/2 group was 9.4 mo, as compared with 5.8 mo in the monotherapy group (hazard ratio for progression or death, 0.39; 95% confidence interval, 0.25 to 0.62; P<0.001).  The rate of complete or partial response with combination 150/2 therapy was 76%, as compared with 54% with monotherapy (P = 0.03).  CONCLUSIONS Dabrafenib and trametinib were safely combined at full monotherapy doses.  The rate of pyrexia was increased with combination therapy, whereas the rate of proliferative skin lesions was nonsignificantly reduced.  Progression-free survival was significantly improved.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhk7I8zrGTVbVg90H21EOLACvtfcHk0lizqF1AdInquw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1eksLrJ&md5=199ae281d44c3b41309b934d88674cd3</span></div><a href="/servlet/linkout?suffix=cit4b&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1210093&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1210093%26sid%3Dliteratum%253Aachs%26aulast%3DFlaherty%26aufirst%3DK.%2BT.%26aulast%3DInfante%26aufirst%3DJ.%2BR.%26aulast%3DDaud%26aufirst%3DA.%26aulast%3DGonzalez%26aufirst%3DR.%26aulast%3DKefford%26aufirst%3DR.%2BF.%26aulast%3DSosman%26aufirst%3DJ.%26aulast%3DHamid%26aufirst%3DO.%26aulast%3DSchuchter%26aufirst%3DL.%26aulast%3DCebon%26aufirst%3DJ.%26aulast%3DIbrahim%26aufirst%3DN.%26aulast%3DKudchadkar%26aufirst%3DR.%26aulast%3DBurris%26aufirst%3DH.%2BA.%26aulast%3DFalchook%26aufirst%3DG.%26aulast%3DAlgazi%26aufirst%3DA.%26aulast%3DLewis%26aufirst%3DK.%26aulast%3DLong%26aufirst%3DG.%2BV.%26aulast%3DPuzanov%26aufirst%3DI.%26aulast%3DLebowitz%26aufirst%3DP.%26aulast%3DSingh%26aufirst%3DA.%26aulast%3DLittle%26aufirst%3DS.%26aulast%3DSun%26aufirst%3DP.%26aulast%3DAllred%26aufirst%3DA.%26aulast%3DOuellet%26aufirst%3DD.%26aulast%3DKim%26aufirst%3DK.%2BB.%26aulast%3DPatel%26aufirst%3DK.%26aulast%3DWeber%26aufirst%3DJ.%26atitle%3DCombined%2520BRAF%2520and%2520MEK%2520inhibition%2520in%2520melanoma%2520with%2520BRAF%2520V600%2520mutations%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2012%26volume%3D367%26spage%3D1694%26epage%3D1703%26doi%3D10.1056%2FNEJMoa1210093" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit4c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Robert, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karaszewska, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schachter, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rutkowski, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mackiewicz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stroiakovski, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lichinitser, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dummer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grange, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mortier, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiarion-Sileni, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drucis, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krajsova, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hauschild, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lorigan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolter, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, G. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flaherty, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nathan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ribas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, A.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crist, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Legos, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubin, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Little, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schadendorf, D.</span></span> <span> </span><span class="NLM_article-title">Improved overall survival in melanoma with combined dabrafenib and trametinib</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>372</i></span>,  <span class="NLM_fpage">30</span>– <span class="NLM_lpage">39</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1412690</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=10.1056%2FNEJMoa1412690" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=25399551" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFSqsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=372&publication_year=2015&pages=30-39&author=C.+Robertauthor=B.+Karaszewskaauthor=J.+Schachterauthor=P.+Rutkowskiauthor=A.+Mackiewiczauthor=D.+Stroiakovskiauthor=M.+Lichinitserauthor=R.+Dummerauthor=F.+Grangeauthor=L.+Mortierauthor=V.+Chiarion-Sileniauthor=K.+Drucisauthor=I.+Krajsovaauthor=A.+Hauschildauthor=P.+Loriganauthor=P.+Wolterauthor=G.+V.+Longauthor=K.+Flahertyauthor=P.+Nathanauthor=A.+Ribasauthor=A.-M.+Martinauthor=P.+Sunauthor=W.+Cristauthor=J.+Legosauthor=S.+D.+Rubinauthor=S.+M.+Littleauthor=D.+Schadendorf&title=Improved+overall+survival+in+melanoma+with+combined+dabrafenib+and+trametinib&doi=10.1056%2FNEJMoa1412690"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4cR"><div class="casContent"><span class="casTitleNuber">4c</span><div class="casTitle"><span class="NLM_cas:atitle">Improved overall survival in melanoma with combined dabrafenib and trametinib</span></div><div class="casAuthors">Robert, Caroline; Karaszewska, Boguslawa; Schachter, Jacob; Rutkowski, Piotr; Mackiewicz, Andrzej; Stroiakovski, Daniil; Lichinitser, Michael; Dummer, Reinhard; Grange, Florent; Mortier, Laurent; Chiarion-Sileni, Vanna; Drucis, Kamil; Krajsova, Ivana; Hauschild, Axel; Lorigan, Paul; Wolter, Pascal; Long, Georgina V.; Flaherty, Keith; Nathan, Paul; Ribas, Antoni; Martin, Anne-Marie; Sun, Peng; Crist, Wendy; Legos, Jeff; Rubin, Stephen D.; Little, Shonda M.; Schadendorf, Dirk</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">372</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">30-39/1-30-39/10, 10 pp.</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: The BRAF inhibitors vemurafenib and dabrafenib have shown efficacy as monotherapies in patients with previously untreated metastatic melanoma with BRAF V600E or V600K mutations.  Combining dabrafenib and the MEK inhibitor trametinib, as compared with dabrafenib alone, enhanced antitumor activity in this population of patients.  Methods: In this open-label, phase 3 trial, we randomly assigned 704 patients with metastatic melanoma with a BRAF V600 mutation to receive either a combination of dabrafenib (150 mg twice daily) and trametinib (2 mg once daily) or vemurafenib (960 mg twice daily) orally as first-line therapy.  The primary end point was overall survival.  Results: At the preplanned interim overall survival anal., which was performed after 77% of the total no. of expected events occurred, the overall survival rate at 12 mo was 72% (95% confidence interval [CI], 67 to 77) in the combination-therapy group and 65% (95% CI, 59 to 70) in the vemurafenib group (hazard ratio for death in the combination-therapy group, 0.69; 95% CI, 0.53 to 0.89; P = 0.005).  The prespecified interim stopping boundary was crossed, and the study was stopped for efficacy in July 2014.  Median progression-free survival was 11.4 mo in the combination therapy group and 7.3 mo in the vemurafenib group (hazard ratio, 0.56; 95% CI, 0.46 to 0.69; P<0.001).  The objective response rate was 64% in the combination therapy group and 51% in the vemurafenib group (P<0.001).  Rates of severe adverse events and study-drug discontinuations were similar in the two groups.  Cutaneous squamous-cell carcinoma and keratoacanthoma occurred in 1% of patients in the combination-therapy group and 18% of those in the vemurafenib group.  Conclusions: Dabrafenib plus trametinib, as compared with vemurafenib monotherapy, significantly improved overall survival in previously untreated patients with metastatic melanoma with BRAF V600E or V600K mutations, without increased overall toxicity. (Funded by GlaxoSmithKline; ClinicalTrials.gov no., NCT01597908.).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5of4j14YrP7Vg90H21EOLACvtfcHk0lizqF1AdInquw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFSqsb0%253D&md5=9d6a8f49bbd196f9463ec15958eb15d1</span></div><a href="/servlet/linkout?suffix=cit4c&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1412690&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1412690%26sid%3Dliteratum%253Aachs%26aulast%3DRobert%26aufirst%3DC.%26aulast%3DKaraszewska%26aufirst%3DB.%26aulast%3DSchachter%26aufirst%3DJ.%26aulast%3DRutkowski%26aufirst%3DP.%26aulast%3DMackiewicz%26aufirst%3DA.%26aulast%3DStroiakovski%26aufirst%3DD.%26aulast%3DLichinitser%26aufirst%3DM.%26aulast%3DDummer%26aufirst%3DR.%26aulast%3DGrange%26aufirst%3DF.%26aulast%3DMortier%26aufirst%3DL.%26aulast%3DChiarion-Sileni%26aufirst%3DV.%26aulast%3DDrucis%26aufirst%3DK.%26aulast%3DKrajsova%26aufirst%3DI.%26aulast%3DHauschild%26aufirst%3DA.%26aulast%3DLorigan%26aufirst%3DP.%26aulast%3DWolter%26aufirst%3DP.%26aulast%3DLong%26aufirst%3DG.%2BV.%26aulast%3DFlaherty%26aufirst%3DK.%26aulast%3DNathan%26aufirst%3DP.%26aulast%3DRibas%26aufirst%3DA.%26aulast%3DMartin%26aufirst%3DA.-M.%26aulast%3DSun%26aufirst%3DP.%26aulast%3DCrist%26aufirst%3DW.%26aulast%3DLegos%26aufirst%3DJ.%26aulast%3DRubin%26aufirst%3DS.%2BD.%26aulast%3DLittle%26aufirst%3DS.%2BM.%26aulast%3DSchadendorf%26aufirst%3DD.%26atitle%3DImproved%2520overall%2520survival%2520in%2520melanoma%2520with%2520combined%2520dabrafenib%2520and%2520trametinib%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2015%26volume%3D372%26spage%3D30%26epage%3D39%26doi%3D10.1056%2FNEJMoa1412690" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit4d"><span><span class="NLM_label">(d) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Robert, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grob, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stroyakovskiy, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karaszewska, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hauschild, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levchenko, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiarion Sileni, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schachter, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garbe, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bondarenko, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gogas, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mandalá, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haanen, J. B. A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lebbé, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mackiewicz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rutkowski, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nathan, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ribas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flaherty, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burgess, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gasal, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schadendorf, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, G. V.</span></span> <span> </span><span class="NLM_article-title">Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>381</i></span>,  <span class="NLM_fpage">626</span>– <span class="NLM_lpage">636</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1904059</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=10.1056%2FNEJMoa1904059" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=31166680" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhs1GqsbbO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=381&publication_year=2019&pages=626-636&author=C.+Robertauthor=J.+J.+Grobauthor=D.+Stroyakovskiyauthor=B.+Karaszewskaauthor=A.+Hauschildauthor=E.+Levchenkoauthor=V.+Chiarion+Sileniauthor=J.+Schachterauthor=C.+Garbeauthor=I.+Bondarenkoauthor=H.+Gogasauthor=M.+Mandal%C3%A1author=J.+B.+A.+G.+Haanenauthor=C.+Lebb%C3%A9author=A.+Mackiewiczauthor=P.+Rutkowskiauthor=P.+D.+Nathanauthor=A.+Ribasauthor=M.+A.+Daviesauthor=K.+T.+Flahertyauthor=P.+Burgessauthor=M.+Tanauthor=E.+Gasalauthor=M.+Voiauthor=D.+Schadendorfauthor=G.+V.+Long&title=Five-year+outcomes+with+dabrafenib+plus+trametinib+in+metastatic+melanoma&doi=10.1056%2FNEJMoa1904059"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4dR"><div class="casContent"><span class="casTitleNuber">4d</span><div class="casTitle"><span class="NLM_cas:atitle">Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma</span></div><div class="casAuthors">Robert, C.; Grob, J. J.; Stroyakovskiy, D.; Karaszewska, B.; Hauschild, A.; Levchenko, E.; Sileni, V. Chiarion; Schachter, J.; Garbe, C.; Bondarenko, I.; Gogas, H.; Mandala, M.; Haanen, J. B. A. G.; Lebbe, C.; Mackiewicz, A.; Rutkowski, P.; Nathan, P. D.; Ribas, A.; Davies, M. A.; Flaherty, K. T.; Burgess, P.; Tan, M.; Gasal, E.; Voi, M.; Schadendorf, D.; Long, G. V.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">381</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">626-636</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">A review.  Background Patients who have unresectable or metastatic melanoma with a BRAF V600E or V600K mutation have prolonged progression-free survival and overall survival when receiving treatment with BRAF inhibitors plus MEK inhibitors.  However, long-term clin. outcomes in these patients remain undefined.  To det. 5-yr survival rates and clin. characteristics of the patients with durable benefit, we sought to review long-term data from randomized trials of combination therapy with BRAF and MEK inhibitors. methods We analyzed pooled extended-survival data from two trials involving previously untreated patients who had received BRAF inhibitor dabrafenib (at a dose of 150 mg twice daily) plus MEK inhibitor trametinib (2 mg once daily) in the COMBI-d and COMBI-v trials.  The median duration of follow-up was 22 mo (range, 0 to 76).  The primary end points in the COMBI-d and COMBI-v trials were progression-free survival and overall survival, resp. results A total of 563 patients were randomly assigned to receive dabrafenib plus trametinib (211 in the COMBI-d trial and 352 in the COMBI-v trial).  The progression-free survival rates were 21% (95% confidence interval [CI], 17 to 24) at 4 years and 19% (95% CI, 15 to 22) at 5 years.  The overall survival rates were 37% (95% CI, 33 to 42) at 4 years and 34% (95% CI, 30 to 38) at 5 years.  In multivariate anal., several baseline factors (e.g., performance status, age, sex, no. of organ sites with metastasis, and lactate dehydrogenase level) were significantly assocd. with both progression-free survival and overall survival.  A complete response occurred in 109 patients (19%) and was assocd. with an improved long-term outcome, with an overall survival rate of 71% (95% CI, 62 to 79) at 5 years. conclusions First-line treatment with dabrafenib plus trametinib led to long-term benefit in approx. one third of the patients who had unresectable or metastatic melanoma with a BRAF V600E or V600K mutation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo3AT72ajVerrVg90H21EOLACvtfcHk0liLVt_XrzINVg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhs1GqsbbO&md5=4aef2f5bbda3d7a8863a0c084bce61b1</span></div><a href="/servlet/linkout?suffix=cit4d&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1904059&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1904059%26sid%3Dliteratum%253Aachs%26aulast%3DRobert%26aufirst%3DC.%26aulast%3DGrob%26aufirst%3DJ.%2BJ.%26aulast%3DStroyakovskiy%26aufirst%3DD.%26aulast%3DKaraszewska%26aufirst%3DB.%26aulast%3DHauschild%26aufirst%3DA.%26aulast%3DLevchenko%26aufirst%3DE.%26aulast%3DChiarion%2BSileni%26aufirst%3DV.%26aulast%3DSchachter%26aufirst%3DJ.%26aulast%3DGarbe%26aufirst%3DC.%26aulast%3DBondarenko%26aufirst%3DI.%26aulast%3DGogas%26aufirst%3DH.%26aulast%3DMandal%25C3%25A1%26aufirst%3DM.%26aulast%3DHaanen%26aufirst%3DJ.%2BB.%2BA.%2BG.%26aulast%3DLebb%25C3%25A9%26aufirst%3DC.%26aulast%3DMackiewicz%26aufirst%3DA.%26aulast%3DRutkowski%26aufirst%3DP.%26aulast%3DNathan%26aufirst%3DP.%2BD.%26aulast%3DRibas%26aufirst%3DA.%26aulast%3DDavies%26aufirst%3DM.%2BA.%26aulast%3DFlaherty%26aufirst%3DK.%2BT.%26aulast%3DBurgess%26aufirst%3DP.%26aulast%3DTan%26aufirst%3DM.%26aulast%3DGasal%26aufirst%3DE.%26aulast%3DVoi%26aufirst%3DM.%26aulast%3DSchadendorf%26aufirst%3DD.%26aulast%3DLong%26aufirst%3DG.%2BV.%26atitle%3DFive-year%2520outcomes%2520with%2520dabrafenib%2520plus%2520trametinib%2520in%2520metastatic%2520melanoma%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2019%26volume%3D381%26spage%3D626%26epage%3D636%26doi%3D10.1056%2FNEJMoa1904059" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Rice, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aay, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anand, N. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blazey, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowles, O. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bussenius, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Costanzo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curtis, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Defina, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubenko, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engst, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joshi, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kennedy, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, A. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koltun, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lougheed, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manalo, J.-C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martini, J.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nuss, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peto, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsang, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnston, S.</span></span> <span> </span><span class="NLM_article-title">Novel carboxamide-based allosteric MEK inhibitors: Discovery and optimization efforts toward XL518 (GDC-0973)</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">416</span>– <span class="NLM_lpage">421</span>, <span class="refDoi"> DOI: 10.1021/ml300049d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml300049d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref5/cit5a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=1%3ACAS%3A528%3ADC%252BC38Xlt1eit7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=416-421&author=K.+D.+Riceauthor=N.+Aayauthor=N.+K.+Anandauthor=C.+M.+Blazeyauthor=O.+J.+Bowlesauthor=J.+Busseniusauthor=S.+Costanzoauthor=J.+K.+Curtisauthor=S.+C.+Definaauthor=L.+Dubenkoauthor=S.+Engstauthor=A.+A.+Joshiauthor=A.+R.+Kennedyauthor=A.+I.+Kimauthor=E.+S.+Koltunauthor=J.+C.+Lougheedauthor=J.-C.+L.+Manaloauthor=J.-F.+Martiniauthor=J.+M.+Nussauthor=C.+J.+Petoauthor=T.+H.+Tsangauthor=P.+Yuauthor=S.+Johnston&title=Novel+carboxamide-based+allosteric+MEK+inhibitors%3A+Discovery+and+optimization+efforts+toward+XL518+%28GDC-0973%29&doi=10.1021%2Fml300049d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5aR"><div class="casContent"><span class="casTitleNuber">5a</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Carboxamide-Based Allosteric MEK Inhibitors: Discovery and Optimization Efforts toward XL518 (GDC-0973)</span></div><div class="casAuthors">Rice, Kenneth D.; Aay, Naing; Anand, Neel K.; Blazey, Charles M.; Bowles, Owen J.; Bussenius, Joerg; Costanzo, Simona; Curtis, Jeffry K.; Defina, Steven C.; Dubenko, Larisa; Engst, Stefan; Joshi, Anagha A.; Kennedy, Abigail R.; Kim, Angie I.; Koltun, Elena S.; Lougheed, Julie C.; Manalo, Jean-Claire L.; Martini, Jean-Francois; Nuss, John M.; Peto, Csaba J.; Tsang, Tsze H.; Yu, Peiwen; Johnston, Stuart</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">416-421</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The ERK/MAP kinase cascade is a key mechanism subject to dysregulation in cancer and is constitutively activated or highly upregulated in many tumor types.  Mutations assocd. with upstream pathway components RAS and Raf occur frequently and contribute to the oncogenic phenotype through activation of MEK and then ERK.  Inhibitors of MEK have been shown to effectively block upregulated ERK/MAPK signaling in a range of cancer cell lines and have further demonstrated early evidence of efficacy in the clinic for the treatment of cancer.  Guided by structural insight, a strategy aimed at the identification of an optimal diphenylamine-based MEK inhibitor with an improved metab. and safety profile vs. PD-0325901 led to the discovery of development candidate 1-({3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]phenyl}carbonyl)-3-[(2S)-piperidin-2-yl]azetidin-3-ol (XL518, GDC-0973) (I).  I exhibits robust in vitro and in vivo potency and efficacy in preclin. models with sustained duration of action and is currently in early stage clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOx-Upr00b8LVg90H21EOLACvtfcHk0liLVt_XrzINVg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xlt1eit7k%253D&md5=04aa82afd24efe83a3b888140781bfc6</span></div><a href="/servlet/linkout?suffix=cit5a&amp;dbid=16384&amp;doi=10.1021%2Fml300049d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml300049d%26sid%3Dliteratum%253Aachs%26aulast%3DRice%26aufirst%3DK.%2BD.%26aulast%3DAay%26aufirst%3DN.%26aulast%3DAnand%26aufirst%3DN.%2BK.%26aulast%3DBlazey%26aufirst%3DC.%2BM.%26aulast%3DBowles%26aufirst%3DO.%2BJ.%26aulast%3DBussenius%26aufirst%3DJ.%26aulast%3DCostanzo%26aufirst%3DS.%26aulast%3DCurtis%26aufirst%3DJ.%2BK.%26aulast%3DDefina%26aufirst%3DS.%2BC.%26aulast%3DDubenko%26aufirst%3DL.%26aulast%3DEngst%26aufirst%3DS.%26aulast%3DJoshi%26aufirst%3DA.%2BA.%26aulast%3DKennedy%26aufirst%3DA.%2BR.%26aulast%3DKim%26aufirst%3DA.%2BI.%26aulast%3DKoltun%26aufirst%3DE.%2BS.%26aulast%3DLougheed%26aufirst%3DJ.%2BC.%26aulast%3DManalo%26aufirst%3DJ.-C.%2BL.%26aulast%3DMartini%26aufirst%3DJ.-F.%26aulast%3DNuss%26aufirst%3DJ.%2BM.%26aulast%3DPeto%26aufirst%3DC.%2BJ.%26aulast%3DTsang%26aufirst%3DT.%2BH.%26aulast%3DYu%26aufirst%3DP.%26aulast%3DJohnston%26aufirst%3DS.%26atitle%3DNovel%2520carboxamide-based%2520allosteric%2520MEK%2520inhibitors%253A%2520Discovery%2520and%2520optimization%2520efforts%2520toward%2520XL518%2520%2528GDC-0973%2529%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D3%26spage%3D416%26epage%3D421%26doi%3D10.1021%2Fml300049d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit5b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Larkin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ascierto, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dréno, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atkinson, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liszkay, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maio, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mandalà, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demidov, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stroyakovskiy, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de la Cruz-Merino, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dutriaux, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garbe, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sovak, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choong, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hack, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McArthur, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ribas, A.</span></span> <span> </span><span class="NLM_article-title">Combined vemurafenib and cobimetinib in <i>BRAF</i>-mutated melanoma</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>371</i></span>,  <span class="NLM_fpage">1867</span>– <span class="NLM_lpage">1876</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1408868</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=10.1056%2FNEJMoa1408868" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=25265494" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=1%3ACAS%3A528%3ADC%252BC2MXlslGgsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=371&publication_year=2014&pages=1867-1876&author=J.+Larkinauthor=P.+A.+Asciertoauthor=B.+Dr%C3%A9noauthor=V.+Atkinsonauthor=G.+Liszkayauthor=M.+Maioauthor=M.+Mandal%C3%A0author=L.+Demidovauthor=D.+Stroyakovskiyauthor=L.+Thomasauthor=L.+de+la+Cruz-Merinoauthor=C.+Dutriauxauthor=C.+Garbeauthor=M.+A.+Sovakauthor=I.+Changauthor=N.+Choongauthor=S.+P.+Hackauthor=G.+A.+McArthurauthor=A.+Ribas&title=Combined+vemurafenib+and+cobimetinib+in+BRAF-mutated+melanoma&doi=10.1056%2FNEJMoa1408868"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5bR"><div class="casContent"><span class="casTitleNuber">5b</span><div class="casTitle"><span class="NLM_cas:atitle">Combined vemurafenib and cobimetinib in BRAF-mutated melanoma</span></div><div class="casAuthors">Larkin, James; Ascierto, Paolo A.; Dreno, Brigitte; Atkinson, Victoria; Liszkay, Gabriella; Maio, Michele; Mandala, Mario; Demidov, Lev; Stroyakovskiy, Daniil; Thomas, Luc; de la Cruz-Merino, Luis; Dutriaux, Caroline; Garbe, Claus; Sovak, Mika A.; Chang, Ilsung; Choong, Nicholas; Hack, Stephen P.; McArthur, Grant A.; Ribas, Antoni</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">371</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">1867-1876, 10 pp.</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background The combined inhibition of BRAF and MEK is hypothesized to improve clin. outcomes in patients with melanoma by preventing or delaying the onset of resistance obsd. with BRAF inhibitors alone.  This randomized phase 3 study evaluated the combination of the BRAF inhibitor vemurafenib and the MEK inhibitor cobimetinib.  We randomly assigned 495 patients with previously untreated unresectable locally advanced or metastatic BRAF V600 mutation-pos. melanoma to receive vemurafenib and cobimetinib (combination group) or vemurafenib and placebo (control group).  The primary end point was investigator-assessed progression-free survival.  The median progression-free survival was 9.9 mo in the combination group and 6.2 mo in the control group (hazard ratio for death or disease progression, 0.51; 95% confidence interval [CI], 0.39 to 0.68; P<0.001).  The rate of complete or partial response in the combination group was 68%, as compared with 45% in the control group (P<0.001), including rates of complete response of 10% in the combination group and 4% in the control group.  Progression-free survival as assessed by independent review was similar to investigator-assessed progression-free survival.  Interim analyses of overall survival showed 9-mo survival rates of 81% (95% CI, 75 to 87) in the combination group and 73% (95% CI, 65 to 80) in the control group.  Vemurafenib and cobimetinib was assocd. with a nonsignificantly higher incidence of adverse events of grade 3 or higher, as compared with vemurafenib and placebo (65% vs. 59%), and there was no significant difference in the rate of study-drug discontinuation.  The no. of secondary cutaneous cancers decreased with the combination therapy.  The addn. of cobimetinib to vemurafenib was assocd. with a significant improvement in progression-free survival among patients with BRAF V600-mutated metastatic melanoma, at the cost of some increase in toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpErdkeTyZ9rVg90H21EOLACvtfcHk0lj9PtMxM-0QAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXlslGgsQ%253D%253D&md5=9b6fb4f9ea883da579d6435ccb5742eb</span></div><a href="/servlet/linkout?suffix=cit5b&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1408868&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1408868%26sid%3Dliteratum%253Aachs%26aulast%3DLarkin%26aufirst%3DJ.%26aulast%3DAscierto%26aufirst%3DP.%2BA.%26aulast%3DDr%25C3%25A9no%26aufirst%3DB.%26aulast%3DAtkinson%26aufirst%3DV.%26aulast%3DLiszkay%26aufirst%3DG.%26aulast%3DMaio%26aufirst%3DM.%26aulast%3DMandal%25C3%25A0%26aufirst%3DM.%26aulast%3DDemidov%26aufirst%3DL.%26aulast%3DStroyakovskiy%26aufirst%3DD.%26aulast%3DThomas%26aufirst%3DL.%26aulast%3Dde%2Bla%2BCruz-Merino%26aufirst%3DL.%26aulast%3DDutriaux%26aufirst%3DC.%26aulast%3DGarbe%26aufirst%3DC.%26aulast%3DSovak%26aufirst%3DM.%2BA.%26aulast%3DChang%26aufirst%3DI.%26aulast%3DChoong%26aufirst%3DN.%26aulast%3DHack%26aufirst%3DS.%2BP.%26aulast%3DMcArthur%26aufirst%3DG.%2BA.%26aulast%3DRibas%26aufirst%3DA.%26atitle%3DCombined%2520vemurafenib%2520and%2520cobimetinib%2520in%2520BRAF-mutated%2520melanoma%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2014%26volume%3D371%26spage%3D1867%26epage%3D1876%26doi%3D10.1056%2FNEJMoa1408868" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, S.</span>; <span class="NLM_string-name">Jin, X.</span>; <span class="NLM_string-name">Liu, Z.</span>; <span class="NLM_string-name">Poon, D.</span>; <span class="NLM_string-name">Tellew, J.</span>; <span class="NLM_string-name">Wan, Y.</span>; <span class="NLM_string-name">Wang, X.</span>; <span class="NLM_string-name">Xie, Y.</span></span> <span> </span><span class="NLM_article-title">Compounds and compositions as protein kinase inhibitors</span>. <i>PCT Int. Appl.</i> <span class="NLM_patent">WO2011025927</span>, <span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=S.+Huang&author=X.+Jin&author=Z.+Liu&author=D.+Poon&author=J.+Tellew&author=Y.+Wan&author=X.+Wang&author=Y.+Xie&title=Compounds+and+compositions+as+protein+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DS.%26atitle%3DCompounds%2520and%2520compositions%2520as%2520protein%2520kinase%2520inhibitors%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit6b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Dummer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ascierto, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gogas, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arance, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mandala, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liszkay, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garbe, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schadendorf, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krajsova, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gutzmer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiarion-Sileni, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dutriaux, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Groot, J. W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamazaki, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loquai, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moutouh-de Parseval, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pickard, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sandor, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robert, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flaherty, K. T.</span></span> <span> </span><span class="NLM_article-title">Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): A multicentre, open-label, randomized phase 3 trial</span>. <i>Lancet Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">603</span>– <span class="NLM_lpage">615</span>, <span class="refDoi"> DOI: 10.1016/S1470-2045(18)30142-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=10.1016%2FS1470-2045%2818%2930142-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=29573941" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=1%3ACAS%3A528%3ADC%252BC1cXlslKltr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2018&pages=603-615&author=R.+Dummerauthor=P.+A.+Asciertoauthor=H.+J.+Gogasauthor=A.+Aranceauthor=M.+Mandalaauthor=G.+Liszkayauthor=C.+Garbeauthor=D.+Schadendorfauthor=I.+Krajsovaauthor=R.+Gutzmerauthor=V.+Chiarion-Sileniauthor=C.+Dutriauxauthor=J.+W.+B.+de+Grootauthor=N.+Yamazakiauthor=C.+Loquaiauthor=L.+A.+Moutouh-de+Parsevalauthor=M.+D.+Pickardauthor=V.+Sandorauthor=C.+Robertauthor=K.+T.+Flaherty&title=Encorafenib+plus+binimetinib+versus+vemurafenib+or+encorafenib+in+patients+with+BRAF-mutant+melanoma+%28COLUMBUS%29%3A+A+multicentre%2C+open-label%2C+randomized+phase+3+trial&doi=10.1016%2FS1470-2045%2818%2930142-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6bR"><div class="casContent"><span class="casTitleNuber">6b</span><div class="casTitle"><span class="NLM_cas:atitle">Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicenter, open-label, randomized phase 3 trial</span></div><div class="casAuthors">Dummer, Reinhard; Ascierto, Paolo A.; Gogas, Helen J.; Arance, Ana; Mandala, Mario; Liszkay, Gabriella; Garbe, Claus; Schadendorf, Dirk; Krajsova, Ivana; Gutzmer, Ralf; Chiarion-Sileni, Vanna; Dutriaux, Caroline; de Groot, Jan Willem B.; Yamazaki, Naoya; Loquai, Carmen; Moutouh-de Parseval, Laure A.; Pickard, Michael D.; Sandor, Victor; Robert, Caroline; Flaherty, Keith T.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">603-615</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Combined BRAF-MEK inhibitor therapy is the std. of care for BRAFV600-mutant advanced melanoma.  We investigated encorafenib, a BRAF inhibitor with unique target-binding properties, alone or in combination with the MEK inhibitor binimetinib, vs. vemurafenib in patients with advanced BRAFV600-mutant melanoma.  COLUMBUS was conducted as a two-part, randomized, open-label phase 3 study at 162 hospitals in 28 countries.  Eligible patients were aged 18 years or older and had histol. confirmed locally advanced (American Joint Committee on Cancer [AJCC] stage IIIB, IIIC, or IV), unresectable or metastatic cutaneous melanoma, or unknown primary melanoma; a BRAFV600E or BRAFV600K mutation; an Eastern Cooperative Oncol. Group (ECOG) performance status of 0 or 1; and were treatment naive or had progressed on or after previous first-line immunotherapy.  In part 1 of the study, patients were randomly assigned (1:1:1) via interactive response technol. to receive either oral encorafenib 450 mg once daily plus oral binimetinib 45 mg twice daily (encorafenib plus binimetinib group), oral encorafenib 300 mg once daily (encorafenib group), or oral vemurafenib 960 mg twice daily (vemurafenib group).  The primary endpoint was progression-free survival by blinded independent central review for encorafenib plus binimetinib vs. vemurafenib.  Efficacy analyses were by intention-to-treat.  Safety was analyzed in patients who received at least one dose of study drug and one post-baseline safety assessment.  The results of part 2 will be published sep.  This study is registered with ClinicalTrials.gov, no. NCT01909453, and EudraCT, no. 2013-001176-38.  Between Dec 30, 2013, and Apr. 10, 2015, 577 of 1345 screened patients were randomly assigned to either the encorafenib plus binimetinib group (n=192), the encorafenib group (n=194), or the vemurafenib group (n=191).  With a median follow-up of 16·6 mo (95% CI 14·8-16·9), median progression-free survival was 14·9 mo (95% CI 11·0-18·5) in the encorafenib plus binimetinib group and 7·3 mo (5·6-8·2) in the vemurafenib group (hazard ratio [HR] 0·54, 95% CI 0·41-0·71; two-sided p<0·0001).  The most common grade 3-4 adverse events seen in more than 5% of patients in the encorafenib plus binimetinib group were increased γ-glutamyltransferase (18 [9%] of 192 patients), increased creatine phosphokinase (13 [7%]), and hypertension (11 [6%]); in the encorafenib group they were palmoplantar erythrodysaesthesia syndrome (26 [14%] of 192 patients), myalgia (19 [10%]), and arthralgia (18 [9%]); and in the vemurafenib group it was arthralgia (11 [6%] of 186 patients).  There were no treatment-related deaths except for one death in the combination group, which was considered possibly related to treatment by the investigator.  Encorafenib plus binimetinib and encorafenib monotherapy showed favorable efficacy compared with vemurafenib.  Overall, encorafenib plus binimetinib appears to have an improved tolerability profile compared with encorafenib or vemurafenib.  Encorafenib plus binimetinib could represent a new treatment option for patients with BRAF-mutant melanoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjPYLzOZ57s7Vg90H21EOLACvtfcHk0lj9PtMxM-0QAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXlslKltr4%253D&md5=4570e5b6091c5683a5f8a2d09110d541</span></div><a href="/servlet/linkout?suffix=cit6b&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2818%2930142-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252818%252930142-6%26sid%3Dliteratum%253Aachs%26aulast%3DDummer%26aufirst%3DR.%26aulast%3DAscierto%26aufirst%3DP.%2BA.%26aulast%3DGogas%26aufirst%3DH.%2BJ.%26aulast%3DArance%26aufirst%3DA.%26aulast%3DMandala%26aufirst%3DM.%26aulast%3DLiszkay%26aufirst%3DG.%26aulast%3DGarbe%26aufirst%3DC.%26aulast%3DSchadendorf%26aufirst%3DD.%26aulast%3DKrajsova%26aufirst%3DI.%26aulast%3DGutzmer%26aufirst%3DR.%26aulast%3DChiarion-Sileni%26aufirst%3DV.%26aulast%3DDutriaux%26aufirst%3DC.%26aulast%3Dde%2BGroot%26aufirst%3DJ.%2BW.%2BB.%26aulast%3DYamazaki%26aufirst%3DN.%26aulast%3DLoquai%26aufirst%3DC.%26aulast%3DMoutouh-de%2BParseval%26aufirst%3DL.%2BA.%26aulast%3DPickard%26aufirst%3DM.%2BD.%26aulast%3DSandor%26aufirst%3DV.%26aulast%3DRobert%26aufirst%3DC.%26aulast%3DFlaherty%26aufirst%3DK.%2BT.%26atitle%3DEncorafenib%2520plus%2520binimetinib%2520versus%2520vemurafenib%2520or%2520encorafenib%2520in%2520patients%2520with%2520BRAF-mutant%2520melanoma%2520%2528COLUMBUS%2529%253A%2520A%2520multicentre%252C%2520open-label%252C%2520randomized%2520phase%25203%2520trial%26jtitle%3DLancet%2520Oncol.%26date%3D2018%26volume%3D19%26spage%3D603%26epage%3D615%26doi%3D10.1016%2FS1470-2045%2818%2930142-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Hatzivassiliou, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yen, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brandhuber, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alvarado, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ludlam, M. J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stokoe, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gloor, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vigers, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morales, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aliagas, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sideris, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoeflich, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaiswal, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seshagiri, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koeppen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belvin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedman, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malek, S.</span></span> <span> </span><span class="NLM_article-title">RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>464</i></span>,  <span class="NLM_fpage">431</span>– <span class="NLM_lpage">435</span>, <span class="refDoi"> DOI: 10.1038/nature08833</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=10.1038%2Fnature08833" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=20130576" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVygtb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=464&publication_year=2010&pages=431-435&author=G.+Hatzivassiliouauthor=K.+Songauthor=I.+Yenauthor=B.+J.+Brandhuberauthor=D.+J.+Andersonauthor=R.+Alvaradoauthor=M.+J.+C.+Ludlamauthor=D.+Stokoeauthor=S.+L.+Gloorauthor=G.+Vigersauthor=T.+Moralesauthor=I.+Aliagasauthor=B.+Liuauthor=S.+Siderisauthor=K.+P.+Hoeflichauthor=B.+S.+Jaiswalauthor=S.+Seshagiriauthor=H.+Koeppenauthor=M.+Belvinauthor=L.+S.+Friedmanauthor=S.+Malek&title=RAF+inhibitors+prime+wild-type+RAF+to+activate+the+MAPK+pathway+and+enhance+growth&doi=10.1038%2Fnature08833"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7aR"><div class="casContent"><span class="casTitleNuber">7a</span><div class="casTitle"><span class="NLM_cas:atitle">RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth</span></div><div class="casAuthors">Hatzivassiliou, Georgia; Song, Kyung; Yen, Ivana; Brandhuber, Barbara J.; Anderson, Daniel J.; Alvarado, Ryan; Ludlam, Mary J. C.; Stokoe, David; Gloor, Susan L.; Vigers, Guy; Morales, Tony; Aliagas, Ignacio; Liu, Bonnie; Sideris, Steve; Hoeflich, Klaus P.; Jaiswal, Bijay S.; Seshagiri, Somasekar; Koeppen, Hartmut; Belvin, Marcia; Friedman, Lori S.; Malek, Shiva</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">464</span>
        (<span class="NLM_cas:issue">7287</span>),
    <span class="NLM_cas:pages">431-435</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Activating mutations in KRAS and BRAF are found in more than 30% of all human tumors and 40% of melanoma, resp., thus targeting this pathway could have broad therapeutic effects.  Small mol. ATP-competitive RAF kinase inhibitors have potent antitumor effects on mutant BRAF(V600E) tumors but, in contrast to mitogen-activated protein kinase kinase (MEK) inhibitors, are not potent against RAS mutant tumor models, despite RAF functioning as a key effector downstream of RAS and upstream of MEK.  Here we show that ATP-competitive RAF inhibitors have two opposing mechanisms of action depending on the cellular context.  In BRAF(V600E) tumors, RAF inhibitors effectively block the mitogen-activated protein kinase (MAPK) signalling pathway and decrease tumor growth.  Notably, in KRAS mutant and RAS/RAF wild-type tumors, RAF inhibitors activate the RAF-MEK-ERK pathway in a RAS-dependent manner, thus enhancing tumor growth in some xenograft models.  Inhibitor binding activates wild-type RAF isoforms by inducing dimerization, membrane localization and interaction with RAS-GTP.  These events occur independently of kinase inhibition and are, instead, linked to direct conformational effects of inhibitors on the RAF kinase domain.  On the basis of these findings, we demonstrate that ATP-competitive kinase inhibitors can have opposing functions as inhibitors or activators of signalling pathways, depending on the cellular context.  Furthermore, this work provides new insights into the therapeutic use of ATP-competitive RAF inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGounpcMETzVoLVg90H21EOLACvtfcHk0lgS_SKlReGxJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVygtb8%253D&md5=eb48bdf352ee9c9e182e63e38fd820a5</span></div><a href="/servlet/linkout?suffix=cit7a&amp;dbid=16384&amp;doi=10.1038%2Fnature08833&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature08833%26sid%3Dliteratum%253Aachs%26aulast%3DHatzivassiliou%26aufirst%3DG.%26aulast%3DSong%26aufirst%3DK.%26aulast%3DYen%26aufirst%3DI.%26aulast%3DBrandhuber%26aufirst%3DB.%2BJ.%26aulast%3DAnderson%26aufirst%3DD.%2BJ.%26aulast%3DAlvarado%26aufirst%3DR.%26aulast%3DLudlam%26aufirst%3DM.%2BJ.%2BC.%26aulast%3DStokoe%26aufirst%3DD.%26aulast%3DGloor%26aufirst%3DS.%2BL.%26aulast%3DVigers%26aufirst%3DG.%26aulast%3DMorales%26aufirst%3DT.%26aulast%3DAliagas%26aufirst%3DI.%26aulast%3DLiu%26aufirst%3DB.%26aulast%3DSideris%26aufirst%3DS.%26aulast%3DHoeflich%26aufirst%3DK.%2BP.%26aulast%3DJaiswal%26aufirst%3DB.%2BS.%26aulast%3DSeshagiri%26aufirst%3DS.%26aulast%3DKoeppen%26aufirst%3DH.%26aulast%3DBelvin%26aufirst%3DM.%26aulast%3DFriedman%26aufirst%3DL.%2BS.%26aulast%3DMalek%26aufirst%3DS.%26atitle%3DRAF%2520inhibitors%2520prime%2520wild-type%2520RAF%2520to%2520activate%2520the%2520MAPK%2520pathway%2520and%2520enhance%2520growth%26jtitle%3DNature%26date%3D2010%26volume%3D464%26spage%3D431%26epage%3D435%26doi%3D10.1038%2Fnature08833" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit7b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Poulikakos, P. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Persaud, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janakiraman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ng, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moriceau, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atefi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Titz, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gabay, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salton, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dahlman, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tadi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wargo, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flaherty, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelley, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Misteli, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chapman, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sosman, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graeber, T. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ribas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lo, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosen, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solit, D. B.</span></span> <span> </span><span class="NLM_article-title">RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>480</i></span>,  <span class="NLM_fpage">387</span>– <span class="NLM_lpage">390</span>, <span class="refDoi"> DOI: 10.1038/nature10662</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=10.1038%2Fnature10662" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=22113612" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsFWqtL%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=480&publication_year=2011&pages=387-390&author=P.+I.+Poulikakosauthor=Y.+Persaudauthor=M.+Janakiramanauthor=X.+Kongauthor=C.+Ngauthor=G.+Moriceauauthor=H.+Shiauthor=M.+Atefiauthor=B.+Titzauthor=M.+T.+Gabayauthor=M.+Saltonauthor=K.+B.+Dahlmanauthor=M.+Tadiauthor=J.+A.+Wargoauthor=K.+T.+Flahertyauthor=M.+C.+Kelleyauthor=T.+Misteliauthor=P.+B.+Chapmanauthor=J.+A.+Sosmanauthor=T.+G.+Graeberauthor=A.+Ribasauthor=R.+S.+Loauthor=N.+Rosenauthor=D.+B.+Solit&title=RAF+inhibitor+resistance+is+mediated+by+dimerization+of+aberrantly+spliced+BRAF%28V600E%29&doi=10.1038%2Fnature10662"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7bR"><div class="casContent"><span class="casTitleNuber">7b</span><div class="casTitle"><span class="NLM_cas:atitle">RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)</span></div><div class="casAuthors">Poulikakos, Poulikos I.; Persaud, Yogindra; Janakiraman, Manickam; Kong, Xiangju; Ng, Charles; Moriceau, Gatien; Shi, Hubing; Atefi, Mohammad; Titz, Bjoern; Gabay, May Tal; Salton, Maayan; Dahlman, Kimberly B.; Tadi, Madhavi; Wargo, Jennifer A.; Flaherty, Keith T.; Kelley, Mark C.; Misteli, Tom; Chapman, Paul B.; Sosman, Jeffrey A.; Graeber, Thomas G.; Ribas, Antoni; Lo, Roger S.; Rosen, Neal; Solit, David B.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">480</span>
        (<span class="NLM_cas:issue">7377</span>),
    <span class="NLM_cas:pages">387-390</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Although clin. trials have shown that RAF inhibitors prolong the survival of patients with BRAF-mutant melanoma, resistance inevitably develops; resistance is shown here to be frequently mediated by the expression of splicing variants of mutant BRAF.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0XPUFDxeK5rVg90H21EOLACvtfcHk0lgS_SKlReGxJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsFWqtL%252FN&md5=b239591d5efd1d965deabf0527c3b9a6</span></div><a href="/servlet/linkout?suffix=cit7b&amp;dbid=16384&amp;doi=10.1038%2Fnature10662&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature10662%26sid%3Dliteratum%253Aachs%26aulast%3DPoulikakos%26aufirst%3DP.%2BI.%26aulast%3DPersaud%26aufirst%3DY.%26aulast%3DJanakiraman%26aufirst%3DM.%26aulast%3DKong%26aufirst%3DX.%26aulast%3DNg%26aufirst%3DC.%26aulast%3DMoriceau%26aufirst%3DG.%26aulast%3DShi%26aufirst%3DH.%26aulast%3DAtefi%26aufirst%3DM.%26aulast%3DTitz%26aufirst%3DB.%26aulast%3DGabay%26aufirst%3DM.%2BT.%26aulast%3DSalton%26aufirst%3DM.%26aulast%3DDahlman%26aufirst%3DK.%2BB.%26aulast%3DTadi%26aufirst%3DM.%26aulast%3DWargo%26aufirst%3DJ.%2BA.%26aulast%3DFlaherty%26aufirst%3DK.%2BT.%26aulast%3DKelley%26aufirst%3DM.%2BC.%26aulast%3DMisteli%26aufirst%3DT.%26aulast%3DChapman%26aufirst%3DP.%2BB.%26aulast%3DSosman%26aufirst%3DJ.%2BA.%26aulast%3DGraeber%26aufirst%3DT.%2BG.%26aulast%3DRibas%26aufirst%3DA.%26aulast%3DLo%26aufirst%3DR.%2BS.%26aulast%3DRosen%26aufirst%3DN.%26aulast%3DSolit%26aufirst%3DD.%2BB.%26atitle%3DRAF%2520inhibitor%2520resistance%2520is%2520mediated%2520by%2520dimerization%2520of%2520aberrantly%2520spliced%2520BRAF%2528V600E%2529%26jtitle%3DNature%26date%3D2011%26volume%3D480%26spage%3D387%26epage%3D390%26doi%3D10.1038%2Fnature10662" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit7c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Heidorn, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milagre, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whittaker, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nourry, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niculescu-Duvas, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhomen, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hussain, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reis-Filho, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Springer, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pritchard, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marais, R.</span></span> <span> </span><span class="NLM_article-title">Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>140</i></span>,  <span class="NLM_fpage">209</span>– <span class="NLM_lpage">221</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2009.12.040</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=10.1016%2Fj.cell.2009.12.040" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=20141835" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=1%3ACAS%3A528%3ADC%252BC3cXkvVWitL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=140&publication_year=2010&pages=209-221&author=S.+J.+Heidornauthor=C.+Milagreauthor=S.+Whittakerauthor=A.+Nourryauthor=I.+Niculescu-Duvasauthor=N.+Dhomenauthor=J.+Hussainauthor=J.+S.+Reis-Filhoauthor=C.+J.+Springerauthor=C.+Pritchardauthor=R.+Marais&title=Kinase-dead+BRAF+and+oncogenic+RAS+cooperate+to+drive+tumor+progression+through+CRAF&doi=10.1016%2Fj.cell.2009.12.040"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7cR"><div class="casContent"><span class="casTitleNuber">7c</span><div class="casTitle"><span class="NLM_cas:atitle">Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF</span></div><div class="casAuthors">Heidorn, Sonja J.; Milagre, Carla; Whittaker, Steven; Nourry, Arnaud; Niculescu-Duvas, Ion; Dhomen, Nathalie; Hussain, Jahan; Reis-Filho, Jorge S.; Springer, Caroline J.; Pritchard, Catrin; Marais, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">140</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">209-221</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">We describe a mechanism of tumorigenesis mediated by kinase-dead BRAF in the presence of oncogenic RAS.  We show that drugs that selectively inhibit BRAF drive RAS-dependent BRAF binding to CRAF, CRAF activation, and MEK-ERK signaling.  This does not occur when oncogenic BRAF is inhibited, demonstrating that BRAF inhibition per se does not drive pathway activation; it only occurs when BRAF is inhibited in the presence of oncogenic RAS.  Kinase-dead BRAF mimics the effects of the BRAF-selective drugs and kinase-dead Braf and oncogenic Ras cooperate to induce melanoma in mice.  Our data reveal another paradigm of BRAF-mediated signaling that promotes tumor progression.  They highlight the importance of understanding pathway signaling in clin. practice and of genotyping tumors prior to administering BRAF-selective drugs, to identify patients who are likely to respond and also to identify patients who may experience adverse effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpMSb6ckHpR07Vg90H21EOLACvtfcHk0lgWBwM1MZxXMw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXkvVWitL0%253D&md5=80af840cb978f5956b3d998b185115f4</span></div><a href="/servlet/linkout?suffix=cit7c&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2009.12.040&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2009.12.040%26sid%3Dliteratum%253Aachs%26aulast%3DHeidorn%26aufirst%3DS.%2BJ.%26aulast%3DMilagre%26aufirst%3DC.%26aulast%3DWhittaker%26aufirst%3DS.%26aulast%3DNourry%26aufirst%3DA.%26aulast%3DNiculescu-Duvas%26aufirst%3DI.%26aulast%3DDhomen%26aufirst%3DN.%26aulast%3DHussain%26aufirst%3DJ.%26aulast%3DReis-Filho%26aufirst%3DJ.%2BS.%26aulast%3DSpringer%26aufirst%3DC.%2BJ.%26aulast%3DPritchard%26aufirst%3DC.%26aulast%3DMarais%26aufirst%3DR.%26atitle%3DKinase-dead%2520BRAF%2520and%2520oncogenic%2520RAS%2520cooperate%2520to%2520drive%2520tumor%2520progression%2520through%2520CRAF%26jtitle%3DCell%26date%3D2010%26volume%3D140%26spage%3D209%26epage%3D221%26doi%3D10.1016%2Fj.cell.2009.12.040" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit7d"><span><span class="NLM_label">(d) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heynen, G. J. J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prahallad, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robert, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haanen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blank, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wesseling, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willems, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zecchin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hobor, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bajpe, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lieftink, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mateus, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vagner, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grernrum, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hofland, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlicker, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wessels, L. F. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beijersbergen, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bardelli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Nicolantonio, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eggermont, A. M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernards, R.</span></span> <span> </span><span class="NLM_article-title">Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>508</i></span>,  <span class="NLM_fpage">118</span>– <span class="NLM_lpage">122</span>, <span class="refDoi"> DOI: 10.1038/nature13121</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=10.1038%2Fnature13121" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=24670642" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=1%3ACAS%3A528%3ADC%252BC2cXlsFyjs7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=508&publication_year=2014&pages=118-122&author=C.+Sunauthor=L.+Wangauthor=S.+Huangauthor=G.+J.+J.+E.+Heynenauthor=A.+Prahalladauthor=C.+Robertauthor=J.+Haanenauthor=C.+Blankauthor=J.+Wesselingauthor=S.+M.+Willemsauthor=D.+Zecchinauthor=S.+Hoborauthor=P.+K.+Bajpeauthor=C.+Lieftinkauthor=C.+Mateusauthor=S.+Vagnerauthor=W.+Grernrumauthor=I.+Hoflandauthor=A.+Schlickerauthor=L.+F.+A.+Wesselsauthor=R.+L.+Beijersbergenauthor=A.+Bardelliauthor=F.+Di+Nicolantonioauthor=A.+M.+M.+Eggermontauthor=R.+Bernards&title=Reversible+and+adaptive+resistance+to+BRAF%28V600E%29+inhibition+in+melanoma&doi=10.1038%2Fnature13121"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7dR"><div class="casContent"><span class="casTitleNuber">7d</span><div class="casTitle"><span class="NLM_cas:atitle">Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma</span></div><div class="casAuthors">Sun, Chong; Wang, Liqin; Huang, Sidong; Heynen, Guus J. J. E.; Prahallad, Anirudh; Robert, Caroline; Haanen, John; Blank, Christian; Wesseling, Jelle; Willems, Stefan M.; Zecchin, Davide; Hobor, Sebastijan; Bajpe, Prashanth K.; Lieftink, Cor; Mateus, Christina; Vagner, Stephan; Grernrum, Wipawadee; Hofland, Ingrid; Schlicker, Andreas; Wessels, Lodewyk F. A.; Beijersbergen, Roderick L.; Bardelli, Alberto; Di Nicolantonio, Federica; Eggermont, Alexander M. M.; Bernards, Rene</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">508</span>
        (<span class="NLM_cas:issue">7494</span>),
    <span class="NLM_cas:pages">118-122</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Treatment of BRAF(V600E) mutant melanoma by small mol. drugs that target the BRAF or MEK kinases can be effective, but resistance develops invariably.  In contrast, colon cancers that harbor the same BRAF(V600E) mutation are intrinsically resistant to BRAF inhibitors, due to feedback activation of the epidermal growth factor receptor (EGFR).  Here we show that 6 out of 16 melanoma tumors analyzed acquired EGFR expression after the development of resistance to BRAF or MEK inhibitors.  Using a chromatin-regulator-focused short hairpin RNA (shRNA) library, we find that suppression of sex detg. region Y-box 10 (SOX10) in melanoma causes activation of TGF-β signalling, thus leading to upregulation of EGFR and platelet-derived growth factor receptor-β (PDGFRB), which confer resistance to BRAF and MEK inhibitors.  Expression of EGFR in melanoma or treatment with TGF-β results in a slow-growth phenotype with cells displaying hallmarks of oncogene-induced senescence.  However, EGFR expression or exposure to TGF-β becomes beneficial for proliferation in the presence of BRAF or MEK inhibitors.  In a heterogeneous population of melanoma cells having varying levels of SOX10 suppression, cells with low SOX10 and consequently high EGFR expression are rapidly enriched in the presence of drug, but this is reversed when the drug treatment is discontinued.  We find evidence for SOX10 loss and/or activation of TGF-β signalling in 4 of the 6 EGFR-pos. drug-resistant melanoma patient samples.  Our findings provide a rationale for why some BRAF or MEK inhibitor-resistant melanoma patients may regain sensitivity to these drugs after a 'drug holiday' and identify patients with EGFR-pos. melanoma as a group that may benefit from re-treatment after a drug holiday.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0kATZtT3jcbVg90H21EOLACvtfcHk0lgWBwM1MZxXMw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXlsFyjs7Y%253D&md5=837e0c482c78e7fab31778c98ecec5d6</span></div><a href="/servlet/linkout?suffix=cit7d&amp;dbid=16384&amp;doi=10.1038%2Fnature13121&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature13121%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DHuang%26aufirst%3DS.%26aulast%3DHeynen%26aufirst%3DG.%2BJ.%2BJ.%2BE.%26aulast%3DPrahallad%26aufirst%3DA.%26aulast%3DRobert%26aufirst%3DC.%26aulast%3DHaanen%26aufirst%3DJ.%26aulast%3DBlank%26aufirst%3DC.%26aulast%3DWesseling%26aufirst%3DJ.%26aulast%3DWillems%26aufirst%3DS.%2BM.%26aulast%3DZecchin%26aufirst%3DD.%26aulast%3DHobor%26aufirst%3DS.%26aulast%3DBajpe%26aufirst%3DP.%2BK.%26aulast%3DLieftink%26aufirst%3DC.%26aulast%3DMateus%26aufirst%3DC.%26aulast%3DVagner%26aufirst%3DS.%26aulast%3DGrernrum%26aufirst%3DW.%26aulast%3DHofland%26aufirst%3DI.%26aulast%3DSchlicker%26aufirst%3DA.%26aulast%3DWessels%26aufirst%3DL.%2BF.%2BA.%26aulast%3DBeijersbergen%26aufirst%3DR.%2BL.%26aulast%3DBardelli%26aufirst%3DA.%26aulast%3DDi%2BNicolantonio%26aufirst%3DF.%26aulast%3DEggermont%26aufirst%3DA.%2BM.%2BM.%26aulast%3DBernards%26aufirst%3DR.%26atitle%3DReversible%2520and%2520adaptive%2520resistance%2520to%2520BRAF%2528V600E%2529%2520inhibition%2520in%2520melanoma%26jtitle%3DNature%26date%3D2014%26volume%3D508%26spage%3D118%26epage%3D122%26doi%3D10.1038%2Fnature13121" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Karoulia, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmed, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xin, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bollard, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krepler, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bollag, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herlyn, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fagin, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lujambio, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gavathiotis, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poulikakos, P. I.</span></span> <span> </span><span class="NLM_article-title">An integrated model of RAF inhibitor action predicts inhibitor activity against oncogenic BRAF signaling</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">485</span>– <span class="NLM_lpage">498</span>, <span class="refDoi"> DOI: 10.1016/j.ccell.2016.06.024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=10.1016%2Fj.ccell.2016.06.024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=27523909" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhtleis77I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2016&pages=485-498&author=Z.+Karouliaauthor=Y.+Wuauthor=T.+A.+Ahmedauthor=Q.+Xinauthor=J.+Bollardauthor=C.+Kreplerauthor=X.+Wuauthor=C.+Zhangauthor=G.+Bollagauthor=M.+Herlynauthor=J.+A.+Faginauthor=A.+Lujambioauthor=E.+Gavathiotisauthor=P.+I.+Poulikakos&title=An+integrated+model+of+RAF+inhibitor+action+predicts+inhibitor+activity+against+oncogenic+BRAF+signaling&doi=10.1016%2Fj.ccell.2016.06.024"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling</span></div><div class="casAuthors">Karoulia, Zoi; Wu, Yang; Ahmed, Tamer A.; Xin, Qisheng; Bollard, Julien; Krepler, Clemens; Wu, Xuewei; Zhang, Chao; Bollag, Gideon; Herlyn, Meenhard; Fagin, James A.; Lujambio, Amaia; Gavathiotis, Evripidis; Poulikakos, Poulikos I.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">485-498</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">The complex biochem. effects of RAF inhibitors account for both the effectiveness and mechanisms of resistance to these drugs, but a unified mechanistic model has been lacking.  Here we show that RAF inhibitors exert their effects via two distinct allosteric mechanisms.  Drug resistance due to dimerization is detd. by the position of the αC helix stabilized by inhibitor, whereas inhibitor-induced RAF priming and dimerization are the result of inhibitor-induced formation of the RAF/RAS-GTP complex.  The biochem. effect of RAF inhibitor in cells is the combined outcome of the two mechanisms.  Therapeutic strategies including αC-helix-IN inhibitors are more effective in multiple mutant BRAF-driven tumor models, including colorectal and thyroid BRAFV600E cancers, in which first-generation RAF inhibitors have been ineffective.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9VLWvQ7ojJrVg90H21EOLACvtfcHk0lgWBwM1MZxXMw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhtleis77I&md5=197711577048b889ea1dac8c87049a01</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2Fj.ccell.2016.06.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccell.2016.06.024%26sid%3Dliteratum%253Aachs%26aulast%3DKaroulia%26aufirst%3DZ.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DAhmed%26aufirst%3DT.%2BA.%26aulast%3DXin%26aufirst%3DQ.%26aulast%3DBollard%26aufirst%3DJ.%26aulast%3DKrepler%26aufirst%3DC.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DBollag%26aufirst%3DG.%26aulast%3DHerlyn%26aufirst%3DM.%26aulast%3DFagin%26aufirst%3DJ.%2BA.%26aulast%3DLujambio%26aufirst%3DA.%26aulast%3DGavathiotis%26aufirst%3DE.%26aulast%3DPoulikakos%26aufirst%3DP.%2BI.%26atitle%3DAn%2520integrated%2520model%2520of%2520RAF%2520inhibitor%2520action%2520predicts%2520inhibitor%2520activity%2520against%2520oncogenic%2520BRAF%2520signaling%26jtitle%3DCancer%2520Cell%26date%3D2016%26volume%3D30%26spage%3D485%26epage%3D498%26doi%3D10.1016%2Fj.ccell.2016.06.024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Cotto-Rios, X. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agianian, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gitego, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zacharioudakis, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giricz, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verma, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poulikakos, P. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gavathiotis, E.</span></span> <span> </span><span class="NLM_article-title">Inhibitors of BRAF dimers using an allosteric site</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">4370</span>, <span class="refDoi"> DOI: 10.1038/s41467-020-18123-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=10.1038%2Fs41467-020-18123-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=32873792" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhsl2isLjE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2020&pages=4370&author=X.+M.+Cotto-Riosauthor=B.+Agianianauthor=N.+Gitegoauthor=E.+Zacharioudakisauthor=O.+Giriczauthor=Y.+Wuauthor=Y.+Zouauthor=A.+Vermaauthor=P.+I.+Poulikakosauthor=E.+Gavathiotis&title=Inhibitors+of+BRAF+dimers+using+an+allosteric+site&doi=10.1038%2Fs41467-020-18123-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9aR"><div class="casContent"><span class="casTitleNuber">9a</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitors of BRAF dimers using an allosteric site</span></div><div class="casAuthors">Cotto-Rios, Xiomaris M.; Agianian, Bogos; Gitego, Nadege; Zacharioudakis, Emmanouil; Giricz, Orsi; Wu, Yang; Zou, Yiyu; Verma, Amit; Poulikakos, Poulikos I.; Gavathiotis, Evripidis</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">4370</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">BRAF kinase, a crit. effector of the ERK signaling pathway, is hyperactivated in many cancers.  Oncogenic BRAFV600E signals as an active monomer in the absence of active RAS, however, in many tumors BRAF dimers mediate ERK signaling.  FDA-approved RAF inhibitors poorly inhibit BRAF dimers, which leads to tumor resistance.  We found that Ponatinib, an FDA-approved drug, is an effective inhibitor of BRAF monomers and dimers.  Ponatinib binds the BRAF dimer and stabilizes a distinct αC-helix conformation through interaction with a previously unrevealed allosteric site.  Using these structural insights, we developed PHI1, a BRAF inhibitor that fully uncovers the allosteric site.  PHI1 exhibits discrete cellular selectivity for BRAF dimers, with enhanced inhibition of the second protomer when the first protomer is occupied, comprising a novel class of dimer selective inhibitors.  This work shows that Ponatinib and BRAF dimer selective inhibitors will be useful in treating BRAF-dependent tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrp3pYoP75dj7Vg90H21EOLACvtfcHk0lgH4O6l_HfFew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhsl2isLjE&md5=cbac9561e74cc6ef85724302925218b8</span></div><a href="/servlet/linkout?suffix=cit9a&amp;dbid=16384&amp;doi=10.1038%2Fs41467-020-18123-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-020-18123-2%26sid%3Dliteratum%253Aachs%26aulast%3DCotto-Rios%26aufirst%3DX.%2BM.%26aulast%3DAgianian%26aufirst%3DB.%26aulast%3DGitego%26aufirst%3DN.%26aulast%3DZacharioudakis%26aufirst%3DE.%26aulast%3DGiricz%26aufirst%3DO.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DZou%26aufirst%3DY.%26aulast%3DVerma%26aufirst%3DA.%26aulast%3DPoulikakos%26aufirst%3DP.%2BI.%26aulast%3DGavathiotis%26aufirst%3DE.%26atitle%3DInhibitors%2520of%2520BRAF%2520dimers%2520using%2520an%2520allosteric%2520site%26jtitle%3DNat.%2520Commun.%26date%3D2020%26volume%3D11%26spage%3D4370%26doi%3D10.1038%2Fs41467-020-18123-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="note"><p class="first last">Other data put the monomeric signaling hypothesis into question:</p></div><div class="NLM_citation" id="rightTab-cit9b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ng, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, P. Y. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xia, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yap, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guan, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, A. S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baccarini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, J.</span></span> <span> </span><span class="NLM_article-title">The dimer-dependent catalytic activity of RAF family kinases is revealed through characterizing their oncogenic mutants</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">5719</span>– <span class="NLM_lpage">5734</span>, <span class="refDoi"> DOI: 10.1038/s41388-018-0365-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=10.1038%2Fs41388-018-0365-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=29930381" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtFyjurnE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2018&pages=5719-5734&author=J.+Yuanauthor=W.+H.+Ngauthor=P.+Y.+P.+Lamauthor=Y.+Wangauthor=H.+Xiaauthor=J.+Yapauthor=S.+P.+Guanauthor=A.+S.+G.+Leeauthor=M.+Wangauthor=M.+Baccariniauthor=J.+Hu&title=The+dimer-dependent+catalytic+activity+of+RAF+family+kinases+is+revealed+through+characterizing+their+oncogenic+mutants&doi=10.1038%2Fs41388-018-0365-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9bR"><div class="casContent"><span class="casTitleNuber">9b</span><div class="casTitle"><span class="NLM_cas:atitle">The dimer-dependent catalytic activity of RAF family kinases is revealed through characterizing their oncogenic mutants</span></div><div class="casAuthors">Yuan, Jimin; Ng, Wan Hwa; Lam, Paula Y. P.; Wang, Yu; Xia, Hongping; Yap, Jiajun; Guan, Shou Ping; Lee, Ann S. G.; Wang, Mei; Baccarini, Manuela; Hu, Jiancheng</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">43</span>),
    <span class="NLM_cas:pages">5719-5734</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Although extensively studied for three decades, the mol. mechanisms that regulate the RAF/MEK/ERK kinase cascade remain ambiguous.  Recent studies identified the dimerization of RAF as a key event in the activation of this cascade.  Here, we show that in-frame deletions in the β3-αC loop activate ARAF as well as BRAF and other oncogenic kinases by enforcing homodimerization.  By characterizing these RAF mutants, we find that ARAF has less allosteric and catalytic activity than the other two RAF isoforms, which arises from its non-canonical APE motif.  Further, these RAF mutants exhibit a strong oncogenic potential, and a differential inhibitor resistance that correlates with their dimer affinity.  Using these unique mutants, we demonstrate that active RAFs, including the BRAF(V600E) mutant, phosphorylate MEK in a dimer-dependent manner.  This study characterizes a special category of oncogenic kinase mutations, and elucidates the mol. basis that underlies the differential ability of RAF isoforms to stimulate MEK-ERK pathway.  Further, this study reveals a unique catalytic feature of RAF family kinases that can be exploited to control their activities for cancer therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrLNAwHWAX5e7Vg90H21EOLACvtfcHk0lgH4O6l_HfFew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtFyjurnE&md5=95743660b4d91f1fce7236f4c90c21df</span></div><a href="/servlet/linkout?suffix=cit9b&amp;dbid=16384&amp;doi=10.1038%2Fs41388-018-0365-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41388-018-0365-2%26sid%3Dliteratum%253Aachs%26aulast%3DYuan%26aufirst%3DJ.%26aulast%3DNg%26aufirst%3DW.%2BH.%26aulast%3DLam%26aufirst%3DP.%2BY.%2BP.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DXia%26aufirst%3DH.%26aulast%3DYap%26aufirst%3DJ.%26aulast%3DGuan%26aufirst%3DS.%2BP.%26aulast%3DLee%26aufirst%3DA.%2BS.%2BG.%26aulast%3DWang%26aufirst%3DM.%26aulast%3DBaccarini%26aufirst%3DM.%26aulast%3DHu%26aufirst%3DJ.%26atitle%3DThe%2520dimer-dependent%2520catalytic%2520activity%2520of%2520RAF%2520family%2520kinases%2520is%2520revealed%2520through%2520characterizing%2520their%2520oncogenic%2520mutants%26jtitle%3DOncogene%26date%3D2018%26volume%3D37%26spage%3D5719%26epage%3D5734%26doi%3D10.1038%2Fs41388-018-0365-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Arora, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Michele, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stes, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vandermarliere, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martens, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gevaert, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Heerde, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Linders, J. T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brehmer, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacoby, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonnet, P.</span></span> <span> </span><span class="NLM_article-title">Structural investigation of B-Raf paradox breaker and inducer inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">1818</span>– <span class="NLM_lpage">1831</span>, <span class="refDoi"> DOI: 10.1021/jm501667n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501667n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVWgtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=1818-1831&author=R.+Aroraauthor=M.+Di+Micheleauthor=E.+Stesauthor=E.+Vandermarliereauthor=L.+Martensauthor=K.+Gevaertauthor=E.+Van+Heerdeauthor=J.+T.+M.+Lindersauthor=D.+Brehmerauthor=E.+Jacobyauthor=P.+Bonnet&title=Structural+investigation+of+B-Raf+paradox+breaker+and+inducer+inhibitors&doi=10.1021%2Fjm501667n"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Investigation of B-Raf Paradox Breaker and Inducer Inhibitors</span></div><div class="casAuthors">Arora, Rohit; Di Michele, Michela; Stes, Elisabeth; Vandermarliere, Elien; Martens, Lennart; Gevaert, Kris; Van Heerde, Erika; Linders, Joannes T. M.; Brehmer, Dirk; Jacoby, Edgar; Bonnet, Pascal</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1818-1831</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The V600E missense mutation in B-Raf kinase leads to an anomalous regulation of the MAPK pathway, uncontrolled cell proliferation, and initiation of tumorigenesis.  While the ATP-competitive B-Raf inhibitors block the MAPK pathway in B-Raf mutant cells, they induce conformational changes to wild-type B-Raf kinase domain leading to heterodimerization with C-Raf causing a paradoxical hyperactivation of MAPK pathway.  A new class of inhibitors (paradox breakers) has been developed that inhibit B-RafV600E activity without agonistically affecting the MAPK pathway in wild-type B-Raf cells.  In this study, we explore the structural, conformational, and cellular effects on the B-Raf kinase domain upon binding of paradox breakers and inducers.  Our results indicate that a subtle structural difference between paradox inducers and breakers leads to significant conformational differences when complexed with B-Raf.  This study provides a novel insight into the activation of B-Raf by ATP-competitive inhibitors and can aid in the design of more potent and selective inhibitors without agonistic function.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDJw-VSU5CabVg90H21EOLACvtfcHk0lgH4O6l_HfFew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVWgtr8%253D&md5=c79cfd000d525f553a5247b9e917b3e7</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1021%2Fjm501667n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501667n%26sid%3Dliteratum%253Aachs%26aulast%3DArora%26aufirst%3DR.%26aulast%3DDi%2BMichele%26aufirst%3DM.%26aulast%3DStes%26aufirst%3DE.%26aulast%3DVandermarliere%26aufirst%3DE.%26aulast%3DMartens%26aufirst%3DL.%26aulast%3DGevaert%26aufirst%3DK.%26aulast%3DVan%2BHeerde%26aufirst%3DE.%26aulast%3DLinders%26aufirst%3DJ.%2BT.%2BM.%26aulast%3DBrehmer%26aufirst%3DD.%26aulast%3DJacoby%26aufirst%3DE.%26aulast%3DBonnet%26aufirst%3DP.%26atitle%3DStructural%2520investigation%2520of%2520B-Raf%2520paradox%2520breaker%2520and%2520inducer%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D1818%26epage%3D1831%26doi%3D10.1021%2Fjm501667n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Peng, S.-B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henry, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaufman, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, W.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vogeti, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rutkoski, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wise, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chun, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Horn, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yadav, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webster, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchanan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mochalkin, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huber, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kays, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donoho, G. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walgren, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCann, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conti, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plowman, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Starling, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flynn, D. L.</span></span> <span> </span><span class="NLM_article-title">Inhibition of RAF isoforms and active dimers by LY3009120 leads to anti-tumor activities in RAS or BRAF mutant cancers</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">384</span>– <span class="NLM_lpage">398</span>, <span class="refDoi"> DOI: 10.1016/j.ccell.2015.08.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=10.1016%2Fj.ccell.2015.08.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=26343583" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVKgsr7O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2015&pages=384-398&author=S.-B.+Pengauthor=J.+R.+Henryauthor=M.+D.+Kaufmanauthor=W.-P.+Luauthor=B.+D.+Smithauthor=S.+Vogetiauthor=T.+J.+Rutkoskiauthor=S.+Wiseauthor=L.+Chunauthor=Y.+Zhangauthor=R.+D.+Van+Hornauthor=T.+Yinauthor=X.+Zhangauthor=V.+Yadavauthor=S.-H.+Chenauthor=X.+Gongauthor=X.+Maauthor=Y.+Websterauthor=S.+Buchananauthor=I.+Mochalkinauthor=L.+Huberauthor=L.+Kaysauthor=G.+P.+Donohoauthor=J.+Walgrenauthor=D.+McCannauthor=P.+Patelauthor=I.+Contiauthor=G.+D.+Plowmanauthor=J.+J.+Starlingauthor=D.+L.+Flynn&title=Inhibition+of+RAF+isoforms+and+active+dimers+by+LY3009120+leads+to+anti-tumor+activities+in+RAS+or+BRAF+mutant+cancers&doi=10.1016%2Fj.ccell.2015.08.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers</span></div><div class="casAuthors">Peng, Sheng-Bin; Henry, James R.; Kaufman, Michael D.; Lu, Wei-Ping; Smith, Bryan D.; Vogeti, Subha; Rutloski, Thomas J.; Wise, Scott; Chun, Lawrence; Zhang, Youyan; Van Horn, Robert D.; Yin, Tinggui; Zhang, Xiaoyi; Yadav, Vipin; Chen, Shih-Hsun; Gong, Xueqian; Ma, Xiwen; Webster, Yue; Buchanan, Sean; Mochalkin, Igor; Huber, Lysiane; Kays, Lisa; Donoho, Gregory P.; Walgren, Jennie; McCann, Denis; Patel, Phenil; Conti, Ilaria; Plowman, Gregory D.; Starling, James J.; Flynn, Daniel L.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">384-398</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">LY3009120 is a pan-RAF and RAF dimer inhibitor that inhibits all RAF isoforms and occupies both protomers in RAF dimers.  Biochem. and cellular analyses revealed that LY3009120 inhibits ARAF, BRAF, and CRAF isoforms with similar affinity, while vemurafenib or dabrafenib have little or modest CRAF activity compared to their BRAF activities.  LY3009120 induces BRAF-CRAF dimerization but inhibits the phosphorylation of downstream MEK and ERK, suggesting that it effectively inhibits the kinase activity of BRAF-CRAF heterodimers.  Further analyses demonstrated that LY3009120 also inhibits various forms of RAF dimers including BRAF or CRAF homodimers.  Due to these unique properties, LY3009120 demonstrates minimal paradoxical activation, inhibits MEK1/2 phosphorylation, and exhibits anti-tumor activities across multiple models carrying KRAS, NRAS, or BRAF mutation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJMiHK-Gub5bVg90H21EOLACvtfcHk0lj0Iq3eRDZy4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVKgsr7O&md5=c167caa6e5a9b47a6ec1ee2ab6d9e0d1</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2Fj.ccell.2015.08.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccell.2015.08.002%26sid%3Dliteratum%253Aachs%26aulast%3DPeng%26aufirst%3DS.-B.%26aulast%3DHenry%26aufirst%3DJ.%2BR.%26aulast%3DKaufman%26aufirst%3DM.%2BD.%26aulast%3DLu%26aufirst%3DW.-P.%26aulast%3DSmith%26aufirst%3DB.%2BD.%26aulast%3DVogeti%26aufirst%3DS.%26aulast%3DRutkoski%26aufirst%3DT.%2BJ.%26aulast%3DWise%26aufirst%3DS.%26aulast%3DChun%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DVan%2BHorn%26aufirst%3DR.%2BD.%26aulast%3DYin%26aufirst%3DT.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DYadav%26aufirst%3DV.%26aulast%3DChen%26aufirst%3DS.-H.%26aulast%3DGong%26aufirst%3DX.%26aulast%3DMa%26aufirst%3DX.%26aulast%3DWebster%26aufirst%3DY.%26aulast%3DBuchanan%26aufirst%3DS.%26aulast%3DMochalkin%26aufirst%3DI.%26aulast%3DHuber%26aufirst%3DL.%26aulast%3DKays%26aufirst%3DL.%26aulast%3DDonoho%26aufirst%3DG.%2BP.%26aulast%3DWalgren%26aufirst%3DJ.%26aulast%3DMcCann%26aufirst%3DD.%26aulast%3DPatel%26aufirst%3DP.%26aulast%3DConti%26aufirst%3DI.%26aulast%3DPlowman%26aufirst%3DG.%2BD.%26aulast%3DStarling%26aufirst%3DJ.%2BJ.%26aulast%3DFlynn%26aufirst%3DD.%2BL.%26atitle%3DInhibition%2520of%2520RAF%2520isoforms%2520and%2520active%2520dimers%2520by%2520LY3009120%2520leads%2520to%2520anti-tumor%2520activities%2520in%2520RAS%2520or%2520BRAF%2520mutant%2520cancers%26jtitle%3DCancer%2520Cell%26date%3D2015%26volume%3D28%26spage%3D384%26epage%3D398%26doi%3D10.1016%2Fj.ccell.2015.08.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Durrant, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrison, D. K.</span></span> <span> </span><span class="NLM_article-title">Targeting the Raf kinases in human cancer: The Raf dimer dilemma</span>. <i>Br. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>118</i></span>,  <span class="NLM_fpage">3</span>– <span class="NLM_lpage">8</span>, <span class="refDoi"> DOI: 10.1038/bjc.2017.399</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=10.1038%2Fbjc.2017.399" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=29235562" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvFKhu7vL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=118&publication_year=2018&pages=3-8&author=D.+E.+Durrantauthor=D.+K.+Morrison&title=Targeting+the+Raf+kinases+in+human+cancer%3A+The+Raf+dimer+dilemma&doi=10.1038%2Fbjc.2017.399"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the Raf kinases in human cancer: the Raf dimer dilemma</span></div><div class="casAuthors">Durrant, David E.; Morrison, Deborah K.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">118</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">3-8</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">The Raf protein kinases are key intermediates in cellular signal transduction, functioning as direct effectors of the Ras GTPases and as the initiating kinases in the ERK cascade.  In human cancer, Raf activity is frequently dysregulated due to mutations in the Raf family member B-Raf or to alterations in upstream Raf regulators, including Ras and receptor tyrosine kinases.  First-generation Raf inhibitors, such as vemurafenib and dabrafenib, have yielded dramatic responses in malignant melanomas contg. B-Raf mutations; however, their overall usefulness has been limited by both intrinsic and acquired drug resistance.  In particular, issues related to the dimerization of the Raf kinases can impact the efficacy of these compds. and are a primary cause of drug resistance.  Here, we will review the importance of Raf dimerization in cell signalling as well as its effects on Raf inhibitor therapy, and we will present the new strategies that are being pursued to overcome the 'Raf Dimer Dilemma'.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpHTShTLpMLiLVg90H21EOLACvtfcHk0lj0Iq3eRDZy4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvFKhu7vL&md5=186dbe3ee9006a384d9b50831000e144</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1038%2Fbjc.2017.399&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fbjc.2017.399%26sid%3Dliteratum%253Aachs%26aulast%3DDurrant%26aufirst%3DD.%2BE.%26aulast%3DMorrison%26aufirst%3DD.%2BK.%26atitle%3DTargeting%2520the%2520Raf%2520kinases%2520in%2520human%2520cancer%253A%2520The%2520Raf%2520dimer%2520dilemma%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2018%26volume%3D118%26spage%3D3%26epage%3D8%26doi%3D10.1038%2Fbjc.2017.399" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Shen, M.</span>; <span class="NLM_string-name">Lyne, P.</span>; <span class="NLM_string-name">Aquila, B.</span>; <span class="NLM_string-name">Drew, L.</span></span> <i>Abstracts of Papers, 98th American Association for Cancer Research Annual Meeting, Los Angeles, CA, United States, April 14–18, 2007</i>; <span class="NLM_publisher-name">American Association for Cancer Research</span>: <span class="NLM_publisher-loc">Philadelphia, PA</span>, <span class="NLM_year">2007</span>; Abstract  <span class="NLM_fpage">5249</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&pages=5249&author=M.+Shen&author=P.+Lyne&author=B.+Aquila&author=L.+Drew&title=Abstracts+of+Papers%2C+98th+American+Association+for+Cancer+Research+Annual+Meeting%2C+Los+Angeles%2C+CA%2C+United+States%2C+April+14%E2%80%9318%2C+2007"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DShen%26aufirst%3DM.%26btitle%3DAbstracts%2520of%2520Papers%252C%252098th%2520American%2520Association%2520for%2520Cancer%2520Research%2520Annual%2520Meeting%252C%2520Los%2520Angeles%252C%2520CA%252C%2520United%2520States%252C%2520April%252014%25E2%2580%259318%252C%25202007%26pub%3DAmerican%2520Association%2520for%2520Cancer%2520Research%26date%3D2007%26spage%3D5249" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit13b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Aquila, B.</span>; <span class="NLM_string-name">Dakin, L.</span>; <span class="NLM_string-name">Ezhuthachan, J.</span>; <span class="NLM_string-name">Lee, S.</span>; <span class="NLM_string-name">Lyne, P.</span>; <span class="NLM_string-name">Pontz, T.</span>; <span class="NLM_string-name">Zheng, X.</span></span> <span> </span><span class="NLM_article-title">Quinazolinone derivatives and their use as B-raf inhibitors</span>. <i>PCT Int. Appl.</i> <span class="NLM_patent">WO2006024834</span>, <span class="NLM_year">2006</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&author=B.+Aquila&author=L.+Dakin&author=J.+Ezhuthachan&author=S.+Lee&author=P.+Lyne&author=T.+Pontz&author=X.+Zheng&title=Quinazolinone+derivatives+and+their+use+as+B-raf+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DAquila%26aufirst%3DB.%26atitle%3DQuinazolinone%2520derivatives%2520and%2520their%2520use%2520as%2520B-raf%2520inhibitors%26date%3D2006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Henry, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaufman, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, S.-B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, Y. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caldwell, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vogeti, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Telikepalli, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, W.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hood, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rutkoski, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vogeti, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wise, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chun, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kays, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hipskind, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wrobleski, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lobb, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clay, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walgren, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCann, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clawson, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manglicmot, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groshong, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Logan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Starling, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flynn, D. L.</span></span> <span> </span><span class="NLM_article-title">Discovery of 1-(3,3-dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2,3-<i>d</i>]pyrimidin-6-yl)phenyl)urea (LY3009120) as a pan-RAF inhibitor with minimal paradoxical activation and activity against BRAF or RAS mutant tumor cells</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">4165</span>– <span class="NLM_lpage">4179</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00067</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00067" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref14/cit14a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=1%3ACAS%3A528%3ADC%252BC2MXotlCisL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=4165-4179&author=J.+R.+Henryauthor=M.+D.+Kaufmanauthor=S.-B.+Pengauthor=Y.+M.+Ahnauthor=T.+M.+Caldwellauthor=L.+Vogetiauthor=H.+Telikepalliauthor=W.-P.+Luauthor=M.+M.+Hoodauthor=T.+J.+Rutkoskiauthor=B.+D.+Smithauthor=S.+Vogetiauthor=D.+Millerauthor=S.+C.+Wiseauthor=L.+Chunauthor=X.+Zhangauthor=Y.+Zhangauthor=L.+Kaysauthor=P.+A.+Hipskindauthor=A.+D.+Wrobleskiauthor=K.+L.+Lobbauthor=J.+M.+Clayauthor=J.+D.+Cohenauthor=J.+L.+Walgrenauthor=D.+McCannauthor=P.+Patelauthor=D.+K.+Clawsonauthor=S.+Guoauthor=D.+Manglicmotauthor=C.+Groshongauthor=C.+Loganauthor=J.+J.+Starlingauthor=D.+L.+Flynn&title=Discovery+of+1-%283%2C3-dimethylbutyl%29-3-%282-fluoro-4-methyl-5-%287-methyl-2-%28methylamino%29pyrido%5B2%2C3-d%5Dpyrimidin-6-yl%29phenyl%29urea+%28LY3009120%29+as+a+pan-RAF+inhibitor+with+minimal+paradoxical+activation+and+activity+against+BRAF+or+RAS+mutant+tumor+cells&doi=10.1021%2Facs.jmedchem.5b00067"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14aR"><div class="casContent"><span class="casTitleNuber">14a</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 1-(3,3-Dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2,3-d]pyrimidin-6-yl)phenyl)urea (LY3009120) as a Pan-RAF Inhibitor with Minimal Paradoxical Activation and Activity against BRAF or RAS Mutant Tumor Cells</span></div><div class="casAuthors">Henry, James R.; Kaufman, Michael D.; Peng, Sheng-Bin; Ahn, Yu Mi; Caldwell, Timothy M.; Vogeti, Lakshminarayana; Telikepalli, Hanumaiah; Lu, Wei-Ping; Hood, Molly M.; Rutkoski, Thomas J.; Smith, Bryan D.; Vogeti, Subha; Miller, David; Wise, Scott C.; Chun, Lawrence; Zhang, Xiaoyi; Zhang, Youyan; Kays, Lisa; Hipskind, Philip A.; Wrobleski, Aaron D.; Lobb, Karen L.; Clay, Julia M.; Cohen, Jeffrey D.; Walgren, Jennie L.; McCann, Denis; Patel, Phenil; Clawson, David K.; Guo, Sherry; Manglicmot, Danalyn; Groshong, Chris; Logan, Cheyenne; Starling, James J.; Flynn, Daniel L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4165-4179</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The RAS-RAF-MEK-MAPK cascade is an essential signaling pathway, with activation typically mediated through cell surface receptors.  The kinase inhibitors vemurafenib and dabrafenib, which target oncogenic BRAF V600E, have shown significant clin. efficacy in melanoma patients harboring this mutation.  Because of paradoxical pathway activation, both agents were demonstrated to promote growth and metastasis of tumor cells with RAS mutations in preclin. models and are contraindicated for treatment of cancer patients with BRAF WT background, including patients with KRAS or NRAS mutations.  To eliminate the issues assocd. with paradoxical MAPK pathway activation and to provide therapeutic benefit to patients with RAS mutant cancers, we sought to identify a compd. not only active against BRAF V600E but also wild type BRAF and CRAF.  On the basis of its superior in vitro and in vivo profile, compd. 13 was selected for further development and is currently being evaluated in phase I clin. studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXIUwbnhct2rVg90H21EOLACvtfcHk0lhnpI7zM5UsXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXotlCisL0%253D&md5=9e5bc7ee7f45d238e2fa40e1d5cfc739</span></div><a href="/servlet/linkout?suffix=cit14a&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00067&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00067%26sid%3Dliteratum%253Aachs%26aulast%3DHenry%26aufirst%3DJ.%2BR.%26aulast%3DKaufman%26aufirst%3DM.%2BD.%26aulast%3DPeng%26aufirst%3DS.-B.%26aulast%3DAhn%26aufirst%3DY.%2BM.%26aulast%3DCaldwell%26aufirst%3DT.%2BM.%26aulast%3DVogeti%26aufirst%3DL.%26aulast%3DTelikepalli%26aufirst%3DH.%26aulast%3DLu%26aufirst%3DW.-P.%26aulast%3DHood%26aufirst%3DM.%2BM.%26aulast%3DRutkoski%26aufirst%3DT.%2BJ.%26aulast%3DSmith%26aufirst%3DB.%2BD.%26aulast%3DVogeti%26aufirst%3DS.%26aulast%3DMiller%26aufirst%3DD.%26aulast%3DWise%26aufirst%3DS.%2BC.%26aulast%3DChun%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DKays%26aufirst%3DL.%26aulast%3DHipskind%26aufirst%3DP.%2BA.%26aulast%3DWrobleski%26aufirst%3DA.%2BD.%26aulast%3DLobb%26aufirst%3DK.%2BL.%26aulast%3DClay%26aufirst%3DJ.%2BM.%26aulast%3DCohen%26aufirst%3DJ.%2BD.%26aulast%3DWalgren%26aufirst%3DJ.%2BL.%26aulast%3DMcCann%26aufirst%3DD.%26aulast%3DPatel%26aufirst%3DP.%26aulast%3DClawson%26aufirst%3DD.%2BK.%26aulast%3DGuo%26aufirst%3DS.%26aulast%3DManglicmot%26aufirst%3DD.%26aulast%3DGroshong%26aufirst%3DC.%26aulast%3DLogan%26aufirst%3DC.%26aulast%3DStarling%26aufirst%3DJ.%2BJ.%26aulast%3DFlynn%26aufirst%3DD.%2BL.%26atitle%3DDiscovery%2520of%25201-%25283%252C3-dimethylbutyl%2529-3-%25282-fluoro-4-methyl-5-%25287-methyl-2-%2528methylamino%2529pyrido%255B2%252C3-d%255Dpyrimidin-6-yl%2529phenyl%2529urea%2520%2528LY3009120%2529%2520as%2520a%2520pan-RAF%2520inhibitor%2520with%2520minimal%2520paradoxical%2520activation%2520and%2520activity%2520against%2520BRAF%2520or%2520RAS%2520mutant%2520tumor%2520cells%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D4165%26epage%3D4179%26doi%3D10.1021%2Facs.jmedchem.5b00067" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit14b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Horn, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huber, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, T. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manro, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iversen, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhagwat, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beckmann, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tiu, R. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchanan, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, S.-B.</span></span> <span> </span><span class="NLM_article-title">RAF inhibitor LY3009120 sensitizes RAS or BRAF mutant cancer to CDK4/6 inhibition by abemaciclib via superior inhibition of phospho-RB and suppression of cyclin D1</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">821</span>– <span class="NLM_lpage">832</span>, <span class="refDoi"> DOI: 10.1038/onc.2017.384</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=10.1038%2Fonc.2017.384" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=29059158" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=1%3ACAS%3A280%3ADC%252BC1M7jsVSmsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2018&pages=821-832&author=S.-H.+Chenauthor=X.+Gongauthor=Y.+Zhangauthor=R.+D.+Van+Hornauthor=T.+Yinauthor=L.+Huberauthor=T.+F.+Burkeauthor=J.+Manroauthor=P.+W.+Iversenauthor=W.+Wuauthor=S.+V.+Bhagwatauthor=R.+P.+Beckmannauthor=R.+V.+Tiuauthor=S.+G.+Buchananauthor=S.-B.+Peng&title=RAF+inhibitor+LY3009120+sensitizes+RAS+or+BRAF+mutant+cancer+to+CDK4%2F6+inhibition+by+abemaciclib+via+superior+inhibition+of+phospho-RB+and+suppression+of+cyclin+D1&doi=10.1038%2Fonc.2017.384"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14bR"><div class="casContent"><span class="casTitleNuber">14b</span><div class="casTitle"><span class="NLM_cas:atitle">RAF inhibitor LY3009120 sensitizes RAS or BRAF mutant cancer to CDK4/6 inhibition by abemaciclib via superior inhibition of phospho-RB and suppression of cyclin D1</span></div><div class="casAuthors">Chen S-H; Gong X; Zhang Y; Van Horn R D; Yin T; Huber L; Burke T F; Wu W; Bhagwat S V; Beckmann R P; Buchanan S G; Peng S-B; Manro J; Iversen P W; Tiu R V</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">821-832</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">KRAS, NRAS and BRAF mutations are among the most important oncogenic drivers in many major cancer types, such as melanoma, lung, colorectal and pancreatic cancer.  There is currently no effective therapy for the treatment of RAS mutant cancers.  LY3009120, a pan-RAF and RAF dimer inhibitor advanced to clinical study has been shown to inhibit both RAS and BRAF mutant cell proliferation in vitro and xenograft tumor growth in vivo.  Abemaciclib, a CDK4/6-selective inhibitor, is currently in phase III studies for ER-positive breast cancer and KRAS mutant lung cancer.  In this study, we found that combinatory treatment with LY3009120 and abemaciclib synergistically inhibited proliferation of tumor cells in vitro and led to tumor growth regression in xenograft models with a KRAS, NRAS or BRAF mutation at the doses of two drugs that were well tolerated in combination.  Further in vitro screen in 328 tumor cell lines revealed that tumor cells with KRAS, NRAS or BRAF mutation, or cyclin D activation are more sensitive, whereas tumor cells with PTEN, PIK3CA, PIK3R1 or retinoblastoma (Rb) mutation are more resistant to this combination treatment.  Molecular analysis revealed that abemaciclib alone inhibited Rb phosphorylation partially and caused an increase of cyclin D1.  The combinatory treatment cooperatively demonstrated more complete inhibition of Rb phosphorylation, and LY3009120 suppressed the cyclin D1 upregulation mediated by abemaciclib.  These results were further verified by CDK4/6 siRNA knockdown.  Importantly, the more complete phospho-Rb inhibition and cyclin D1 suppression by LY3009120 and abemaciclib combination led to more significant cell cycle G0/G1 arrest of tumor cells.  These preclinical findings suggest that combined inhibition of RAF and d-cyclin-dependent kinases might provide an effective approach to treat patients with tumors harboring mutations in RAS or RAF genes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSejUtYs4tFGEh5eUSa2oe_fW6udTcc2eYsG2kLEN4fYbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1M7jsVSmsQ%253D%253D&md5=b7d3e64c63e0c6e9e4f6fcda729584ee</span></div><a href="/servlet/linkout?suffix=cit14b&amp;dbid=16384&amp;doi=10.1038%2Fonc.2017.384&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fonc.2017.384%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DS.-H.%26aulast%3DGong%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DVan%2BHorn%26aufirst%3DR.%2BD.%26aulast%3DYin%26aufirst%3DT.%26aulast%3DHuber%26aufirst%3DL.%26aulast%3DBurke%26aufirst%3DT.%2BF.%26aulast%3DManro%26aufirst%3DJ.%26aulast%3DIversen%26aufirst%3DP.%2BW.%26aulast%3DWu%26aufirst%3DW.%26aulast%3DBhagwat%26aufirst%3DS.%2BV.%26aulast%3DBeckmann%26aufirst%3DR.%2BP.%26aulast%3DTiu%26aufirst%3DR.%2BV.%26aulast%3DBuchanan%26aufirst%3DS.%2BG.%26aulast%3DPeng%26aufirst%3DS.-B.%26atitle%3DRAF%2520inhibitor%2520LY3009120%2520sensitizes%2520RAS%2520or%2520BRAF%2520mutant%2520cancer%2520to%2520CDK4%252F6%2520inhibition%2520by%2520abemaciclib%2520via%2520superior%2520inhibition%2520of%2520phospho-RB%2520and%2520suppression%2520of%2520cyclin%2520D1%26jtitle%3DOncogene%26date%3D2018%26volume%3D37%26spage%3D821%26epage%3D832%26doi%3D10.1038%2Fonc.2017.384" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rebocho, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marais, R.</span></span> <span> </span><span class="NLM_article-title">New insight puts CRAF in sight as a therapeutic target</span>. <i>Cancer Discov.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">98</span>– <span class="NLM_lpage">99</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-11-0118</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=10.1158%2F2159-8290.CD-11-0118" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=22318779" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=1%3ACAS%3A528%3ADC%252BC3MXovFalt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2011&pages=98-99&author=A.+P.+Rebochoauthor=R.+Marais&title=New+insight+puts+CRAF+in+sight+as+a+therapeutic+target&doi=10.1158%2F2159-8290.CD-11-0118"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">New Insight Puts CRAF in Sight as a Therapeutic Target</span></div><div class="casAuthors">Rebocho, Ana Paula; Marais, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">98-99</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research, Inc.</span>)
        </div><div class="casAbstract">A review.  By selectively depleting components of the RAF-MEK-ERK pathway in transgenic mice, it is now shown in 2 studies that CRAF is crit. for signaling to MEK downstream of oncogenic Kras and that BRAF is not required.  Cancer Discovery; 1(2); 98-9.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGown_LK1MCqvbVg90H21EOLACvtfcHk0ljE44309YUguA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXovFalt7g%253D&md5=fc2cd219ee60d00cb7d32a3a83a05e86</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-11-0118&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-11-0118%26sid%3Dliteratum%253Aachs%26aulast%3DRebocho%26aufirst%3DA.%2BP.%26aulast%3DMarais%26aufirst%3DR.%26atitle%3DNew%2520insight%2520puts%2520CRAF%2520in%2520sight%2520as%2520a%2520therapeutic%2520target%26jtitle%3DCancer%2520Discov.%26date%3D2011%26volume%3D1%26spage%3D98%26epage%3D99%26doi%3D10.1158%2F2159-8290.CD-11-0118" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Nishiguchi, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rico, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanner, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aversa, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taft, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Subramanian, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Setti, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burger, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamez, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barsanti, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Appleton, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mamo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tandeske, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dix, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tellew, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathews Griner, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooke, V. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Abbema, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merritt, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gampa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haling, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaziri, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hekmat-Nejad, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jansen, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polyakov, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sethuraman, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amiri, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lees, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stuart, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dillon, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramurthy, S.</span></span> <span> </span><span class="NLM_article-title">Design and discovery of <i>N</i>-(2-methyl-5′-morpholino-6′-((tetrahydro-2<i>H</i>-pyran-4-yl)oxy)-[3,3′-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide (RAF709): A potent, selective, and efficacious RAF inhibitor targeting RAS mutant cancers</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">4869</span>– <span class="NLM_lpage">4881</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01862</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01862" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref16/cit16a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=1%3ACAS%3A528%3ADC%252BC2sXos1Sgt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=4869-4881&author=G.+A.+Nishiguchiauthor=A.+Ricoauthor=H.+Tannerauthor=R.+J.+Aversaauthor=B.+R.+Taftauthor=S.+Subramanianauthor=L.+Settiauthor=M.+T.+Burgerauthor=L.+Wanauthor=V.+Tamezauthor=A.+Smithauthor=Y.+Louauthor=P.+A.+Barsantiauthor=B.+A.+Appletonauthor=M.+Mamoauthor=L.+Tandeskeauthor=I.+Dixauthor=J.+E.+Tellewauthor=S.+Huangauthor=L.+A.+Mathews+Grinerauthor=V.+G.+Cookeauthor=A.+Van+Abbemaauthor=H.+Merrittauthor=S.+Maauthor=K.+Gampaauthor=F.+Fengauthor=J.+Yuanauthor=Y.+Wangauthor=J.+R.+Halingauthor=S.+Vaziriauthor=M.+Hekmat-Nejadauthor=J.+M.+Jansenauthor=V.+Polyakovauthor=R.+Zangauthor=V.+Sethuramanauthor=P.+Amiriauthor=M.+Singhauthor=E.+Leesauthor=W.+Shaoauthor=D.+D.+Stuartauthor=M.+P.+Dillonauthor=S.+Ramurthy&title=Design+and+discovery+of+N-%282-methyl-5%E2%80%B2-morpholino-6%E2%80%B2-%28%28tetrahydro-2H-pyran-4-yl%29oxy%29-%5B3%2C3%E2%80%B2-bipyridin%5D-5-yl%29-3-%28trifluoromethyl%29benzamide+%28RAF709%29%3A+A+potent%2C+selective%2C+and+efficacious+RAF+inhibitor+targeting+RAS+mutant+cancers&doi=10.1021%2Facs.jmedchem.6b01862"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16aR"><div class="casContent"><span class="casTitleNuber">16a</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Discovery of N-(2-Methyl-5'-morpholino-6'-((tetrahydro-2H-pyran-4-yl)oxy)-[3,3'-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide (RAF709): A Potent, Selective, and Efficacious RAF Inhibitor Targeting RAS Mutant Cancers</span></div><div class="casAuthors">Nishiguchi, Gisele A.; Rico, Alice; Tanner, Huw; Aversa, Robert J.; Taft, Benjamin R.; Subramanian, Sharadha; Setti, Lina; Burger, Matthew T.; Wan, Lifeng; Tamez, Victoriano; Smith, Aaron; Lou, Yan; Barsanti, Paul A.; Appleton, Brent A.; Mamo, Mulugeta; Tandeske, Laura; Dix, Ina; Tellew, John E.; Huang, Shenlin; Mathews Griner, Lesley A.; Cooke, Vesselina G.; Van Abbema, Anne; Merritt, Hanne; Ma, Sylvia; Gampa, Kalyani; Feng, Fei; Yuan, Jing; Wang, Yingyun; Haling, Jacob R.; Vaziri, Sepideh; Hekmat-Nejad, Mohammad; Jansen, Johanna M.; Polyakov, Valery; Zang, Richard; Sethuraman, Vijay; Amiri, Payman; Singh, Mallika; Lees, Emma; Shao, Wenlin; Stuart, Darrin D.; Dillon, Michael P.; Ramurthy, Savithri</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">4869-4881</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">RAS oncogenes have been implicated in >30% of human cancers, all representing high unmet medical need.  The exquisite dependency on CRAF kinase in KRAS mutant tumors has been established in genetically engineered mouse models and human tumor cells.  To date, many small mol. approaches are under investigation to target CRAF, yet kinase-selective and cellular potent inhibitors remain challenging to identify.  Herein, we describe 14 (RAF709) [Aversa, Biaryl amide compds. as kinase inhibitors and their prepn. WO 2014151616, 2014], a selective B/C RAF inhibitor, which was developed through a hypothesis-driven approach focusing on drug-like properties.  A key challenge encountered in the medicinal chem. campaign was maintaining a balance between good soly. and potent cellular activity (suppression of pMEK and proliferation) in KRAS mutant tumor cell lines.  We investigated the small mol. crystal structure of lead mol. 7 and hypothesized that disruption of the crystal packing would improve soly., which led to a change from N-methylpyridone to a tetrahydropyranyl oxy-pyridine deriv. 14 proved to be sol., kinase selective, and efficacious in a KRAS mutant xenograft model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmcZ2Rl42uP7Vg90H21EOLACvtfcHk0ljE44309YUguA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXos1Sgt7s%253D&md5=ed35a93d83b721a8e639a992bee43f04</span></div><a href="/servlet/linkout?suffix=cit16a&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01862&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01862%26sid%3Dliteratum%253Aachs%26aulast%3DNishiguchi%26aufirst%3DG.%2BA.%26aulast%3DRico%26aufirst%3DA.%26aulast%3DTanner%26aufirst%3DH.%26aulast%3DAversa%26aufirst%3DR.%2BJ.%26aulast%3DTaft%26aufirst%3DB.%2BR.%26aulast%3DSubramanian%26aufirst%3DS.%26aulast%3DSetti%26aufirst%3DL.%26aulast%3DBurger%26aufirst%3DM.%2BT.%26aulast%3DWan%26aufirst%3DL.%26aulast%3DTamez%26aufirst%3DV.%26aulast%3DSmith%26aufirst%3DA.%26aulast%3DLou%26aufirst%3DY.%26aulast%3DBarsanti%26aufirst%3DP.%2BA.%26aulast%3DAppleton%26aufirst%3DB.%2BA.%26aulast%3DMamo%26aufirst%3DM.%26aulast%3DTandeske%26aufirst%3DL.%26aulast%3DDix%26aufirst%3DI.%26aulast%3DTellew%26aufirst%3DJ.%2BE.%26aulast%3DHuang%26aufirst%3DS.%26aulast%3DMathews%2BGriner%26aufirst%3DL.%2BA.%26aulast%3DCooke%26aufirst%3DV.%2BG.%26aulast%3DVan%2BAbbema%26aufirst%3DA.%26aulast%3DMerritt%26aufirst%3DH.%26aulast%3DMa%26aufirst%3DS.%26aulast%3DGampa%26aufirst%3DK.%26aulast%3DFeng%26aufirst%3DF.%26aulast%3DYuan%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DHaling%26aufirst%3DJ.%2BR.%26aulast%3DVaziri%26aufirst%3DS.%26aulast%3DHekmat-Nejad%26aufirst%3DM.%26aulast%3DJansen%26aufirst%3DJ.%2BM.%26aulast%3DPolyakov%26aufirst%3DV.%26aulast%3DZang%26aufirst%3DR.%26aulast%3DSethuraman%26aufirst%3DV.%26aulast%3DAmiri%26aufirst%3DP.%26aulast%3DSingh%26aufirst%3DM.%26aulast%3DLees%26aufirst%3DE.%26aulast%3DShao%26aufirst%3DW.%26aulast%3DStuart%26aufirst%3DD.%2BD.%26aulast%3DDillon%26aufirst%3DM.%2BP.%26aulast%3DRamurthy%26aufirst%3DS.%26atitle%3DDesign%2520and%2520discovery%2520of%2520N-%25282-methyl-5%25E2%2580%25B2-morpholino-6%25E2%2580%25B2-%2528%2528tetrahydro-2H-pyran-4-yl%2529oxy%2529-%255B3%252C3%25E2%2580%25B2-bipyridin%255D-5-yl%2529-3-%2528trifluoromethyl%2529benzamide%2520%2528RAF709%2529%253A%2520A%2520potent%252C%2520selective%252C%2520and%2520efficacious%2520RAF%2520inhibitor%2520targeting%2520RAS%2520mutant%2520cancers%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D4869%26epage%3D4881%26doi%3D10.1021%2Facs.jmedchem.6b01862" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit16b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Ramurthy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taft, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aversa, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barsanti, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burger, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishiguchi, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rico, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Setti, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Subramanian, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamez, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanner, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Appleton, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mamo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tandeske, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tellew, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yue, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaudhary, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iyer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hassan, A. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathews
Griner, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">La Bonte, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooke, V. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Abbema, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merritt, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gampa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mishina, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haling, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaziri, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hekmat-Nejad, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polyakov, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sethuraman, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amiri, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sellers, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lees, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dillon, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stuart, D. D.</span></span> <span> </span><span class="NLM_article-title">Design and discovery of <i>N</i>-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamide, a selective, efficacious, and well-tolerated RAF inhibitor targeting RAS mutant cancers: The path to the clinic</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">2013</span>– <span class="NLM_lpage">2027</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00161</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00161" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref16/cit16b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=1%3ACAS%3A528%3ADC%252BC1MXovVKnu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=2013-2027&author=S.+Ramurthyauthor=B.+R.+Taftauthor=R.+J.+Aversaauthor=P.+A.+Barsantiauthor=M.+T.+Burgerauthor=Y.+Louauthor=G.+A.+Nishiguchiauthor=A.+Ricoauthor=L.+Settiauthor=A.+Smithauthor=S.+Subramanianauthor=V.+Tamezauthor=H.+Tannerauthor=W.+Wanauthor=C.+Huauthor=B.+A.+Appletonauthor=M.+Mamoauthor=L.+Tandeskeauthor=J.+E.+Tellewauthor=S.+Huangauthor=Q.+Yueauthor=A.+Chaudharyauthor=H.+Tianauthor=R.+Iyerauthor=A.+Q.+Hassanauthor=L.+A.+Mathews%0AGrinerauthor=L.+R.+La+Bonteauthor=V.+G.+Cookeauthor=A.+Van+Abbemaauthor=H.+Merrittauthor=K.+Gampaauthor=F.+Fengauthor=J.+Yuanauthor=Y.+Mishinaauthor=Y.+Wangauthor=J.+R.+Halingauthor=S.+Vaziriauthor=M.+Hekmat-Nejadauthor=V.+Polyakovauthor=R.+Zangauthor=V.+Sethuramanauthor=P.+Amiriauthor=M.+Singhauthor=W.+R.+Sellersauthor=E.+Leesauthor=W.+Shaoauthor=M.+P.+Dillonauthor=D.+D.+Stuart&title=Design+and+discovery+of+N-%283-%282-%282-hydroxyethoxy%29-6-morpholinopyridin-4-yl%29-4-methylphenyl%29-2-%28trifluoromethyl%29isonicotinamide%2C+a+selective%2C+efficacious%2C+and+well-tolerated+RAF+inhibitor+targeting+RAS+mutant+cancers%3A+The+path+to+the+clinic&doi=10.1021%2Facs.jmedchem.9b00161"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16bR"><div class="casContent"><span class="casTitleNuber">16b</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Discovery of N-(3-(2-(2-Hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamide, a Selective, Efficacious, and Well-Tolerated RAF Inhibitor Targeting RAS Mutant Cancers: The Path to the Clinic</span></div><div class="casAuthors">Ramurthy, Savithri; Taft, Benjamin R.; Aversa, Robert J.; Barsanti, Paul A.; Burger, Matthew T.; Lou, Yan; Nishiguchi, Gisele A.; Rico, Alice; Setti, Lina; Smith, Aaron; Subramanian, Sharadha; Tamez, Victoriano; Tanner, Huw; Wan, Lifeng; Hu, Cheng; Appleton, Brent A.; Mamo, Mulugeta; Tandeske, Laura; Tellew, John E.; Huang, Shenlin; Yue, Qin; Chaudhary, Apurva; Tian, Hung; Iyer, Raman; Hassan, A. Quamrul; Mathews Griner, Lesley A.; La Bonte, Laura R.; Cooke, Vesselina G.; Van Abbema, Anne; Merritt, Hanne; Gampa, Kalyani; Feng, Fei; Yuan, Jing; Mishina, Yuji; Wang, Yingyun; Haling, Jacob R.; Vaziri, Sepideh; Hekmat-Nejad, Mohammad; Polyakov, Valery; Zang, Richard; Sethuraman, Vijay; Amiri, Payman; Singh, Mallika; Sellers, William R.; Lees, Emma; Shao, Wenlin; Dillon, Michael P.; Stuart, Darrin D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2013-2027</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Direct pharmacol. inhibition of RAS has remained elusive, and efforts to target CRAF have been challenging due to the complex nature of RAF signaling, downstream of activated RAS, and the poor overall kinase selectivity of putative RAF inhibitors.  Herein, we describe 15, a selective B/C RAF inhibitor, which was developed by focusing on drug-like properties and selectivity.  Our previous tool compd., 3, was potent, selective, efficacious, and well tolerated in preclin. models, but the high human intrinsic clearance precluded further development and prompted further investigation of close analogs.  A structure-based approach led to a pyridine series with an alc. side chain that could interact with the DFG loop and significantly improved cell potency.  Further mitigation of human intrinsic clearance and time-dependent inhibition led to the discovery of 15.  Due to its excellent properties, it was progressed through toxicol. studies and is being tested in phase 1 clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRb3eMaZSvx7Vg90H21EOLACvtfcHk0ljNilHcos3B0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXovVKnu74%253D&md5=8afaef4860ed341c0c80e1fd3e2138b5</span></div><a href="/servlet/linkout?suffix=cit16b&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00161&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00161%26sid%3Dliteratum%253Aachs%26aulast%3DRamurthy%26aufirst%3DS.%26aulast%3DTaft%26aufirst%3DB.%2BR.%26aulast%3DAversa%26aufirst%3DR.%2BJ.%26aulast%3DBarsanti%26aufirst%3DP.%2BA.%26aulast%3DBurger%26aufirst%3DM.%2BT.%26aulast%3DLou%26aufirst%3DY.%26aulast%3DNishiguchi%26aufirst%3DG.%2BA.%26aulast%3DRico%26aufirst%3DA.%26aulast%3DSetti%26aufirst%3DL.%26aulast%3DSmith%26aufirst%3DA.%26aulast%3DSubramanian%26aufirst%3DS.%26aulast%3DTamez%26aufirst%3DV.%26aulast%3DTanner%26aufirst%3DH.%26aulast%3DWan%26aufirst%3DW.%26aulast%3DHu%26aufirst%3DC.%26aulast%3DAppleton%26aufirst%3DB.%2BA.%26aulast%3DMamo%26aufirst%3DM.%26aulast%3DTandeske%26aufirst%3DL.%26aulast%3DTellew%26aufirst%3DJ.%2BE.%26aulast%3DHuang%26aufirst%3DS.%26aulast%3DYue%26aufirst%3DQ.%26aulast%3DChaudhary%26aufirst%3DA.%26aulast%3DTian%26aufirst%3DH.%26aulast%3DIyer%26aufirst%3DR.%26aulast%3DHassan%26aufirst%3DA.%2BQ.%26aulast%3DMathews%2BGriner%26aufirst%3DL.%2BA.%26aulast%3DLa%2BBonte%26aufirst%3DL.%2BR.%26aulast%3DCooke%26aufirst%3DV.%2BG.%26aulast%3DVan%2BAbbema%26aufirst%3DA.%26aulast%3DMerritt%26aufirst%3DH.%26aulast%3DGampa%26aufirst%3DK.%26aulast%3DFeng%26aufirst%3DF.%26aulast%3DYuan%26aufirst%3DJ.%26aulast%3DMishina%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DHaling%26aufirst%3DJ.%2BR.%26aulast%3DVaziri%26aufirst%3DS.%26aulast%3DHekmat-Nejad%26aufirst%3DM.%26aulast%3DPolyakov%26aufirst%3DV.%26aulast%3DZang%26aufirst%3DR.%26aulast%3DSethuraman%26aufirst%3DV.%26aulast%3DAmiri%26aufirst%3DP.%26aulast%3DSingh%26aufirst%3DM.%26aulast%3DSellers%26aufirst%3DW.%2BR.%26aulast%3DLees%26aufirst%3DE.%26aulast%3DShao%26aufirst%3DW.%26aulast%3DDillon%26aufirst%3DM.%2BP.%26aulast%3DStuart%26aufirst%3DD.%2BD.%26atitle%3DDesign%2520and%2520discovery%2520of%2520N-%25283-%25282-%25282-hydroxyethoxy%2529-6-morpholinopyridin-4-yl%2529-4-methylphenyl%2529-2-%2528trifluoromethyl%2529isonicotinamide%252C%2520a%2520selective%252C%2520efficacious%252C%2520and%2520well-tolerated%2520RAF%2520inhibitor%2520targeting%2520RAS%2520mutant%2520cancers%253A%2520The%2520path%2520to%2520the%2520clinic%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D2013%26epage%3D2027%26doi%3D10.1021%2Facs.jmedchem.9b00161" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bae, I. H.</span>; <span class="NLM_string-name">Son, J. B.</span>; <span class="NLM_string-name">Han, S. M.</span>; <span class="NLM_string-name">Kwak, E. J.</span>; <span class="NLM_string-name">Kim, H. S.</span>; <span class="NLM_string-name">Song, J. Y.</span>; <span class="NLM_string-name">Byun, E. Y.</span>; <span class="NLM_string-name">Jun, S. A.</span>; <span class="NLM_string-name">Ahn, Y. G.</span>; <span class="NLM_string-name">Suh, K. H.</span></span> <span> </span><span class="NLM_article-title">Thieno[3,2-<i>d</i>]pyrimidine derivatives having inhibitory activity for protein kinases</span>.  <i>PCT Int. Appl.</i> <span class="NLM_patent">WO2013100632</span>, <span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=I.+H.+Bae&author=J.+B.+Son&author=S.+M.+Han&author=E.+J.+Kwak&author=H.+S.+Kim&author=J.+Y.+Song&author=E.+Y.+Byun&author=S.+A.+Jun&author=Y.+G.+Ahn&author=K.+H.+Suh&title=Thieno%5B3%2C2-d%5Dpyrimidine+derivatives+having+inhibitory+activity+for+protein+kinases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBae%26aufirst%3DI.%2BH.%26atitle%3DThieno%255B3%252C2-d%255Dpyrimidine%2520derivatives%2520having%2520inhibitory%2520activity%2520for%2520protein%2520kinases%26jtitle%3DPCT%2520Int.%2520Appl.%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span> </span><span class="NLM_article-title">Clinical development
of LY3009120 (<b>1</b>) was terminated in 2018</span>. <a href="https://clinicaltrials.gov/ct2/show/NCT02014116" class="extLink">https://clinicaltrials.gov/ct2/show/NCT02014116</a> (accessed 6–18-<span class="NLM_year">2020</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Clinical+development%0Aof+LY3009120+%281%29+was+terminated+in+2018.+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT02014116+%28accessed+6%E2%80%9318-2020%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26atitle%3DClinical%2520development%250Aof%2520LY3009120%2520%25281%2529%2520was%2520terminated%2520in%25202018%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Hatzivassiliou, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haling, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Price, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heald, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hewitt, J. F. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zak, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peck, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orr, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merchant, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoeflich, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luoh, S.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ludlam, M. J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiesmann, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ultsch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedman, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malek, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belvin, M.</span></span> <span> </span><span class="NLM_article-title">Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>501</i></span>,  <span class="NLM_fpage">232</span>– <span class="NLM_lpage">236</span>, <span class="refDoi"> DOI: 10.1038/nature12441</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=10.1038%2Fnature12441" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=23934108" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1Cgtr3N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=501&publication_year=2013&pages=232-236&author=G.+Hatzivassiliouauthor=J.+R.+Halingauthor=H.+Chenauthor=K.+Songauthor=S.+Priceauthor=R.+Healdauthor=J.+F.+M.+Hewittauthor=M.+Zakauthor=A.+Peckauthor=C.+Orrauthor=M.+Merchantauthor=K.+P.+Hoeflichauthor=J.+Chanauthor=S.-M.+Luohauthor=D.+J.+Andersonauthor=M.+J.+C.+Ludlamauthor=C.+Wiesmannauthor=M.+Ultschauthor=L.+S.+Friedmanauthor=S.+Malekauthor=M.+Belvin&title=Mechanism+of+MEK+inhibition+determines+efficacy+in+mutant+KRAS-+versus+BRAF-driven+cancers&doi=10.1038%2Fnature12441"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19aR"><div class="casContent"><span class="casTitleNuber">19a</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers</span></div><div class="casAuthors">Hatzivassiliou, Georgia; Haling, Jacob R.; Chen, Huifen; Song, Kyung; Price, Steve; Heald, Robert; Hewitt, Joanne F. M.; Zak, Mark; Peck, Ariana; Orr, Christine; Merchant, Mark; Hoeflich, Klaus P.; Chan, Jocelyn; Luoh, Shiuh-Ming; Anderson, Daniel J.; Ludlam, Mary J. C.; Wiesmann, Christian; Ultsch, Mark; Friedman, Lori S.; Malek, Shiva; Belvin, Marcia</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">501</span>
        (<span class="NLM_cas:issue">7466</span>),
    <span class="NLM_cas:pages">232-236</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">KRAS and BRAF activating mutations drive tumorigenesis through constitutive activation of the MAPK pathway.  As these tumors represent an area of high unmet medical need, multiple allosteric MEK inhibitors, which inhibit MAPK signaling in both genotypes, are being tested in clin. trials.  Impressive single-agent activity in BRAF-mutant melanoma has been obsd.; however, efficacy has been far less robust in KRAS-mutant disease.  Owing to distinct mechanisms regulating MEK activation in KRAS- vs. BRAF-driven tumors, different mechanisms of inhibition are required for optimal antitumor activity in each genotype.  Structural and functional anal. illustrates that MEK inhibitors with superior efficacy in KRAS-driven tumors (GDC-0623 and G-573, the former currently in phase I clin. trials) form a strong hydrogen-bond interaction with S212 in MEK that is crit. for blocking MEK feedback phosphorylation by wild-type RAF.  Conversely, potent inhibition of active, phosphorylated MEK is required for strong inhibition of the MAPK pathway in BRAF-mutant tumors, resulting in superior efficacy in this genotype with GDC-0973 (also known as cobimetinib), a MEK inhibitor currently in phase III clin. trials.  The authors' study highlights that differences in the activation state of MEK in KRAS-mutant tumors vs. BRAF-mutant tumors can be exploited through the design of inhibitors that uniquely target these distinct activation states of MEK.  These inhibitors are currently being evaluated in clin. trials to det. whether improvements in therapeutic index within KRAS vs. BRAF preclin. models translate to improved clin. responses in patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQUdtElnPqJLVg90H21EOLACvtfcHk0ljNilHcos3B0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1Cgtr3N&md5=12ceb67132291cbaff64c20c67b61b32</span></div><a href="/servlet/linkout?suffix=cit19a&amp;dbid=16384&amp;doi=10.1038%2Fnature12441&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature12441%26sid%3Dliteratum%253Aachs%26aulast%3DHatzivassiliou%26aufirst%3DG.%26aulast%3DHaling%26aufirst%3DJ.%2BR.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DSong%26aufirst%3DK.%26aulast%3DPrice%26aufirst%3DS.%26aulast%3DHeald%26aufirst%3DR.%26aulast%3DHewitt%26aufirst%3DJ.%2BF.%2BM.%26aulast%3DZak%26aufirst%3DM.%26aulast%3DPeck%26aufirst%3DA.%26aulast%3DOrr%26aufirst%3DC.%26aulast%3DMerchant%26aufirst%3DM.%26aulast%3DHoeflich%26aufirst%3DK.%2BP.%26aulast%3DChan%26aufirst%3DJ.%26aulast%3DLuoh%26aufirst%3DS.-M.%26aulast%3DAnderson%26aufirst%3DD.%2BJ.%26aulast%3DLudlam%26aufirst%3DM.%2BJ.%2BC.%26aulast%3DWiesmann%26aufirst%3DC.%26aulast%3DUltsch%26aufirst%3DM.%26aulast%3DFriedman%26aufirst%3DL.%2BS.%26aulast%3DMalek%26aufirst%3DS.%26aulast%3DBelvin%26aufirst%3DM.%26atitle%3DMechanism%2520of%2520MEK%2520inhibition%2520determines%2520efficacy%2520in%2520mutant%2520KRAS-%2520versus%2520BRAF-driven%2520cancers%26jtitle%3DNature%26date%3D2013%26volume%3D501%26spage%3D232%26epage%3D236%26doi%3D10.1038%2Fnature12441" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit19b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Yen, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shanahan, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merchant, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orr, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunsaker, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Durk, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">La, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neve, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gustafson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venkatanarayan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foster, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rudolph, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klijn, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malek, S.</span></span> <span> </span><span class="NLM_article-title">Pharmacological induction of RAS-GTP confers RAF inhibitor sensitivity in KRAS mutant tumors</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">611</span>– <span class="NLM_lpage">625</span>, <span class="refDoi"> DOI: 10.1016/j.ccell.2018.09.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=10.1016%2Fj.ccell.2018.09.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=30300582" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvVOgsr%252FF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2018&pages=611-625&author=I.+Yenauthor=F.+Shanahanauthor=M.+Merchantauthor=C.+Orrauthor=T.+Hunsakerauthor=M.+Durkauthor=H.+Laauthor=X.+Zhangauthor=S.+E.+Martinauthor=E.+Linauthor=J.+Chanauthor=Y.+Yuauthor=D.+Aminauthor=R.+M.+Neveauthor=A.+Gustafsonauthor=A.+Venkatanarayanauthor=S.+A.+Fosterauthor=J.+Rudolphauthor=C.+Klijnauthor=S.+Malek&title=Pharmacological+induction+of+RAS-GTP+confers+RAF+inhibitor+sensitivity+in+KRAS+mutant+tumors&doi=10.1016%2Fj.ccell.2018.09.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19bR"><div class="casContent"><span class="casTitleNuber">19b</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological Induction of RAS-GTP Confers RAF Inhibitor Sensitivity in KRAS Mutant Tumors</span></div><div class="casAuthors">Yen, Ivana; Shanahan, Frances; Merchant, Mark; Orr, Christine; Hunsaker, Thomas; Durk, Matthew; La, Hank; Zhang, Xiaolin; Martin, Scott E.; Lin, Eva; Chan, John; Yu, Yihong; Amin, Dhara; Neve, Richard M.; Gustafson, Amy; Venkatanarayan, Avinashnarayan; Foster, Scott A.; Rudolph, Joachim; Klijn, Christiaan; Malek, Shiva</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">611-625.e7</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Targeting KRAS mutant tumors through inhibition of individual downstream pathways has had limited clin. success.  Here we report that RAF inhibitors exhibit little efficacy in KRAS mutant tumors.  In combination drug screens, MEK and PI3K inhibitors synergized with pan-RAF inhibitors through an RAS-GTP-dependent mechanism.  Broad cell line profiling with RAF/MEK inhibitor combinations revealed synergistic efficacy in KRAS mutant and wild-type tumors, with KRASG13D mutants exhibiting greater synergy vs. KRASG12 mutant tumors.  Mechanistic studies demonstrate that MEK inhibition induced RAS-GTP levels, RAF dimerization and RAF kinase activity resulting in MEK phosphorylation in synergistic tumor lines regardless of KRAS status.  Taken together, our studies uncover a strategy to rewire KRAS mutant tumors to confer sensitivity to RAF kinase inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFoaNP8uQOe7Vg90H21EOLACvtfcHk0lgEDD0yurW7MA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvVOgsr%252FF&md5=7f68e31356ca67eb93c5c0ef88d707e3</span></div><a href="/servlet/linkout?suffix=cit19b&amp;dbid=16384&amp;doi=10.1016%2Fj.ccell.2018.09.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccell.2018.09.002%26sid%3Dliteratum%253Aachs%26aulast%3DYen%26aufirst%3DI.%26aulast%3DShanahan%26aufirst%3DF.%26aulast%3DMerchant%26aufirst%3DM.%26aulast%3DOrr%26aufirst%3DC.%26aulast%3DHunsaker%26aufirst%3DT.%26aulast%3DDurk%26aufirst%3DM.%26aulast%3DLa%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DMartin%26aufirst%3DS.%2BE.%26aulast%3DLin%26aufirst%3DE.%26aulast%3DChan%26aufirst%3DJ.%26aulast%3DYu%26aufirst%3DY.%26aulast%3DAmin%26aufirst%3DD.%26aulast%3DNeve%26aufirst%3DR.%2BM.%26aulast%3DGustafson%26aufirst%3DA.%26aulast%3DVenkatanarayan%26aufirst%3DA.%26aulast%3DFoster%26aufirst%3DS.%2BA.%26aulast%3DRudolph%26aufirst%3DJ.%26aulast%3DKlijn%26aufirst%3DC.%26aulast%3DMalek%26aufirst%3DS.%26atitle%3DPharmacological%2520induction%2520of%2520RAS-GTP%2520confers%2520RAF%2520inhibitor%2520sensitivity%2520in%2520KRAS%2520mutant%2520tumors%26jtitle%3DCancer%2520Cell%26date%3D2018%26volume%3D34%26spage%3D611%26epage%3D625%26doi%3D10.1016%2Fj.ccell.2018.09.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wenglowsky, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreno, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laird, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gloor, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Risom, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rudolph, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sturgis, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voegtli, W. C.</span></span> <span> </span><span class="NLM_article-title">Pyrazolopyridine inhibitors of B-Raf<sup>V600E</sup>. Part 4: Rational design and kinase selectivity profile of cell potent type II inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">6237</span>– <span class="NLM_lpage">6241</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2012.08.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=10.1016%2Fj.bmcl.2012.08.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=22954737" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhtlajsb7L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=6237-6241&author=S.+Wenglowskyauthor=D.+Morenoauthor=E.+R.+Lairdauthor=S.+L.+Gloorauthor=L.+Renauthor=T.+Risomauthor=J.+Rudolphauthor=H.+L.+Sturgisauthor=W.+C.+Voegtli&title=Pyrazolopyridine+inhibitors+of+B-RafV600E.+Part+4%3A+Rational+design+and+kinase+selectivity+profile+of+cell+potent+type+II+inhibitors&doi=10.1016%2Fj.bmcl.2012.08.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Pyrazolopyridine inhibitors of B-RafV600E. Part 4: Rational design and kinase selectivity profile of cell potent type II inhibitors</span></div><div class="casAuthors">Wenglowsky, Steve; Moreno, David; Laird, Ellen R.; Gloor, Susan L.; Ren, Li; Risom, Tyler; Rudolph, Joachim; Sturgis, Hillary L.; Voegtli, Walter C.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">6237-6241</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Cell potent inhibitors of B-RafV600E that bind to the kinase in the DFG-out conformation are reported.  These compds. utilize the hinge-binding group and lipophilic linker from a previously disclosed series of B-RafV600E inhibitors that bind to the kinase in an atypical DFG-in, αC-helix-out conformation.  This new series demonstrates that DFG-out kinase inhibitors can be rationally designed from related inhibitors which utilize an unconventional binding mode.  Kinase selectivity profiles are compared.  The pattern of kinase selectivity was found to be detd. by the feature of the inhibitor which extends into the back pocket of the kinase and leads to the kinase conformation, rather than by the hinge-binding group or other minor modifications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfijQ1ttxu5LVg90H21EOLACvtfcHk0lgEDD0yurW7MA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhtlajsb7L&md5=d02430d27f3103572a52009eeec246ec</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2012.08.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2012.08.007%26sid%3Dliteratum%253Aachs%26aulast%3DWenglowsky%26aufirst%3DS.%26aulast%3DMoreno%26aufirst%3DD.%26aulast%3DLaird%26aufirst%3DE.%2BR.%26aulast%3DGloor%26aufirst%3DS.%2BL.%26aulast%3DRen%26aufirst%3DL.%26aulast%3DRisom%26aufirst%3DT.%26aulast%3DRudolph%26aufirst%3DJ.%26aulast%3DSturgis%26aufirst%3DH.%2BL.%26aulast%3DVoegtli%26aufirst%3DW.%2BC.%26atitle%3DPyrazolopyridine%2520inhibitors%2520of%2520B-RafV600E.%2520Part%25204%253A%2520Rational%2520design%2520and%2520kinase%2520selectivity%2520profile%2520of%2520cell%2520potent%2520type%2520II%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D6237%26epage%3D6241%26doi%3D10.1016%2Fj.bmcl.2012.08.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Furet, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caravatti, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guagnano, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schoepfer, J.</span></span> <span> </span><span class="NLM_article-title">Entry into a new class of protein kinase inhibitors by pseudo ring design</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">897</span>– <span class="NLM_lpage">900</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2007.12.041</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=10.1016%2Fj.bmcl.2007.12.041" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=18248988" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsFWksb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=897-900&author=P.+Furetauthor=G.+Caravattiauthor=V.+Guagnanoauthor=M.+Langauthor=T.+Meyerauthor=J.+Schoepfer&title=Entry+into+a+new+class+of+protein+kinase+inhibitors+by+pseudo+ring+design&doi=10.1016%2Fj.bmcl.2007.12.041"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21aR"><div class="casContent"><span class="casTitleNuber">21a</span><div class="casTitle"><span class="NLM_cas:atitle">Entry into a new class of protein kinase inhibitors by pseudo ring design</span></div><div class="casAuthors">Furet, Pascal; Caravatti, Giorgio; Guagnano, Vito; Lang, Marc; Meyer, Thomas; Schoepfer, Joseph</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">897-900</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A pyrimidin-4-yl-urea motif forming a pseudo ring by intramol. hydrogen bonding has been designed to mimic the pyrido[2,3-d]pyrimidin-7-one core structure of a well-established class of protein kinase inhibitors.  Potent inhibition of a no. of protein kinases was obtained with the first prototype compd. synthesized to probe the design concept.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5MZZKS4I03LVg90H21EOLACvtfcHk0lgEDD0yurW7MA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsFWksb0%253D&md5=989b4bb7f1d5177be45d4edf31290de5</span></div><a href="/servlet/linkout?suffix=cit21a&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2007.12.041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2007.12.041%26sid%3Dliteratum%253Aachs%26aulast%3DFuret%26aufirst%3DP.%26aulast%3DCaravatti%26aufirst%3DG.%26aulast%3DGuagnano%26aufirst%3DV.%26aulast%3DLang%26aufirst%3DM.%26aulast%3DMeyer%26aufirst%3DT.%26aulast%3DSchoepfer%26aufirst%3DJ.%26atitle%3DEntry%2520into%2520a%2520new%2520class%2520of%2520protein%2520kinase%2520inhibitors%2520by%2520pseudo%2520ring%2520design%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D897%26epage%3D900%26doi%3D10.1016%2Fj.bmcl.2007.12.041" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit21b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Mathieu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gradl, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aliagas, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunzner-Toste, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pulk, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alicke, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boggs, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buckmelter, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choo, E. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dinkel, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gloor, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gould, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansen, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hastings, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hatzivassiliou, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laird, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreno, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ran, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voegtli, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wenglowsky, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grina, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rudolph, J.</span></span> <span> </span><span class="NLM_article-title">Potent and selective aminopyrimidine-based B-Raf inhibitors with favorable physicochemical and pharmacokinetic properties</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">2869</span>– <span class="NLM_lpage">2881</span>, <span class="refDoi"> DOI: 10.1021/jm300016v</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300016v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref21/cit21b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=1%3ACAS%3A528%3ADC%252BC38XitlGjtbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=2869-2881&author=S.+Mathieuauthor=S.+N.+Gradlauthor=L.+Renauthor=Z.+Wenauthor=I.+Aliagasauthor=J.+Gunzner-Tosteauthor=W.+Leeauthor=R.+Pulkauthor=G.+Zhaoauthor=B.+Alickeauthor=J.+W.+Boggsauthor=A.+J.+Buckmelterauthor=E.+F.+Chooauthor=V.+Dinkelauthor=S.+L.+Gloorauthor=S.+E.+Gouldauthor=J.+D.+Hansenauthor=G.+Hastingsauthor=G.+Hatzivassiliouauthor=E.+R.+Lairdauthor=D.+Morenoauthor=Y.+Ranauthor=W.+C.+Voegtliauthor=S.+Wenglowskyauthor=J.+Grinaauthor=J.+Rudolph&title=Potent+and+selective+aminopyrimidine-based+B-Raf+inhibitors+with+favorable+physicochemical+and+pharmacokinetic+properties&doi=10.1021%2Fjm300016v"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21bR"><div class="casContent"><span class="casTitleNuber">21b</span><div class="casTitle"><span class="NLM_cas:atitle">Potent and Selective Aminopyrimidine-Based B-Raf Inhibitors with Favorable Physicochemical and Pharmacokinetic Properties</span></div><div class="casAuthors">Mathieu, Simon; Gradl, Stefan N.; Ren, Li; Wen, Zhaoyang; Aliagas, Ignacio; Gunzner-Toste, Janet; Lee, Wendy; Pulk, Rebecca; Zhao, Guiling; Alicke, Bruno; Boggs, Jason W.; Buckmelter, Alex J.; Choo, Edna F.; Dinkel, Victoria; Gloor, Susan L.; Gould, Stephen E.; Hansen, Joshua D.; Hastings, Gregg; Hatzivassiliou, Georgia; Laird, Ellen R.; Moreno, David; Ran, Yingqing; Voegtli, Walter C.; Wenglowsky, Steve; Grina, Jonas; Rudolph, Joachim</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2869-2881</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Recent clin. data provided proof-of-concept for selective B-Raf inhibitors in treatment of B-RafV600E mutant melanoma.  Pyrazolopyridine-type B-Raf inhibitors previously described by the authors are potent and selective but exhibit low soly. requiring the use of amorphous dispersion-based formulation for achieving efficacious drug exposures.  Through structure-based design, a new class of highly potent aminopyrimidine-based B-Raf inhibitors was discovered with improved soly. and pharmacokinetic profiles.  The hinge binding moiety possesses a basic center imparting high soly. at gastric pH, addressing the dissoln. limitation obsd. with the previous series.  In our search for an optimal linker-hinge binding moiety system, amide-linked thieno[3,2-d]pyrimidine analogs I and II (G945), mols. with desirable physicochem. properties, emerged as lead compds. with strong efficacy in a B-RafV600E mutant mouse xenograft model.  Synthesis, SAR, lead selection, and evaluation of key compds. in animal studies will be described.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGos8je6g5RG6LVg90H21EOLACvtfcHk0lj3iN9Xcfn_mA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XitlGjtbw%253D&md5=53373bfc102c5dfa271c4f429d11139a</span></div><a href="/servlet/linkout?suffix=cit21b&amp;dbid=16384&amp;doi=10.1021%2Fjm300016v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300016v%26sid%3Dliteratum%253Aachs%26aulast%3DMathieu%26aufirst%3DS.%26aulast%3DGradl%26aufirst%3DS.%2BN.%26aulast%3DRen%26aufirst%3DL.%26aulast%3DWen%26aufirst%3DZ.%26aulast%3DAliagas%26aufirst%3DI.%26aulast%3DGunzner-Toste%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DW.%26aulast%3DPulk%26aufirst%3DR.%26aulast%3DZhao%26aufirst%3DG.%26aulast%3DAlicke%26aufirst%3DB.%26aulast%3DBoggs%26aufirst%3DJ.%2BW.%26aulast%3DBuckmelter%26aufirst%3DA.%2BJ.%26aulast%3DChoo%26aufirst%3DE.%2BF.%26aulast%3DDinkel%26aufirst%3DV.%26aulast%3DGloor%26aufirst%3DS.%2BL.%26aulast%3DGould%26aufirst%3DS.%2BE.%26aulast%3DHansen%26aufirst%3DJ.%2BD.%26aulast%3DHastings%26aufirst%3DG.%26aulast%3DHatzivassiliou%26aufirst%3DG.%26aulast%3DLaird%26aufirst%3DE.%2BR.%26aulast%3DMoreno%26aufirst%3DD.%26aulast%3DRan%26aufirst%3DY.%26aulast%3DVoegtli%26aufirst%3DW.%2BC.%26aulast%3DWenglowsky%26aufirst%3DS.%26aulast%3DGrina%26aufirst%3DJ.%26aulast%3DRudolph%26aufirst%3DJ.%26atitle%3DPotent%2520and%2520selective%2520aminopyrimidine-based%2520B-Raf%2520inhibitors%2520with%2520favorable%2520physicochemical%2520and%2520pharmacokinetic%2520properties%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D2869%26epage%3D2881%26doi%3D10.1021%2Fjm300016v" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit21c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group"><span class="NLM_string-name">De Morin, F. F.</span>; <span class="NLM_string-name">Chen, J. J.</span>; <span class="NLM_string-name">Hitchcock, S.</span>; <span class="NLM_string-name">Liu, G.</span>; <span class="NLM_string-name">Paras, N. A.</span>; <span class="NLM_string-name">Petkus, J.</span>; <span class="NLM_string-name">Smith, A. L.</span>; <span class="NLM_string-name">Tasker, A.</span>; <span class="NLM_string-name">Zhu, J.</span></span> <span> </span><span class="NLM_article-title">Preparation of nitrogen-containing bicyclic heteroaryl compounds as antitumor agents</span>. US Patent <span class="NLM_patent">7989461</span>, <span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=F.+F.+De+Morin&author=J.+J.+Chen&author=S.+Hitchcock&author=G.+Liu&author=N.+A.+Paras&author=J.+Petkus&author=A.+L.+Smith&author=A.+Tasker&author=J.+Zhu&title=Preparation+of+nitrogen-containing+bicyclic+heteroaryl+compounds+as+antitumor+agents"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BMorin%26aufirst%3DF.%2BF.%26atitle%3DPreparation%2520of%2520nitrogen-containing%2520bicyclic%2520heteroaryl%2520compounds%2520as%2520antitumor%2520agents%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="note"><p class="first last">A focused kinase panel (including RAF kinases) was created from a broad kinome panel in order to routinely measure selectivity of kinases which were relevant in terms of homology and pathway, and monitor critical off-targets. The list of kinases is presented in <a href="/doi/suppl/10.1021/acs.jmedchem.0c02085/suppl_file/jm0c02085_si_004.pdf" class="ext-link">Table S2</a>, and RAF kinases are not included in the totals in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xing, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klug-Mcleod, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rai, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lunney, E. A.</span></span> <span> </span><span class="NLM_article-title">Kinase Hinge binding scaffolds and their hydrogen bond patterns</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">6520</span>– <span class="NLM_lpage">6527</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2015.08.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=10.1016%2Fj.bmc.2015.08.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=26358279" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVentr3L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2015&pages=6520-6527&author=L.+Xingauthor=J.+Klug-Mcleodauthor=B.+Raiauthor=E.+A.+Lunney&title=Kinase+Hinge+binding+scaffolds+and+their+hydrogen+bond+patterns&doi=10.1016%2Fj.bmc.2015.08.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Kinase hinge binding scaffolds and their hydrogen bond patterns</span></div><div class="casAuthors">Xing, Li; Klug-Mcleod, Jacquelyn; Rai, Brajesh; Lunney, Elizabeth A.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">6520-6527</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Protein kinases constitute a major class of intracellular signaling mols., and describe some of the most prominent drug targets.  Kinase inhibitors commonly employ small chem. scaffolds that form hydrogen bonds with the kinase hinge residues connecting the N- and C-terminal lobes of the catalytic domain.  In general the satisfied hydrogen bonds are required for potent inhibition, therefore constituting a conserved feature in the majority of inhibitor-kinase interactions.  From systematically analyzing the kinase scaffolds extd. from Pfizer crystal structure database (CSDb) the authors recognize that large no. of kinase inhibitors of diverse chem. structures are derived from a relatively small no. of common scaffolds.  Depending on specific substitution patterns, scaffolds may demonstrate versatile binding capacities to interact with kinase hinge.  Afforded by thousands of ligand-protein binary complexes, the hinge hydrogen bond patterns were analyzed with a focus on their three-dimensional configurations.  Most of the compds. engage H6 NH for hinge recognition.  Dual hydrogen bonds are commonly obsd. with addnl. recruitment of H4 CO upstream and/or H6 CO downstream.  Triple hydrogen bonds accounts for small no. of binary complexes.  An unusual hydrogen bond with a non-canonical H5 conformation is obsd., requiring a peptide bond flip by a glycine residue at the H6 position.  Addnl. hydrogen bonds to kinase hinge do not necessarily correlate with an increase in potency; conversely they appear to compromise kinase selectivity.  Such learnings could enhance the prospect of successful therapy design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRC-xiTiNvELVg90H21EOLACvtfcHk0lj3iN9Xcfn_mA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVentr3L&md5=048b4b99628c6e1ae273b00a47ab2377</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2015.08.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2015.08.006%26sid%3Dliteratum%253Aachs%26aulast%3DXing%26aufirst%3DL.%26aulast%3DKlug-Mcleod%26aufirst%3DJ.%26aulast%3DRai%26aufirst%3DB.%26aulast%3DLunney%26aufirst%3DE.%2BA.%26atitle%3DKinase%2520Hinge%2520binding%2520scaffolds%2520and%2520their%2520hydrogen%2520bond%2520patterns%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2015%26volume%3D23%26spage%3D6520%26epage%3D6527%26doi%3D10.1016%2Fj.bmc.2015.08.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="note"><p class="first last">A larger panel of 218 kinases found no kinases that were inhibited to a degree of greater than 50% at 10 nM (<a href="/doi/suppl/10.1021/acs.jmedchem.0c02085/suppl_file/jm0c02085_si_004.pdf" class="ext-link">Table S3</a>).</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="note"><p class="first last">Example of <i>N</i>-methyl-polarized CH protein interactions:</p></div><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hanan, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Abbema, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrett, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blair, W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blaney, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eigenbrot, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flynn, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibbons, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurley, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kenny, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kulagowski, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magnuson, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morris, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pastor, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rawson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ultsch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sampath, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyssikatos, J. P.</span></span> <span> </span><span class="NLM_article-title">Discovery of potent and selective pyrazolopyrimidine janus kinase 2 inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">10090</span>– <span class="NLM_lpage">10107</span>, <span class="refDoi"> DOI: 10.1021/jm3012239</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm3012239" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFSgs7vO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=10090-10107&author=E.+J.+Hananauthor=A.+van+Abbemaauthor=K.+Barrettauthor=W.+S.+Blairauthor=J.+Blaneyauthor=C.+Changauthor=C.+Eigenbrotauthor=S.+Flynnauthor=P.+Gibbonsauthor=C.+A.+Hurleyauthor=J.+R.+Kennyauthor=J.+Kulagowskiauthor=L.+Leeauthor=S.+M.+Magnusonauthor=C.+Morrisauthor=J.+Murrayauthor=R.+M.+Pastorauthor=T.+Rawsonauthor=M.+Siuauthor=M.+Ultschauthor=A.+Zhouauthor=D.+Sampathauthor=J.+P.+Lyssikatos&title=Discovery+of+potent+and+selective+pyrazolopyrimidine+janus+kinase+2+inhibitors&doi=10.1021%2Fjm3012239"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Potent and Selective Pyrazolopyrimidine Janus Kinase 2 Inhibitors</span></div><div class="casAuthors">Hanan, Emily J.; van Abbema, Anne; Barrett, Kathy; Blair, Wade S.; Blaney, Jeff; Chang, Christine; Eigenbrot, Charles; Flynn, Sean; Gibbons, Paul; Hurley, Christopher A.; Kenny, Jane R.; Kulagowski, Janusz; Lee, Leslie; Magnuson, Steven R.; Morris, Claire; Murray, Jeremy; Pastor, Richard M.; Rawson, Tom; Siu, Michael; Ultsch, Mark; Zhou, Aihe; Sampath, Deepak; Lyssikatos, Joseph P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">10090-10107</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The discovery of somatic Jak2 mutations in patients with chronic myeloproliferative neoplasms has led to significant interest in discovering selective Jak2 inhibitors for use in treating these disorders.  A high-throughput screening effort identified the pyrazolo[1,5-a]pyrimidine scaffold as a potent inhibitor of Jak2.  Optimization of lead compds. in this chem. series for activity against Jak2, selectivity against other Jak family kinases, and good in vivo pharmacokinetic properties led to the discovery of (I).  In a SET2 xenograft model that is dependent on Jak2 for growth, I demonstrated a time-dependent knock-down of pSTAT5, a downstream target of Jak2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqLsbJk8ilR07Vg90H21EOLACvtfcHk0lg7GfJ1cv7yNA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFSgs7vO&md5=b08cc250ae2498a164c6ce416743c968</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Fjm3012239&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm3012239%26sid%3Dliteratum%253Aachs%26aulast%3DHanan%26aufirst%3DE.%2BJ.%26aulast%3Dvan%2BAbbema%26aufirst%3DA.%26aulast%3DBarrett%26aufirst%3DK.%26aulast%3DBlair%26aufirst%3DW.%2BS.%26aulast%3DBlaney%26aufirst%3DJ.%26aulast%3DChang%26aufirst%3DC.%26aulast%3DEigenbrot%26aufirst%3DC.%26aulast%3DFlynn%26aufirst%3DS.%26aulast%3DGibbons%26aufirst%3DP.%26aulast%3DHurley%26aufirst%3DC.%2BA.%26aulast%3DKenny%26aufirst%3DJ.%2BR.%26aulast%3DKulagowski%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DL.%26aulast%3DMagnuson%26aufirst%3DS.%2BM.%26aulast%3DMorris%26aufirst%3DC.%26aulast%3DMurray%26aufirst%3DJ.%26aulast%3DPastor%26aufirst%3DR.%2BM.%26aulast%3DRawson%26aufirst%3DT.%26aulast%3DSiu%26aufirst%3DM.%26aulast%3DUltsch%26aufirst%3DM.%26aulast%3DZhou%26aufirst%3DA.%26aulast%3DSampath%26aufirst%3DD.%26aulast%3DLyssikatos%26aufirst%3DJ.%2BP.%26atitle%3DDiscovery%2520of%2520potent%2520and%2520selective%2520pyrazolopyrimidine%2520janus%2520kinase%25202%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D10090%26epage%3D10107%26doi%3D10.1021%2Fjm3012239" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="note"><p class="first last">Given that the biochemical potencies of <b>6</b> and <b>7</b> are at the lower limits of detection, we cannot exclude the possibility that the observed cellular potency improvement of <b>7</b> may be due to greater permeability.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Greco, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bravo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parsons, J. C.</span></span> <span> </span><span class="NLM_article-title">The search for synergy: A critical review from a response surface perspective</span>. <i>Pharmacol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">331</span>– <span class="NLM_lpage">385</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=7568331" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=1%3ACAS%3A280%3ADyaK28%252FjsFSgtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=1995&pages=331-385&author=W.+R.+Grecoauthor=G.+Bravoauthor=J.+C.+Parsons&title=The+search+for+synergy%3A+A+critical+review+from+a+response+surface+perspective"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27aR"><div class="casContent"><span class="casTitleNuber">27a</span><div class="casTitle"><span class="NLM_cas:atitle">The search for synergy: a critical review from a response surface perspective</span></div><div class="casAuthors">Greco W R; Bravo G; Parsons J C</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological reviews</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">331-85</span>
        ISSN:<span class="NLM_cas:issn">0031-6997</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRXywHk-SVAkdenUz0lpNqnfW6udTcc2eZ6gji0SY6387ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK28%252FjsFSgtQ%253D%253D&md5=80f1b0c8e20e587625a5d68339d30709</span></div><a href="/servlet/linkout?suffix=cit27a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGreco%26aufirst%3DW.%2BR.%26aulast%3DBravo%26aufirst%3DG.%26aulast%3DParsons%26aufirst%3DJ.%2BC.%26atitle%3DThe%2520search%2520for%2520synergy%253A%2520A%2520critical%2520review%2520from%2520a%2520response%2520surface%2520perspective%26jtitle%3DPharmacol.%2520Rev.%26date%3D1995%26volume%3D47%26spage%3D331%26epage%3D385" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit27b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, G. K. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moffat, J. G.</span></span> <span> </span><span class="NLM_article-title">Unlocking the potential of high-throughput drug combination assays using acoustic dispensing</span>. <i>J. Lab. Autom.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">125</span>– <span class="NLM_lpage">132</span>, <span class="refDoi"> DOI: 10.1177/2211068215593759</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=10.1177%2F2211068215593759" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=26160862" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVaitb%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2016&pages=125-132&author=G.+K.+Y.+Chanauthor=S.+Wilsonauthor=S.+Schmidtauthor=J.+G.+Moffat&title=Unlocking+the+potential+of+high-throughput+drug+combination+assays+using+acoustic+dispensing&doi=10.1177%2F2211068215593759"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27bR"><div class="casContent"><span class="casTitleNuber">27b</span><div class="casTitle"><span class="NLM_cas:atitle">Unlocking the potential of high-throughput drug combination assays using acoustic dispensing</span></div><div class="casAuthors">Chan, Grace Ka Yan; Wilson, Stacy; Schmidt, Stephen; Moffat, John G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Laboratory Automation</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">125-132</span>CODEN:
                <span class="NLM_cas:coden">JLAOBH</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">Assessment of synergistic effects of drug combinations in vitro is a crit. part of anticancer drug research.  However, the complexities of dosing and analyzing two drugs over the appropriate range of doses have generally led to compromises in exptl. design that restrict the quality and robustness of the data.  In particular, the use of a single dose response of combined drugs, rather than a full two-way matrix of varying doses, has predominated in higher-throughput studies.  Acoustic dispensing unlocks the potential of high-throughput dose matrix anal.  We have developed acoustic dispensing protocols that enable compd. synergy assays in a 384-well format.  This exptl. design is considerably more efficient and flexible with respect to time, reagent usage, and labware than is achievable using traditional serial-diln. approaches.  Data anal. tools integrated in Genedata Screener were used to efficiently deconvolute the combination compd. mapping scheme and calc. compd. potency and synergy metrics.  We have applied this workflow to evaluate interactions among drugs targeting different nodes of the mitogen-activated protein kinase pathway in a panel of cancer cell lines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6qXA6OcoF1rVg90H21EOLACvtfcHk0lg7GfJ1cv7yNA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVaitb%252FO&md5=d88b45023c8e90f772035f4b952f8391</span></div><a href="/servlet/linkout?suffix=cit27b&amp;dbid=16384&amp;doi=10.1177%2F2211068215593759&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F2211068215593759%26sid%3Dliteratum%253Aachs%26aulast%3DChan%26aufirst%3DG.%2BK.%2BY.%26aulast%3DWilson%26aufirst%3DS.%26aulast%3DSchmidt%26aufirst%3DS.%26aulast%3DMoffat%26aufirst%3DJ.%2BG.%26atitle%3DUnlocking%2520the%2520potential%2520of%2520high-throughput%2520drug%2520combination%2520assays%2520using%2520acoustic%2520dispensing%26jtitle%3DJ.%2520Lab.%2520Autom.%26date%3D2016%26volume%3D21%26spage%3D125%26epage%3D132%26doi%3D10.1177%2F2211068215593759" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="note"><p class="first last">Detailed synthetic schemes are provided in the Supporting Information (<a href="/doi/suppl/10.1021/acs.jmedchem.0c02085/suppl_file/jm0c02085_si_004.pdf" class="ext-link">Scheme S1</a>).</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Qin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span> <span> </span><span class="NLM_article-title">Pd-catalyzed amidation of aryl(het) halides with <i>tert</i>-butyl carbamate</span>. <i>Tetrahedron Lett.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">4445</span>– <span class="NLM_lpage">4448</span>, <span class="refDoi"> DOI: 10.1016/j.tetlet.2010.06.083</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=10.1016%2Fj.tetlet.2010.06.083" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=1%3ACAS%3A528%3ADC%252BC3cXptVagtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2010&pages=4445-4448&author=L.+Qinauthor=H.+Cuiauthor=D.+Zouauthor=J.+Liauthor=Y.+Wuauthor=Z.+Zhuauthor=Y.+Wu&title=Pd-catalyzed+amidation+of+aryl%28het%29+halides+with+tert-butyl+carbamate&doi=10.1016%2Fj.tetlet.2010.06.083"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Pd-catalyzed amidation of aryl(Het) halides with tert-butyl carbamate</span></div><div class="casAuthors">Qin, Lijin; Cui, Hongmeng; Zou, Dapeng; Li, Jingya; Wu, Yangjie; Zhu, Zhiwu; Wu, Yusheng</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron Letters</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">33</span>),
    <span class="NLM_cas:pages">4445-4448</span>CODEN:
                <span class="NLM_cas:coden">TELEAY</span>;
        ISSN:<span class="NLM_cas:issn">0040-4039</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Pd-catalyzed cross-coupling reaction of tert-Bu carbamate with various aryl(Het) halides with Cs2CO3 as base in 1,4-dioxane as solvent was investigated, which resulted in the formation of the desired compds. in moderate to excellent yields.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqUf_uWurXB37Vg90H21EOLACvtfcHk0ljjuB6HEoXwkA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXptVagtbo%253D&md5=ab2e56cea9014a08ebaa0cf175dc3994</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1016%2Fj.tetlet.2010.06.083&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tetlet.2010.06.083%26sid%3Dliteratum%253Aachs%26aulast%3DQin%26aufirst%3DL.%26aulast%3DCui%26aufirst%3DH.%26aulast%3DZou%26aufirst%3DD.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DZhu%26aufirst%3DZ.%26aulast%3DWu%26aufirst%3DY.%26atitle%3DPd-catalyzed%2520amidation%2520of%2520aryl%2528het%2529%2520halides%2520with%2520tert-butyl%2520carbamate%26jtitle%3DTetrahedron%2520Lett.%26date%3D2010%26volume%3D51%26spage%3D4445%26epage%3D4448%26doi%3D10.1016%2Fj.tetlet.2010.06.083" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bogolubsky, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryabukhin, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pakhomov, G. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ostapchuk, E. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shivanyuk, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tolmachev, A. A.</span></span> <span> </span><span class="NLM_article-title">A facile synthesis of <i>N</i>-carbamoylamino acids</span>. <i>Synlett</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_fpage">2279</span>– <span class="NLM_lpage">2282</span>, <span class="refDoi"> DOI: 10.1055/s-2008-1078017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=10.1055%2Fs-2008-1078017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=1%3ACAS%3A528%3ADC%252BD1cXht1amsL3F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&pages=2279-2282&author=A.+V.+Bogolubskyauthor=S.+V.+Ryabukhinauthor=G.+G.+Pakhomovauthor=E.+N.+Ostapchukauthor=A.+N.+Shivanyukauthor=A.+A.+Tolmachev&title=A+facile+synthesis+of+N-carbamoylamino+acids&doi=10.1055%2Fs-2008-1078017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">A facile synthesis of N-carbamoylamino acids</span></div><div class="casAuthors">Bogolubsky, Andrey V.; Ryabukhin, Sergey V.; Pakhomov, Gennadiy G.; Ostapchuk, Eugeniy N.; Shivanyuk, Alexander N.; Tolmachev, Andrey A.</div><div class="citationInfo"><span class="NLM_cas:title">Synlett</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume"></span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">2279-2282</span>CODEN:
                <span class="NLM_cas:coden">SYNLES</span>;
        ISSN:<span class="NLM_cas:issn">0936-5214</span>.
    
            (<span class="NLM_cas:orgname">Georg Thieme Verlag</span>)
        </div><div class="casAbstract">N-Carbamoyl amino acids were obtained through the alkylation of monosubstituted parabanates and subsequent hydrolysis.  This new methodol. furnishes structurally and functionally diverse N-carbamoyl amino acids in high preparative yields and excellent purity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpNK4re9LM3VbVg90H21EOLACvtfcHk0ljjuB6HEoXwkA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXht1amsL3F&md5=d9367b1e64f96a90705489c5e35bd3e6</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1055%2Fs-2008-1078017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-2008-1078017%26sid%3Dliteratum%253Aachs%26aulast%3DBogolubsky%26aufirst%3DA.%2BV.%26aulast%3DRyabukhin%26aufirst%3DS.%2BV.%26aulast%3DPakhomov%26aufirst%3DG.%2BG.%26aulast%3DOstapchuk%26aufirst%3DE.%2BN.%26aulast%3DShivanyuk%26aufirst%3DA.%2BN.%26aulast%3DTolmachev%26aufirst%3DA.%2BA.%26atitle%3DA%2520facile%2520synthesis%2520of%2520N-carbamoylamino%2520acids%26jtitle%3DSynlett%26date%3D2008%26spage%3D2279%26epage%3D2282%26doi%3D10.1055%2Fs-2008-1078017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Kinzel, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchwald, S. L.</span></span> <span> </span><span class="NLM_article-title">A new palladium precatalyst allows for the fast Suzuki-Miyaura coupling reactions of unstable polyfluorophenyl and 2-heteroaryl boronic acids</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>132</i></span>,  <span class="NLM_fpage">14073</span>– <span class="NLM_lpage">14075</span>, <span class="refDoi"> DOI: 10.1021/ja1073799</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja1073799" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref31/cit31a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtF2nu7vP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=132&publication_year=2010&pages=14073-14075&author=T.+Kinzelauthor=Y.+Zhangauthor=S.+L.+Buchwald&title=A+new+palladium+precatalyst+allows+for+the+fast+Suzuki-Miyaura+coupling+reactions+of+unstable+polyfluorophenyl+and+2-heteroaryl+boronic+acids&doi=10.1021%2Fja1073799"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31aR"><div class="casContent"><span class="casTitleNuber">31a</span><div class="casTitle"><span class="NLM_cas:atitle">A New Palladium Precatalyst Allows for the Fast Suzuki-Miyaura Coupling Reactions of Unstable Polyfluorophenyl and 2-Heteroaryl Boronic Acids</span></div><div class="casAuthors">Kinzel, Tom; Zhang, Yong; Buchwald, Stephen L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">132</span>
        (<span class="NLM_cas:issue">40</span>),
    <span class="NLM_cas:pages">14073-14075</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Boronic acids which quickly deboronate under basic conditions, such as polyfluorophenylboronic acid and five-membered 2-heteroarom. boronic acids, are esp. challenging coupling partners for Suzuki-Miyaura reactions.  Nevertheless, being able to use these substrates is highly desirable for a no. of applications.  Having found that monodentate biarylphosphine ligands can promote these coupling processes, we developed a precatalyst that forms the catalytically active species under conditions where boronic acid decompn. is slow.  With this precatalyst, Suzuki-Miyaura reactions of a wide range of (hetero)aryl chlorides, bromides, and triflates with polyfluorophenyl, 2-furan, 2-thiophene, and 2-pyrroleboronic acids and their analogs proceed at room temp. or 40 °C in short reaction times to give the desired products in excellent yields.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQcxyqTMX_GLVg90H21EOLACvtfcHk0ljjuB6HEoXwkA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtF2nu7vP&md5=1022a0f192fb806ea9d567bf0c2d739a</span></div><a href="/servlet/linkout?suffix=cit31a&amp;dbid=16384&amp;doi=10.1021%2Fja1073799&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja1073799%26sid%3Dliteratum%253Aachs%26aulast%3DKinzel%26aufirst%3DT.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DBuchwald%26aufirst%3DS.%2BL.%26atitle%3DA%2520new%2520palladium%2520precatalyst%2520allows%2520for%2520the%2520fast%2520Suzuki-Miyaura%2520coupling%2520reactions%2520of%2520unstable%2520polyfluorophenyl%2520and%25202-heteroaryl%2520boronic%2520acids%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2010%26volume%3D132%26spage%3D14073%26epage%3D14075%26doi%3D10.1021%2Fja1073799" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit31b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Düfert, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Billingsley, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchwald, S. L.</span></span> <span> </span><span class="NLM_article-title">Suzuki-Miyaura cross-coupling of unprotected, nitrogen-rich heterocycles: Substrate scope and mechanistic investigation</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>135</i></span>,  <span class="NLM_fpage">12877</span>– <span class="NLM_lpage">12885</span>, <span class="refDoi"> DOI: 10.1021/ja4064469</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja4064469" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref31/cit31b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1WltrjE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=135&publication_year=2013&pages=12877-12885&author=M.+A.+D%C3%BCfertauthor=K.+L.+Billingsleyauthor=S.+L.+Buchwald&title=Suzuki-Miyaura+cross-coupling+of+unprotected%2C+nitrogen-rich+heterocycles%3A+Substrate+scope+and+mechanistic+investigation&doi=10.1021%2Fja4064469"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31bR"><div class="casContent"><span class="casTitleNuber">31b</span><div class="casTitle"><span class="NLM_cas:atitle">Suzuki-Miyaura Cross-Coupling of Unprotected, Nitrogen-Rich Heterocycles: Substrate Scope and Mechanistic Investigation</span></div><div class="casAuthors">Dufert, M. Alexander; Billingsley, Kelvin L.; Buchwald, Stephen L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">135</span>
        (<span class="NLM_cas:issue">34</span>),
    <span class="NLM_cas:pages">12877-12885</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The Suzuki-Miyaura cross-coupling of unprotected, nitrogen-rich heterocycles using precatalysts P1 or P2 is reported.  The procedure allows for the reaction of variously substituted indazole, benzimidazole, pyrazole, indole, oxindole, and azaindole halides under mild conditions in good to excellent yields.  Addnl., the mechanism behind the inhibitory effect of unprotected azoles on Pd-catalyzed cross-coupling reactions is described based on evidence gained through exptl., crystallog., and theor. investigations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGE4glX6IYJrVg90H21EOLACvtfcHk0ljjuB6HEoXwkA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1WltrjE&md5=54d0f5fab5732a011a35412cc580406e</span></div><a href="/servlet/linkout?suffix=cit31b&amp;dbid=16384&amp;doi=10.1021%2Fja4064469&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja4064469%26sid%3Dliteratum%253Aachs%26aulast%3DD%25C3%25BCfert%26aufirst%3DM.%2BA.%26aulast%3DBillingsley%26aufirst%3DK.%2BL.%26aulast%3DBuchwald%26aufirst%3DS.%2BL.%26atitle%3DSuzuki-Miyaura%2520cross-coupling%2520of%2520unprotected%252C%2520nitrogen-rich%2520heterocycles%253A%2520Substrate%2520scope%2520and%2520mechanistic%2520investigation%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2013%26volume%3D135%26spage%3D12877%26epage%3D12885%26doi%3D10.1021%2Fja4064469" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huffman, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNamara, J. M.</span></span> <span> </span><span class="NLM_article-title">Pd-catalyzed <i>N</i>-arylation of heteroarylamines</span>. <i>Org. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">3481</span>– <span class="NLM_lpage">3484</span>, <span class="refDoi"> DOI: 10.1021/ol0265923</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ol0265923" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=1%3ACAS%3A528%3ADC%252BD38Xms1Omur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2002&pages=3481-3484&author=J.+Yinauthor=M.+M.+Zhaoauthor=M.+A.+Huffmanauthor=J.+M.+McNamara&title=Pd-catalyzed+N-arylation+of+heteroarylamines&doi=10.1021%2Fol0265923"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Pd-Catalyzed N-Arylation of Heteroarylamines</span></div><div class="casAuthors">Yin, Jingjun; Zhao, Matthew M.; Huffman, Mark A.; McNamara, James M.</div><div class="citationInfo"><span class="NLM_cas:title">Organic Letters</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">3481-3484</span>CODEN:
                <span class="NLM_cas:coden">ORLEF7</span>;
        ISSN:<span class="NLM_cas:issn">1523-7060</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The palladium-catalyzed N-(hetero)arylation of a no. of heteroarylamines including 2-aminopyridines, 2-aminothiazoles, and their analogs has been realized using Xantphos as the ligand.  Weak bases such as Cs2CO3, Na2CO3, and K3PO4 were used in most cases to allow for the introduction of functional groups.  Choice of the base and solvent was crit. for the success of these reactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpto0A1OmazwbVg90H21EOLACvtfcHk0lh3lQhKHjx8pw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xms1Omur8%253D&md5=95f39b69250ce41d7c97d66ecc7f1ae8</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1021%2Fol0265923&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fol0265923%26sid%3Dliteratum%253Aachs%26aulast%3DYin%26aufirst%3DJ.%26aulast%3DZhao%26aufirst%3DM.%2BM.%26aulast%3DHuffman%26aufirst%3DM.%2BA.%26aulast%3DMcNamara%26aufirst%3DJ.%2BM.%26atitle%3DPd-catalyzed%2520N-arylation%2520of%2520heteroarylamines%26jtitle%3DOrg.%2520Lett.%26date%3D2002%26volume%3D4%26spage%3D3481%26epage%3D3484%26doi%3D10.1021%2Fol0265923" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fors, B. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watson, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biscoe, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchwald, S. L.</span></span> <span> </span><span class="NLM_article-title">A highly active catalyst for Pd-catalyzed amination reactions: Cross-coupling reactions using aryl mesylates and the highly selective monoarylation of primary amines using aryl chlorides</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>130</i></span>,  <span class="NLM_fpage">13552</span>– <span class="NLM_lpage">13554</span>, <span class="refDoi"> DOI: 10.1021/ja8055358</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja8055358" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtFeqs77L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=130&publication_year=2008&pages=13552-13554&author=B.+P.+Forsauthor=D.+A.+Watsonauthor=M.+R.+Biscoeauthor=S.+L.+Buchwald&title=A+highly+active+catalyst+for+Pd-catalyzed+amination+reactions%3A+Cross-coupling+reactions+using+aryl+mesylates+and+the+highly+selective+monoarylation+of+primary+amines+using+aryl+chlorides&doi=10.1021%2Fja8055358"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">A Highly Active Catalyst for Pd-Catalyzed Amination Reactions: Cross-Coupling Reactions Using Aryl Mesylates and the Highly Selective Monoarylation of Primary Amines Using Aryl Chlorides</span></div><div class="casAuthors">Fors, Brett P.; Watson, Donald A.; Biscoe, Mark R.; Buchwald, Stephen L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">130</span>
        (<span class="NLM_cas:issue">41</span>),
    <span class="NLM_cas:pages">13552-13554</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A catalyst system based on a new biarylmonophosphine ligand (BrettPhos, I) that shows excellent reactivity for C-N cross-coupling reactions is reported.  This catalyst system enables the use of aryl mesylates as a coupling partner in C-N bond-forming reactions.  Addnl., the use of BrettPhos permits the highly selective monoarylation of an array of primary aliph. amines and anilines at low catalyst loadings and with fast reaction times, including the first monoarylation of methylamine.  Lastly, oxidative addn. complexes of BrettPhos are included, which provide insight into the origin of reactivity for this system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq1Noy8GnOtfrVg90H21EOLACvtfcHk0lh3lQhKHjx8pw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtFeqs77L&md5=f1e43af9fe1a21426ca3d408ab1c4779</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1021%2Fja8055358&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja8055358%26sid%3Dliteratum%253Aachs%26aulast%3DFors%26aufirst%3DB.%2BP.%26aulast%3DWatson%26aufirst%3DD.%2BA.%26aulast%3DBiscoe%26aufirst%3DM.%2BR.%26aulast%3DBuchwald%26aufirst%3DS.%2BL.%26atitle%3DA%2520highly%2520active%2520catalyst%2520for%2520Pd-catalyzed%2520amination%2520reactions%253A%2520Cross-coupling%2520reactions%2520using%2520aryl%2520mesylates%2520and%2520the%2520highly%2520selective%2520monoarylation%2520of%2520primary%2520amines%2520using%2520aryl%2520chlorides%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2008%26volume%3D130%26spage%3D13552%26epage%3D13554%26doi%3D10.1021%2Fja8055358" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kabsch, W.</span></span> <span> </span><span class="NLM_article-title">Integration, scaling, space-group assignment and post-refinement</span>. <i>Acta Crystallogr. D Biol. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">133</span>– <span class="NLM_lpage">144</span>, <span class="refDoi"> DOI: 10.1107/S0907444909047374</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=10.1107%2FS0907444909047374" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=20124693" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhs1Sisb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2010&pages=133-144&author=W.+Kabsch&title=Integration%2C+scaling%2C+space-group+assignment+and+post-refinement&doi=10.1107%2FS0907444909047374"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Integration, scaling, space-group assignment and post-refinement</span></div><div class="casAuthors">Kabsch, Wolfgang</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">133-144</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">Important steps in the processing of rotation data are described that are common to most software packages.  These programs differ in the details and in the methods implemented to carry out the tasks.  Here, the working principles underlying the data-redn. package XDS are explained, including the new features of automatic detn. of spot size and reflecting range, recognition and assignment of crystal symmetry and a highly efficient algorithm for the detn. of correction/scaling factors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGW7t3Bb1P_rVg90H21EOLACvtfcHk0lh3lQhKHjx8pw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhs1Sisb4%253D&md5=eb1db34f3c959b4921771eb9f57b2159</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1107%2FS0907444909047374&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444909047374%26sid%3Dliteratum%253Aachs%26aulast%3DKabsch%26aufirst%3DW.%26atitle%3DIntegration%252C%2520scaling%252C%2520space-group%2520assignment%2520and%2520post-refinement%26jtitle%3DActa%2520Crystallogr.%2520D%2520Biol.%2520Crystallogr.%26date%3D2010%26volume%3D66%26spage%3D133%26epage%3D144%26doi%3D10.1107%2FS0907444909047374" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Winn, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballard, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowtan, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dodson, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emsley, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evans, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keegan, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krissinel, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leslie, A. G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCoy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNicholas, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murshudov, G. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pannu, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potterton, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powell, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Read, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vagin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, K. S.</span></span> <span> </span><span class="NLM_article-title">Overview of the <i>CCP</i>4 suite and current developments</span>. <i>Acta Crystallogr. D Biol. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>67</i></span>,  <span class="NLM_fpage">235</span>– <span class="NLM_lpage">242</span>, <span class="refDoi"> DOI: 10.1107/S0907444910045749</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=10.1107%2FS0907444910045749" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=21460441" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=1%3ACAS%3A528%3ADC%252BC3MXktFWqt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2011&pages=235-242&author=M.+D.+Winnauthor=C.+C.+Ballardauthor=K.+D.+Cowtanauthor=E.+J.+Dodsonauthor=P.+Emsleyauthor=P.+R.+Evansauthor=R.+M.+Keeganauthor=E.+B.+Krissinelauthor=A.+G.+W.+Leslieauthor=A.+McCoyauthor=S.+J.+McNicholasauthor=G.+N.+Murshudovauthor=N.+S.+Pannuauthor=E.+A.+Pottertonauthor=H.+R.+Powellauthor=R.+J.+Readauthor=A.+Vaginauthor=K.+S.+Wilson&title=Overview+of+the+CCP4+suite+and+current+developments&doi=10.1107%2FS0907444910045749"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Overview of the CCP4 suite and current developments</span></div><div class="casAuthors">Winn, Martyn D.; Ballard, Charles C.; Cowtan, Kevin D.; Dodson, Eleanor J.; Emsley, Paul; Evans, Phil R.; Keegan, Ronan M.; Krissinel, Eugene B.; Leslie, Andrew G. W.; McCoy, Airlie; McNicholas, Stuart J.; Murshudov, Garib N.; Pannu, Navraj S.; Potterton, Elizabeth A.; Powell, Harold R.; Read, Randy J.; Vagin, Alexei; Wilson, Keith S.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">235-242</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">A review.  The CCP4 (Collaborative Computational Project, No. 4) software suite is a collection of programs and assocd. data and software libraries which can be used for macromol. structure detn. by X-ray crystallog.  The suite is designed to be flexible, allowing users a no. of methods of achieving their aims.  The programs are from a wide variety of sources but are connected by a common infrastructure provided by std. file formats, data objects and graphical interfaces.  Structure soln. by macromol. crystallog. is becoming increasingly automated and the CCP4 suite includes several automation pipelines.  After giving a brief description of the evolution of CCP4 over the last 30 years, an overview of the current suite is given.  While detailed descriptions are given in the accompanying articles, here it is shown how the individual programs contribute to a complete software package.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_wWMMIol6UrVg90H21EOLACvtfcHk0liFEgkfVgncXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXktFWqt70%253D&md5=c407e4d47bef46864be336d60147c17d</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1107%2FS0907444910045749&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444910045749%26sid%3Dliteratum%253Aachs%26aulast%3DWinn%26aufirst%3DM.%2BD.%26aulast%3DBallard%26aufirst%3DC.%2BC.%26aulast%3DCowtan%26aufirst%3DK.%2BD.%26aulast%3DDodson%26aufirst%3DE.%2BJ.%26aulast%3DEmsley%26aufirst%3DP.%26aulast%3DEvans%26aufirst%3DP.%2BR.%26aulast%3DKeegan%26aufirst%3DR.%2BM.%26aulast%3DKrissinel%26aufirst%3DE.%2BB.%26aulast%3DLeslie%26aufirst%3DA.%2BG.%2BW.%26aulast%3DMcCoy%26aufirst%3DA.%26aulast%3DMcNicholas%26aufirst%3DS.%2BJ.%26aulast%3DMurshudov%26aufirst%3DG.%2BN.%26aulast%3DPannu%26aufirst%3DN.%2BS.%26aulast%3DPotterton%26aufirst%3DE.%2BA.%26aulast%3DPowell%26aufirst%3DH.%2BR.%26aulast%3DRead%26aufirst%3DR.%2BJ.%26aulast%3DVagin%26aufirst%3DA.%26aulast%3DWilson%26aufirst%3DK.%2BS.%26atitle%3DOverview%2520of%2520the%2520CCP4%2520suite%2520and%2520current%2520developments%26jtitle%3DActa%2520Crystallogr.%2520D%2520Biol.%2520Crystallogr.%26date%3D2011%26volume%3D67%26spage%3D235%26epage%3D242%26doi%3D10.1107%2FS0907444910045749" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McCoy, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grosse-Kunstleve, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winn, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Storoni, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Read, R. J.</span></span> <span> </span><span class="NLM_article-title"><i>Phaser</i> crystallographic software</span>. <i>J. Appl. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">658</span>– <span class="NLM_lpage">674</span>, <span class="refDoi"> DOI: 10.1107/S0021889807021206</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=10.1107%2FS0021889807021206" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=19461840" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=1%3ACAS%3A528%3ADC%252BD2sXnslWqsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2007&pages=658-674&author=A.+J.+McCoyauthor=R.+W.+Grosse-Kunstleveauthor=P.+D.+Adamsauthor=M.+D.+Winnauthor=L.+C.+Storoniauthor=R.+J.+Read&title=Phaser+crystallographic+software&doi=10.1107%2FS0021889807021206"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Phaser crystallographic software</span></div><div class="casAuthors">McCoy, Airlie J.; Grosse-Kunstleve, Ralf W.; Adams, Paul D.; Winn, Martyn D.; Storoni, Laurent C.; Read, Randy J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Applied Crystallography</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">658-674</span>CODEN:
                <span class="NLM_cas:coden">JACGAR</span>;
        ISSN:<span class="NLM_cas:issn">0021-8898</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">Phaser is a program for phasing macromol. crystal structures by both mol. replacement and exptl. phasing methods.  The novel phasing algorithms implemented in Phaser have been developed using max. likelihood and multivariate statistics.  For mol. replacement, the new algorithms have proved to be significantly better than traditional methods in discriminating correct solns. from noise, and for single-wavelength anomalous dispersion exptl. phasing, the new algorithms, which account for correlations between F+ and F-, give better phases (lower mean phase error with respect to the phases given by the refined structure) than those that use mean F and anomalous differences ΔF.  One of the design concepts of Phaser was that it be capable of a high degree of automation.  To this end, Phaser (written in C++) can be called directly from Python, although it can also be called using traditional CCP4 keyword-style input.  Phaser is a platform for future development of improved phasing methods and their release, including source code, to the crystallog. community.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPeVyjN_FMGbVg90H21EOLACvtfcHk0liFEgkfVgncXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXnslWqsLk%253D&md5=c63b722ae97e0a74e6a5a079d388f09f</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1107%2FS0021889807021206&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0021889807021206%26sid%3Dliteratum%253Aachs%26aulast%3DMcCoy%26aufirst%3DA.%2BJ.%26aulast%3DGrosse-Kunstleve%26aufirst%3DR.%2BW.%26aulast%3DAdams%26aufirst%3DP.%2BD.%26aulast%3DWinn%26aufirst%3DM.%2BD.%26aulast%3DStoroni%26aufirst%3DL.%2BC.%26aulast%3DRead%26aufirst%3DR.%2BJ.%26atitle%3DPhaser%2520crystallographic%2520software%26jtitle%3DJ.%2520Appl.%2520Crystallogr.%26date%3D2007%26volume%3D40%26spage%3D658%26epage%3D674%26doi%3D10.1107%2FS0021889807021206" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Emsley, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowtan, K.</span></span> <span> </span><span class="NLM_article-title"><i>Coot</i>: Model-building tools for molecular graphics</span>. <i>Acta Crystallogr. D Biol. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">2126</span>– <span class="NLM_lpage">2132</span>, <span class="refDoi"> DOI: 10.1107/S0907444904019158</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=10.1107%2FS0907444904019158" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=15572765" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVars73P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2004&pages=2126-2132&author=P.+Emsleyauthor=K.+Cowtan&title=Coot%3A+Model-building+tools+for+molecular+graphics&doi=10.1107%2FS0907444904019158"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Coot: model-building tools for molecular graphics</span></div><div class="casAuthors">Emsley, Paul; Cowtan, Kevin</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">D60</span>
        (<span class="NLM_cas:issue">12, Pt. 1</span>),
    <span class="NLM_cas:pages">2126-2132</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">CCP4mg is a project that aims to provide a general-purpose tool for structural biologists, providing tools for x-ray structure soln., structure comparison and anal., and publication-quality graphics.  The map-fitting tools are available as a stand-alone package, distributed as 'Coot'.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMisM42468k7Vg90H21EOLACvtfcHk0liFEgkfVgncXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVars73P&md5=1be390f3bb6fd584468499ad0921161e</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1107%2FS0907444904019158&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444904019158%26sid%3Dliteratum%253Aachs%26aulast%3DEmsley%26aufirst%3DP.%26aulast%3DCowtan%26aufirst%3DK.%26atitle%3DCoot%253A%2520Model-building%2520tools%2520for%2520molecular%2520graphics%26jtitle%3DActa%2520Crystallogr.%2520D%2520Biol.%2520Crystallogr.%26date%3D2004%26volume%3D60%26spage%3D2126%26epage%3D2132%26doi%3D10.1107%2FS0907444904019158" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Murshudov, G. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vagin, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dodson, E. J.</span></span> <span> </span><span class="NLM_article-title">Refinement of macromolecular structures by the maximum-likelihood method</span>. <i>Acta Crystallogr. D Biol. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">240</span>– <span class="NLM_lpage">255</span>, <span class="refDoi"> DOI: 10.1107/S0907444996012255</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=10.1107%2FS0907444996012255" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=15299926" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=1%3ACAS%3A528%3ADyaK2sXjs1Gnsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=1997&pages=240-255&author=G.+N.+Murshudovauthor=A.+A.+Vaginauthor=E.+J.+Dodson&title=Refinement+of+macromolecular+structures+by+the+maximum-likelihood+method&doi=10.1107%2FS0907444996012255"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Refinement of macromolecular structures by the maximum-likelihood method</span></div><div class="casAuthors">Murshudov, Garib N.; Vagin, Alexei A.; Dodson, Eleanor J.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">D53</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">240-255</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">Munksgaard</span>)
        </div><div class="casAbstract">A review with many refs. on the math. basis of max. likelihood.  The likelihood function for macromol. structures is extended to include prior phase information and exptl. std. uncertainties.  The assumption that different parts of a structure might have different errors is considered.  A method for estg. σA using "free" reflections is described and its effects analyzed.  The derived equations have been implemented in the program REFMAC.  This has been tested on several proteins at different stages of refinement (bacterial α-amylase, cytochrome c', cross-linked insulin and oligopeptide binding protein).  The results derived using the max.-likelihood residual are consistently better than those obtained from least-squares refinement.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWg7mzQRNBhbVg90H21EOLACvtfcHk0lhbqRTFz3D6ZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXjs1Gnsb4%253D&md5=ec7f141ce1542f7ff458b98ecfe3f8af</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1107%2FS0907444996012255&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444996012255%26sid%3Dliteratum%253Aachs%26aulast%3DMurshudov%26aufirst%3DG.%2BN.%26aulast%3DVagin%26aufirst%3DA.%2BA.%26aulast%3DDodson%26aufirst%3DE.%2BJ.%26atitle%3DRefinement%2520of%2520macromolecular%2520structures%2520by%2520the%2520maximum-likelihood%2520method%26jtitle%3DActa%2520Crystallogr.%2520D%2520Biol.%2520Crystallogr.%26date%3D1997%26volume%3D53%26spage%3D240%26epage%3D255%26doi%3D10.1107%2FS0907444996012255" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Adams, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Afonine, P. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bunkóczi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, V. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, I. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Echols, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Headd, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hung, L.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kapral, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grosse-Kunstleve, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCoy, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moriarty, N. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oeffner, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Read, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terwilliger, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zwart, P. H.</span></span> <span> </span><span class="NLM_article-title"><i>PHENIX</i>: A comprehensive python-based system for macromolecular structure solution</span>. <i>Acta Crystallogr. D Biol. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">213</span>– <span class="NLM_lpage">221</span>, <span class="refDoi"> DOI: 10.1107/S0907444909052925</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=10.1107%2FS0907444909052925" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=20124702" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhs1Sisbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2010&pages=213-221&author=P.+D.+Adamsauthor=P.+V.+Afonineauthor=G.+Bunk%C3%B3cziauthor=V.+B.+Chenauthor=I.+W.+Davisauthor=N.+Echolsauthor=J.+J.+Headdauthor=L.-W.+Hungauthor=G.+J.+Kapralauthor=R.+W.+Grosse-Kunstleveauthor=A.+J.+McCoyauthor=N.+W.+Moriartyauthor=R.+Oeffnerauthor=R.+J.+Readauthor=D.+C.+Richardsonauthor=J.+S.+Richardsonauthor=T.+C.+Terwilligerauthor=P.+H.+Zwart&title=PHENIX%3A+A+comprehensive+python-based+system+for+macromolecular+structure+solution&doi=10.1107%2FS0907444909052925"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">PHENIX: a comprehensive Python-based system for macromolecular structure solution</span></div><div class="casAuthors">Adams, Paul D.; Afonine, Pavel V.; Bunkoczi, Gabor; Chen, Vincent B.; Davis, Ian W.; Echols, Nathaniel; Headd, Jeffrey J.; Hung, Li Wei; Kapral, Gary J.; Grosse-Kunstleve, Ralf W.; McCoy, Airlie J.; Moriarty, Nigel W.; Oeffner, Robert; Read, Randy J.; Richardson, David C.; Richardson, Jane S.; Terwilliger, Thomas C.; Zwart, Peter H.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">213-221</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">A review.  Macromol. X-ray crystallog. is routinely applied to understand biol. processes at a mol. level.  However, significant time and effort are still required to solve and complete many of these structures because of the need for manual interpretation of complex numerical data using many software packages and the repeated use of interactive three-dimensional graphics.  PHENIX has been developed to provide a comprehensive system for macromol. crystallog. structure soln. with an emphasis on the automation of all procedures.  This has relied on the development of algorithms that minimize or eliminate subjective input, the development of algorithms that automate procedures that are traditionally performed by hand and, finally, the development of a framework that allows a tight integration between the algorithms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpm_HgKRpa-ObVg90H21EOLACvtfcHk0lhbqRTFz3D6ZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhs1Sisbc%253D&md5=67b439ff4bd61c659cae37ca4209b7bc</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1107%2FS0907444909052925&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444909052925%26sid%3Dliteratum%253Aachs%26aulast%3DAdams%26aufirst%3DP.%2BD.%26aulast%3DAfonine%26aufirst%3DP.%2BV.%26aulast%3DBunk%25C3%25B3czi%26aufirst%3DG.%26aulast%3DChen%26aufirst%3DV.%2BB.%26aulast%3DDavis%26aufirst%3DI.%2BW.%26aulast%3DEchols%26aufirst%3DN.%26aulast%3DHeadd%26aufirst%3DJ.%2BJ.%26aulast%3DHung%26aufirst%3DL.-W.%26aulast%3DKapral%26aufirst%3DG.%2BJ.%26aulast%3DGrosse-Kunstleve%26aufirst%3DR.%2BW.%26aulast%3DMcCoy%26aufirst%3DA.%2BJ.%26aulast%3DMoriarty%26aufirst%3DN.%2BW.%26aulast%3DOeffner%26aufirst%3DR.%26aulast%3DRead%26aufirst%3DR.%2BJ.%26aulast%3DRichardson%26aufirst%3DD.%2BC.%26aulast%3DRichardson%26aufirst%3DJ.%2BS.%26aulast%3DTerwilliger%26aufirst%3DT.%2BC.%26aulast%3DZwart%26aufirst%3DP.%2BH.%26atitle%3DPHENIX%253A%2520A%2520comprehensive%2520python-based%2520system%2520for%2520macromolecular%2520structure%2520solution%26jtitle%3DActa%2520Crystallogr.%2520D%2520Biol.%2520Crystallogr.%26date%3D2010%26volume%3D66%26spage%3D213%26epage%3D221%26doi%3D10.1107%2FS0907444909052925" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hoeflich, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merchant, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orr, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otter, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berry, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kasman, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koeppen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rice, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, N.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engst, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnston, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedman, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belvin, M.</span></span> <span> </span><span class="NLM_article-title">Intermittent administration of MEK inhibitor GDC-0973 plus PI3K inhibitor GDC-0941 triggers robust apoptosis and tumor growth inhibition</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>72</i></span>,  <span class="NLM_fpage">210</span>– <span class="NLM_lpage">219</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-11-1515</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=10.1158%2F0008-5472.CAN-11-1515" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=22084396" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvVCltA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2012&pages=210-219&author=K.+P.+Hoeflichauthor=M.+Merchantauthor=C.+Orrauthor=J.+Chanauthor=D.+D.+Otterauthor=L.+Berryauthor=I.+Kasmanauthor=H.+Koeppenauthor=K.+Riceauthor=N.-Y.+Yangauthor=S.+Engstauthor=S.+Johnstonauthor=L.+S.+Friedmanauthor=M.+Belvin&title=Intermittent+administration+of+MEK+inhibitor+GDC-0973+plus+PI3K+inhibitor+GDC-0941+triggers+robust+apoptosis+and+tumor+growth+inhibition&doi=10.1158%2F0008-5472.CAN-11-1515"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Intermittent Administration of MEK Inhibitor GDC-0973 plus PI3K Inhibitor GDC-0941 Triggers Robust Apoptosis and Tumor Growth Inhibition</span></div><div class="casAuthors">Hoeflich, Klaus P.; Merchant, Mark; Orr, Christine; Chan, Jocelyn; Den Otter, Doug; Berry, Leanne; Kasman, Ian; Koeppen, Hartmut; Rice, Ken; Yang, Nai-Ying; Engst, Stefan; Johnston, Stuart; Friedman, Lori S.; Belvin, Marcia</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">210-219</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Combinations of MAP/ERK kinase (MEK) and phosphoinositide 3-kinase (PI3K) inhibitors have shown promise in preclin. cancer models, leading to the initiation of clin. trials cotargeting these two key cancer signaling pathways.  GDC-0973, a novel selective MEK inhibitor, and GDC-0941, a class I PI3K inhibitor, are in early stage clin. trials as both single agents and in combination.  The discovery of these selective inhibitors has allowed investigation into the precise effects of combining inhibitors of two major signaling branches downstream of RAS.  Here, we investigated multiple biomarkers in the mitogen-activated protein kinase (MAPK) and PI3K pathway to search for points of convergence that explain the increased apoptosis seen in combination.  Using washout studies in vitro and alternate dosing schedules in mice, we showed that intermittent inhibition of the PI3K and MAPK pathway is sufficient for efficacy in BRAF and KRAS mutant cancer cells.  The combination of GDC-0973 with the PI3K inhibitor GDC-0941 resulted in combination efficacy in vitro and in vivo via induction of biomarkers assocd. with apoptosis, including Bcl-2 family proapoptotic regulators.  Therefore, these data suggest that continuous exposure of MEK and PI3K inhibitors in combination is not required for efficacy in preclin. cancer models and that sustained effects on downstream apoptosis biomarkers can be obsd. in response to intermittent dosing.  Cancer Res; 72(1); 210-9.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokHbA7g6hLGrVg90H21EOLACvtfcHk0lhbqRTFz3D6ZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvVCltA%253D%253D&md5=40032bf35d5e6335856a645d5c331df8</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-11-1515&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-11-1515%26sid%3Dliteratum%253Aachs%26aulast%3DHoeflich%26aufirst%3DK.%2BP.%26aulast%3DMerchant%26aufirst%3DM.%26aulast%3DOrr%26aufirst%3DC.%26aulast%3DChan%26aufirst%3DJ.%26aulast%3DOtter%26aufirst%3DD.%2BD.%26aulast%3DBerry%26aufirst%3DL.%26aulast%3DKasman%26aufirst%3DI.%26aulast%3DKoeppen%26aufirst%3DH.%26aulast%3DRice%26aufirst%3DK.%26aulast%3DYang%26aufirst%3DN.-Y.%26aulast%3DEngst%26aufirst%3DS.%26aulast%3DJohnston%26aufirst%3DS.%26aulast%3DFriedman%26aufirst%3DL.%2BS.%26aulast%3DBelvin%26aufirst%3DM.%26atitle%3DIntermittent%2520administration%2520of%2520MEK%2520inhibitor%2520GDC-0973%2520plus%2520PI3K%2520inhibitor%2520GDC-0941%2520triggers%2520robust%2520apoptosis%2520and%2520tumor%2520growth%2520inhibition%26jtitle%3DCancer%2520Res.%26date%3D2012%26volume%3D72%26spage%3D210%26epage%3D219%26doi%3D10.1158%2F0008-5472.CAN-11-1515" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7K0V" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7K0V','PDB','7K0V'); return false;">PDB: 7K0V</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3C4C" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3C4C','PDB','3C4C'); return false;">PDB: 3C4C</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i47"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02085">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_30760"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c02085?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c02085</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Molecular formula strings of compounds <b>1</b>–<b>14</b> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02085/suppl_file/jm0c02085_si_001.csv">CSV</a>)</p></li><li><p class="inline">Crystallographic data of compound <b>6</b> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02085/suppl_file/jm0c02085_si_002.cif">CIF</a>)</p></li><li><p class="inline">Crystallographic data of compound <b>7</b> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02085/suppl_file/jm0c02085_si_003.cif">CIF</a>)</p></li><li><p class="inline">Detailed synthetic chemistry schemes, NMR and HPLC spectra for compound <b>7</b>, small-molecule X-ray crystal structures and statistics for compounds <b>6</b> and <b>7</b>, detailed kinase selectivity panel data for compounds <b>1</b>–<b>7</b>, crystallographic statistics for protein cocrystal structure of <b>7</b>, data on synergistic effects of GNE-0749 + cobimetinib and nonsynergistic effects of vemurafenib + cobimetinib in KRAS mutant cell line, HCT116 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02085/suppl_file/jm0c02085_si_004.pdf">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c02085/suppl_file/jm0c02085_si_001.csv">jm0c02085_si_001.csv (1.58 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c02085/suppl_file/jm0c02085_si_002.cif">jm0c02085_si_002.cif (438.96 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c02085/suppl_file/jm0c02085_si_003.cif">jm0c02085_si_003.cif (496.34 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c02085/suppl_file/jm0c02085_si_004.pdf">jm0c02085_si_004.pdf (1.04 MB)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.0c02085&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.0c02085%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2021.64.issue-7%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.0c02085" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                5MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"677a7f918cca3c40","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
